Scientific Programme by Day Saturday, October 2, 2021

UEG Week Final Programme Saturday, October 2, 2021

Scientific Programme by DaySaturday, October 2, 2021

Vienna Live Session

18:00 – 18:45 TV StudioThe UEG Week PremiereChairs: Axel Dignass, DE

Herbert Tilg, ATHelena Cortez-Pinto, PT

1 / 232 Audience Voting Case-Based Live Stream Question & Answer Recorded Session

Debate Tandem Talk National Scholar Best Abstract Prize Rising Star

UEG Week Final Programme Sunday, October 3, 2021

Scientific Programme by DaySunday, October 3, 2021

Vienna Live Session

08:00 – 09:00 TV StudioOpeningChairs: Herbert Tilg, AT

Axel Dignass, DEHelena Cortez-Pinto, PT

08:00 - 08:10 IP001Words of welcome Herbert Tilg, ATAxel Dignass, DE

08:10 - 08:25 IP002NAFLD: From basic mechanisms to new therapies Elisabetta Bugianesi, IT

08:25 - 08:40 IP003Endoscopic strategies targeting metabolic disorders Jacques Deviere, BE

08:40 - 08:45 IP004From T-cells to nutritional advice Nadine Cerf-Bensussan, FR

08:45 - 08:50 IP005From T-cells to nutritional advice Raanan Shamir, IL

08:50 - 09:00Q&A

Live Session

09:00 – 10:00 TV StudioMistakes in...IChairs: Marianna Arvanitakis, BE

09:00 - 09:10 IP006Mistakes in GI bleeding Bjorn Rembacken, UK

09:10 - 09:20 IP007Mistakes in capsule endoscopy Cristina Carretero, ES

09:20 - 09:30 IP008Mistakes in PPI treatment Arjan Bredenoord, NL

09:30 - 10:00Panel discussion

Live Session

09:00 – 10:00 Hall 1Artificial intelligence: Impact for the lower GI tractChairs: Daan W. Hommes, NL

Eyal Klang, IL

09:00 - 09:20 IP009Polyp detection and characterisation Cesare Hassan, IT

09:20 - 09:40 IP010Role of AI in IBD endoscopy Raf Bisschops, BE

09:40 - 10:00 IP011IBD treatment algorithm driven by AI Silvio Danese, IT

Live Session

09:00 – 10:00 Hall 2Cutting edge approaches to the treatment of rectalcancerChairs: Thomas Rösch, DE

Antonino Spinelli, IT

09:00 - 09:20 IP012Imaging in early rectal cancer Regina G.H. Beets-Tan, NL

09:20 - 09:40 IP013Techniques beyond ESD: eFTR and EID Leon M.G. Moons, NL

09:40 - 10:00 IP014Advances in surgical excision for rectal lesions Dieter Hahnloser, CH

Live Session

09:00 – 10:00 Hall 3Role of H. pylori in diseases and symptomsChairs: Emad El-Omar, AU

Tamara Matysiak-Budnik, FR

09:00 - 09:20 IP015The only good bug is a dead bug Colm O'Morain, IE

09:20 - 09:40 IP016H. pylori and dyspepsia Alexander Charles Ford, UK

09:40 - 10:00 IP017H. pylori and malignancy Georgina L. Hold, AU




Live Abstract-based Session

09:00 – 10:00 Hall 4Towards a better understanding of dyspepsia andgastroparesis to improve therapeutic managementChairs: Jan Tack, BE

Marten Alexander Lantinga, NL

09:00 - 09:12 OP001MANAGEMENT OF FUNCTIONAL DYSPEPSIA IN EUROPE –EXPERT OPINION IN A CASE-BASED DELPHI APPROACH Jolien Schol, BE

09:12 - 09:24 OP002DUODENAL DYSBIOSIS AND EFFICACY OF PROTON PUMPINHIBITORS IN FUNCTIONAL DYSPEPSIA: CAUSE ORCONSEQUENCE? Lucas Wauters, BE

09:24 - 09:36 OP003GASTROPARESIS IS ASSOCIATED WITH INCREASEDMORTALITY: RESULTS FROM A COHORT OF MORE THAN 13000 PATIENTS-YEAR Guillaume Gourcerol, FR

09:36 - 09:48 OP004SYMPTOMS AND DUODENAL MUCOSAL INTEGRITY AREIMPROVED BY A DIETARY INTERVENTION IN FUNCTIONALDYSPEPSIA Karen Van den Houte, BE

09:48 - 10:00 OP005ENDOSCOPIC PYLOROMYOTOMY (G-POEM) IMPROVESSYMPTOMS IN PATIENTS WITH REFRACTORYGASTROPARESIS – A RANDOMIZED SHAM CONTROLLEDTRIAL Rastislav Hustak, CZ


09:00 – 10:00 Hall 5Challenges in clinical pancreatologyChairs: Juan Enrique Dominguez-Munoz, ES

Peter Hegyi, HU

09:00 - 09:12 OP006HISTOPATHOLOGICAL DIAGNOSIS OF SOLID PANCREATICTUMORS FROM A PROSPECTIVE ENDOSCOPICULTRASOUND-BASED REGISTRY: NOT EVERYTHING ISPANCREATIC CANCER Julio Iglesias-Garcia, ES

09:12 - 09:24 OP007CHRONIC PANCREATITIS PROGNOSIS SCORE (COPPS):RESULTS FROM AN INTERNATIONAL PROSPECTIVEMULTICENTER VALIDATION STUDY Georg Beyer, DE

09:24 - 09:36 OP008ARTIFICIAL PANCREAS - BIHORMONAL CLOSED LOOPGLUCOSE CONTROL -VERSUS CURRENT CARE AFTERTOTAL PANCREATECTOMY (APPEL5+): OUTPATIENTRANDOMIZED CONTROLLED CROSSOVER TRIAL Charlotte van Veldhuisen, NL09:36 - 09:48 OP009TIMELINE OF DEVELOPMENT OF PANCREATIC CANCERAND IMPLICATIONS FOR SUCCESSFUL EARLY DETECTIONIN HIGH-RISK INDIVIDUALS Kasper A. Overbeek, NL

09:48 - 10:00 OP010AGE-DEPENDENT ASSOCIATION OF PANCREATIC FAMILYHISTORY WITH RECURRENT AND CHRONIC PANCREATITIS,IDIOPATHIC ETIOLOGY AND RISK FACTORS: SECONDARYANALYSIS OF AN INTERNATIONAL COHORT OF 2,335ACUTE PANCREATITIS PATIENTS Márk Félix Juhász, HU

Live Translational/Basic Science Session

09:00 – 10:00 Hall 6Novel insights in onset and treatment of obesityChairs: Ashley Blackshaw, UK

Jessica Rose Biesiekierski, AU

09:00 - 09:20 IP018Microbiome and pathogenesis of obesity Massimo Federici, IT

09:20 - 09:40 IP019Taste receptors and obesity: New target for treatment? Inge Depoortere, BE

09:40 - 10:00 IP020Endoscopic treatment of obesity Roman Turro, ES


09:00 – 10:00 Hall 7Advances in cirrhosisChairs: Mark Thursz, UK

Juan Carlos Garcia Pagan, ES

09:00 - 09:12 OP011A BLOOD-BASED BIOMARKER PANEL PREDICTS RISK FORACUTE KIDNEY INJURY AND ACUTE-ON-CHRONIC LIVERFAILURE IN PATIENTS WITH CIRRHOSIS Lukas Hartl, AT

09:12 - 09:24 OP012INCREASED SURVIVAL IN PATIENTS WITH HEPATICENCEPHALOPATHY TREATED WITH RIFAXIMIN-ALPHA INCOMBINATION WITH LACTULOSE: AN OBSERVATIONALSTUDY IN 4669 PATIENTS FROM UK CLINICAL PRACTICE Sean Walsh, UK




09:24 - 09:36 OP013VON WILLEBRAND FACTOR FOR OUTCOME PREDICTIONWITHIN DIFFERENT CLINICAL STAGES OF ADVANCEDCHRONIC LIVER DISEASE Bernhard Scheiner, AT09:36 - 09:48 OP014INFLUENCE OF NON NEOPLASTIC PORTAL VEINTHROMBOSIS ON SURVIVAL IN CIRRHOTIC PATIENTS WITHHEPATOCELLUAR CARICINOMA Sarah Shalaby, IT

09:48 - 10:00 OP015THE ASSOCIATION OF LIVER STEATOSIS ASSESSED BY THECONTROLLED ATTENUATED PARAMETER AND SEVERITYOF LIVER DISEASE WITH THE PRESENCE OF CIRRHOTICCARDIOMYOPATHY Marcel Razpotnik, AT

Live Session

09:00 – 10:00 Hall 8East meets WestChairs: Haruhiro Inoue, JP

Helmut Messmann, DE

09:00 - 09:05 IP021Screening for oesophageal squamous cell cancer Pierre Henri Deprez, BE

09:05 - 09:10 IP022Screening for oesophageal squamous cell cancer Sergey V. Kashin, RU

09:10 - 09:20Q&A

09:20 - 09:25 IP023Gastric intestinal metaplasia and early gastric cancer Mario Dinis-Ribeiro, PT

09:25 - 09:30 IP024Gastric intestinal metaplasia and early gastric cancer Tsuneo Oyama, JP

09:30 - 09:40Q&A

09:40 - 09:45 IP025ESD for early gastric cancer Haruhiro Inoue, JP

09:45 - 09:50 IP026ESD for early gastric cancer Helmut Messmann, DE

09:50 - 10:00Q&A

E-Poster Session

09:00 – 19:00 Poster ExhibitionSurgery

09:00 - 09:00 P1059SURGEON AND HOSPITAL VOLUME OF GASTRECTOMY ANDSURVIVAL IN GASTRIC ADENOCARCINOMA IN APOPULATION-BASED COHORT STUDY Johannes Asplund, SE

09:00 - 09:00 P1060COLORECTAL CANCER SURVIVAL AT DR. ORLANDO SMITHHOSPITAL, TORTOLA, BRITISH VIRGIN ISLANDS David Nelson, VG

09:00 - 09:00 P1061MORTALITY FOLLOWING APPENDICECTOMY IN PATIENTSWITH LIVER CIRRHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Adil Rashid

09:00 - 09:00 P1064FEATURES OF GUNSHOT COLON DAMAGE WITHEXPANSIVE BULLETS VS CONVENTIONAL BULLETS (DATAOF JOINT FORCES OPERATION AT THE EAST OF UKRAINE2014 - 2020 YY.) Kostiantyn Gumeniuk, UA

09:00 - 09:00 P1065RECTAL DEFECT HEALING: EXPERIMENTAL ASSESSMENTSTUDY OF DIFFERENT REINFORCEMENT PROCEDURES Freddy Mboti, BE

09:00 - 09:00 P1066MORTALITY RISK AFTER APPENDICECTOMY IN PATIENTSWITH LIVER CIRRHOSIS: A POPULATION-BASED COHORTSTUDY FROM ENGLAND Adil Rashid

09:00 - 09:00 P1067ANASTOMOTIC LEAK RISK WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS USE: MYTH OR REALITY? Paula Marques, PT

09:00 - 09:00 P1068BILE ACID MALABSORPTION IN PATIENTS WITH ANDWITHOUT CHRONIC DIARRHOEA FOLLOWING RIGHT-SIDED HEMICOLECTOMY FOR COLON CANCER Helene Mathilde Larsen, DK

09:00 - 09:00 P1069SHOULD WE (RE)CONSIDER THE ROUTINE USE OFINTRAOPERATIVE CHOLANGIOGRAPHY DURINGCHOLECYSTECTOMY? - A SYSTEMATIC REVIEW AND META-ANALYSIS Norbert Kovács, HU

09:00 - 09:00 P1070ENDOLUMINAL VACUUM THERAPY (EVT) AS A TREATMENTOPTION FOR UPPER GASTROINTESTINAL (UGI) TRACTLEAKS; 10-YEARS’ EXPERIENCE IN A SPECIALISTOESPHAGOGASTRIC CENTRE Zeeshan Afzal




09:00 - 09:00 P1071INCIDENCE, RISK FACTORS AND OUTCOMES OF MESHINFECTION AFTER INCISIONAL HERNIA REPAIR SURGERYIN THE UNITED STATES: A NATIONWIDE DATABASESTUDY Andrea Carolina Quiroga Centeno, CO09:00 - 09:00 P1072ENDOSCOPIC TREATMENT OF GASTRO-BRONCHIAL ANDGASTRO-COLIC FISTULAS POST SLEEVE GASTRECTOMY Alessandra D'Alessandro, IT

09:00 - 09:00 P1073FEWER BRANCHES OF LEFT COLIC ARTERY AND THEIRIMPACTS ON LAPAROSCOPIC SURGERY IN PATIENTS WITHPERSISTENT DESCENDING MESOCOLON Hiroaki Nozawa, JP

09:00 - 09:00 P1074DEVELOPMENT OF GASTRIC ENDOSCOPIC FULL-THICKNESS RESECTION FOLLOWED BY BAND LIGATIONAND OVER-THE-SCOPE CLIP CLOSURE Hideki Kobara, JP

09:00 - 09:00 P1075PERORAL ENDOSCOPIC SEPTOTOMY USING ALAPAROSCOPIC VESSEL-TISSUE SEALER FOR TREATMENTOF ZENKER’S DIVERTICULUM: FEASIBILITY AND SAFETY OFENDOSCOPIC SCISSORS TECHNIQUE Filippo Mocciaro, IT

E-Poster Session

09:00 – 19:00 Poster ExhibitionLiver & biliary

09:00 - 09:00 P0631CASR AS AN IMPORTANT PROTECTIVE FACTOR COMBINEDTO THE REGULATION OF HEPATIC STELLATE CELLACTIVATION Jun Lou, CN

09:00 - 09:00 P0632THE ROLE AND MECHANISM OF IRBIT IN HYPOXIAINDUCED ACTIVATION OF HEPATIC STELLATE CELLS Zhe Jin, CN

09:00 - 09:00 P0633DOPAMINE REGULATES AUTOPHAGY DURING TGF-Β1-INDUCED ACTIVATION OF HEPATIC STELLATE CELLS Xiaoxu Yang, CN

09:00 - 09:00 P0634KALLISTATIN AS A BIOMARKER OF NON-ALCOHOLIC FATTYLIVER DISEASE PROGRESSION IN PATIENTS WITHHYPERTENSION Anastasiia Rozhdestvenska, UA

09:00 - 09:00 P0635ASSOCIATION OF OXIDATIVE STRESS WITH THE SEVERITYOF LIVER FIBROSIS IN PATIENTS WITH OPISTHORCHISFELINEUS INVASION Vladislav Tsukanov, RU

09:00 - 09:00 P0636LIVER TRANSAMINASES, LEPTIN AND INTERLEUKIN-6LEVEL IN PATIENTS WITH NON-ALCOHOLICSTEATOHEPATITIS COMBINED WITH OBESITY ANDARTERIAL HYPERTENSION DURING TREATMENT WITHURSODEOXYCHOLIC ACID, STATINS AND SARTANS Olesia Bochar, UA09:00 - 09:00 P0637UNDERSTANDING THE TRANSCRIPTOMIC CHANGES OFMAFLD IN HIGH FAT DIET MURINE MODELS AND ITSREVERSION BY ANTI-STEATOTIC TREATMENTS THROUGHMETA-ANALYSIS Nadezda Apostolova, ES

09:00 - 09:00 P0638ELEVATED LIVER AMINOTRANSFERASES LEVEL ANDCOVID-19 PROGNOSIS Masoud Faghieh Dinavari, IR

09:00 - 09:00 P0639THE ANTIRETROVIRAL DRUG RILPIVIRINE DIMINISHESIP-10/CXCL10 EXPRESSION: RELEVANCE IN THE CONTEXTOF LIVER DISEASE Nadezda Apostolova, ES

09:00 - 09:00 P0640SERPINB3 AS A PRO-INFLAMMATORY MEDIATOR IN NAFLDPROGRESSION Francesca Protopapa, IT

09:00 - 09:00 P0641HUMAN ALPHA-1-DEFENSIN IN PATIENTS WITHALCOHOLIC HEPATITIS AND LIVER CIRRHOSIS Viachaslau Pryshchepenka, BY

09:00 - 09:00 P0642RELATIONSHIP BETWEEN INTESTINAL DYSBIOSIS ANDOBESITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVERDISEASE.

09:00 - 09:00 P0643PROCALCITONIN, NONALCOHOLIC FATTY LIVER DISEASEAND GUT MICROBIOME Doina Georgescu, RO

09:00 - 09:00 P0644EVALUATION OF LIVER FIBROSIS IN PATIENTS WITHRHEUMATOID ARTHRITIS TREATED WITH METHOTREXATE.UTILITY OF FIBROSCAN AND BIOMARKERS IN CLINICALPRACTICE Agustin Castiella Eguzkiza, ES

09:00 - 09:00 P0645POSSIBLE APPLICATION OF PARAMETERS OF FATTY ACIDSIN BLOOD SERUM AND ERYTHROCYTE MEMBRANES INDIAGNOSIS OF SEVERITY RATE OF NONALCOHOLIC FATTYLIVER DISEASE Margarita Vitalievna Kruchinina, RU




09:00 - 09:00 P0646HYPOADIPONECTINEMIA AS A MARKER OF INCREASEDCARDIOVASCULAR RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: CORRELATION WITHALBUMIN/CREATININE RATIO Mona Ahmed Amin, EG09:00 - 09:00 P0647THE IMPACT OF PNPLA3 RS738409 RISK G ALLELES ONHEPATIC STEATOSIS, THE METABOLIC SYNDROME ANDPORTAL HYPERTENSION IN ADVANCED FATTY LIVERDISEASE Antonina Antonenko, AT

09:00 - 09:00 P0648RELATIONSHIP BETWEEN FATTY LIVER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN Hideaki Taniguchi, JP

09:00 - 09:00 P0649DISEASE BURDEN IN PATIENTS WITH ACUTE HEPATICPORPHYRIA: EXPERIENCE FROM THE PHASE 3 ENVISIONSTUDY Bruce Wang, US

09:00 - 09:00 P0650EXPLORE PART B: A PROSPECTIVE, INTERNATIONAL,LONG-TERM NATURAL HISTORY STUDY OF PATIENTS WITHACUTE HEPATIC PORPHYRIA WITH RECURRENTSYMPTOMS David Cassiman, BE

09:00 - 09:00 P0651METABOLIC ASSOCIATED FATTY LIVER DISEASE IN THECHRONIC HEPATITIS C PATIENTS Yasser Fouad, EG

09:00 - 09:00 P0652DIETARY PATTERNS IN PATIENTS WITH SIMPLE STEATOSISAND NON-ALCOHOLIC STEATOHEPATITIS: PROSPECTIVECOMPARATIVE TRIAL Sergey Morozov, RU

09:00 - 09:00 P0653ASSOCIATION OF GLUTATHIONE-S-TRANSFERASE GENESDELETION POLYMORPHISM WITH THEECHOCARDIOGRAPHIC PREDICTORS OF MYOCARDIALHYPERTROPHY IN NON-ALCOHOLIC FATTY LIVER DISEASEPATIENTS Vasyl Prysyazhnyuk, UA

09:00 - 09:00 P0654PREVALENCE AND RISK FACTORS ASSOCIATED WITHPROGRESSION TO ADVANCED FIBROSIS AND CIRRHOSISIN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD):ANALYSIS OF A PROSPECTIVE REGISTRY Nicolau Vallejo-Senra, ES

09:00 - 09:00 P0655ACCURACY OF FIB-4 AND HEPAMET FIBROSIS SCORE TOIDENTIFY ADVANCED LIVER FIBROSIS IN PATIENTS WITHNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Nicolau Vallejo-Senra, ES

09:00 - 09:00 P0656DISTINCTIVE CLINICAL FEATURES OF NON-ALCOHOLICAND MIXED FATTY LIVER DISEASE Nicolau Vallejo-Senra, ES09:00 - 09:00 P0659NOVEL PATHOGENIC ALG8 VARIANTS AND EVIDENCE FORSOMATIC LOSS OF HETEROZYGOSITY IN 199 AUTOSOMALDOMINANT POLYCYSTIC LIVER DISEASE PATIENTS Melissa M. Boerrigter, NL

09:00 - 09:00 P0660THE INTERRELATION BETWEEN OVERT OR SUBCLINICALHYPOTHYROIDISM AND NON-ALCOHOLIC FATTY LIVERDISEASE Sarah Elshinshawy, EG

09:00 - 09:00 P0661HIGH INCIDENCE OF HEPATITIS B CORE ANTIBODYPOSITIVITY IN METABOLIC-ASSOCIATED FATTY LIVERDISEASE-RELATED CIRRHOSIS Coşkun Özer Demirtaş, TR

09:00 - 09:00 P0662COMBINING GENETIC TESTING AND NOVEL BIOMARKERSFOR ASSESSING NAFLD AND ITS COMPLICATIONS IN LIVERTRANSPLANT RECIPIENTS Carmen-Cristina Ester, RO

09:00 - 09:00 P0663FAST IS NOT SUPERIOR TO LSM FOR NONINVASIVEDIAGNOSIS OF FIBROSIS STAGE OR ‘ACTIVE FIBROTICNASH’ IN NONALCOHOLIC FATTY LIVER DISEASE Rudolf Stauber, AT

09:00 - 09:00 P0664COLONIC DIVERTICULOSIS AND NON-ALCOHOLIC FATTYLIVER DISEASE: IS THERE A CONNECTION? Ivana Pantic, RS

09:00 - 09:00 P0665HEPATIC AMYLOIDOSIS: PREVALENCE STUDY ANDCLINICAL CHARACTERIZATION OF A RARE AND DEADLYDISEASE Emanuel Dias, PT

09:00 - 09:00 P0666ARE HEPATIC STEATOSIS PREDICTIVE SCORES STILLUSEFUL TO PREDICT METABOLIC ASSOCIATED FATTYLIVER DISEASE (MAFLD) IN CROHN’S DISEASE PATIENTS? Tiago Lima Capela, PT

09:00 - 09:00 P0667NONINVASIVE BIOLOGICAL STEATOSIS AND FIBROSISSCORES, USEFUL TOOLS FOR EVALUATING MAFLD(METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVERDISEASE) PATIENTS Radu Cotrau, RO

09:00 - 09:00 P0668METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVERDISEASE (MAFLD) – RATHER A BYSTANDER THAN A DRIVEROF MORTALITY Georg Semmler, AT




09:00 - 09:00 P0669VITAMIN D DEFICIENCY IS ASSOCIATED WITH SIGNIFICANTSTEATOSIS, ADVANCED FIBROSIS AND NON-ALCOHOLICSTEATOHEPATITIS (NASH), IN NON-ALCOHOLIC FATTYLIVER DISEASE (NAFLD) Khellaf Amalou, DZ09:00 - 09:00 P0670EFFECT OF CHOLECYSTECTOMY ON HEPATIC STEATOSISAND INSULIN RESISTANCE ASSESSED BY CONTROLLEDATTENUATION PARAMETER (CAP) AND MRI IN NON-ALCOHOLIC FATTY LIVER (NAFLD) ALGERIAN PATIENTS: APILOT STUDY Khellaf Amalou, DZ

09:00 - 09:00 P0672APOPTOSIS MARKERS IN NON-ALCOHOLIC FATTY LIVERDISEASE IN CHILDREN Natalia Zavhorodnia, UA

09:00 - 09:00 P0673NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) ANDSEVERITY OF COVID-19 DISEASE DEPENDING ON THEITGA2 C807T AND ITGB3 T1565C POLYMORPHISM Nataliya Virstyuk, UA

09:00 - 09:00 P0674FEATURES OF THE SERUM LONG-CHAIN FREE FATTY ACIDSCONTENT IN CHILDREN WITH NON-ALCOHOLIC FATTYLIVER DISEASE Natalia Zavhorodnia, UA

09:00 - 09:00 P0675INSULIN LEVELS ARE ASSOCIATED TO LIVER FUNCTIONTEST AND LIVER DISEASE IN COHORTS WITH UP TO 24YEARS OF FOLLOW-UP Andreas Schult, SE

09:00 - 09:00 P0676HEPATORENAL INDEX AS A NON-INVASIVE MARKER OFNON-ALCOHOLIC FATTY LIVER DISEASE IN CHILDREN Natalia Zavhorodnia, UA

09:00 - 09:00 P0677HOW HAS THE SEVERE-ACUTE-RESPIRATORY-SYNDROMECORONAVIRUS 2 PANDEMIC AFFECTED ALCOHOLCONSUMPTION? A NATIONAL SURVEY FOR THEASSESSMENT OF ALCOHOL DRINKING HABITS IN ASAMPLE OF ITALIAN CITIZENS DURING LOCKDOWN Mario Romeo, IT

09:00 - 09:00 P0678COST-EFFECTIVENESS OF RIFAXIMIN-Α VERSUSLACTULOSE IN PREVENTING RECURRENT EPISODES OFOVERT HEPATIC ENCEPHALOPATHY: A SYSTEMATICREVIEW AND META-ANALYSIS Massimo Orlando, IT

09:00 - 09:00 P0679PREVALANCE AND SIGNIFICANCE OF ASYMPTOMATICCYTOMEGALOVIRUS AND EPSTEIN-BARR VIRUSINFECTIONS IN PATIENTS WITH ALCOHOLIC LIVERDISEASE - TO TREAT OR IGNORE? Anna Rycyk, PL

09:00 - 09:00 P0680OUTCOMES OF PATIENTS WITH ALCOHOLIC LIVERDISEASE AFFECTED WITH THE METABOLIC SYNDROME Leore Cohen Mendel, IL09:00 - 09:00 P0681ALCOHOL USE DISORDER AND ALCOHOL RELATED LIVERDISEASE: TIME FOR SCREENING? Camelia Gianina Foncea, RO

09:00 - 09:00 P0682DEVELOPMENT OF A 90-DAY MORTALITY PREDICTIVEMODEL FOR ALCOHOLIC HEPATITIS Joel Ferreira-Silva, PT

09:00 - 09:00 P0683EFFECT OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB)SUPPLEMENTATION ON PLASMA AMINO ACID LEVELS INLIVER CIRRHOSIS Silvia Espina, ES

09:00 - 09:00 P0684DIP THE TAP - IMPROVING NEEDLE TO DIAGNOSIS TIME INSPONTANEOUS BACTERIAL PERIOTINITIS: A RENEWEDSCREENING ROLE FOR BEDSIDE LEUCOCYTE ESTERASETEST KITS - DURING COVID 19 PANDEMIC A MULTISITESTUDY Flora Kokwaro

09:00 - 09:00 P0685CAN SERUM FERRITIN PREDICT 30 DAYS MORTALITY INPATIENTS WITH DECOMPENSATED CIRRHOSIS? Sahar Nasr, TN

09:00 - 09:00 P0686PROTEASE-DEPENDENT LOSS OF INTESTINAL EPITHELIALINTEGRITY IN SPONTANEOUS BACTERIAL PERITONITIS Eva Rinner, DE

09:00 - 09:00 P0687ELEVATED SERUM LEVELS OF METHYLGLYOXAL AREASSOCIATED WITH AN IMPAIRED LIVER FUNCTION ANDLIVER-RELATED COMPLICATIONS IN PATIENTS WITH LIVERCIRRHOSIS Maurice Michel, DE

09:00 - 09:00 P0688A NOVEL ROLE FOR THE P53 FAMILY IN BACTERIALTRANSLOCATION Karsten Gülow, DE

09:00 - 09:00 P0689IMPACT OF PROLONGED HOSPITAL STAY ON THEDEVELOPMENT OF FUNGAL INFECTION IN CIRRHOTICPATIENTS Nouha Trad, TN

09:00 - 09:00 P0691INCIDENCE OF CHRONIC KIDNEY DISEASE IN NORTHERNIRELAND LIVER TRANSPLANT RECIPIENTS- A 10 YEARRETROSPECTIVE REVIEW Rebecca O' Kane, UK




09:00 - 09:00 P0693QUALITY OF LIFE IMPROVEMENT IS A TOP-RATED BUTRARELY ASSESSED OUTCOME IN EUROPEAN ANDAUSTRALIAN PATIENTS WITH HEPATICENCEPHALOPATHY: QUALITY OF LIFE TARGETING ANDMONITORING NEEDS TO BE PRIORITISED Juha Halonen09:00 - 09:00 P0694PROCALCITONIN AS A PROGNOSTIC TOOL IN THEMANAGEMENT OF REFRACTORY ASCITES Margarida Gomes Gonçalves, PT

09:00 - 09:00 P0695PREDICTION OF ESOPHAGEAL VARICES IN PATIENTS WITHCOMPENSATED ADVANCED CHRONIC LIVER DISEASE:EXTERNAL VALIDATION OF COOK COUNTY SCORE Renato Medas, PT

09:00 - 09:00 P0696WHAT IS THE CLINICAL IMPACT OF ASCITES CHOLESTEROLAND PROBNP LEVELS IN OUR ROUTINE PRACTICE FOR THEDIFFERENTIAL DIAGNOSIS OF ASCITES ETIOLOGY? Filiz Akyuz, TR

09:00 - 09:00 P0697INTERNATIONAL FRENCH-SPEAKING MULTICENTREPRACTICE SURVEY ON HEPATIC HYDROTHORAX (HH) :RESULTS OF THE "HEP HEP" STUDY AMONG 529HEPATOGASTROENTEROLOGIST (HG) OR PNEUMOLOGIST(PN) RESPONDENTS Jean-François David Cadranel, FR

09:00 - 09:00 P0698PREVALENCE AND CLINICAL IMPACT OF SARCOPENIA ANDMYOSTEATOSIS IN LIVER TRANSPLANT CANDIDATES Irena Mikova, CZ

09:00 - 09:00 P0699ALTERATIONS OF THE AUTONOMIC NERVOUS SYSTEMFUNCTION IN PATIENTS WITH LIVER CIRRHOSIS. ACOMPARISON TO NORMAL SUBJECTS John Vlachogiannakos, GR

09:00 - 09:00 P0700RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH ANDWITHOUT CIRRHOTIC CARDIOMYOPATHY DIAGNOSEDACCORDING TO NEW MULTIDISCIPLINARY CRITERIA Marcel Razpotnik, AT

09:00 - 09:00 P0701ALCOHOL AS A RISK FACTOR FOR MORTALITY IN LIVERTRANSPLANT PATIENTS IN SWEDEN Knut Stokkeland, SE

09:00 - 09:00 P0702VALIDATION OF NON-INVASIVE ALGORITHMS FORDIAGNOSING ESOPHAGEAL VARICES IN PATIENTS WITHCOMPENSATED ADVANCED CHRONIC LIVER DISEASE Frane Paštrović, HR

09:00 - 09:00 P0703PREDICTORS OF BLEEDING AFTER PROPHYLACTICENDOSCOPIC VARICEAL LIGATION Renato Medas, PT09:00 - 09:00 P0704PREDICTIVE FACTORS OF BACTERIAL INFECTION INPATIENTS WITH LIVER CIRRHOSIS: EXPERIENCE OF THEHEPATO-GASTROENTEROLOGY DEPARTMENTCASABLANCA UNIVERSITY HOSPITAL Sara Nacer, MA

09:00 - 09:00 P0705DESIGNING A PROGNOSTIC PREDICTION MODEL FORCIRRHOSIS-RELATED DEATH IN A 10 YEARS’ COHORT OFCIRRHOTIC PATIENTS Leila Pasharavesh, IR

09:00 - 09:00 P0706THE SPECTRUM OF DECOMPENSATED CIRRHOSIS: WHICHSCORES PERFORM THE BEST IN PREDICTINGMORTALITY? Inês Costa-Santos, PT

09:00 - 09:00 P0707A DEEP LEARNING-BASED SYSTEM FOR PREDICTING THERISK OF HEMORRHAGE OF GASTROESOPHAGEAL VARICESQUANTITATIVELY UNDER ENDOSCOPY Jing Wang, CN

09:00 - 09:00 P0708THE IMPACT OF THE COVID 19 PANDEMIC ONHEPATOCELLULAR CARCINOMA SCREENING IN PATIENTSWITH CIRRHOSIS Nouha Trad, TN

09:00 - 09:00 P0709VALUE OF HITACHI SHEAR WAVE ELASTOGRAPHY (SWE)TO RULE-IN AND RULE-OUT THE PRESENCE OFESOPHAGEAL VARICES IN PATIENTS WITH COMPENSATEDADVANCED LIVER DISEASE Simona Bota, AT

09:00 - 09:00 P0710HEMORRHAGIC ASCITES: A POOR PROGNOSTIC MARKERIN DECOMPENSATED LIVER CIRRHOSIS Maria Azevedo Silva, PT

09:00 - 09:00 P0711ACUTE HAEMODYNAMIC RESPONSE TO INTRAVENOUSPROPRANOLOL PREDICTS DECOMPENSATION ANDMORTALITY IN PATIENTS WITH CIRRHOSIS Benedikt Hofer, AT

09:00 - 09:00 P0712PARAMETRIC ARRIVAL TIME (PAT) IN RULING OUT SEVERELIVER FIBROSIS Raluca Lupusoru, RO

09:00 - 09:00 P0713RELIABILITY OF ALBI AND PALBI SCORES IN PREDICTINGTHE OCCURRENCE OF COMPLICATIONS IN CIRRHOTICPATIENTS Maha Mtir, TN




09:00 - 09:00 P0714THE SUBPOPULATION COMPOSITION OF BLOOD T-KILLERS AND THE FREQUENCY OF SEVERE LIVER FIBROSISDIFFER IN PATIENTS WITH VIRAL HEPATITIS C WITHGENOTYPES 1 AND 3 IN THE INDUSTRIAL CENTER OFEASTERN SIBERIA Vladislav Tsukanov, RU09:00 - 09:00 P0715THE SHIFT IN PREVALENCE, INCIDENCE, AND MORTALITYRATES OF VIRAL HEPATITIS TYPES A, B, C AND D INBRAZILIAN CITIZENS BETWEEN 1999 AND 2019 Lucas Monteiro, BR

09:00 - 09:00 P0716RETRIEVAL OF LOST PATIENTS IN THE SYSTEM FORHEPATITIS C MICROELIMINATION: A SINGLE-CENTERRETROSPECTIVE STUDY Hsu-Heng Yen, TW

09:00 - 09:00 P0717CHRONIC HEPATITIS B UNDER TENOFOVIR OR ENTECAVIR:PERFORMANCE OF THE PAGE-B SCORE TO PREDICTHEPATOCELLULAR CARCINOMA Daniela Falcão, PT

09:00 - 09:00 P0718SIGNIFICANT HARM REDUCTION DESPITE HIGHREINFECTION RATES AMONG ACTIVE PEOPLE WHO INJECTDRUGS ENROLLING IN AN EXTERNALIZED MODEL FOR HCVMICROELIMINATION Sabela Lens, ES

09:00 - 09:00 P0719THE EFFECT OF DIRECT-ACTING ANTIVIRAL REGIMENSAND TELEMEDICINE ON THE TREATMENT OF INMATESWITH CHRONIC HEPATITIS C INFECTION IN ISRAELIPRISONS Efrat Broide, IL

09:00 - 09:00 P0720EXTERNAL VALIDATION OF NEW FIB-4 THRESHOLDS FORRULING IN CHRONIC HEPATITIS B RELATED FIBROSIS Sahar Nasr, TN

09:00 - 09:00 P0721TREATMENT OF HEPATITIS C WITH DIRECT ACTINGANTIVIRAL DRUGS CAN PROTECT AGAINST SEVERE ACUTERESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION MOHAMED Alboraie, EG

09:00 - 09:00 P0722ELIMINATION OF HEPATITIS C BASED ON FOCUSPROGRAM Fátima Nélia Abreu, PT

09:00 - 09:00 P0724DIABETES MELLITUS INCREASES THE RISK OFHEPATOCELLULAR CARCINOMA AFTER DIRECT-ACTINGANTIVIRAL TREATMENT FOR HEPATITIS C: A SYSTEMATICREVIEW WITH META-ANALYSIS Szilárd Váncsa, HU

09:00 - 09:00 P0725CHRONIC HEPATITIS B GENOTYPE E: A REALITY IN ADISTRICT HOSPITAL IN PORTUGAL Bárbara Morão, PT09:00 - 09:00 P0726DIABETES MELLITUS DOES NOT INCREASE THE RISK OFRECURRENT HEPATOCELLULAR CARCINOMA AFTERDIRECT-ACTING ANTIVIRAL TREATMENT FOR HEPATITIS C:SYSTEMATIC REVIEW WITH META-ANALYSIS Szilárd Váncsa, HU

09:00 - 09:00 P0727CHRONIC HEPATITIS B GENOTYPE E: CLINICALCHARACTERISTICS AND RESPONSE TO ANTI-VIRALAGENTS Bárbara Morão, PT

09:00 - 09:00 P0728SEROPREVALENCE OF HEPATITIS B AND C VIRUSES INCHILDREN ABOVE THE AGE OF 3 YEARS: AN EGYPTIANHOSPITAL-BASED CROSS-SECTIONAL SURVEY STUDY Muhammad Abdel-Gawad, EG

09:00 - 09:00 P0729CHARACTERISTICS AND IMPACT OF SEX IN PATIENTS WITHPRIMARY SCLEROSING CHOLANGITIS: A MULTICENTERRETROSPECTIVE STUDY Alejandro Mínguez, ES

09:00 - 09:00 P0730INTRAHEPATIC CHOLESTASIS OF PREGNANCY – WHATCOMES NEXT? Bárbara Morão, PT

09:00 - 09:00 P0732PREDICTORS OF NON-RESPONSE TO CORTICOSTEROIDSIN SEVERE ACUTE AUTOIMMUNE HEPATITIS Mafalda João, PT

09:00 - 09:00 P0733AUTOIMMUNE HEPATITIS AND PRIMARY BILIARYCHOLANGITIS OVERLAP SYNDROME – WHAT ARE THEDIFFERENCES? Isabel Garrido, PT

09:00 - 09:00 P0734RISK STRATIFICATION IN AUTOIMMUNE HEPATITIS: EARLYNORMALIZATION OF TRANSAMINASES MAY IDENTIFYPATIENTS WITH SUBOPTIMAL TREATMENT RESPONSE Renato Medas, PT

09:00 - 09:00 P0735OUTCOMES OF PATIENTS WITH ACUTE SEVEREAUTOIMMUNE HEPATITIS: PREDICTORS OF NON-RESPONSE TO CORTICOSTEROIDS AND NEED FOR LIVERTRANSPLANTATION Ahad Eshraghian, IR




09:00 - 09:00 P0737PREVALENCE OF INSULIN RESISTANCE IN PATIENTSBEFORE AND AFTER LIVER TRANSPLANTATION, AND ITSPROGRESSION DURING THE FOLLOW-UP. A PROSPECTIVESTUDY Irena Mikova, CZ09:00 - 09:00 P0738DRUG INDUCED LIVER INJURY: ROLE OF CIRCULATINGLIVER-SPECIFIC MICRORNAS AND KERATIN-18 Giacomo Germani, IT

09:00 - 09:00 P0739MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING FORTHE DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS David Marti Aguado, ES

09:00 - 09:00 P0740ULTRASOUND VISCOELASTIC LIVER MEASUREMENTS ANDFACTORS THAT INFLUENCE THEM Roxana Sirli, RO

09:00 - 09:00 P0741THE ROLE OF VASCULARIZATION PARAMETERSQUANTIFICATION FOR THE ASSESSMENTS OFINCONCLUSIVE FOCAL LIVER LESIONS CHARACTERIZED BYCEUS Tudor Voicu Moga, RO

09:00 - 09:00 P0742DIAGNOSTIC ACCURACY OF ACOUSTIC RADIATION FORCEIMPULSE (ARFI) IMAGING AND TRANSIENT ELASTOGRAPHYFOR STAGING HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Khellaf Amalou, DZ

09:00 - 09:00 P0743ACCURACY OF MR IMAGING-ESTIMATED PROTON DENSITYFAT FRACTION FOR DETECTION AND CLASSIFICATION OFSTEATOSIS IN NONALCOHOLIC FATTY LIVER DISEASE Khellaf Amalou, DZ

09:00 - 09:00 P0744LOW INTERQUARTILE RANGE OF LIVER STIFFNESSMEASUREMENT IS INDEPENDENTLY ASSOCIATED WITH30-DAY MORTALITY AMONG HOSPITALIZED NON-CRITICALLY ILL PATIENTS WITH COVID-19 Marko Zelenika, HR

09:00 - 09:00 P0745LIVER STIFFNESS IS ASSOCIATED WITH DISEASE SEVERITYAND WORSE CLINICAL SCENARIOS IN CORONAVIRUSDISEASE 2019: A PROSPECTIVE TRANSIENTELASTOGRAPHY STUDY Coşkun Özer Demirtaş, TR

09:00 - 09:00 P0746ACCURACY OF ULTRASONOGRAPHY FOR DETECTINGHEPATIC STEATOSIS IN NAFLD SUSPECTED PATIENTS Zeineb Benzarti, TN

09:00 - 09:00 P0747COMPARISON BETWEEN ACOUSTIC RADIATION FORCEIMPULSE (ARFI) ELASTOGRAPHY AGAINST TRANSIENTELASTOGRAPHY (FIBROSCAN) IN NON-ALCOHOLIC FATTYLIVER DISEASE (NAFLD) Thazin Min09:00 - 09:00 P0748TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) INPATIENTS WITH UNRESECTABLE HEPATOCELLULARCARCINOMA: EXPERIENCE OF A TUNISIAN CENTER Amani Hassine, TN

09:00 - 09:00 P0749THE SYNERGISTIC EFFECTS OF IFN-Γ AND IL-1Β ON THEMECHANISM OF PROGRAMMED CELL DEATH 1 LIGAND 1EXPRESSION IN HEPATOCELLULAR CARCINOMA Yasunao Numata, JP

09:00 - 09:00 P0750MICRORNA-122 CONJUGATED POLYMER NANOPARTICLESAS A PROTECTIVE TOOL AGAINST DEVELOPMENT OFHEPATOCELLULAR CARCINOMA IN AN EXPERIMENTALMODEL Eman EL-Ahwany, EG

09:00 - 09:00 P0751DISTINCT EFFECTS OF IGFBP2 ON VIABILITY OFHEPATOMA CELLS – A MATTER OF DOSE Frederik Kolligs, DE

09:00 - 09:00 P0752GENOME-WIDE CRISPR/CAS9 KNOCKOUT SCREENING FORTHE IDENTIFICATION OF CRITICAL RESISTANCE DRIVERSIN DIMETHYL FUMARATE TREATED TUMORS Jan Teubner, DE

09:00 - 09:00 P0754FIRST REPORT OF V-SET AND IMMUNOGLOBULIN DOMAINCONTAINING 1 EXPRESSION IN HEPATOCELLULARCARCINOMA Simona Gurzu, RO

09:00 - 09:00 P0755INTERLEUKIN GENES ASSOCIATED WITH THEDEVELOPMENT OF HEPATOCELLULAR CARCINOMA AS ARESULT OF VIRAL HEPATITIS B AND C Viachaslau Pryshchepenka, BY

09:00 - 09:00 P0756A NOMOGRAM-BASED PROGNOSTIC MODEL FORADVANCED HEPATOCELLULAR CARCINOMA PATIENTSTREATED WITH SORAFENIB: A MULTICENTER STUDY Giovanni Marasco, IT

09:00 - 09:00 P0757MACHINE LEARNING MODELS IN THE PREDICTION OF ONE-YEAR MORTALITY IN PATIENTS WITH ADVANCEDHEPATOCELLULAR CANCER TREATED WITHIMMUNOTHERAPY Thomas Ka Luen Lui, HK




09:00 - 09:00 P0758THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIESPATIENTS WITH ADVERSE CLINICAL OUTCOME FROMIMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA Ambreen Muhammed09:00 - 09:00 P0759NEW TOOLS FOR PREDICTING SURVIVAL IN PATIENTSWITH HEPATOCELLULAR CARCINOMA TREATED WITHSORAFENIB Alexandra Pires, PT

09:00 - 09:00 P0760PROGNOSIS OF HEPATOCELLULAR CARCINOMA IN POSTVIRAL CIRRHOSIS : PERFORMANCE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO AND THE PLATELET-TO-LYMPHOCYTE RATIO Maroua Ben Abbes, TN

09:00 - 09:00 P0761NURSE INTERVENTION OPTIMIZES THE CARE OF PATIENTSWITH HEPATOCELLULAR CARCINOMA UNDERSECOND/THIRD-LINE TREATMENTS Gemma Iserte Fort, ES

09:00 - 09:00 P0762FAILURE OF ULTRASOUND-BASED SURVEILLANCE FORHEPATOCELLULAR CARCINOMA IN PATIENTS AT RISK ISFREQUENT AND ASSOCIATED WITH DETECTION AT LATERTUMOR STAGES, NON-CURATIVE TREATMENT OPTIONSAND REDUCED SURVIVAL. RESULTS FROM A GERMANMULTI-CENTER RETROSPECTIVE COHORT STUDY Christoph Schramm, DE

09:00 - 09:00 P0764OUTCOME OF LIVER TRANSPLANTATION FOR METASTATICNEUROENDOCRINE TUMOURS Klara Chmelova, CZ

09:00 - 09:00 P0765VALIDATION OF PROGNOSTIC SCORES FOR PATIENTSWITH HEPATOCELLULAR CARCINOMA SUBMITTED TOTACE THERAPY Maria Manuela Estevinho, PT

09:00 - 09:00 P0766PREDICTIVE FACTORS FOR SUSTAINED COMPLETERESPONSE AFTER TRANSARTERIAL CHEMOEMBOLIZATION(TACE) IN PATIENTS WITH HEPATOCELLULARCARCINOMA Sahar Nasr, TN

09:00 - 09:00 P0767CLINICAL AND PATHOLOGICAL CHARACTERIZATION OFLIVER LYMPHOMAS: A RETROSPECTIVE SINGLE-CENTERSTUDY Emanuel Dias, PT

09:00 - 09:00 P0768VARIABILITY IN PRESENTATION AND OUTCOMES INCHILDREN WITH CONGENITAL PORTOSYSTEMIC SHUNTS Valérie McLin, CH

09:00 - 09:00 P0769DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABELUSE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS) Georg Semmler, AT09:00 - 09:00 P0770NATURAL HISTORY OF PATIENTS WITH NON-CIRRHOTICPORTAL HYPERTENSION Joel Silva, PT

09:00 - 09:00 P0771ANALYSIS OF THE PREVALENCE OF NON-OBESE FATTYLIVER DISEASE AND ITS INFLUENCING FACTORS Jiang Deng, CN

09:00 - 09:00 P0772THE CURRENT ROLE OF SPECIALIST PALLIATIVE CARE INPATIENTS WITH END STAGE LIVER DISEASE - A SINGLECENTRE REVIEW Aisling Ni Nuallain, IE

09:00 - 09:00 P0773HEPATOCELLULAR CARCINOMA (HCC) AWARENESS ANDSURVEILLANCE IN PATIENTS WITH CHRONIC LIVERDISEASES (CLD) FOLLOWED IN TERTIARY GREEK LIVERCENTERS Paraskevi Fytili, GR

09:00 - 09:00 P0775PREVALENCE OF PERIODONTAL DISEASE IN PATIENTSWITH LIVER CIRRHOSIS AND ITS INFLUENCE ON THESHORT-TERM OUTCOME OF THE DISEASE Srinivas Reddy Thummala, IN

09:00 - 09:00 P0776RESISTANCE OF FIRST-LINE EMPIRIC ANTIMICROBIALTHERAPY IN PATIENTS WITH ACUTE CHOLANGITISACCORDING TO TOKYO GUIDELINES 2018 Bogdan Miutescu, RO

09:00 - 09:00 P0777PERCUTANEOUS CHOLECYSTOSTOMY: A TREATMENT FORACUTE CHOLECYSTITIS IN CRITICALLY UNWELL, CO-MORBID OR ELDERLY PATIENTS Helen Whitmore

09:00 - 09:00 P0778THE LEVEL OF FIBROBLAST GROWTH FACTOR 19 INPATIENTS AFTER CHOLECYSTECTOMY Alina Makarova, RU

09:00 - 09:00 P0779DIABETES MELLITUS WAS ASSOCIATED WITH A HIGHERRATE OF ACUTE CHOLANGITIS AMONG PATIENTS WITHCOMMON BILE DUCT STONE

09:00 - 09:00 P0780THREE-MONTHS DURATION OF FULLY-COVERED METALSTENT FOR REFRACTORY DOMINANT EXTRA-HEPATICBILIARY STRICTURE AMONG PRIMARY SCLEROSINGCHOLANGITIS PATIENTS: EFFICACY AND SAFETY




09:00 - 09:00 P0781ROLE OF ENDOSCOPIC ULTRASOUND IN EVALUATION OFBILE DUCT DILATATION: EXPERIENCE OF A TERTIARYCENTER Marta Librero Jiménez, ES09:00 - 09:00 P0782ERCP IN BILROTH-II CASES. EXPERIENCE, TIPS ANDTRICKS Aleksandr Filin, RU

09:00 - 09:00 P0783DIAGNOSTIC ACCURACY OF DIGITAL SINGLE-OPERATORCHOLANGIOSCOPY FOR INDETERMINATE BILIARYSTRICTURE: AN ITALIAN SINGLE-CENTER EXPERIENCE Sebastian Manuel Milluzzo, IT

E-Poster Session

09:00 – 19:30 Poster ExhibitionE-Poster Sessions

E-Poster Session

09:00 – 19:00 Poster ExhibitionNutrition

09:00 - 09:00 P0184OUTCOME OF INTENSIVE TREATMENT FOR OBESITY ATOUR HOSPITAL Bunzo Matsuura, JP

09:00 - 09:00 P0185RESTORATIVE OBESITY SURGERY ENDOLUMINALLY FORTREATMENT OF WEIGHT REGAIN AFTER ROUX-EN-Y-GASTRIC BYPASS: OUTCOMES AT 12-MONTHS FOLLOW-UP Carmen H. Bautista Altamirano, ES

09:00 - 09:00 P0186SCLEROSING MESENTERITIS, A METABOLICPHENOMENON? Hagai Schweistein, IL

09:00 - 09:00 P0187EFFICACY AND SAFETY OF NEW SPECIALIZED FOODPRODUCT SPP1 FOR THE TREATMENT OF PATIENTS WITHNON-ALCOHOLIC STEATOHEPATITIS Sergey Morozov, RU

09:00 - 09:00 P0188EFFICACY, SAFETY AND COST EFFECTIVENESS OFINTRAGASTRIC BALLOON THERAPY COMPARED TO AMULTIDISCIPLINARY WEIGHT LOSS PROGRAM IN A REAL-WORLD POPULATION – A PROPENSITY SCORE MATCHINGANALYSIS Jürgen Stein, DE

09:00 - 09:00 P0189REDO ENDOSCOPIC SLEEVE GASTROPLASTY: REPEATINGDOES NOT MEAN FAILING Maria Valeria Matteo, IT

09:00 - 09:00 P0190OBESITY TREATMENT BY GASTRIC ENDOSCOPY SLEEVEPLICATION: EFFICACY AND SAFETY AT 24 MONTHSFOLLOW-UP Carmen H. Bautista Altamirano, ES09:00 - 09:00 P0191ENDOSCOPIC SLEEVE GASTROPLASTY AS NEW HOPE FORMILD OBESITY Maria Valeria Matteo, IT

09:00 - 09:00 P0192HIGHER BODY MASS INDEX IS ASSOCIATED WITH BETTERCLINICAL OUTCOMES IN PATIENTS WITH CYSTICFIBROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF3100 PATIENTS Rita Nagy, HU

09:00 - 09:00 P0193EFFECTS OF GREEN TEA AND POST-FERMENTED GREENTEA EXTRACT ON OBESE ADULTS: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL FOCUSED ONCHANGE OF GUT MICROBIOTA Munjin Ju, KR

09:00 - 09:00 P0194EVALUATION OF CYTOKINE GDF15 AS A BIOMARKER OFOBESITY Leonardo Cláudio Orlando, BR

09:00 - 09:00 P0196COMPARING THE PREVALENCE OF ORTHOREXIA NERVOSAAND PSYCHOSOCIAL SENSATIONS IN PATIENTS WITHIRRITABLE BOWEL SYNDROME, EATING DISORDERS ANDHEALTHY CONTROLS Jessica Rose Biesiekierski, AU

09:00 - 09:00 P0197EFFECT OF A THIRTY-DAY GLUTEN-FREE DIET ON GUTMICROBIOTA COMPOSITION IN HEALTHY SUBJECTS Giacomo Caio, IT

09:00 - 09:00 P0198CHANGES IN INCRETINS, BILE ACIDS AND THEMICROBIOME AFTER DUODENAL MUCOSAL RESURFACINGIN PATIENTS WITH TYPE 2 DIABETES. Suzanne Meiring, NL

09:00 - 09:00 P0199PREVALENCE OF MICRONUTRIENT DEFICIENCY ANDRELATIONS WITH POLYENDOCRINE SYNDROME TYPE 3 INPATIENTS WITH CHRONIC AUTOIMMUNE ATROPHICGASTRITIS Safa Senel, TR

09:00 - 09:00 P0200EARLY CHILDHOOD FOOD ALLERGY IN FAMILIES WITHATOPY IN BULGARIA Silviya Kuneva, BG

09:00 - 09:00 P0201EFFECTS OF LACTOFERRIN ON THE MICROBIOTA IN AMURINE MODEL OF ANTIBIOTICS-INDUCED DYSBIOSIS Andrea Bellés, ES




09:00 - 09:00 P0202LACTOSE MALABSORPTION BY THIRD-GENERATIONHYDROGEN BREATH TEST: NEW DATA COLLECTION ANDTIME IMPLEMENTATION Filippo Scevola, IT09:00 - 09:00 P0203NATIVE AND SATURATED BOVINE LACTOFERRINMODULATE THE EXPRESSION OF TOLL-LIKE RECEPTORS(TLRS) IN MICE TREATED WITH ANTIBIOTICS Andrea Bellés, ES

09:00 - 09:00 P0204ASSESSMENT OF GUT MICROBIOTA IN IBS PATIENTSAFTER A 4-WEEK STARCH-AND SUCROSE-REDUCED DIETSHOWS INCREASED BETA DIVERSITY, UNALTERED ALPHADIVERSITY AND SPECIFIC CHANGES IN GENERA Clara Nilholm, SE

09:00 - 09:00 P0205FEEL4DIABETES HEALTHY DIET SCORE APPLIED FOR TYPE1 DIABETES PATIENTS WITH LONG DURATION INBULGARIA Lubomir Dimitrov, BG

09:00 - 09:00 P0206BENEFICIAL EFFECTS OF LINSEED DIET-SUPPLEMENTATION AND SPONTANEOUS PHYSICALACTIVITY ON INFLAMMATION AND THE MUCOSA-ASSOCIATED MICROBIOTA Claire Plissonneau, FR

09:00 - 09:00 P0207A MEDITERRANEAN DIET-BASED NUTRITIONALEDUCATION PROGRAM POSITIVELY MODIFIES THEINTESTINAL MICROENVIRONMENT OF HEALTHYINDIVIDUALS: RESULTS FROM A PROSPECTIVEINTERVENTION Lihi Godny, IL

09:00 - 09:00 P0208UNBALANCED NUTRIENTS INTAKE IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE: A CROSS-SECTIONALANALYSIS IN A HOMOGENEOUS COHORT FROMSOUTHERN ITALY Federica Crispino, IT

09:00 - 09:00 P0209ASSOCIATION OF IRRITABLE BOWEL SYNDROME ANDMICRONUTRIENTS: A SYSTEMATIC REVIEW Yao Neng Teo, SG

09:00 - 09:00 P0210INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITHFRUCTOSE Raphael Fagundes Rosa, NL

09:00 - 09:00 P0211DIET AND COLONIC MICROBIOTA METABOLISM ANDCOMPOSITION Claudia Barber Caselles, ES

09:00 - 09:00 P0213VITAMIN D RECEPTOR ACTIVATION EXERTS ANTI-SECRETORY ACTIONS IN COLONIC EPITHELIAL CELLS Caitriona E. Curley, IE09:00 - 09:00 P0214DIETARY PATTERNS AND GASTROESOPHAGEAL REFLUXES:CORRELATION ANALYSIS Sergey Morozov, RU

09:00 - 09:00 P0216SAFE PATIENT SELECTION AND USE OF TRANSNASALENDOSCOPY(TNE) FOR PEG INSERTION IN MOTORNEURONE DISEASE(MND) Mohammed Shamsaldeen, UK

09:00 - 09:00 P0217GASTROSTOMY “BUTTON” DIAMETER AND LENGTHVARIATIONS AFTER PERCUTANEOUS ENDOSCOPICGASTROSTOMY: ONE SIZE DOES NOT FIT ALL Vítor Macedo Silva, PT

09:00 - 09:00 P0218SCHEDULED PERCUTANEOUS ENDOSCOPICGASTROSTOMY TUBE REPLACEMENT DID NOT REDUCEPEG RELATED COMPLICATIONS

09:00 - 09:00 P0219STRUCTURED, STEPWISE, MULTIDISCIPLINARY TEAMAPPROACH TO MANAGING BURIED BUMPER SYNDROME(BBS): IMPROVING PATIENT OUTCOMES Angus Kitchin, UK

09:00 - 09:00 P0220IMPACT OF TED, A GLP-2 AGONIST, ON INFLAMMATORYBOWEL DISEASE-ASSOCIATED SHORT BOWEL SYNDROME:A TERTIARY SINGLE-CENTER STUDY Mathieu Uzzan, FR

E-Poster Session

09:00 – 19:00 Poster ExhibitionEndoscopy and imaging

09:00 - 09:00 P0859DOES ANTIBIOTIC PROPHYLAXIS REDUCE THE INFECTIONRATE IN CHILDREN AFTER PERCUTANEOUS ENDOSCOPICGASTROSTOMY INSERTION? Oana Belei, RO

09:00 - 09:00 P0860I-SCAN ENDOSCOPIC PATTERNS OF HELICOBACTERPYLORI-INDUCED GASTRITIS Ahmed Altonbary, EG

09:00 - 09:00 P0861TWO NEEDLE PASSES ACHIEVE SIMILAR SENSITIVITYCOMPARED TO THREE PASSES REGARDING SOLIDPANCREATIC LESION DETECTION IN ENDOSCOPICULTRASOUND-GUIDED FINE NEEDLE ASPIRATION Eleni Koukoulioti, GR




09:00 - 09:00 P0862ME-BLI TO JUDGE THE DEPTH OF INVASION OF EARLYESOPHAGEAL CANCER WITH TYPE B2 BLOOD VESSELSAND ANALYSIS OF RELATED FACTORS Wei Ning, CN09:00 - 09:00 P0863A PROMISING METHOD FOR ACCURATELY CALCULATINGTHE PERCENTAGE OF GASTRIC INTESTINAL METAPLASIAAREA Ning Wei, CN

09:00 - 09:00 P0864PREDICTION OF DEPTH MAP FROM REAL GASTROGRAPHYIMAGE WITH STYLE TRANSFER NETWORKS AND VIRTUALGASTROGRAPHY Joo Young Park, KR

09:00 - 09:00 P0865RESULTS OF A GASTRIC CANCER SCREENING PROGRAMWITH CHROMOENDOSCOPY IN HIGH-RISK PATIENTS. ASINGLE-CENTRE EXPERIENCE Rita González Núñez, ES

09:00 - 09:00 P0866EVALUATION OF PHARYNGEAL BACKGROUND MUCOSA INPATIENTS WITH SUPERFICIAL HYPOPHARYNGEALSQUAMOUS CELL CARCINOMA WHO UNDERWENTENDOSCOPIC RESECTION Yusuke Nishimura, JP

09:00 - 09:00 P0867MORPHOLOGICAL COMPLEXITY OF INTRAPAPILLARYCAPILLARY LOOPS FOR PREDICTING THE INVASION DEPTHOF SUPERFICIAL ESOPHAGEAL CARCINOMA IN NARROW-BAND IMAGING ENDOSCOPY Jeongeun Hwang, KR

09:00 - 09:00 P0868THE SWEDISH STANDARDIZED COURSE OF CARE FORUPPER GI CANCER – CANCER PREVALENCE ANDPREDICTIVE VALUES OF ENTRY CRITERIA Michiel Van Nieuwenhoven, SE

09:00 - 09:00 P0869DELIBERATE FOREIGN BODY SWALLOWING IN PATIENTSWITH UNDERLYING MENTAL HEALTH DISEASE: ARETROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY Warren Seow, AU

09:00 - 09:00 P0870SAFETY AND EFFICACY OF DUAL EMISSION ENDOSCOPICLASER TREATMENT IN PATIENTS WITH UPPER OR LOWERGASTRO-INTESTINAL VASCULAR LESIONS CAUSINGCHRONIC ANAEMIA: RESULTS FROM THE FIRST MULTI-CENTRE COHORT STUDY Alessandro Rimondi, IT

09:00 - 09:00 P0871YIELD OF ENDOSCOPIC INVESTIGATION IN OVERT VERSUSOCCULT GASTROINTESTINAL BLEEDING IN LARGETERTIARY CARE HOSPITAL Gina Sparacino, US

09:00 - 09:00 P0872DIAGNOSTIC OUTCOMES AFTER CANCELLEDGASTROSCOPY: RESULTS OF TELEPHONE VETTING&GT;600 PATIENTS DURING THE COVID-19 PANDEMIC Ella Mozdiak09:00 - 09:00 P0873THE ROLE OF COMPUTED TOMOGRAPHY IN FISH BONEIMPACTION IN ESOPHAGUS AND ACCURACY OF PATIENT'SCOMPLAINING LOCATION COMPARED WITH THEIMPACTION LOCATION: A RETROSPECTIVE, SINGLE-CENTER STUDY Gyu Man Oh, KR

09:00 - 09:00 P0874WHITE LIGHT ENDOSCOPY VERSUS MAGNIFICATIONENDOSCOPY WITH OPTICAL ENHANCEMENT FOR THEEVALUATION OF DYSPEPTIC PATIENTS: A DIAGNOSTICTRIAL Miguel Puga-Tejada, EC

09:00 - 09:00 P0875COMPROMISED PERFORMANCE OF LUGOLCHROMOENDOSCOPY AND ASSOCIATED ENDOSCOPICPATTERNS IN PATIENTS WITH ADVANCED ACHALASIA Anastasios Manolakis, GR

09:00 - 09:00 P0876A REAL-TIME DEEP-LEARNING PIPELINE FOR THEDETECTION AND CHARACTERIZATION OF EARLYESOPHAGEAL SQUAMOUS CELL CARCINOMA UNDERNARROW BAND IMAGING ENDOSCOPY Jie Zhou, CN

09:00 - 09:00 P0877CLINICAL UTILITY OF DUODENAL BIOPSIES IN THEDIAGNOSIS OF IRON DEFICIENCY ANEMIA. ARETROSPECTIVE STUDY Theodoros Voulgaris, GR

09:00 - 09:00 P0878REAL-TIME USE OF ARTIFICIAL INTELLIGENCE FORDIAGNOSING EARLY GASTRIC CANCER BY ENDOSCOPY: AMULTICENTER, DIAGNOSTIC STUDY Xinqi He, CN

09:00 - 09:00 P0879DOES IMAGE ENHANCED ENDOSCOPY IMPROVEDETECTION OF NEOPLASIA IN BARRETT’S OESOPHAGUSSURVEILLANCE: A NETWORK META ANALYSIS Chun Wai Sin

09:00 - 09:00 P0880INTEGRATED FRAME INFORMATIVENESS ASSESSMENTALGORITHM FOR BARRETT’S NEOPLASIA Jelmer Jukema, NL

09:00 - 09:00 P0881APPROPRIATENESS OF GASTROSCOPY REFERRALS INPRIMARY CARE Lieke Maria Koggel, NL




09:00 - 09:00 P0882GASTROINTESTINAL RESIDUE REMOVAL USING ABALLOON OVERTUBE UNDER ULTRATHIN ENDOSCOPICNAVIGATION: AN EXPERIMENTAL ANIMAL STUDY Kazuhiro Kozuka, JP09:00 - 09:00 P0883WAFER PAPER AND RING-MOUNTED POLYGLYCOLIC ACIDSHEET METHOD FOR SHIELDING ULCER AFTER GASTRICENDOSCOPIC SUBMUCOSAL DISSECTION Nobuya Kobayashi, JP

09:00 - 09:00 P0884DETECTION OF GASTRIC PREMALIGNANT CONDITIONSAMONG NON-EXPERT ENDOSCOPISTS ON OPTICALDIAGNOSIS USING A NEW VIRTUAL CHROMOENDOSCOPY Pedro Genaro Delgado-Guillena, ES

09:00 - 09:00 P0885EVALUATION OF THE EFFECTIVENESS OF ENDOSCOPICMANAGEMENT OF ANASTOMOTIC FISTULAS AFTEROESOPHAGEAL CANCER SURGERY Teddy Deregnaucourt, FR

09:00 - 09:00 P0886RESIDUAL NEOPLASIA AFTER NON-CURATIVEENDOSCOPIC SUBMUCOSAL DISSECTION: A WESTERNSINGLE-CENTER EXPERIENCE João Santos-Antunes, PT

09:00 - 09:00 P0887AZITHROMYCIN VERSUS ERYTHROMYCIN IN INTRAVENOUSINFUSION IN UPPER GASTROINTESTINAL BLEEDING:PRELIMINARY RESULTS OF A NON-INFERIOR,PROSPECTIVE, RANDOMIZED, DOUBLE-BLINDCONTROLLED CLINICAL TRIAL Maria Boquera Ferrer, ES

09:00 - 09:00 P0888IMPACT ON AEROSOL GENERATION OF A MOUTHPIECEDESIGNED TO REDUCE DROPLET SPREAD OF COVID-19DURING UPPER GASTROINTESTINAL ENDOSCOPY, ASINGLE CENTER RANDOMIZED CONTROLLED TRIAL Pieter Sinonquel, BE

09:00 - 09:00 P0889ENDOSCOPIC GRADING OF GASTRIC INTESTINALMETAPLASIA IN PATIENTS WITH AUTOIMMUNE GASTRITIS:PSEUDOPYLORIC METAPLASIA MUDDIES THE WATERS Emanuele Dilaghi, IT

09:00 - 09:00 P0890CHALLENGING CLOSURE OF TUNNEL ENTRY DURING PER-ORAL ENDOSCOPIC MYOTOMY: RISK FACTORS ANDMANAGEMENT-RELATED DISCREPANCIES BETWEEN EASTAND WEST Anastasios Manolakis, GR

09:00 - 09:00 P0891COMPARISON OF PATIENT-RELATED EXPERIENCE OFOESOPHAGOGASTRODUODENOSCOPY WITHCOLONOSCOPY AND CAPSULE ENDOSCOPY Gary Neill

09:00 - 09:00 P0892PILLCAM ESO CAPSULE: AN ALTERNATIVE DIAGNOSTICTOOL DURING THE COVID-19 PANDEMIC. FIRST IRISHEXPERIENCE Mary Nwaezeigwe, IE09:00 - 09:00 P0893DIRECT AND NON-DIRECT COSTS IN DIRECT-TO-TESTUPPER GASTROINTESTINAL ENDOSCOPY: NURSEENDOSCOPISTS VERSUS DOCTORS Ahaan Gupta

09:00 - 09:00 P0894MORBIDITY AND MORTALITY RELATED TO THETREATMENT OF GASTRIC VARICES BY ENDOSCOPIC INTRAVARICEAL INJECTION OF N-2-BUTYL-CYANOACRYLATE(NBC): RESULTS OF THE FIRST ALGERIAN PROSPECTIVESTUDY Fhadidja Saidani, DZ

09:00 - 09:00 P0895OVER-THE-SCOPE CLIPS (OTSC) VERSUS STANDARDENDOSCOPIC TREATMENT IN PATIENTS WITH ACUTE NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING James Lau, HK

09:00 - 09:00 P0896EMERGENCY ENDOSCOPY IN CHILDREN DURING SARS-COV-2 PANDEMIC IN A TERTIARY CENTER – A CHANGINGPATTERN? Ana Sofia Vilardouro, PT

09:00 - 09:00 P0897DIFFERENTIAL DIAGNOSTICS AND LONG-TERMPROGNOSIS OF NON-ATROPHIC DUODENAL CHANGES INCHILDREN UNDERGOINGESOPHAGOGASTRODUODENOSCOPY WITH SYSTEMATICBIOPSY SAMPLING Sofia Kröger, FI

09:00 - 09:00 P0898ARTIFICIAL INTELLIGENT CHRONIC ATROPHIC GASTRITISDIAGNOSTIC SYSTEM: AN EFFECTIVE GASTRICPRECANCEROUS RISK-SURVEILLANCE ASSISTED TOOL Yijie Zhu, CN

09:00 - 09:00 P0899OTSG XCAVATOR – FIRST MULTICENTRE DATA ONCLINICAL USE Markus Brand, DE

09:00 - 09:00 P0900DEEP-LEARNING-MODEL FOR IMAGE-BASEDCLASSIFICATION OF CHOLANGIOSCOPIC BILE DUCTLESIONS Malte Zumblick, DE

09:00 - 09:00 P0901MEAN WEIGHT LOSS POST-ENDOSCOPIC SLEEVEGASTROPLASTY IS INDEPENDENT OF THE SUTUREPATTERN: RESULTS FROM A RANDOMIZED CONTROLLEDTRIAL Vincent Huberty, BE




09:00 - 09:00 P0902PREMEDICATION WITH SIMETHICONE FOR IMPROVINGTHE QUALITY OF GASTRIC MUCOSAL VISUALISATIONDURING UPPER GASTROINTESTINAL ENDOSCOPY: ADOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL Léo Duez, BE09:00 - 09:00 P0903TREATMENT OF DUODENAL ULCER BLEEDING - EFFICACYOF TRAUMATIC AND ATRAUMATIC OVER-THE-SCOPE-CLIPS (OTSC) – A MULTICENTER RETROSPECTIVEANALYSIS Marcus Hollenbach, DE

09:00 - 09:00 P0904THE ROLE OF ENDOSCOPIC SUBMUCOSAL DISSECTION INTHE MANAGEMENT OF GASTRIC INFLAMMATORY FIBROIDPOLYPS Emanuel Dias, PT

09:00 - 09:00 P0905STEROID LIFTING METHOD: A NEW STRATEGY FOR THEPREVENTION OF STRICTURES AFTER ESOPHAGEALENDOSCOPIC SUBMUCOSAL DISSECTION Francisco Baldaque-Silva, SE

09:00 - 09:00 P0908DIAGNOSIS AND MANAGEMENT OF HYPERPLASTICGASTRIC POLYPS Salma Souissi, TN

09:00 - 09:00 P0909THE DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCEAND COMPUTER-AIDED DIAGNOSIS FOR THE DETECTIONAND CHARACTERISATION OF COLORECTAL POLYPS: ASYSTEMATIC REVIEW AND META-ANALYSIS Scarlet Nazarian

09:00 - 09:00 P0910ENDOSCOPIC RETROGRADE APPENDICITIS THERAPY: ANEW THERAPEUTIC METHOD FOR ACUTE APPENDICITIS INCHILDREN WITH LEUKEMIA Jiyu Zhang, CN

09:00 - 09:00 P0911COST-EFFECTIVENESS ANALYSIS OF ENDOSCOPICRESECTION FOR COLORECTAL LATERALLY SPREADINGTUMORS: ENDOSCOPIC SUBMUCOSAL DISSECTIONVERSUS PIECEMEAL ENDOSCOPIC MUCOSAL RESECTION Masau Sekiguchi, JP

09:00 - 09:00 P0912COVID-19 IN THE ENDOSCOPY UNIT: HOW LIKELY ISTRANSMISSION OF INFECTION? RESULTS FROM ANINTERNATIONAL, MULTICENTER STUDY Ioannis S Papanikolaou, GR

09:00 - 09:00 P0913AN ENDOSCOPIC TREATMENT STRATEGY FORSUPERFICIAL TUMORS IN PATIENTS WITH ULCERATIVECOLITIS Masafumi Nishio, JP

09:00 - 09:00 P0914ACETO-ELECTRIC CHROMOENDOSCOPY FOR EVALUATINGTHE PIT PATTERN IN COLORECTAL POLYPS Shunsuke Yamamoto, JP09:00 - 09:00 P0915THE ROLE OF CROSS-SECTIONAL IMAGING IN THEMANAGEMENT OF PATIENTS WITH COMPLEX COLORECTALPOLYPS Clare Westwood, UK

09:00 - 09:00 P0916ADENOMA DETECTION RATE IS NOT ASSOCIATED WITHCOLORECTAL CANCER INCIDENCE AND MORTALITY IN ANORGANISED FIT-BASED CRC SCREENING PROGRAM Giulio Antonelli, IT

09:00 - 09:00 P0917STRICTURE FORMATION AFTER ENDOSCOPICSUBMUCOSAL DISSECTION OF SUPERFICIAL COLORECTALLESIONS: A WESTERN SINGLE-CENTER EXPERIENCE André Filipe Veiga Mascarenhas, PT

09:00 - 09:00 P0918INCREMENTAL YIELD OF ARTIFICIAL INTELLIGENCE INFOLLOW-UP SCREENING COLONOSCOPIES – AN INTERIMANALYSIS ON 432 PATIENTS Sebastian Manuel Milluzzo, IT

09:00 - 09:00 P0919A NOVEL ONE-DAY VIRTUAL-LIVE HYBRID TRAININGCOURSE IS FEASIBLE AND HAS A POSITIVE IMPACT ONCOLONOSCOPY KEY PERFORMANCE INDICATORS OFEXPERIENCED ENDOSCOPY TRAINEES Louise Krott, BE

09:00 - 09:00 P0920SURVEILLANCE INTERVAL OF PATIENTS WITH HIGH-RISKADENOMAS REMOVED DURING SCREENINGCOLONOSCOPY Thomas Yuen Tung Lam, HK

09:00 - 09:00 P0921DOES AI-ASSISTED COLONOSCOPY IMPROVE ADENOMADETECTION IN SCREENING COLONOSCOPY? A LARGE-SCALE MULTI-CENTRE RANDOMISED CONTROLLEDSTUDY Hong Xu, CN

09:00 - 09:00 P0923THE RISK FOR ADVANCED NEOPLASIA AFTERPOLYPECTOMY OF UP TO TWO DIMINUTIVE POLYPS WITHLOW GRADE DYSPLASIA VS. NORMAL COLONOSCOPY Orly Sneh-Arbib, IL

09:00 - 09:00 P0924EVALUATION OF 『CAD EYE™』BASED ON ARTIFICIALINTELLIGENCE TECHNOLOGY FOR DETECTION ANDCHARACTERIZATION OF COLORECTAL NEOPLASIA IN ACLINICAL SETTING Ikko Tanaka, JP




09:00 - 09:00 P0925ESD KNIVES FEATURE COMPARISON - WHICH KNIFE TOUSE FOR ESD? Kota Momose, JP09:00 - 09:00 P0926ENDOSCOPIC THERMAL DYNAMICS FOR EVALUATING THELESION WITH INFLAMMATION OR CANCER CORRELATESTO THE HISTOLOGICAL FINDINGS Hidetoshi Ohta, JP

09:00 - 09:00 P0927COMPLETION COLONOSCOPY IN PATIENTS WITHADENOMAS IDENTIFIED ON FLEXIBLE SIGMOIDOSCOPY; ISIT ALWAYS NECESSARY? Larissa Good

09:00 - 09:00 P0928 OFFLINE TEST OF AN ARTIFICIAL INTELLIGENCE (AI)BASED AUTOMATIC POLYP DETECTION SYSTEM AND IT'SPOTENTIAL TO INCREASE ADENOMA PER COLONOSCOPY(APC) AND ADENOMA DETECTION RATE (ADR) Harold Jacob, IL

09:00 - 09:00 P0929ENDOSCOPY AND RADIOLOGY IN THE EVALUATION OFRESPONSE TO CHEMORADIOTHERAPY IN LOW RECTALCANCER Pedro Currais, PT

09:00 - 09:00 P0930ENDOSCOPIC SUBMUCOSAL DISSECTION FOR LESIONSINVOLVING ILEOCECAL VALVE WITH/WITHOUT EXTENSIONINTO TERMINAL ILEUM: A MULTICENTER 10-YEAR STUDY Hidenori Tanaka, JP

09:00 - 09:00 P0931EFFICACY OF SINGLE-BALLOON OVERTUBE FORENDOSCOPIC SUBMUCOSAL DISSECTION IN THEPROXIMAL COLON: A PROPENSITY SCORE MATCHEDANALYSIS Hidenori Tanaka, JP

09:00 - 09:00 P0932QUANTIFYING POLYP AND ENDOSCOPY WORKLOAD SINCEINTRODUCTION OF FAECAL IMMUNOCHEMICAL TEST (FIT)IN A TERTIARY CENTRE Michael Ding

09:00 - 09:00 P0933COMPUTER-AIDED CHARACTERISATION OF COLORECTALPOLYPS USING DEEP-LEARNING Rawen Kader

09:00 - 09:00 P0934COMBINED FORWARD AND RETROFLEXION WITHDRAWALDURING COLONOSCOPY USING A SECOND-GENERATIONSHORT-TURN RADIUS COLONOSCOPE Martha Arevalo-Mora, EC

09:00 - 09:00 P0935ARTIFICIAL INTELLIGENCE FOR POLYP DETECTIONDURING COLONOSCOPY – AN IN-DEPTH ANALYSIS OF ACOMMERCIALLY AVAILABLE SYSTEM Joel Troya, DE09:00 - 09:00 P0936BOWEL PREPARATION QUALITY AND ITS IMPACT ONCOLONOSCOPY SCREENING INTERVAL AFTER A NEGATIVECOLONOSCOPY Lisa-Maria Rockenbauer, AT

09:00 - 09:00 P0937ENDOSCOPIC SIGMOIDOPEXY FOR RECURRENT SIGMOIDVOLVULUS IN INOPERABLE PATIENTS: A RETROSPECTIVESERIES OF 15 PATIENTS Salome Ouazana, FR

09:00 - 09:00 P0938THE FELLOWSHIP-TRAINING’S IMPACT ON COLONOSCOPYQUALITY AND EFFICIENCY IN A CANCER HOSPITAL Takashi Watanabe, JP

09:00 - 09:00 P0939CLINICAL AND PATHOLOGICAL FEATURE OF DEPRESSED-TYPE COLORECTAL NEOPLASM Kudo Shin-ei, JP

09:00 - 09:00 P0940CHARACTERISTICS OF DEPRESSED TYPE COLORECTALNEOPLASMS IN MAGNIFYING ENDOSCOPY ANDENDOCYTOSCOPY Shinei Kudo, JP

09:00 - 09:00 P0941AN ARTIFICIAL INTELLIGENCE-BASED QUALITYIMPROVEMENT SYSTEM SIGNIFICANTLY IMPROVED THEEFFICACY OF COMPUTER-AIDED DETECTION SYSTEM INCOLONOSCOPY: A 2*2 FACTORIAL ANALYSIS Lihui Zhang, CN

09:00 - 09:00 P0942NEW COMPUTER-AIDED POLYP DETECTION SYSTEM(ENDO-AID) INCREASED THE 5-10MM ADENOMADETECTION RATE IN JUNIOR ENDOSCOPISTS DURINGCOLONOSCOPIES – A PILOT STUDY Ho Shing Louis Lau, HK

09:00 - 09:00 P0943ENDOSCOPIC MEASUREMENT FUNDAMENTALS - FIRST INHUMAN STUDY FOR SAFETY AND USABILITY Safwat Odeh, IL

09:00 - 09:00 P0944EFICACY AND SAFETY OF ENDOSCOPIC MUCOSALRESECTION FOR DIFFICULT COLORECTAL LESIONS Raquel Muñoz González, ES

09:00 - 09:00 P0945DEVELOPMENT AND EVALUATION OF A DEEP LEARNINGNETWORK TO RECOGNIZE DIFFERENT INTERVENTIONSDURING COLONOSCOPY Joel Troya, DE




09:00 - 09:00 P0946EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSEBOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATEWITH SODIUM PICOSULFATE IN SPECIAL GROUPS OFPATIENTS Tamás Molnár, HU09:00 - 09:00 P0947ARTIFICIAL INTELLIGENCE IN ENDOSCOPIC SCREENINGFOR COLORECTAL CANCER – EXPENSIVE ADD-ON OR COSTSAVING? Stephan Döring, DE

09:00 - 09:00 P0948EFFICACY OF ULTRA-LOW VOLUME BOWEL PREPARATIONFLUIDS (≤1L), A SYSTEMATIC REVIEW AND META-ANALYSIS Milou van Riswijk, NL

09:00 - 09:00 P0949OPTIMIZING DETECTION RATES OF ADENOMAS ANDPOLYPS THROUGH ADVANCED IMAGING METHODS Anna Hinterberger, AT

09:00 - 09:00 P0950REAL-TIME ARTIFICIAL INTELLIGENCE-AIDEDCOLONOSCOPY EXPERIENCE: THE IMPACT ON ROUTINECLINICAL PRACTICE IN A HIGH-VOLUME CENTER -PRELIMINARY DATA Costanza Alvisi, IT

09:00 - 09:00 P0951PATIENT ACCEPTABILITY OF OPTICAL DIAGNOSIS FORDIMINUTIVE POLYPS WITH A RESECT AND DISCARDSTRATEGY IN BOWEL CANCER SCREENINGCOLONOSCOPY Ahmir Ahmad

09:00 - 09:00 P0952HIGH CONFIDENCE OPTICAL DIAGNOSIS OF SMALLPOLYPS AT COLONOSCOPY VERSUS HISTOPATHOLOGY:MOVING TOWARDS A NEW GOLD STANDARD? Ahmir Ahmad

09:00 - 09:00 P0953LEARNING CURVE OF OPTICAL DIAGNOSIS WITH A RESECTAND DISCARD STRATEGY FOR SCREENING COLONOSCOPY:PRELIMINARY RESULTS FROM THE DISCARD3 STUDY Ahmir Ahmad

09:00 - 09:00 P0954SMALL POLYPS AT COLONOSCOPY AND THE NICECLASSIFICATION: LIKELY CAUSES OF OPTICAL DIAGNOSISERROR Ahmir Ahmad

09:00 - 09:00 P0955POWERSPIRAL ENTEROSCOPE PROVIDES AN EXCELLENTSOLUTION FOR DIFFICULT COLONOSCOPY Abdulbaqi Al-toma, NL

09:00 - 09:00 P0956NO SURVEILLANCE INTERVAL CHANGE WITH OPTICALDIAGNOSIS OF SMALL POLYPS DURING BOWEL CANCERSCREENING COLONOSCOPY Ahmir Ahmad09:00 - 09:00 P0957CLINICAL USEFULNESS OF THE “HOLD-AND-DRAG”CLOSURE USING SB CLIP FOR LARGE MUCOSAL DEFECTSAFTER COLORECTAL ENDOSCOPIC SUBMUCOSALDISSECTION Kenjiro Shigita, JP

09:00 - 09:00 P0958IMPLICATIONS OF THE BRITISH SOCIETY OFGASTROENTEROLOGY 2020 POLYP SURVEILLANCEGUIDELINES; EXPERIENCE FROM A TERTIARY REFERRALCENTRE Conchubhair Winters

09:00 - 09:00 P0959PREDICTIVE FACTORS OF COMPLICATIONS INCOLORECTAL SUBMUCOSAL DISSECTION, A FRENCHTERTIARY CENTER EXPERIENCE Mathilde Vinson, FR

09:00 - 09:00 P0960HIGH FREQUENCY OF COLORECTAL POLYPS IN PATIENTSOF SPORADIC ADENOMAS OR ADENOCARCINOMAS OF THEPAPILLA OF VATER: A PROPENSITY SCORE MATCHINGSTUDY Fan Zhou, CN

09:00 - 09:00 P0961INCOMPLETE RESECTION RATES OF 4-20MM NON-PEDUNCULATED COLORECTAL POLYPS WHEN USINGROUTINE SUBMUCOSAL INJECTION Leslie Motchum, CA

09:00 - 09:00 P0962INFLUENCE OF SEDATION TYPE ON POLYP DETECTIONRATE IN DIAGNOSTIC AND SCREENING COLONOSCOPIES:A TERTIARY CARE CENTER EXPERIENCE Fady Daniel, LB

09:00 - 09:00 P0963MULTIMODAL MONITORING OF THE DEGREE OF HYPNOSISDURING SEDATION AND ANESTHESIA FOR GI ENDOSCOPICPROCEDURES - THE FUTURE IN PATIENT SAFETY Sonia Elena Popovici, RO

09:00 - 09:00 P0964SHORTER COLONOSCOPY PROCEDURE TIMES INADEQUATELY CLEANSED PATIENTS WHO ALSO ATTAINHAREFIELD CLEANSING SCALE HIGH-QUALITY COLONSEGMENTS Juha Halonen

09:00 - 09:00 P0965NON-CURATIVE COLORECTAL ENDOSCOPIC SUBMUCOSALDISSECTION: PRE-PROCEDURAL AND PROCEDURALFEATURES INFLUENCE Matteo Lucarini, IT




09:00 - 09:00 P0966TECHNICAL OUTCOMES AND RISK OF STRICTURE AFTERENDOSCOPIC SUBMUCOSAL DISSECTION FOR LARGECOLORECTAL LESIONS Roberta Maselli, IT09:00 - 09:00 P0967HOT AVULSION VERSUS ARGON PLASMA COAGULATIONFOR THE MANAGEMENT OF THE NON-LIFTING POLYP: AMULTICENTRE, RANDOMISED CONTROLLED TRIAL Chloe Attree, AU

09:00 - 09:00 P0968PREDICTING THE RISK OF SUBMUCOSAL INVASION INSUPERFICIAL COLORECTAL LESIONS BASED ON GROSSMORPHOLOGY IN A WESTERN POPULATION André Filipe Veiga Mascarenhas, PT

09:00 - 09:00 P0969A COMPUTER-AIDED OPTICAL CLASSIFICATION OFCOLORECTAL POLYPS INCLUDING SERRATED ADENOMAS Peter Klare, DE

09:00 - 09:00 P0970DEVELOPMENT AND COMPARISON OF THE POLYPDETECTION SYSTEM ENDOMIND WITH A COMMERCIALLYAVAILABLE CADE SYSTEM Alexander Hann, DE

09:00 - 09:00 P097210-YEAR PREVALENCE OF OVERALL COLONOSCOPY ANDSCREENING COLONOSCOPY USE IN GERMANY: A CLAIMSDATA ANALYSIS Michel Hornschuch, DE

09:00 - 09:00 P0973EFFICACY OF ARGON PLASMA COAGULATION INPREVENTION OF BLEEDING RECURRENCE FROMGASTROINTESTINAL ANGIODYSPLASIA Sahar Nasr, TN

09:00 - 09:00 P0974A RETROSPECTIVE STUDY OF POLYPECTOMY OF LESIONS &GT;10MM- ARE WE DOING IT RIGHT AND ARE WECLEARING THE MARGINS? Neasa McGettigan, IE

09:00 - 09:00 P0975COLORECTAL CANCER SCREENING INTERRUPTIONDURING COVID-19: EXPERIENCE FROM AN ENDOSCOPYCENTRE OF SOUTHERN ITALY Federica Crispino, IT

09:00 - 09:00 P0976PREDICTIVE FACTORS OF INADEQUATE BOWELPREPARATION Sara Nacer, MA

09:00 - 09:00 P0977ENDOSCOPIC FULL-THICKNESS RESECTION (EFTR) FOREARLY COLORECTAL CARCINOMA (CRC) - ARETROSPECTIVE ANALYSIS OF 31 CONSECUTIVE CASES Petros Stathopoulos, DE

09:00 - 09:00 P0978ENDOSCOPIC MANAGEMENT OF SIGMOID COLONVOLVULUS - A RETROSPECTIVE COHORT OF 76 CASES Maria Inês Canha, PT09:00 - 09:00 P0979PROSPECTIVE OBSERVATIONAL STUDY OF 1L NER1006COMPARED TO 2L POLYETHYLENE GLYCOL IN INPATIENTSAND OUTPATIENTS Marcus Hollenbach, DE

09:00 - 09:00 P0980SHORT- AND LONG-TERM OUTCOMES OF WESTERN-BASED ENDOSCOPIC SUBMUCOSAL DISSECTION FORCOLORECTAL LESIONS Roberta Maselli, IT

09:00 - 09:00 P0982SAFETY AND EFFICACY OF PROCEDURALIST-DIRECTEDBALANCED-SEDATION FOR THE ENDOSCOPIC MUCOSALRESECTION OF LARGE NON-PEDUNCULATED COLORECTALPOLYPS Sunil Gupta, AU

09:00 - 09:00 P0983AUGMENTATION OF BOWEL PREPARATION FOR REPEATCOLONOSCOPY : WHAT IS THE BEST APPROACH? Thomas Archer, UK

09:00 - 09:00 P0985STRICTURE FORMATION FOLLOWING ENDOSCOPICRESECTION FOR LARGE NON-PEDUNCULATEDCOLORECTAL POLYPS Sunil Gupta, AU

09:00 - 09:00 P0986IS THIS THE TIP OF THE ICEBERG? SIX MONTH OUTCOMESFOR PATIENTS DECLINING ENDOSCOPIC INVESTIGATION Thomas Archer, UK

09:00 - 09:00 P0987CAN AN EDUCATIONAL VIDEO IMPROVE THE ADEQUACY OFBOWEL PREPARATION FOR PATIENTS UNDERGOING THEIRFIRST COLONOSCOPY? THE EBOPS STUDY Thomas Archer, UK

09:00 - 09:00 P0988A SMARTPHONE APP FOR IMPROVEMENT OFCOLONOSCOPY PREPARATION Adil Ait errami, MA

09:00 - 09:00 P0989PROSPECTIVE VALIDATION OF TECHNICAL DIFFICULTYSCORING SCALE OF COMMON BILE DUCT STONE REMOVALDURING ERCP BASED ON DEEP LEARNING Li Huang, CN

09:00 - 09:00 P0990DOES INCREASED ERCP VOLUME IMPROVECHOLANGIOGRAM INTERPRETATION – A NEWPERFORMANCE MEASURE FOR ERCP TRAINING? Shyam Vedantam, US




09:00 - 09:00 P0991DOES COMBINING EUS-GUIDED TISSUE ACQUISITIONWITH ERCP IN PATIENTS WITH DISTAL BILIARYOBSTRUCTION INCREASE THE RISK OF PANCREATITIS? Myrte Gorris, NL09:00 - 09:00 P0993SAFETY AND EFFICACY OF DIRECT PERORALCHOLANGIOPANCREATOSCOPY IN ELDERLY PATIENTS: ACASE-CONTROL STUDY Marcantonio Gesualdo, IT

09:00 - 09:00 P0994A UK COLLABORATIVE STUDY ON THE USE OFINTRADUCTAL FULLY COVERED METAL STENTS IN A NON-LIVER TRANSPLANT SETTING Wafaa Ahmed

09:00 - 09:00 P0995THE FREQUENCY OF PANCREATIC DIVISUM IN THETURKISH POPULATION AND ITS ROLE AS A PREDISPOSINGFACTOR IN PATIENTS WITH CHRONIC PANCREATITIS ANDRECURRENT ACUTE PANCREATITIS ATTACKS Erkan Parlak, TR

09:00 - 09:00 P0996TIMING OF ADMISSION AND ENDOSCOPIC DRAINAGE INPATIENTS WITH ACUTE CHOLANGITIS: WEEKDAY VERSUSWEEKEND Bogdan Miutescu, RO

09:00 - 09:00 P0997THE USEFULNESS OF ERCP BILE ASPIRATED CULTURE INPATIENTS WITH ACUTE CHOLANGITIS Bogdan Miutescu, RO

09:00 - 09:00 P0998USE OF FULLY COVERED SELF-EXPANDING METAL STENTSFOR MANAGEMENT OF BENIGN BILIARY STRICTURE: ASYSTEMATIC REVIEW AND META-ANALYSIS Arthur Schmidt, DE

09:00 - 09:00 P0999EFFECTIVENESS OF DIFFERENT TISSUE ACQUISITIONTECHNIQUES IN INVESTIGATING INDETERMINATE BILIARYSTRICTURES: A SYSTEMATIC REVIEW AND META-ANALYSIS Georgia Dimopoulou, CY

09:00 - 09:00 P1000A SIMPLE CLINICAL SCORE AIMED AT INCREASING THESAFETY OF HANDS-ON ERCP TRAINING: AN INTERIMANALYSIS OF THE INTERNATIONAL, PROSPECTIVE,MULTICENTRIC TIERS STUDY Theodor Alexandru Voiosu, RO

09:00 - 09:00 P1001IS ERCP PERFORMED OUT OF WORKING HOURSEFFECTIVE AND RELIABLE FOR THE TREATMENT OF ACUTECHOLANGITIS ? Bülent Ödemiş, TR

09:00 - 09:00 P1002AUTOMATIC DETECTION OF BILIARY MASSES IN PATIENTSWITH INDETERMINATE BILIARY STENOSIS: THE FUTUREOF ARTIFICIAL INTELLIGENCE IN SINGLE-OPERATORCHOLANGIOSCOPY João Afonso, PT09:00 - 09:00 P1004ENDOSCOPIC PAPILLECTOMY: RESULTS OF A TERTIARYREFERRAL CENTER EXPERIENCE Francesca Aprile, IT

09:00 - 09:00 P1005COMBINED ENDOSCOPIC-RADIOLOGICAL APPROACH FORTHE MANAGEMENT OF COMPLETE TRANSECTION OF THEBILIARY TRACT: RESULTS AND FOLLOW-UP OF ACONSECUTIVE SERIES OF 60 PATIENTS Fabrizio Cereatti, FR

09:00 - 09:00 P1007EFFICACY OF DOUBLE GUIDEWIRE TECHNIQUE INDIFFICULT BILIARY CANNULATION Fatima Zahra Ajana, MA

09:00 - 09:00 P1009MORPHOLOGICAL CLASSIFICATION IN CHOLANGIOSCOPY:MORE OBJECTIVITY, MORE ACCURACY? Ana Luísa Santos, PT

09:00 - 09:00 P1010IS URGENT ERCP THE BEST CHOICE FOR ACUTE BILIARYPANCREATITIS? Sorin Alexandru Coman, RO

09:00 - 09:00 P1011ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY WASNOT MORE COST-EFFECTIVE THAN FINE NEEDLEASPIRATION WITH RAPID ON-SITE EVALUATION INGASTROINTESTINAL LESIONS DIAGNOSIS

09:00 - 09:00 P1012ANXIETY AND CANCEROPHOBIA IN PATIENTS WITH SMALLGASTROINTESTINAL SUBEPITHELIAL LESIONS ANDTUMOURS: BASELINE RESULTS OF A PROSPECTIVE STUDY(QUALI-BANDING-SET) Francesc Bas-Cutrina, ES

09:00 - 09:00 P1013EFFICACY AND SAFETY OF DOUBLE PIGTAIL STENTS INTHE CONTEXT OF HEPATICOGASTROSTOMYDYSFUNCTION AND REPEATED INTRAHEPATIC ACCESS Michiel Bronswijk, BE

09:00 - 09:00 P1014ENDOSCOPIC ULTRASONOGRAPHY AS ADDITIONALPREOPERATIVE WORKUP IS VALUABLE IN HALF OF THEPATIENTS WITH A PANCREATIC BODY OR TAIL LESION Myrte Gorris, NL

09:00 - 09:00 P1015LUMEN-APPOSING METAL STENTS FOR EUS-GUIDEDDRAINAGE OF PANCREATIC PSEUDOCYSTS: RESULTS OF ALARGE MULTICENTER COHORT Arnaldo Amato, IT




09:00 - 09:00 P1016LUMEN-APPOSING METAL STENTS FOR EUS-GUIDEDDRAINAGE OF WALLED-OFF PANCREATIC NECROSIS:RESULTS OF A LARGE MULTICENTER COHORT Arnaldo Amato, IT09:00 - 09:00 P1017ENDOSCOPIC ULTRASOUND GUIDED ELASTOGRAPHY FORTHE DIAGNOSIS OF MALIGNANCY IN RESECTABLEPANCREATIC TUMORS Julio Iglesias-Garcia, ES

09:00 - 09:00 P1018ACCURACY OF ENDOSCOPIC ULTRASOUND-GUIDEDTISSUE ACQUISITION FOR THE CYTO-HISTOLOGICALDIAGNOSIS OF SOLID PANCREATIC TUMORS: ANALISYS OFA LARGE PROSPECTIVE REGISTRY Julio Iglesias-Garcia, ES

09:00 - 09:00 P1019POSSIBILITIES OF ENDOSCOPIC ULTRASONOGRAPHY ANDOTHER MODERN ENDOSCOPIC TECHNIQUES ININFLAMMATORY BOWEL DISEASES Anastasia Titaeva, RU

09:00 - 09:00 P1020APPLICATION OF ARTIFICIAL INTELLIGENCE FOR REAL-TIME ANATOMICAL RECOGNITION DURING ENDOSCOPICULTRASOUND EVALUATION: A PILOT STUDY Roberto Oleas, EC

09:00 - 09:00 P1021WET SUCTION TECHNIQUE: THE CORNERSTONE OF EUS-GUIDED SAMPLING OF SOLID LESIONS? Inês Marques de Sá, PT

09:00 - 09:00 P1022EUS AND PET-CT RESTAGING FOR ESOPHAGEAL ANDGASTRIC ADENOCARCINOMA.COMPARED PERFORMANCEAND SURVIVAL PREDICTION Eduardo Redondo-Cerezo, ES

09:00 - 09:00 P1023SAFETY AND EFFICACY OF ANTEROGRADE EUS-GUIDEDPANCREATIC DUCT DRAINAGE IN AFTER-SURGICALOBSTRUCTION: PRELIMINARY RESULTS OFINTERVENTIONAL MULTICENTRE PROTOCOL Raffaele Manta, IT

09:00 - 09:00 P1024EUS-GUIDED GALLBLADDER DRAINAGE USING A LUMEN-APPOSING METAL STENT FOR ACUTE CHOLECYSTITIS:RESULTS OF A MULTICENTER STUDY Cecilia Binda, IT

09:00 - 09:00 P1025ROLE OF EUS AND EUS GUIDED BIOPSY IN THE DIAGNOSISOF SOLID PSEUDOPAPILLARY NEOPLASM OF THEPANCREAS Katarzyna Monika Pawlak, PL

09:00 - 09:00 P1026CREATION OF A PATIENT REPORTED EXPERIENCEMEASURE TOOL TO EVALUATE PATIENTS’ EXPERIENCEDURING ENDOSCOPIC ULTRASONOGRAPHY (EUS): PREUSSTUDY. Laura Apadula, IT09:00 - 09:00 P1027DEEP LEARNING-BASED NAVIGATION SYSTEM FORPANCREATIC ENDOSCOPIC ULTRASONOGRAPHY Huiling Wu, CN

09:00 - 09:00 P1028EUS-GUIDED HEPATICOGASTROSTOMY FOR BENIGNBILIARY DISEASE: A SINGLE CENTER PRELIMINARYEXPERIENCE Alessio Renga, IT

09:00 - 09:00 P1029DYNAMIC CONTRAST HARMONIC IMAGING BYENDOSCOPIC ULTRASOUND ANDIMMUNOHISTOCHEMICAL ANALYSIS IN GASTRIC CANCER-A FEASIBILITY STUDY Victor-Mihai Sacerdotianu, RO

09:00 - 09:00 P1030ENDOSCOPIC ULTRASOUND-GUIDED ETHANOL ANDRADIOFREQUENCY ABLATION OF FUNCTIONINGINSULINOMAS: A SYSTEMATIC LITERATURE REVIEW Ghassan El-Sayed

09:00 - 09:00 P1031ELECTROCAUTERY-ENHANCED DELIVERY SYSTEM OFLUMEN APPOSING METAL STENT FOR EUS-GUIDEDBILIARY AND GALLBLADDER DRAINAGE: A SINGLE-CENTRESTUDY Martha Arevalo-Mora, EC

09:00 - 09:00 P1032ENDOSCOPIC ULTRASOUND SHARE-WAVE ELASTOGRAPHYOF THE RIGHT AND LEFT HEPATIC LOBE PREDICTS LIVERCIRRHOSIS: A DIAGNOSTIC TRIAL Miguel Puga-Tejada, EC

09:00 - 09:00 P1033ENDOSCOPIC ULTRASOUND GUIDED BILIARY DRAINAGEAS A SALVAGE TECHNIQUE FOR ENDOSCOPICRETROGRADE CHOLANGIO-PANCREATOGRAPHY,PROSPECTIVE MULTICENTER EGYPTIAN STUDY Mohammed Gouda, EG

09:00 - 09:00 P1034SAFETY AND FEASIBILITY OF DUAL EMISSIONENDOSCOPIC LASER TREATMENT IN A COHORT OF 12PATIENTS UNDERGOING SMALL BOWEL OPERATIVEENTEROSCOPY Matilde Topa, IT

09:00 - 09:00 P1035A NOVEL DEEP LEARNING-BASED SMALL BOWEL DISEASEASSISTED DIAGNOSTIC SYSTEM UNDER DOUBLE BALLOONENTEROSCOPY Yijie Zhu, CN




09:00 - 09:00 P1036CLINICAL PRACTICE OF SPIRAL ENTEROSCOPY (SPE) INTHE LEARNING PHASE OF A REAL-WORLD SETTING Martin Raithel, DE09:00 - 09:00 P1037PERCEPTION AND EXPECTATIONS TOWARDS ARTIFICIALINTELLIGENCE IN CAPSULE ENDOSCOPY Romain Leenhardt, FR

09:00 - 09:00 P1038APPLICATION OF A SIMPLE IMAGING BUNDLE COULDIMPROVE NEOPLASTIC POLYP PREDICTION ON CCE Serhiy Semenov, IE

09:00 - 09:00 P1039MAGNETIC-ASSISTED CAPSULE ENDOSCOPY IN CHILDREN:PRELIMINARY REPORT ON FEASIBILITY, SAFETY ANDIMPACT ON GASTRIC TRANSIT TIME. Letizia Zenzeri, IT

09:00 - 09:00 P1040USEFULNESS OF ENDOSCOPIC DELIVERY METHOD FORPATIENTS WITH CAPSULE ENDOSCOPY STAGNATION INTHE STOMACH Akihiko Sumioka, JP

09:00 - 09:00 P1041THE DIAGNOSTIC PERFORMANCE OF PAN-ENTERICCAPSULE ENDOSCOPY AND MAGNETIC RESONANCEENTEROCOLONOGRAPHY IN PATIENTS WITH SUSPECTEDCROHN’S DISEASE Jacob Broder Brodersen, DK

09:00 - 09:00 P1042GUIDED CAPSULE FOR UPPER AND MIDGASTROINTESTINAL BLEEDING Jean-Francois Rey, FR

09:00 - 09:00 P1043AUTOMATIC DETECTION OF ENTERIC PROTUBERANTLESIONS IN CAPSULE ENDOSCOPY USING ACONVOLUTIONAL NEURAL NETWORK Miguel Jose Mascarenhas Saraiva, PT

09:00 - 09:00 P1044NEW PATIENT PROTOCOL TO IMPROVE DISTALESOPHAGEAL MUCOSAL AND Z-LINE VISIBILITY WITHMAGNETICALLY CONTROLLED CAPSULE ENDOSCOPY(MCCE) Adam Finta, HU

09:00 - 09:00 P1045AUTOMATIC DETECTION OF ENTERIC ULCERS ANDEROSIONS IN CAPSULE ENDOSCOPY USING ACONVOLUTIONAL NEURAL NETWORK Tiago Ribeiro, PT

09:00 - 09:00 P1046DEEP LEARNING AND CAPSULE ENDOSCOPY: AUTOMATICDETECTION OF MULTIPLE GASTRIC LESIONS IN WIRELESSCAPSULE ENDOSCOPY Miguel Jose Mascarenhas Saraiva, PT

09:00 - 09:00 P1047ARTIFICIAL INTELLIGENCE AND CAPSULE ENDOSCOPY:AUTOMATIC DETECTION OF GASTRIC PROTRUDINGLESIONS USING A CONVOLUTIONAL NEURAL NETWORK João Afonso, PT09:00 - 09:00 P1048PERFORMANCE OF A DEEP LEARNING SYSTEM FORAUTOMATIC DIAGNOSIS OF PROTRUDING LESIONS INCOLON CAPSULE ENDOSCOPY: A MULTICENTRIC STUDY Pedro Cardoso, PT

09:00 - 09:00 P1049AUTOMATIC DETECTION OF COLONIC ULCERS ANDEROSIONS IN COLON CAPSULE ENDOSCOPY IMAGESUSING A CONVOLUTIONAL NEURAL NETWORK João Afonso, PT

09:00 - 09:00 P1050AUTOMATIC DETECTION OF ULCERS AND EROSIONS IN PILLCAM™ CROHN’S CAPSULE USING A CONVOLUTIONALNEURAL NETWORK João Afonso, PT

09:00 - 09:00 P1051A PROSPECTIVE COMPARISON OF TWO HEADED ANDSINGLE HEADED CAPSULES FOR THE INVESTIGATION OFSUSPECTED SMALL BOWEL BLEEDING. ARE TWO HEADSBETTER THAN ONE? Eilís M. McCarthy, IE

09:00 - 09:00 P1052ARTIFICIAL INTELLIGENCE AND CAPSULE ENDOSCOPY:AUTOMATIC DETECTION OF GASTRIC VASCULAR LESIONSUSING A CONVOLUTIONAL NEURAL NETWORK Miguel Jose Mascarenhas Saraiva, PT

09:00 - 09:00 P1053DIAGNOSTIC ACCURACY OF RADIOLOGIC ANDENDOSCOPIC IMAGING IN THE PRE-OPERATIVE WORKUPOF LEFT-SIDED PANCREATIC LESIONS: IS ENDOSCOPICULTRASONOGRAPHY HELPFUL TO DIFFERENTIATE? Myrte Gorris, NL

09:00 - 09:00 P1054INTESTINAL ULTRASOUND INSTEAD OF ENDOSCOPY:LARGE POTENTIAL ROLE AND COST SAVINGS Raphael Luber

09:00 - 09:00 P1055COMBINED ENDOSCOPIC STENTING FOR CONCOMITANTMALIGNANT GASTRIC OUTLET OBSTRUCTION ANDMALIGNANT BILIARY OBSTRUCTION: DATA FROM A SINGLEREFERRAL CENTER Filippo Mocciaro, IT

09:00 - 09:00 P1056ETIOLOGY AND OUTCOME OF ENDOSCOPIC MANAGEMENTOF ESOPHAGEAL STRICTURES IN CHILDREN: A LARGESINGLE-CENTER EXPERIENCE OF 259 CASES Venkata Umesh Reddy Devarapalli, IN




09:00 - 09:00 P1057MODIFIED ENDOSCOPIC VACUUM THERAPY FOR THETREATMENT OF GASTROINTESTINAL FISTULAS ANDPERFORATIONS: EXPERIENCE FROM A BRAZILIANTERTIARY CARE CENTER Danielle Queiroz Bonilha, BR09:00 - 09:00 P1058PROPHYLACTIC TRANSCATHETER ARTERIALEMBOLIZATION IS ASSOCIATED WITH LOWER ODDS OFREBLEEDING IN NON-VARICEAL UPPERGASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEWAND META-ANALYSIS Eszter Boros, HU

E-Poster Session

09:00 – 19:00 Poster ExhibitionCOVID-19

09:00 - 09:00 P1076AN ANALYSIS OF GI AND NON-GI MANIFESTATIONS OFCOVID-19 DURING THE FIRST WAVE OF THE COVID-19PANDEMIC IN DARLINGTON, UNITED KINGDOM Anjan Dhar

09:00 - 09:00 P1077COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIANCASE-CONTROL DOUBLE-CENTER STUDY Maria Guarino, IT

09:00 - 09:00 P1078GASTROINTESTINAL BLEEDING IN COVID-19 PATIENTS: ASYSTEMATIC REVIEW WITH META-ANALYSIS Giovanni Marasco, IT

09:00 - 09:00 P1079SUCCESSFUL ENDOSCOPY RECOVERY STRATEGY AFTERTHE FIRST WAVE OF THE COVID-19 PANDEMIC IN ANORTHEAST LONDON HOSPITAL Paolo Giuffrida, UK

09:00 - 09:00 P1080FREQUENCY AND OUTCOMES OF SARS-COV-2 INFECTIONIN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASINGLE TERTIARY CENTER EXPERIENCE Ilhami Yuksel, TR

09:00 - 09:00 P1081PROSPECTIVE MULTICENTER EVALUATION OF THEGASTROINTESTINAL MANIFESTATIONS OF COVID-19 INOUTPATIENTS Katarzyna Monika Pawlak, PL

09:00 - 09:00 P1082PERCUTANEOUS ENDOSCOPIC GASTROSTOMY DURINGTHE COVID-19 PANDEMIC: TO PEG OR NOT TO PEG? Mohamed G. Shiha, UK

09:00 - 09:00 P1083IMPACT OF COVID-19 PANDEMIC ON NON-COVID-19PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS Maria Azevedo Silva, PT

09:00 - 09:00 P1084A NOVEL MICROBIOME FORMULA (SIM01) AS ANADJUVANT THERAPY FOR COVID-19: AN OPEN-LABELPILOT STUDY Lin Zhang, CN09:00 - 09:00 P1085A PROSPECTIVE OBSERVATIONAL STUDY ON THEEVALUATION OF THE RISK OF TRANSMISSION DUE TODROPLETS AND AEROSOLS DURINGESOPHAGOGASTRODUODENOSCOPY AND THEUSEFULNESS OF EXTRAORAL SUCTION DEVICES Hironori Sunakawa, JP

09:00 - 09:00 P1086IMPACT OF THE COVID-19 PANDEMIC IN THE DIAGNOSISAND CHARACTERISTICS OF COLORECTAL CANCERPATIENTS María José Domper Arnal, ES

09:00 - 09:00 P1087EVIDENCE-BASED SELECTION ON THE APPROPRIATE FITCUT-OFF POINT IN CRC SCREENING PROGRAMS IN THECOVID PANDEMIC Patricia Carrera-Lasfuentes, ES

09:00 - 09:00 P1088HEPATOKINES AND COVID-19 SEVERITY Michał Kukla, PL

09:00 - 09:00 P1089IMPACT OF COVID-19 PANDEMIC ON DIAGNOSIS OFOESOPHAGEAL AND GASTRIC CANCERS – A SINGLETERTIARY CENTRE STUDY Olufemi Aoko, IE

09:00 - 09:00 P1090EVALUATION OF LIVER ALTERATIONS IN PATIENTS WITHPOST-ACUTE COVID-19 SYNDROME - A PILOT STUDY Felix Bende, RO

09:00 - 09:00 P1091ELEVATED AMINOTRANSFERASES AT ADMISSION IS APREDICTOR OF ACUTE KIDNEY INJURY IN HOSPITALIZEDPATIENTS WITH COVID-19 Yulia Khruleva, RU

09:00 - 09:00 P1092SARS-COV-2 INFECTS AND REPLICATES IN CELLS OF THEHUMAN PANCREAS Jana Krüger, DE

09:00 - 09:00 P1093CONSULTANT-LED TRIAGE OF 2WW REFERRALS USINGSPECIFIC VETTING CRITERIA IN THE ERA OF COVID-19PANDEMIC: IMPACT ON THE DIAGNOSTIC YIELD FORNEOPLASIA AND THE BACKLOG OF ENDOSCOPYREFERRALS AND IMPLICATIONS FOR THE CLINICALPRACTICE Guiomar Moral Villarejo, ES




09:00 - 09:00 P1094IMPACT EVALUATION OF TELECONSULTATION ONGASTROENTEROLOGY DURING THE SARS-COV-2PANDEMIC Pedro Antunes, PT09:00 - 09:00 P1095MAINTAINING ERCP CAPACITY AND HIGH QUALITY KEYPERFORMANCE QUALITY INDICATORS (KPIS) DURING THECHALLENGE OF COVID-19 RESTRICTIONS: WHAT HAVE WELEARNT? Ioannis Varmpompitis

09:00 - 09:00 P1096PREVALENCE AND SEVERITY OF DIARRHEA AND CLOSTRIDIOIDES DIFFICILE INFECTION IN PATIENTSTREATED FOR COVID-19 INFECTION Alexey Okhlobystin, RU

09:00 - 09:00 P1097SATISFACTION WITH TELECONSULTATION ININFLAMMATORY BOWEL DISEASE PATIENTS DURING THECOVID-19 PANDEMIC Pedro Campelo, PT

09:00 - 09:00 P1098DOES THE PRESENCE OF GASTROINTESTINAL SYMPTOMSPREDICT MILDER DISEASE IN COVID-19 PATIENTS ? – APROSPECTIVE EVALUATION jayanta Samanta, IN

09:00 - 09:00 P1099ELEVATED PANCREATIC ENZYME LEVEL IN COVID-19PATIENTS: IS IT A SILENT BYSTANDER? jayanta Samanta, IN

09:00 - 09:00 P1100THE IMPACT OF THE COVID-19 PANDEMIC ON THEMANAGEMENT OF CIRRHOTIC PATIENTS Amani Hassine, TN

09:00 - 09:00 P1101OUTCOMES OF PATIENTS WITH DECOMPENSATEDCIRRHOSIS AND CORONAVIRUS DISEASE 19: MORTALITYAND SAFETY OF LIVER TRANSPLANTATION Ahad Eshraghian, IR

E-Poster Session

09:00 – 19:00 Poster ExhibitionPancreas

09:00 - 09:00 P0784THE OBESTATIN/GPR39 SYSTEM REGULATES THESYNTHESIS AND SECRETION OF PANCREATIC ENZYMESFORM ACINAR CELLS Yolanda Pazos-Randulfe, ES

09:00 - 09:00 P0785OPTIMIZATION OF DOSE LEVELS OF ORALLYADMINISTERED PANCREATIC ENZYME SUPPLEMENTS INTHE DYNAMIC IN-VITRO GASTROINTESTINAL MODEL TINY-TIM Mª Luisa Orera-Peña, ES09:00 - 09:00 P0786CHARACTERIZATION OF HCO3

- SECRETION IN HUMANPANCREATIC DUCTAL ORGANOID CULTURES Tamara Madacsy, HU

09:00 - 09:00 P0787ALLELIC REGULATION OF CK19 DURING MATURATION OFPANCREATIC DUCTAL CELLS Jana Krüger, DE

09:00 - 09:00 P0788CHARACTERIZATION OF 2D AND 3D DUCTAL ORGANOIDCULTURES DERIVED FROM MOUSE AND HUMANPANCREATIC TISSUES Viktória Szabó, HU

09:00 - 09:00 P0789FERULIC ACID ATTENUATES PANRCEATICOBILIARY DUCTOCCLUSION INDUCED INFLAMMATION IN BOTH PANCREASAND LIVER Sumeyye Cilingir, TR

09:00 - 09:00 P0790S100A12 AND CALPROTECTIN ARE POTENTIALBIOMARKERS OF PANCREATITIS IN SEPTIC PATIENTS Vlad Pavel, DE

09:00 - 09:00 P0791FATTY PANCREAS REPRESENTS A RISK FACTOR FORACUTE PANCREATITIS: A PILOT STUDY

09:00 - 09:00 P0792INCIDENCE OF ACUTE PANCREATITIS AMONG PATIENTSWITH LEPTOSPIROSIS REQUIRING EXTRACORPOREALMEMBRANE OXYGENATION (ECMO): A DESCRIPTIVESTUDY Tristan Paulo Madrigal, PH

09:00 - 09:00 P0794PROGNOSTIC SCORES IN POST-ENDOSCOPICRETROGRADE CHOLANGIOPANCREATOGRAPHY ACUTEPANCREATITIS: IS THERE A BETTER OPTION? Vítor Macedo Silva, PT

09:00 - 09:00 P0795FINDING PREDICTORS OF AZATHIOPRINE-INDUCEDPANCREATITIS IN PATIENTS WITH INFLAMMATORY BOWELDISEASE Marta Freitas, PT

09:00 - 09:00 P0796HOW TO PREDICT MICROLITHIASIS IN IDIOPATHICPANCREATITIS – A MACHINE LEARNING DERIVED TOOL Michal Zorniak, DE




09:00 - 09:00 P0797MACHINE LEARNING MODEL FOR EARLY PREDICTION OFNECROTISING PANCREATITIS: A COHORT ANALYSIS Szabolcs Kiss, HU09:00 - 09:00 P0798THE CHARACTERISTICS AND THE POTENTIALPROGNOSTIC ROLE OF ACUTE ABDOMINAL ON-ADMISSIONPAIN IN ACUTE PANCREATITIS: A PROSPECTIVE COHORT-ANALYSIS OF 1432 CASES Mária Földi, HU

09:00 - 09:00 P0799COVID-19 AND ACUTE PANCREATITIS: MORE SERIOUS ANDLETHAL Olivia Sierra, ES

09:00 - 09:00 P0800THERAPEUTIC ANTICOAGULATION FOR SPLANCHNIC VEINTHROMBOSIS IN ACUTE PANCREATITIS: A SYSTEMATICREVIEW AND META-ANALYSIS Noor J Sissingh, NL

09:00 - 09:00 P0801PREVENTION OF BILIARY EVENTS AFTER ACUTE BILIARYPANCREATITIS WITH URSODEOXYCHOLIC ACID (PANURSOSTUDY) Lucía Guilabert, ES

09:00 - 09:00 P0802HISTORY OF HIGH BLOOD PRESSURE AS POSSIBLE RISKFACTOR OF ACUTE PANCREATITIS Marta Librero Jiménez, ES

09:00 - 09:00 P0803INCREASED FREQUENCY OF LOCAL COMPLICATIONS INDIABETIC PATIENTS WITH ACUTE PANCREATITIS Marta Librero Jiménez, ES

09:00 - 09:00 P0804OPTIMAL TIMING OF CHOLECYSTECTOMY AFTERNECROTISING BILIARY PANCREATITIS Hester Timmerhuis, NL

09:00 - 09:00 P0805ENDOSCOPIC ULTRASOUND (EUS) DEPENDENT DECISIONTO PERFORM ENDOSCOPIC RETROGRADECHOLANGIOPANCREATOGRAPHY (ERCP) IN EARLY BILIARYPANCREATITIS WITHOUT CHOLESTASIS ONCONVENTIONAL IMAGING Simona Bota, AT

09:00 - 09:00 P0806TRANSGASTRAL ENDOSCOPIC DRAINAGE OF PANCREATICPSEUDOCYSTS AND WALLED-OFF NECROSIS - A DETAILEDGLANCE AT PERIPROCEDURAL ADVERSE EVENTS ANDSUPERINFECTION Benjamin Walter, DE

09:00 - 09:00 P0807THE ROLE OF CFTR MUTATIONS IN ACUTE BILIARYPANCREATITIS Ágnes Rita Martonosi, HU

09:00 - 09:00 P0808METABOLIC ASSOCIATED FATTY LIVER DISEASE ISASSOCIATED WITH A MORE SEVERE ACUTE PANCREATITIS:A PROSPECTIVE COHORT ANALYSIS OF 2053 CASES Szilárd Váncsa, HU09:00 - 09:00 P0809PREVALENCE OF GASTROINTESTINAL BLEEDING INPANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Marie Anne Engh, HU

09:00 - 09:00 P0811INVALIDITY OF TOKYO-GUIDELINES IN ACUTE BILIARYPANCREATITIS: A PROSPECTIVE, INTERNATIONAL,MULTICENTER COHORT ANALYSIS OF 944 PANCREATITISCASES Márk Félix Juhász, HU

09:00 - 09:00 P0812LACTATED RINGER’S SOLUTION DOES NOT REDUCEINFLAMMATION IN ACUTE PANCREATITIS – A META-ANALYSIS Klementina Ocskay, HU

09:00 - 09:00 P0813TECHNICAL EVOLUTION OF ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE OF WALLED-OFF NECROSIS Diana Ramos Silva, PT

09:00 - 09:00 P0814DYNAMICS OF SERUM PROCALCITONIN FOR PREDICTINGOUTCOME IN PATIENTS OF INFECTED PANCREATICNECROSIS JAHNVI Dhar, IN

09:00 - 09:00 P0815PREDICTORS OF DEVELOPMENT OF INTRA-ABDOMINALHYPERTENSION IN ACUTE PANCREATITIS AND ITS IMPACTON THE OUTCOME OF THE DISEASE jayanta Samanta, IN

09:00 - 09:00 P0816OUTCOME OF EUS GUIDED DRAINAGES IN IRISH TERTIARYREFERRAL CENTRES: A MULTICENTRE REVIEW Gregory Mellotte, IE

09:00 - 09:00 P0817LIPOCALIN-2 LEVELS ARE ALTERED IN THE PANCREATICJUICE OF EARLY CHRONIC PANCREATITIS PATIENTS ANDARE ASSOCIATED TO THE DEGREE OF EXOCRINEPANCREATIC DYSFUNCTION AND THE ACTIVE SMOKINGHABIT Yolanda Pazos-Randulfe, ES

09:00 - 09:00 P0818INVESTIGATING THE ROLE OF ORAI1 CA2+ CHANNEL IN THEPROGRESSION OF CHRONIC PANCREATITIS Viktória Szabó, HU

09:00 - 09:00 P0819COMMON CASR POLYMORPHISMS DO NOT INCREASECHRONIC PANCREATITIS RISK Amanda Takáts, HU




09:00 - 09:00 P0821BICARBONATE DEFECTIVE CFTR VARIANTS IN CHRONICPANCREATITIS: A META-ANALYSIS Gergő Berke, HU09:00 - 09:00 P0822OPEN LABEL, RANDOMIZED, CROSSOVER CLINICAL TRIALTO ASSESS THE EFFICACY OF INCREASING DOSES OFPANCREATIC ENZYMES, WITH OR WITHOUT INHIBITION OFGASTRIC ACID SECRETION, IN PATIENTS WITHPANCREATIC EXOCRINE INSUFFICIENCY SECONDARY TOCHRONIC PANCREATITIS Daniel De la Iglesia-Garcia, ES

09:00 - 09:00 P0823IGG4 RELATED AUTOIMMUNE PANCREATITIS ANDSCLEROSING CHOLANGITIS: IMPACT OF DISEASEDISTRIBUTION ON PROGNOSIS Stephanie Poo

09:00 - 09:00 P0824DIFFERENTIAL ENDOSCOPIC ULTRASOUND FINDINGS INFOCAL TYPE 1 AUTOIMMUNE PANCREATITIS ANDPANCREATIC CANCER: A PROOF-OF-CONCEPT STUDY Matteo Tacelli, IT

09:00 - 09:00 P0825THE VALUE OF CA19.9 MONITORING IN A PANCREATICCYST SURVEILLANCE PROGRAM: A PROSPECTIVE COHORTSTUDY Sanne C. Jaarsma, NL

09:00 - 09:00 P0826THE RISK OF INVASIVENESS OR DEVELOPMENT OFINDICATIONS FOR SURGERY IN PATIENTS WITH SMALL(≤20 MM) PANCREATIC NEOPLASTIC CYSTS Sanne C. Jaarsma, NL

09:00 - 09:00 P0827ASSOCIATION BETWEEN PANCREATIC INTRADUCTALPAPILLARY MUCINOUS NEOPLASMS ANDEXTRAPANCREATIC MALIGNANCIES: A SYSTEMATICREVIEW AND META-ANALYSIS Paraskevas Gkolfakis, BE

09:00 - 09:00 P0828ACCURACY OF INTRACYSTIC CA 72.4 LEVELS FOR THEDIAGNOSIS OF MUCINOUS CYSTIC PANCREATIC LESION José Lariño-Noia, ES

09:00 - 09:00 P0829THE USE OF A MOBILE APPLICATION TO DISSEMINATE THEGUIDELINES ON CYSTIC NEOPLASMS OF THE PANCREAS: ASNAPSHOT STUDY OF 1000 CASE-SIMULATIONS Alberto Balduzzi, IT

09:00 - 09:00 P0830SYSTEMATIC REVIEW AND META-ANALYSIS OFOBSERVATIONAL STUDIES ON BD-IPMNS RISK OFPROGRESSION TO HIGH-RISK LESIONS Alberto Balduzzi, IT

09:00 - 09:00 P0831INTERNATIONAL EXTERNAL VALIDATION OF ASTRATIFICATION TOOL TO IDENTIFY BRANCH-DUCTINTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS ATLOWEST RISK OF PROGRESSION Kasper A. Overbeek, NL09:00 - 09:00 P0832NEW KID ON THE BLOCK: PANCREATIC CYST FLUIDGLUCOSE IS AN ACCURATE, BEDSIDE, LOW COSTDIAGNOSTIC TEST OF MUCINOUS CYSTS Dana Ben-Ami Shor, IL

09:00 - 09:00 P0833SURVEILLANCE OF CYSTIC PANCREATIC LESIONS INPATIENTS OVER 75 YEARS OF AGE Yessica Dominguez-Novoa, ES

09:00 - 09:00 P0834A MODEL BASED ANALYSIS ON THE MAXIMUM EFFECT OFPANCREATIC CYST SURVEILLANCE Brechtje D.M. Koopmann, NL

09:00 - 09:00 P0835EUS TTNB IS SUPERIOR TO FNA FOR DIAGNOSIS OF PCLS –A PROSPECTIVE TERTIARY CENTER ANALYSIS Clement Wu, SG

09:00 - 09:00 P0836WHOLE GENOME SEQUENCING IDENTIFIES RAREGERMLINE VARIANTS ENRICHED IN CANCER RELATEDGENES IN FIRST-DEGREE RELATIVES OF FAMILIALPANCREATIC CANCER PATIENTS Ming Tan, DK

09:00 - 09:00 P0837CLASS I HISTONE DEACETYLASE INHIBITORS CONTROLTHE MYC NETWORK IN PANCREATIC DUCTALADENOCARCINOMA Markus Rösch, DE

09:00 - 09:00 P0838A DRUG REPURPOSING APPROACH TO INHIBIT AMPK INCONTEXT OF PANCREATIC DUCTAL ADENOCARCINOMA Franziska Génevaux, DE

09:00 - 09:00 P0839SCREENING OF A DRUG-LIBRARY IN HDAC-2 PROFICIENTAND DEFICIENT MURINE PANCREATIC DUCTALADENOCARCINOMA CELLS TO IDENTIFY NEW POTENTIALCOMBINATION THERAPIES Marc Kidess, DE

09:00 - 09:00 P0840CHANGES OF THE DUODENAL MICROBIOTA IN PATIENTSWITH PANCREATIC CANCER ARE NOT RELATED WITH BILEAND PANCREATIC DUCT OBSTRUCTION Livia Archibugi, IT

09:00 - 09:00 P0841RNA-SEQUENCING OF PANCREATIC CANCER FROM EUS-ACQUIRED TISSUE IS USEFUL TO DEFINE MOLECULARSUBTYPES AND PROGNOSIS Livia Archibugi, IT




09:00 - 09:00 P0842IMMUNOMODULATION INDUCED BY ENDOSCOPICULTRASOUND-GUIDED ABLATION WITH THEHYBRIDTHERM PROBE IN LOCALLY ADVANCED ANDBORDERLINE RESECTABLE PANCREATIC CANCER:RESULTS FROM A PHASE II RANDOMIZED CONTROLLEDTRIAL Sabrina Gloria Giulia Testoni, IT09:00 - 09:00 P0843DISCRIMINATION BETWEEN PANCREATIC CANCER,PANCREATITIS AND HEALTHY CONTROLS USING URINARYPOLYAMINE PANEL Samuli Nissinen, FI

09:00 - 09:00 P0844GLYCEMIC STATUS OF PATIENTS WITH NEWLY DIAGNOSEDPANCREATIC DUCTAL ADENOCARCINOMA: A DEEPER DIVEIS NEEDED TO SEEK ALTERNATIVE BIOMARKERS! Ana Garcia Garcia de Paredes, US

09:00 - 09:00 P0845PANCREATIC CANCER SCREENING IN A CLINICAL PRACTISESETTING Luisa Adán-Merino, ES

09:00 - 09:00 P0846STANDARDIZATION OF A RADIOFREQUENCY ABLATIONSYSTEM WITH EX-VIVO PANCREATIC ADENOCARCINOMAABLATION Gemma Rossi, IT

09:00 - 09:00 P0848INTERSTITIAL LUNG DISEASE IN PANCREATIC CANCER:PREVALENCE, ETIOLOGY, SEVERITY, RISK FACTOR, ANDPROGNOSIS Hung Yuan Yu, TW

09:00 - 09:00 P0849THE NATURAL DISEASE COURSE OF THE DEVELOPMENTOF PANCREATIC DUCTAL ADENOCARCINOMA: RESULTS OFA MICROSIMULATION MODEL Brechtje D.M. Koopmann, NL

09:00 - 09:00 P0850EVALUATION OF MMR STATUS AND PD-L1 EXPRESSIONUSING SPECIMENS OBTAINED BY EUS- FNB IN PATIENTSWITH PANCREATIC CANCER Alina Liliana Constantin, RO

09:00 - 09:00 P0852COMPARISON OF ENDOSCOPIC ULTRASOUNDELASTOGRAPHY IN DIFFERENTIAL DIAGNOSIS OFMALIGNANT PANCREATIC NEOPLASM VERSUS MASSFORMING CHRONIC PANCREATITIS: PROPENSITY SCOREMATCHING ANALYSIS In Rae Cho, KR

09:00 - 09:00 P0854CAUSES OF DEATH IN PATIENTS WITH METASTATICDIGESTIVE NEUROENDOCRINE TUMOURS Juliette Beringer, FR

09:00 - 09:00 P0855SOMATOSTATIN ANALOGS IN PATIENTS WITH ZOLLINGERELLISON SYNDROME (ZES): AN OBSERVATIONAL STUDY Sara Massironi, IT09:00 - 09:00 P0856QUANTITATIVE CONTRAST-ENHANCED ENDOSCOPICULTRASOUND IN PANCREATIC DUCTALADENOCARCINOMA AND PANCREATIC NEUROENDOCRINETUMORS: CAN WE PREDICT SURVIVAL USING PERFUSIONPARAMETERS? Alina Liliana Constantin, RO

09:00 - 09:00 P0857GLYOXALASE I: A NOVEL TARGET FOR NEUROENDOCRINETUMORS? Marcus Hollenbach, DE

09:00 - 09:00 P0858PREOPERATIVE ASSESSMENT OF SMALL NON-FUNCTIONING PANCREATIC ENDOCRINE NEOPLASMS:ROLE OF ENDOSCOPIC ULTRASOUND AND NUCLEARIMAGING Marianna Signoretti, IT

E-Poster Session

09:00 – 19:00 Poster ExhibitionSmall intestinal

09:00 - 09:00 P0130SOLVING THE ENIGMA OF NON-IGE MEDIATEDGASTROINTESTINAL FOOD ALLERGY IN THE PEDIATRICAGE: RESULTS FROM THE NIGEFA STUDY Laura Carucci, IT

09:00 - 09:00 P0131RELEVANCE AND OUTCOME OF NON-SPECIFIC ENTERITISDURING LONG-TERM FOLLOW-UP Ana Catarina Gomes, PT

09:00 - 09:00 P0132PANETH CELLS REGULATE LYMPHANGIOGENESIS INNORMAL PHYSIOLOGY AND EXPERIMENTAL PORTALHYPERTENSION Oriol Juanola, CH

09:00 - 09:00 P0133ACUTE INTESTINOTROPHIC EFFECTS OF SHORT ANDLONG-ACTING GLP-2 ANALOGUES IN RATS Jolanta Skarbaliene, DK

09:00 - 09:00 P0134THE NOVEL DUAL GLP-1 AND GLP-2 RECEPTOR AGONISTDAPIGLUTIDE ATTENUATES INTESTINAL INSUFFICIENCYIN A MURINE SHORT BOWEL MODEL Johannes Reiner, DE

09:00 - 09:00 P0135GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2ANALOGUE, EXPOSURE DOES NOT CORRELATE WITHHEPATIC INDOCYANINE GREEN CLEARANCE Mikkel Askjær Agersnap, DK




09:00 - 09:00 P0136GEOGRAPHIC EVOLUTION OF PEDIATRIC INTESTINALFAILURE (PIF) MANAGEMENT IN THE UNITED STATES (US) David F Mercer, US09:00 - 09:00 P0137SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROMEAND THERMAL FOOD PROCESSING PATTERN Vladimir Pilipenko, RU

09:00 - 09:00 P0138A RETROSPECTIVE ANALYSIS OF PATIENTS ON A WAITINGLIST FOR SMALL INTESTINAL BACTERIAL OVERGROWTH(SIBO) BREATH TESTING DURING THE COVID-19PANDEMIC AND INTRODUCTION OF A HOME TESTINGPATHWAY Jabed Ahmed

09:00 - 09:00 P0139INTESTINAL TUBERCULOSIS: A FREQUENTLYMISDIAGNOSED DISEASE Sahar Nasr, TN

09:00 - 09:00 P0140FUNCTIONAL GASTROINTESTINAL DISORDERS ANDASSOCIATED HEALTH IMPAIRMENT IN INDIVIDUALS WITHCOELIAC DISEASE Imran Aziz, UK

09:00 - 09:00 P0141HLA RISK STRATIFICATION COULD BE USED TO TARGETSEROLOGICAL SCREENING OF CELIAC DISEASE AMONG AT-RISK RELATIVES Saana Paavola, FI

09:00 - 09:00 P0142CHANGES IN BODY COMPOSITION AMONG PATIENTS WITHCOELIAC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS Zsófia Vereczkei, HU

09:00 - 09:00 P0143COVID, COELIAC DISEASE AND MONEY – WHAT ARE THERISKS OF A NON-BIOPSY PROTOCOL AND THE COSTS OFDUODENAL BIOPSIES WITH A NEGATIVE TTG? Angus Kitchin, UK

09:00 - 09:00 P0144SEROLOGIC DIAGNOSIS OF CELIAC DISEASE IN ADULTS:AN UNFULFILLED QUESTION Giuseppe Losurdo, IT

09:00 - 09:00 P0145DRUG INDUCED ENTEROPATHY IN COELIAC DISEASE: AMULTIVARIATE ANALYSIS OF COMMONLY PRESCRIBEDMEDICATIONS Ciaran McHale, IE

09:00 - 09:00 P0146PREVALENCE AND SIGNIFICANCE OF SUBCLINICAL IRONDEFICIENCY IN SCREEN-DETECTED COELIAC DISEASE: APROSPECTIVE STUDY Marleena Repo, FI

09:00 - 09:00 P0147CONCOMITANT AUTOIMMUNITY IN CELIAC DISEASE:ASSOCIATION TO THE DISEASE FEATURES AND LONG-TERM TREATMENT OUTCOMES Riku Tauschi, FI09:00 - 09:00 P0148WHAT IS THE ROLE OF MULTIPLE URINE GIPS INESTABLISHED COELIAC DISEASE? William Holland

09:00 - 09:00 P0149CELIACSHIELDTM GLUTEN CHALLENGE STUDY – GLUTENIMMUNOGENIC PEPTIDE MEASUREMENTS IN URINEVALIDATE THE LATIGLUTENASE MECHANISM OF ACTIONAND PROVIDE A MEASURE OF COMPLIANCE IN A CLINICALTRIAL SETTING Jennifer Sealey Voyksner, US

09:00 - 09:00 P0150THE DEVELOPMENT AND VALIDATION OF A HIGH-CAPACITY SEROLOGICAL ASSAY FOR COELIAC DISEASE Rolf A. Klaasen, NO

09:00 - 09:00 P0152LOW YIELD OF REPEATED SCREENING OF AT-RISKRELATIVES FOR CELIAC DISEASE: A LONG-TERM FOLLOW-UP STUDY Saana Paavola, FI

09:00 - 09:00 P0153THE INCIDENCE OF CELIAC DISEASE AMONG PATIENTSWITH GASTROENTEROLOGICAL DISORDERS Svetlana Bykova, RU

09:00 - 09:00 P0154MICRORNAS ARE POTENTIAL EARLY MARKERS OF COELIACDISEASE AND MAY REGULATE THE COELIAC DISEASE-SPECIFIC TRANSCRIPTIONAL CHANGES IN THE SMALLINTESTINE Ineke Tan, NL

09:00 - 09:00 P0155REAL-LIFE PERFORMANCE OF MULTIPLEX CELIACANTIBODY TEST IN THE DIAGNOSIS OF PEDIATRIC CELIACDISEASE Anat Guz Mark, IL

09:00 - 09:00 P0156VOMITING AND NAUSEA IN CELIAC DISEASE: PREVALENCE,ASSOCIATED FACTORS AND RESPONSE TO A GLUTEN-FREE DIET Iida Ahonen, FI

09:00 - 09:00 P0157PERSISTENT SYMPTOMS ARE COMMON AND ASSOCIATEDWITH HEALTH CONCERNS AND DECREASED QUALITY OFLIFE IN ADULT CELIAC DISEASE PATIENTS DIAGNOSED INCHILDHOOD Satu Vuolle, FI




09:00 - 09:00 P0158FUNCTIONAL STATUS OF DUODENAL MUCOSA IN CELIACDISEASE PATIENTS Olga Akhmadullina, RU09:00 - 09:00 P0159NATURAL HISTORY OF CELIAC DISEASE: COMPARISONBETWEEN CHILDHOOD AND ADULT-ONSET DISEASE Hadrien Alric, FR

09:00 - 09:00 P0160THE ASSOCIATIONS OF AGE, SEX AND GENETICS WITH THECLINICAL FEATURES OF CELIAC DISEASE Sara Koskimaa, FI

09:00 - 09:00 P0161ASSOCIATION OF CELIAC DISEASE SEROLOGY STATUSWITH THE INCIDENCE OF HYPOTHYROIDISM AMONGPATIENTS WITH CELIAC AUTOIMMUNITY - A COHORTSTUDY Rachel Gingold-Belfer, IL

09:00 - 09:00 P0162FATIGUE IN NEWLY DIAGNOSED AND UNTREATED CELIACDISEASE – A CONTROLLED STUDY Berit Mære Skjellerudsveen, NO

09:00 - 09:00 P0163GLUTEN IMMUNOGENIC PEPTIDES: DYNAMICS OFEXCRETION IN URINE AFTER LOW LEVELS OF GLUTENINGESTION Laura Coto, ES

09:00 - 09:00 P0165SCREENING FOR ADULT COELIAC DISEASE IN THEGENERAL POPULATION Ina Lervåg Andersen, NO

09:00 - 09:00 P0166PREDICTIVE FACTORS FOR LONG-TERM COMPLICATIONSIN CELIAC DISEASE: A LARGE RETROSPECTIVE STUDYFROM THE CELAC GROUP Hadrien Alric, FR

09:00 - 09:00 P0167IDENTIFICATION OF MARKERS OF OXIDATIVE STRESS INCELIAC DISEASE Ilaria Marsilio, IT

09:00 - 09:00 P0168NUTRITIONAL STATUS AND BODY COMPOSITIONASSESSMENT IN CELIAC DISEASE Daria Maniero, IT

09:00 - 09:00 P0169EXPERIENCES OF A GLUTEN-FREE DIET IN PATIENTS WITHCELIAC DISEASE: A MULTI-NATIONAL SURVEY Lisa Meckley, US

09:00 - 09:00 P0170AUTOIMMUNE GASTRITIS ASSOCIATED WITH COELIACDISEASE: ARE THERE ANY DISTINCTIVE CLINICALFEATURES? Laura Conti, IT

09:00 - 09:00 P0172INCREASED PREVALENCE OF CELIAC DISEASE IN PATIENTSWITH CYSTIC FIBROSIS: A SYSTEMATIC REVIEW ANDMETA–ANALYSIS Marcell Imrei, HU09:00 - 09:00 P0174ADHERENCE TO CELIAC DIAGNOSTIC GUIDELINES:RESULTS FROM THE GERMAN CELIAC REGISTRY (GECER) Sibylle Koletzko, DE

09:00 - 09:00 P0175GENE MUTATION ANALYSIS IN NONAMPULLARYDUODENAL EPITHELIAL TUMORS Shigeki Fukusada, JP

09:00 - 09:00 P0176IMPACT OF EFFICACY AND SAFETY OF DUODENALLAPAROSCOPIC ENDOSCOPIC COOPERATIVE SURGERY (D-LECS) FOR THE TREATMENT OF SUPERFICIAL DUODENALEPITHELIAL TUMOR (SDET) Hiroyuki Aoyagi, JP

09:00 - 09:00 P0177ENDOSCOPIC APPROACH TO DUODENAL ADENOMAS INFAMILIAL ADENOMATOUS POLYPOSIS Joana Lemos Garcia, PT

09:00 - 09:00 P0178SHORT AND LONG-TERM OUTCOME OF COLDPOLYPECTOMY FOR SUPERFICIAL NON-AMPULLARYDUODENAL EPITHELIAL TUMORS Kenichiro Okimoto, JP

09:00 - 09:00 P0179TIMING OF ENTEROSCOPY IN OVERT-OBSCUREGASTROINTESTINAL BLEEDING - A SYSTEMATIC REVIEWAND META-ANALYSIS Ana Catarina Gomes, PT

09:00 - 09:00 P0180QUALITY OF LIFE OUTCOMES IN ANAEMIC PATIENTS WITHSUSPECTED SMALL BOWEL BLEEDING Fintan O'Hara, IE

09:00 - 09:00 P0181VERY HIGH DIAGNOSTIC AND THERAPEUTIC YIELDS OFEMERGENT CAPSULE ENDOSCOPY IN SUSPECTED SMALLBOWEL BLEEDING, IRRESPECTIVE OF CLINICAL GIBLEEDING SCORES Maria Manuela Estevinho, PT

09:00 - 09:00 P0182THE CORRELATION BETWEEN CAPSULE ENDOSCOPY ANDSUBSEQUENT DEVICE ASSISTED ENTEROSCOPY FINDINGSOF SMALL BOWEL VASCULAR LESIONS Caroline Walker, IE

09:00 - 09:00 P0183EFFICACY OF PHARMACOLOGICAL TREATMENT FORTREATING SMALL BOWEL GASTROINTESTINALANGIODYSPLASIAS (GIADS)-RELATED BLEEDING: ASYSTEMATIC REVIEW AND META-ANALYSIS Paraskevas Gkolfakis, BE




E-Poster Session

09:00 – 19:00 Poster ExhibitionH. pylori

09:00 - 09:00 P0092THE ROLE OF HELICOBACTER PYLORI INFECTION INMICROBIOME VARIABILITY IN FUNCTIONAL DYSPEPSIA INKARACHI, PAKISTAN Hareem Rehman, PK

09:00 - 09:00 P0093IODINE SUPPLY OF CHILDREN WITH GASTRIC PATHOLOGYASSOCIATED WITH H. PYLORI Tetiana Zimnytska, UA

09:00 - 09:00 P0094HELICOBACTER PYLORI INFECTION IS ASSOCIATED WITHCAROTID INTIMA AND MEDIA THICKENING. A SYSTEMATICREVIEW AND META-ANALYSIS Orsolya Anna Simon, HU

09:00 - 09:00 P0095HELICOBACTER PYLORI INFECTION INHIBITS EXPRESSIONAND FUNCTION OF THE POLYCOMB REPRESSIVE COMPLEX2 Rebecca FitzGerald, IE

09:00 - 09:00 P0096CORRELATION BETWEEN THE INTENSITY OFHELICOBACTER PYLORI COLONIZATION AND SEVERITY OFGASTRITIS: RESULTS OF A PROSPECTIVE STUDY Salma Souissi, TN

09:00 - 09:00 P0097THE ANATOMIC DISTRIBUTION AND FREQUENCY OFPREMALIGNANT LESIONS OF STOMACH RELATED TOHELICOBACTER PYLORI INFECTION IN MIDDLE-AGED ANDOLDER PATIENTS Cundullah Torun, TR

09:00 - 09:00 P0098ASSESSMENT OF THE ENDOSCOPIC KYOTOCLASSIFICATION IN THE DIAGNOSIS OF HELICOBACTERPYLORI INFECTION fatma Ben Farhat, TN

09:00 - 09:00 P0099THE PATIENT EXPERIENCE AND CLINICAL EFFICACY OF ANOVEL VIRTUAL C13UBT SERVICE AT AN IRISH TERTIARYREFERRAL CENTER DURING THE COVID 19 PANDEMIC Sandeep Sihag, IE

09:00 - 09:00 P0100NEW RAPID H.PYLORI BLOOD TEST BASED ON FLID ANDCAG A ANTIBODIES DETECTION Christian Schulz, DE

09:00 - 09:00 P0101FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPYIN EUROPE: RESULTS FROM 30,000 CASES OF THEEUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG) Olga P. Nyssen, ES09:00 - 09:00 P0102EMPIRICAL FIRST-LINE TREATMENT USE ANDEFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) Olga Perez Nyssen, ES

09:00 - 09:00 P0103EXPERIENCE WITH SINGLE CAPSULE BISMUTHQUADRUPLE THERAPY IN 5,000 PATIENTS FROM THEEUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) Olga P. Nyssen, ES

09:00 - 09:00 P0104BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATAOF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT(HP-EUREG) Ángeles Pérez-Aísa*, ES

09:00 - 09:00 P0105ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTERPYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2020:ANALYSIS OF THE EUROPEAN REGISTRY ON H.PYLORI MANAGEMENT (HP-EUREG) Luis Bujanda, ES

09:00 - 09:00 P0106EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN426 PATIENTS FROM THE EUROPEAN REGISTRY ON H.PYLORI MANAGEMENT (HP-EUREG) Olga P. Nyssen, ES

09:00 - 09:00 P0107NON-BISMUTH QUADRUPLE CONCOMITANT TREATMENTFOR H. PYLORI ERADICATION: SYSTEMATIC REVIEW ANDMETA-ANALYSIS Olga P. Nyssen, ES

09:00 - 09:00 P0108ASSESSMENT OF FIRST-LINE TREATMENT IN GREECE:DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTERPYLORI MANAGEMENT (HP-EUREG) Theodore Rokkas, GR

09:00 - 09:00 P0110LEVOFLOXACIN + TETRACYCLINE QUADRUPLE REGIMENFOR ERADICATION OF HELICOBACTER PYLORI: AMULTICENTER MULTINATIONAL RANDOMIZED CLINICALTRIAL Pezhman Alavi Nejad, IR




09:00 - 09:00 P0111DIAGNOSIS, TREATMENT PATTERNS, AND EFFECTIVENESSOF HELICOBACTER PYLORI ERADICATION IN CHINA: STUDYDESIGN FOR A RETROSPECTIVE REAL-WORLD STUDY Fang Zhou, CN09:00 - 09:00 P0112FIRST LINE ERADICATION THERAPY FOR HELICOBACTERPYLORI GUIDED BY MOLECULAR ANALYSIS OF GENOTYPICRESISTANCES ON STOOLS: A PILOT STUDY Giuseppe Losurdo, IT

09:00 - 09:00 P0113ESOMEPRAZOLE VERSUS VONOPRAZAN – BASEDTHERAPIES FOR HELICOBACTER PYLORI ERADICATION: ARETROSPECTIVE CLINICAL STUDY Thomas J. Borody, AU

09:00 - 09:00 P0114CHARACTERISTICS OF PATIENTS WITH HELICOBACTERPYLORI INFECTION WHO STOP CLINICAL SURVEILLANCE INGASTROENTEROLOGY CLINICS Inés Ariño Pérez, ES

09:00 - 09:00 P0115MISTAKES IN DIAGNOSTIC AND THERAPEUTICMANAGEMENT OF HELICOBACTER PYLORI INFECTION INTHE LAST DECADE Inés Ariño Pérez, ES

09:00 - 09:00 P0116FIRST-LINE HELICOBACTER PYLORI ERADICATION RATE INDAILY CLINICAL PRACTICE IN TWO SPANISH MEDICALCENTERS: 2010-2019 Inés Ariño Pérez, ES

09:00 - 09:00 P0117MANAGEMENT OF HELICOBACTER PYLORI INFECTIONDURING THE LAST DECADE: TEMPORAL PRESCRIPTIONTRENDS FOR THE FIRST-LINE OF NON-ALLERGICPATIENTS AND ITS ADEQUACY TO CLINICAL GUIDELINES Inés Ariño Pérez, ES

09:00 - 09:00 P0118EFFICACY AND SAFETY OF VONOPRAZAN-BASEDQUADRUPLE REGIMENS FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH PEPTIC ULCER:A POOLED ANALYSIS OF TWO PHASE III TRIALS Xiaohua Hou, CN

09:00 - 09:00 P0119LONG-TERM EFFECTS OF THE ERADICATION OF HELICOBACTER PYLORI ON METABOLIC PARAMETERS,DEPENDING ON SEX, IN SOUTH KOREA Jaehyung Park, KR

09:00 - 09:00 P0124EVALUATION OF FIRST-LINE BISMUTH CONTAINING 7-DAYQUINTET THERAPY FOR HELICOBACTER PYLORIERADICATION Yeji Choi, KR

09:00 - 09:00 P0125LONG-TERM RISK OF UPPER GASTROINTESTINALBLEEDING AFTER HELICOBACTER PYLORI ERADICATION: APOPULATION-BASED COHORT STUDY Fang Jiang, CN09:00 - 09:00 P0126PRIMARY RESISTANCE OF HELICOBACTER PYLORI TOCLARITHROMYCIN IN TUNISIA Manel Moalla, TN

09:00 - 09:00 P0127IMPACT OF LACTOBACILLUS REUTERI SUPPLEMENTATIONON CLARITHROMYCIN-BASED SEQUENTIAL THERAPY FORHELICOBACTER PYLORI ERADICATION Adeel Rahat, PK

09:00 - 09:00 P0128EUPATILIN IMPROVES THE STATE OF GASTRIC MUCOSALMICROCIRCULATION THROUGH THE INFLUENCE ONENDOTHELIAL NITRIC OXIDE SYNTHASE IN PATIENTSWITH H. PYLORI-ASSOCIATED CHRONIC GASTRITIS ANDCONCOMITANT TYPE 2 DIABETES MELLITUS Igor Skrypnyk, UA

09:00 - 09:00 P0129INTERACTION BETWEEN HOST GENETICS AND HELICOBACTER PYLORI IN GASTRIC CANCER: A GENOME-WIDE ASSOCIATION STUDY IN THE KOREAN POPULATION Cheol-Min Shin, KR

E-Poster Session

09:00 – 19:00 Poster ExhibitionIBD

09:00 - 09:00 P0221FUNGAL MICROBIOTA IN THE ILEAL MUCOSA OF PATIENTSWITH CROHN’S DISEASE Maya Olaisen, NO

09:00 - 09:00 P0223EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS Martina Sciberras, MT

09:00 - 09:00 P0224INFLAMMATORY BOWEL DISEASE NEW-ONSET DURINGSECUKINUMAB THERAPY: REAL-WORLD DATA FROM ATERCIARY CENTRE Asunción Ojeda Gómez, ES

09:00 - 09:00 P0225PATHOLOGIC INVOLVEMENT OF THE FARNESOID XRECEPTOR/FIBROBLAST GROWTH FACTOR 19 AXIS TO THECROHN’S DISEASE EARLY POSTSURGICAL RECURRENCE Roger Suau, ES

09:00 - 09:00 P0226IMPAIRED LUMINAL CONTROL OF INTESTINALMACROPHAGE MATURATION IN PATIENTS WITHULCERATIVE COLITIS DURING REMISSION Lujain Maasfeh, SE




09:00 - 09:00 P0227THERAPEUTIC POTENTIAL OF TNK1 IN PREVENTION ANDHEALING OF INTESTINAL BARRIER BREACH Hongxia Li, DE09:00 - 09:00 P0228THE VARIATIONS OF GUT MICROBIOME FROM ULCERATIVECOLITIS PATIENTS ARE NOT AS GREAT AS EXPECTED Chen Li, CN

09:00 - 09:00 P0229ASSOCIATION BETWEEN SERUM VITAMIN D METABOLITESAND HEMATOLOGICAL MARKERS OF INFLAMMATION INPATIENTS WITH INFLAMMATORY BOWEL DISEASE Aysegül Aksan, DE

09:00 - 09:00 P0230PROTEOMIC AND LIPIDOMIC ANALYSIS REVEALALTERATIONS OF COMPLEMENT ACTIVATION AND LIPIDMETABOLISM IN PERIPHERAL BLOOD MONONUCLEARCELLS OF PATIENTS WITH INFLAMMATORY BOWELDISEASE Sara Notararigo, ES

09:00 - 09:00 P0231DOES BIOTIN DEFICIENCY PLAY A ROLE IN IBDPATHOGENESIS? PRELIMINARY RESULTS OF A CROSS-SECTIONAL STUDY Aysegül Aksan, DE

09:00 - 09:00 P0232IS VITAMIN D DEFICIENCY RELATED TO FATMALABSORPTION OR INFLAMMATION IN INFLAMMATORYBOWEL DISEASE? PRELIMINARY RESULTS FROM THE FAT-D STUDY Aysegül Aksan, DE

09:00 - 09:00 P0233SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORINGEPITHELIAL INTEGRITY AND MITIGATING COLITIS IN ACHRONIC DSS MODEL Priya Handa, US

09:00 - 09:00 P0234URINARY METABOLOME IN NEWLY DIAGNOSEDTREATMENT-NAÏVE CROHN’S DISEASE PATIENTS:RESULTS FROM THE IBDOMICS STUDY Laila Aldars-García, ES

09:00 - 09:00 P0235BIFIDOBACTERIUM LONGUM NCC3001 PROMOTESCOLONIC TISSUE REPAIR VIA PHOSPHOLIPIDMETABOLISM AND THE PURINE SALVAGE PATHWAY INEXPERIMENTAL CHRONIC COLITIS Maria Vicario, CH

09:00 - 09:00 P0236CORRELATION OF MUCOSAL MICROBIAL DIVERSITY WITHMARKER OF INFLAMMATION IN CROHN’S DISEASE Amit Kumar Dutta, IN

09:00 - 09:00 P0237ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OFPERSISTENT HISTOLOGICAL ACTIVITY DESPITEENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITHBIOLOGICS Vedran Tomasic, HR09:00 - 09:00 P0238HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZELUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS Sarit Cohen-Kedar, IL

09:00 - 09:00 P0239UNTARGETED SERUM METABOLOME IN LONGITUDINALCROHN'S DISEASE (CD) COHORT ENROLLED DURINGREMISSION SHOWS STRONG INDIVIDUALIZED SIGNATUREAND CD-ASSOCIATED SIGNALS THAT ARE MAINTAINEDALSO IN PATIENTS WHO NORMALIZED THEIR FECALCALPROTECTIN Nina Levhar, IL

09:00 - 09:00 P0240MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORYBOWEL DISEASES (IBD) Hanan Abu-Taha, IL

09:00 - 09:00 P0241ROLE OF NOTCH PATHWAY IN CROHN'S DISEASE:IMPLICATIONS IN FIBROSIS Cristina Bauset, ES

09:00 - 09:00 P0242CROHN’S DISEASE ASSOCIATED FIBROSIS MODULATESTHE EXPRESSION OF COLLAGEN RECEPTORS Cristina Bauset, ES

09:00 - 09:00 P0243SUCCINATE RECEPTOR (SUCNR1) MEDIATES LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS INDUCED BY TNFΑ Cristina Bauset, ES

09:00 - 09:00 P0244PATIENTS WITH NEWLY DIAGNOSED FISTULIZINGPERIANAL CROHN'S DISEASE HAVE DISTINCT MICROBIALSIGNATURE Henit Yanai, IL

09:00 - 09:00 P0245SINGLE CELL RNA SEQUENCING IDENTIFIES DISTINCTINTESTINAL INFLAMMATION PATTERNS BETWEENPRIMARY SCLEROSING CHOLANGITIS-ASSOCIATEDCOLITIS AND ULCERATIVE COLITIS Werna T. C. Uniken Venema, NL

09:00 - 09:00 P0246CELLULAR IMMUNE RESPONSE TRIGGERED BYGRANULOCYTOAPHERESIS IN ULCERATIVE COLITISPATIENTS UNDER BIOLOGICAL TREATMENT Esteban Sáez González, ES




09:00 - 09:00 P0247EXPRESSION PROFILING OF WNT PATHWAY GENES INCOLON BIOPSIES OF PATIENTS WITH ULCERATIVE COLITISAND CROHN’S DISEASE Chenggang Lu, US09:00 - 09:00 P0248FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINALMUCOSAL HEALTH VIA HIF1Α-INDUCED EPITHELIALPRODUCTION OF IL-18 Raphael Fagundes Rosa, NL

09:00 - 09:00 P0249MICRONUTRIENT DEFICIENCY IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE- NEGLECTED ENTITY? Georgiana- Emmanuela Gîlcă-Blanariu, RO

09:00 - 09:00 P0250STRUCTURAL ALTERATIONS OF COLONIC MICROVILLI INMICROSCOPIC COLITIS AND RESTORATION BY ORALBUDESONIDE Danila Guagnozzi, ES

09:00 - 09:00 P0251INTESTINAL FIBROBLASTS FROM CROHN’S DISEASEPATIENTS EXPRESSED INCREASED AUTOPHAGY ANDDECREASED APOPTOSIS Cristina Bauset, ES

09:00 - 09:00 P0252IMMUNOLOGICAL MECHANISMS BEHIND RESISTANCE TOBIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASEMOLECULAR RESISTANCE TO BIOLOGICAL THERAPY ININFLAMMATORY BOWEL DISEASE Øystein Kittel Moe, NO

09:00 - 09:00 P0253IMPACT OF EXCLUSIVE ENTERAL NUTRITION ONINTESTINAL HOMEOSTASIS IN A MOUSE MODEL OFCOLITIS Kawthar Boumessid, FR

09:00 - 09:00 P0254ROLE OF P2X7 IN INTESTINAL FIBROSIS ANDINFLAMMASOME ACTIVATION: RELEVANCE IN CROHN´SDISEASE Cristina Bauset, ES

09:00 - 09:00 P0255COLONIC MUCOSA BARRIER DEFECTS IN COLLAGENOUSAND ISCHEMIC COLITIS Stratigoula Sakellariou, GR

09:00 - 09:00 P0256INVOLVEMENT OF MACROPHAGES IN THE ACTIVATION OFMESENCHYMAL EPITHELIAL TRANSITION IN CROHN'SDISEASE: ROLE OF THE MICROENVIRONMENT Cristina Bauset, ES

09:00 - 09:00 P0257CHARACTERIZATION OF CYTOKINE AND DRUGCONCENTRATIONS IN SERUM, MUCOSA AND FAECESDURING INDUCTION TREATMENT OF SEVERE ULCERATIVECOLITIS WITH INFLIXIMAB Joep van Oostrom, NL09:00 - 09:00 P0258VOLUNTARY EXERCISE COMBINED WITH CONCOMITANTALKALINE PHOSPHATASE TREATMENT RESOLVESEXPERIMENTAL COLITIS IN OBESE MICE BY IMPROVINGCOLONIC MICROCIRCULATION AND ATTENUATINGINFLAMMATION, OXIDATIVE STRESS, AND RESTORATIONOF ADIPONECTIN/LEPTIN RATIO Marcin Magierowski, PL

09:00 - 09:00 P0259EVALUATION OF THE HETEROGENEITY OF THEMANAGEMENT AND THE COMPLICATIONS OF CROHN’SDISEASE IN CATALONIA. A POPULATION QUALITY CARESTUDY Eduard Brunet, ES

09:00 - 09:00 P0260INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TOSPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU(ENEIDA REGISTRY) Ana Gutierrez Casbas, ES

09:00 - 09:00 P0261FEAR OF COVID-19 AMONG PERSONS WITH IBDACCORDING TO EMPLOYMENT STATUS, EDUCATIONALBACKGROUND AND RESIDENTIAL SETTING, AS COMPAREDTO PERSONS WITH OTHER GASTROINTESTINALCONDITIONS Bobby Lo, DK

09:00 - 09:00 P0263MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE INIBD PATIENTS Martina Sciberras, MT

09:00 - 09:00 P0264VACCINATION STRATEGIES IN INFLAMMATORY BOWELDISEASE PATIENTS: PERSPECTIVE OF PHYSICIANS ANDPATIENTS. Rocío Ferreiro-Iglesias, ES

09:00 - 09:00 P0265SARS-COV-2 VACCINE ACCEPTANCE AMONGGASTROENTEROLOGIST AND INFLAMMATORY BOWELDISEASE PATIENTS: VACUNEII PROJECT Alejandro Hernandez Camba, ES

09:00 - 09:00 P0266ADHERENCE TO VACCINATION RECOMMENDATIONS ININFLAMMATORY BOWEL DISEASE PATIENT: A LONG WAYFOR IMPROVING. Rocío Ferreiro-Iglesias, ES




09:00 - 09:00 P0267INFLAMMATORY BOWEL DISEASE (IBD) ANDIMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSISOF COVID-19. RESULTS FROM THE ENEIDA PROJECT OFGETECCU Yamile Zabana Abdo, ES09:00 - 09:00 P0268COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTORBUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASETHE RISK OF COVID-19 IN INFLAMMATORY BOWELDISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROLSTUDY Yamile Zabana Abdo, ES

09:00 - 09:00 P0269IMPACT OF OVERWEIGHT AND OBESITY ON DISEASEOUTCOME IN THE PEDIATRIC SWISS IBD COHORT Thea von Graffenried, CH

09:00 - 09:00 P0270THE NATURAL DISEASE COURSE OF CROHN’S DISEASE INA DANISH POPULATION-BASED INCEPTION COHORT WITHMORE THAN FIFTY YEARS OF FOLLOW-UP Johan Burisch, DK

09:00 - 09:00 P0271LARGE DIFFERENCES IN IBD CARE AND EDUCATIONACROSS EUROPE, FIRST RESULTS OF THE PAN-EUROPEANVIPER SURVEY Radislav Nakov, BG

09:00 - 09:00 P0272THE NATURAL DISEASE COURSE OF ULCERATIVE COLITISIN A DANISH POPULATION-BASED INCEPTION COHORTWITH MORE THAN FIFTY YEARS OF FOLLOW-UP Johan Burisch, DK

09:00 - 09:00 P0273ABNORMAL FRAILTY SCREENING IS INDEPENDENTLYASSOCIATED WITH BOTH ALL-CAUSE AND DISEASE-RELATED HOSPITAL ADMISSIONS IN OLDER PATIENTSWITH INFLAMMATORY BOWEL DISEASES Jeroen P.W. Maljaars, NL

09:00 - 09:00 P0274THE ASSOCIATION BETWEEN FAECAL SHORT-CHAIN FATTYACIDS CONCENTRATION AND THE CLINICAL ACTIVITY OFULCERATIVE COLITIS AND CROHN’S DISEASE -PRELIMINARY STUDY Olga Kaczmarczyk, PL

09:00 - 09:00 P0275SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS ARISK FACTOR FOR SEVERE COVID-19: DATA FROM THESICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE(SN-IBD) Fabio Salvatore Macaluso, IT

09:00 - 09:00 P0276CHANGE IN URGENCY AMONG CROHN’S DISEASEPATIENTS: ANALYSES FROM THE SPARC IBD James D Lewis, US

09:00 - 09:00 P0277VACCINATION AGAINST SARS-COV-2 IN IBD: ACCEPTANCEAND CONCERNS IN A COHORT FROM SOUTHERN ITALY Federica Crispino, IT09:00 - 09:00 P0278INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION INPATIENTS WITH INFLAMMATORY BOWEL DISEASE INSOUTHERN SPAIN (ANDALUSIA) Beatriz Gros Alcalde, ES

09:00 - 09:00 P0279RISK OF TYPE 2 DIABETES AFTER SMALL AND LARGEBOWEL RESECTIONS: A NATIONWIDE COHORT STUDY OFPATIENTS WITH INFLAMMATORY BOWEL DISEASE Kristine Højgaard Allin, DK

09:00 - 09:00 P0280INCIDENCE, CLINICAL PRESENTATION, AND SEVERITY OFSARS-COV-2 INFECTION IN INFLAMMATORY BOWELDISEASE PATIENTS IN THE “SECOND AND THE THIRDWAVE” OF INFECTION Alicia Algaba, ES

09:00 - 09:00 P0281DISEASE SEVERITY AND EFFICACY OF BIOLOGICALTREATMENT IN PAEDIATRIC AND ADULT INFLAMMATORYBOWEL DISEASE Mikkel Malham, DK

09:00 - 09:00 P0282ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASEAND SPONDYLOARTHROPATHIES: FINDINGS FROM ANATIONWIDE STUDY IN SWEDEN Sarita Shrestha, SE

09:00 - 09:00 P0283ASSOCIATION BETWEEN DAILY INTAKE OF ADDED SUGARAND DISEASE ACTIVITY OR QUALITY OF LIFE IN PATIENTSWITH INFLAMMATORY BOWEL DISEASE Ioanna Pefkianaki, GR

09:00 - 09:00 P0284CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADICINFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERAOF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROMTHE ENEIDA REGISTRY Carlos González-Muñoza, ES

09:00 - 09:00 P0285ANTIOXIDANT VITAMINS AND ELECTROLYTES INCREASEDINTAKE IS ASSOCIATED WITH LOWER DISEASE ACTIVITYAND BETTER QUALITY OF LIFE IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Ioanna Pefkianaki, GR

09:00 - 09:00 P0286IMPACT OF INFLAMMATORY BOWEL DISEASES ON THEPHENOTYPE AND SEVERITY OFSPONDYLOARTHROPATHIES AND PSORIASIS - ASYSTEMATIC REVIEW WITH META-ANALYSIS Mohamed Attauabi, DK




09:00 - 09:00 P0287IMPACT OF INFLAMMATORY BOWEL DISEASES ON THEPHENOTYPE AND SEVERITY OF PRIMARY SCLEROSINGCHOLANGITIS - A SYSTEMATIC REVIEW WITH META-ANALYSIS Mohamed Attauabi, DK09:00 - 09:00 P0288CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWELDISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME Marta Vernero, IT

09:00 - 09:00 P0289MULTIPLE SCLEROSIS PREVALENCE IN HIGHER INCROHN’S DISEASE PATIENTS THAN IN GENERALPOPULATION, BUT DOES NOT INFLUENCE INFLAMMATORYBOWEL DISEASE OUTCOME Marta Vernero, IT

09:00 - 09:00 P0290NEITHER INFLAMMATORY BOWEL DISEASE NORIMMUNOSUPPRESSANTS ARE ASSOCIATED WITH ANINCREASED RISK FOR SEVERE COVID-19. ANOBSERVATIONAL DUTCH COHORT-STUDY Lennard Gilissen, NL

09:00 - 09:00 P0291HIGH DISEASE BURDEN OF CROHN'S DISEASE (CD) IN ALATIN AMERICAN IBD REFERENCE CENTER Alicia Maria Sambuelli, AR

09:00 - 09:00 P0292FACTORS INDEPENDENTLY ASSOCIATED WITH FATIGUE INIBD: RESULTS FROM THE BASELINE DATASET OF THEPREDICCT STUDY Lauranne Derikx

09:00 - 09:00 P0293THE NATURAL HISTORY OF COVID-19 IN PATIENTS WITHIBD: A NATIONWIDE STUDY BY THE HELLENIC SOCIETYFOR THE STUDY OF IBD Georgios Kokkotis, GR

09:00 - 09:00 P0294PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOULDBE VACCINATED AGAINST PNEUMOCOCCUS ANDINFLUENZA DESPITE IMMUNOSUPPRESSIVE THERAPY Dóra Dohos, HU

09:00 - 09:00 P0295PREDICCT COHORT BASELINE HABITUAL NUTRIENTINTAKE BY IBD PATIENTS Janet Kyle

09:00 - 09:00 P0296PATIENT PERCEPTIONS ABOUT CAUSES OF FLARE ININFLAMMATORY BOWEL DISEASE (IBD): RESULTS FROMTHE BASELINE DATASET OF THE PREDICCT STUDY Spyridon (Spyros) Siakavellas

09:00 - 09:00 P0297TRANSFORMATION OF FECAL MICROBIOTA COMPOSITIONDUE TO BOWEL PREPARATION WITH MAGNESIUM-OXIDAND SODIUM PICOSULFATE AMONGST PATIENTS WITHINFLAMMATORY BOWEL DISEASE Mariann Rutka, HU09:00 - 09:00 P0298NON-IBD CHANGES IN THE ORAL MUCOSA IN PATIENTSWITH INFLAMMATORY BOWEL DISEASES. A CROSSSECTIONAL STUDY IN POLISH PATIENTS Rafał Filip, PL

09:00 - 09:00 P0299A TERTIARY MULTICENTER COHORT OF PATIENTS WITHCHRONIC INTESTINAL PSEUDO-OBSTRUCTION ANDCROHN’S DISEASE: A RARE ASSOCIATION WITH A HIGHPREVALENCE OF MONOGENIC DISORDERS Flore De Castelbajac, FR

09:00 - 09:00 P0300PRESENCE OF THE HLA-DQA1*05 ALLELE AND ITSASSOCIATION WITH THE SECONDARY LOSS OF RESPONSETO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWELDISEASE Isabela Angulo McGrath, ES

09:00 - 09:00 P0301MICRORNA PROFILING ON THE LEVELS OF COLON TISSUEAND EPITHELIAL CELL-POPULATIONS IN PATIENTS WITHACTIVE AND INACTIVE ULCERATIVE COLITIS Ruta Inciuraite, LT

09:00 - 09:00 P0302INFLAMMATORY BOWEL DISEASE PATIENTS WITH A FIRSTDEGREE RELATIONSHIP BEAR STRIKING SIMILARITIES: ARETROSPECTIVE SINGLE CENTER OBSERVATIONALSTUDY Afroditi Mpitouli, GR

09:00 - 09:00 P0303THE EFFECT OF PHENOTYPE AND GENOTYPE ON THEPLASMA PROTEOME IN PATIENTS WITH INFLAMMATORYBOWEL DISEASE Arno R. Bourgonje, NL

09:00 - 09:00 P0304THE APA I POLYMORPHISM IN THE VITAMIN D RECEPTORGENE IS ASSOCIATED WITH A STRICTURING BEHAVIOUR INCROHN´S DISEASE PATIENTS Cristina Bauset, ES

09:00 - 09:00 P0305PECULIARITIES OF FATTY ACID PROFILES OFERYTHROCYTE MEMBRANES AND BLOOD SERUMDEPENDING ON ACTIVITY RATE OF CROHN’S DISEASE Margarita Vitalievna Kruchinina, RU




09:00 - 09:00 P0306COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITHLOWER DISABILITY THAN PARTIAL MUCOSAL HEALING INCROHN’S DISEASE: A PROSPECTIVE MULTICENTRICSTUDY. Clara Yzet, FR09:00 - 09:00 P0307TELEDERMA: TELEMEDICINE SYSTEM FORDERMATOLOGICAL LESIONS IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Marta Ramos Alonso, ES

09:00 - 09:00 P0308IMPORTANCE OF IBD BIOPSY PROTOCOL IN CLINICALPRACTICE: ANALYSES COMPARING TWO BRITISHPATIENTS’ COHORTS Ehab Abdelmalek, UK

09:00 - 09:00 P0309MISDIAGNOSIS IN PAEDIATRIC INFLAMMATORY BOWELDISEASE – FINDINGS FROM A REAL-WORLD STUDY INEUROPE Fritha Hennessy

09:00 - 09:00 P0310PRACTICAL DEEP LEARNING TOOL FOR SCORING OFULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRALREADING Milagros Henkel, CA

09:00 - 09:00 P0311CHROMOENDOSCOPY FOR DETECTING DYSPLASIA IN IBDPATIENTS: PRELIMINARY RESULTS FROM A SINGLE-CENTRE, PROSPECTIVE OBSERVATIONAL STUDY Federica Borrelli de Andreis, IT

09:00 - 09:00 P0312AI AUTOMATED WORKFLOW FOR IMPROVING DETECTIONAND SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITYUNDER MULTIPLE SCORING SYSTEMS Milagros Henkel, CA

09:00 - 09:00 P0313IRON DEFICIENCY ANAEMIA IN INFLAMMATORY BOWELDISEASE: DIAGNOSIS, QUALITY OF LIFE AND IRONTREATMENT PREFERENCES AMONG EUROPEANPATIENTS Diana Francis

09:00 - 09:00 P0314CORRELATION OF EX VIVO MUCOSAL CYTOKINE PROFILESWITH CLINICAL AND ENDOSCOPIC SCORES IN ULCERATIVECOLITIS Vesna Eraković Haber, HR

09:00 - 09:00 P0315IMPACT OF INFLAMMATORY BOWEL DISEASE IN PEDIATRICPATIENTS AND THEIR FAMILIES ACCORDING TO DISEASECONTROL Laura María Palomino Pérez, ES

09:00 - 09:00 P0316THE USE OF PANENTERIC CROHN’S CAPSULES TO ASSESSTREATMENT OUTCOME OF VEDOLIZUMAB IN IBDPATIENTS: A 1 YEAR PROOF OF CONCEPT STUDY Matthew Johnson09:00 - 09:00 P0317THE OUTCOME OF COLONOSCOPIC SURVEILLANCE ANDSURGERY IN A COHORT OF INFLAMMATORY BOWELDISEASE PATIENTS WHO DEVELOPED COLO-RECTALCANCER OVER A 12 YEAR REVIEW PERIOD AT A DISTRICTGENERAL HOSPITAL John Wye, UK

09:00 - 09:00 P0318HEAVY PSEUDOPOLYP BURDEN IN INFLAMMATORY BOWELDISEASE PREDICTS MORE SEVERE DISEASE: AMULTICENTRE COHORT STUDY Andrea Vella Baldacchino, MT

09:00 - 09:00 P0319SENSITIVITY AND SPECIFICITY OF DIFFERENTPARAMETERS FOR THE DIAGNOSIS AND DIFFERENTIATIONOF IRON DEFICIENCY IN INFLAMMATORY BOWEL DISEASE Aysegül Aksan, DE

09:00 - 09:00 P0320ANCA-ASSOCIATED VASCULITIS IN PATIENTS WITHINFLAMMATORY BOWEL DISEASES: ONE OF THEPREDICTORS OF SEVERE COURSE AND REASONS FOR NON-RESPONSE TO BASIC THERAPY Gulustan Babayeva, AZ

09:00 - 09:00 P0322PLATELET-TO-LYMPHOCYTE RATIO INDEX: STILL NOTABOVE FECAL CALPROTECTIN FOR NON-INVASIVEASSESSMENT OF ENDOSCOPIC ACTIVITY IN ULCERATIVECOLITIS Vítor Macedo Silva, PT

09:00 - 09:00 P0323PREVALENCE AND RISK FACTORS FOR MALIGNANCY ININFLAMMATORY BOWEL DISEASE Maria Capilla Lozano, ES

09:00 - 09:00 P0324THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FORASSESSING DISABILITY IN INFLAMMATORY BOWELDISEASE PATIENTS: VALIDATION OF THE GREEK VERSION Olga Giouleme, GR

09:00 - 09:00 P0325CORRELATION OF THE FIRST LATERAL FLOW-BASEDPOINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITHTHE REFERENCE ELISA TECHNIQUE M. Begoña Ruiz-Argüello, ES




09:00 - 09:00 P0326THERAPEUTIC DRUG MONITORING: PERFORMANCE OFTHE FIRST LATERAL FLOW-BASED POINT OF CARE TESTFOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGERPRICK Amagoia Ametzazurra, ES09:00 - 09:00 P0327NON-INVASIVE BIOMARKERS OF TYPE III COLLAGENCROSS-LINKING REFLECT FIBROLYSIS IN CROHN'SDISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR Martin Pehrsson, DK

09:00 - 09:00 P0328PERFORMANCE OF SCREENING STRATEGIES FOR LATENTTUBERCULOSIS INFECTION IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE: RESULTS FROM THEENEIDA REGISTRY OF GETECCU Sabino Riestra, ES

09:00 - 09:00 P0329DIFFERENCES IN DIRECT HEALTHCARE COST UTILIZATIONIN THE FIRST YEAR OF IBD DIAGNOSIS: A BINATIONALSTUDY Hee Seung Hong, KR

09:00 - 09:00 P0330TELEMEDICINE IS AN EFFECTIVE TOOL TO MONITORDISEASE ACTIVITY IN IBD PATIENTS IN THE COVID-19 ERA:A SINGLE CENTRE EXPERIENCE BASED ON OBJECTIVEDATA Anita Busacca, IT

09:00 - 09:00 P0331ULTRASONOGRAPHIC SCORES FOR CROHN’S DISEASEACTIVITY ASSESSMENT – STILL LAG BEHIND CEUS Marta Freitas, PT

09:00 - 09:00 P0332SMALL-BOWEL ANGIOECTASIA: DO THE FEATURES ANDAPPROACH REALLY MATTER? Maria Manuela Estevinho, PT

09:00 - 09:00 P0333ASSOCIATION OF ENDOSCOPIC WITH HISTOLOGICREMISSION IN PATIENTS WITH INFLAMMATORY BOWELDISEASE IN CLINICAL REMISSION TREATED WITH ANTI-TNFA AGENTS Afroditi Mpitouli, GR

09:00 - 09:00 P0334CAN DYSPLASIA SURVEILLANCE BE BETTER TARGETED BYUSING FAECAL CALPROTECTIN MEASUREMENTS INULCERATIVE COLITIS? Anna-Maija Puolanne, FI

09:00 - 09:00 P0335COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGHLEVELS BETWEEN POINT-OF-CARE TESTING ANDCURRENT STANDARD OF CARE (ENZYME LINKEDIMMUNOSORBENT ASSAY) IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Ilaria Marsilio, IT

09:00 - 09:00 P0336PEDIATRIC INFLAMMATORY BOWEL DISEASE AFFECTS THEPATIENTS AND THEIR FAMILIES IN DIFFERENT WAYSDEPENDING ON THE AGE AT DIAGNOSIS Marta Velasco Rodríguez-Belvís, ES09:00 - 09:00 P0337INCIDENCE AND RISK FACTORS FOR NEOPLASIA ININFLAMMATORY BOWEL DISEASE Joana Lemos Garcia, PT

09:00 - 09:00 P0338SERIOUS ADVERSE EVENTS IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE: WHO IS MOST AT RISK? Daniel Tassone, AU

09:00 - 09:00 P0339IMPROVEMENT IN PATIENT ACTIVATION MEASURE (PAM)IS SEEN FOLLOWING A FOCUSED FRAMEWORK OFEDUCATION IN A NEWLY DIAGNOSED INFLAMMATORYBOWEL DISEASE COHORT Lovesh Dyall

09:00 - 09:00 P0340THE IBD DISK IS WELL CORRELATED WITH ENDOSCOPICAND BIOMARKER EVIDENCE OF INFLAMMATION INCROHN'S DISEASE PATIENTS Eran Zittan, IL

09:00 - 09:00 P0341SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGENREMODELING PREDICT AND MONITOR INFLIXIMABTREATMENT RESPONSE IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Marta Sorokina Alexdóttir, DK

09:00 - 09:00 P0342SERUM LEVELS OF INFLIXIMAB AND ADALIMUMABBIOSIMILARS CAN BE MEASURED EQUIVALENTLY TOORIGINATOR DRUGS BY QUANTUM BLUE RAPID TESTINGAS TOOL FOR THERAPEUTIC DRUG MONITORING Leslie Anchling, CH

09:00 - 09:00 P0343BIOMARKERS REFLECTING EXTRACELLULAR MATRIXTURNOVER AND INFLAMMATION CAN BE USED TOMONITOR DISEASE ACTIVITY AND TREATMENT RESPONSEIN PATIENTS WITH CROHN’S DISEASE UNDERGOINGINFLIXIMAB INDUCTION THERAPY Marta Sorokina Alexdóttir, DK

09:00 - 09:00 P0344TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTSAND THE TYPE IV COLLAGEN FORMATION/DEGRADATIONRATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING(MONTREAL B2) CROHN'S DISEASE Arno R. Bourgonje, NL

09:00 - 09:00 P0345TYPE IV COLLAGEN FORMATION/DEGRADATION RATIOPREDICTS RESPONSE TO INFLIXIMAB INDUCTIONTHERAPY IN PATIENTS WITH ULCERATIVE COLITIS Arno R. Bourgonje, NL




09:00 - 09:00 P0346INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITHRESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’SDISEASE Jose Luis Rueda García, ES09:00 - 09:00 P0347COMPARATIVE ASSESSMENT C-REACTIVE PROTEINBETWEEN A POINT-OF-CARE TESTING AND CURRENTSTANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING)

Greta Lorenzon, IT

09:00 - 09:00 P0348CLINICAL CHARACTERISTICS ASSOCIATED WITHBIOCHEMICAL REMISSION THREE MONTHS AFTERDIAGNOSIS OF CROHN’S DISEASE Vibeke Strande, NO

09:00 - 09:00 P0349CLINICAL AND ULTRASONOGRAPHIC ENTHESITIS ININFLAMMATORY BOWEL DISEASE PATIENTS WITH ANDWITHOUT PSORIASIS Alessandra Soriano, IT

09:00 - 09:00 P0350ASSESSEMENT OF CUMULATIVE BOWEL DAMAGE USINGLEMANN INDEX AND MARIA SCORE IN SURGICALLY NAIVEPATIENTS WITH CROHN'S DISEASE Viktor Domislovic, HR

09:00 - 09:00 P0351CLINICAL CHARACTERISTICS ASSOCIATED WITHBIOCHEMICAL REMISSION THREE MONTHS AFTERDIAGNOSIS OF ULCERATIVE COLITIS Vibeke Strande, NO

09:00 - 09:00 P0352PAIN IN ULCERATIVE COLITIS: A FORGOTTEN PATIENT-REPORTED OUTCOME Mafalda João, PT

09:00 - 09:00 P0353FECAL CALPROTECTIN: ROLE IN MONITORING ILEALCROHN'S DISEASE ACTIVITY DETECTED BY INTESTINALULTRASONOGRAPHY Angela Algarra García, ES

09:00 - 09:00 P0354PSYCHOLOGICAL MORBIDITY PREDICTS MALADAPTIVEDECISION-MAKING IN PEOPLE WITH INFLAMMATORYBOWEL DISEASE Lydia Grinsted Tate

09:00 - 09:00 P0355COLORECTAL CANCER SURVEILLANCE IN COMPLEX IBDPATIENTS WITH STRICTURES Alexander Kokrashvili, UK

09:00 - 09:00 P0356DIGESTIVE FISTULAS IN CROHN'S DISEASE (CD) OTHERTHAN ANO-PERINEAL MANIFESTATIONS (APM): WHATPROGNOSIS? Fatima Zahra Ajana, MA

09:00 - 09:00 P0357HUMAN NEUTROPHIL ELASTASE DERIVED FRAGMENT OFCALPROTECTIN (S100A9) IS A SERUM BIOMARKER(CPA9-HNE) FOR MONITORING OF ANTI-TNFΑ TREATMENTRESPONSE IN CROHN’S DISEASE Joachim Høg Mortensen, DK09:00 - 09:00 P0358WATCH OUT FOR SIGNS OF ANXIETY AND DEPRESSION INIBD PATIENTS DURING AN ACUTE FLARE-UP Jochen Gerhard Klaus, DE

09:00 - 09:00 P0360ENDOSCOPIC MAYO SUBSCORE FAILS IN ULCERATIVECOLITIS WITH CONCOMITANT PRESENCE OF PRIMARYSCLEROSING CHOLANGITIS Pavel Wohl, CZ

09:00 - 09:00 P0361THE IBD DISK IS WELL CORRELATED WITH MUCOSALDISEASE ACTIVITY AND MAYO SCORE IN PATIENTS WITHULCERATIVE COLITIS Eran Zittan, IL

09:00 - 09:00 P0362MY IBD CARE, A DIGITAL THERAPEUTIC FOR IBD, IS SAFEAND EFFECTIVE: CASE-CONTROL STUDY IN TWO UKCENTRES Gareth Parkes

09:00 - 09:00 P0363THE CORRELATION BETWEEN 6-THIOGUANINENUCLEOTIDE CONCENTRATIONS AND LEUKOCYTEFRACTION IN PATIENTS WITH INFLAMMATORY BOWELDISEASE RECEIVING THIOPURINE TREATMENT Tomoya Nakamura, JP

09:00 - 09:00 P0364INFLIXIMAB PHARMACOKINETIC PEAK CO AND 1-WEEKSERUM LEVELS PREDICT 8-WEEK TROUGH LEVELS ININFLAMMATORY BOWEL DISEASE Per Martin Hellström, SE

09:00 - 09:00 P0365COVID-19 PANDEMIC PSYCHOLOGICAL EFFECTS ONPATIENTS WITH INFLAMMATORY BOWEL DISEASE INTUNISIA Sahar Nasr, TN

09:00 - 09:00 P0366DIAGNOSTIC WORK-UP OF CHILDREN AND ADOLESCENTSWITH INFLAMMATORY BOWEL DISEASE: EVOLUTION IN APOPULATION-BASED COHORT OVER A 26-YEAR PERIOD(1988-2014). Dominique Turck, FR

09:00 - 09:00 P0367ASSESSMENT OF THE DEGREE OF INTESTINALDESTRUCTION IN CROHN'S DISEASE AT THE TIME OFDIAGNOSIS Amani Hassine, TN




09:00 - 09:00 P0368DEEP REMISSION IN CROHN’S DISEASE ON BIOLOGICTHERAPY: TOWARDS A NEW DEFINITION Fabiana Castiglione, IT09:00 - 09:00 P0369FEATURES OF THE COURSE OF COVID-19 ININFLAMMATORY BOWEL DISEASE PATIENTS WITHHERPESVIRUS LESIONS Gulustan Babayeva, AZ

09:00 - 09:00 P0370HS-GC/MS-BASED METABOLOMICS APPROACH FORVOLATILE COMPOUNDS ANALYSIS IN IBD Natalya Zakharzhevskaya, RU

09:00 - 09:00 P0371PRECISION DIAGNOSTICS IN IBD: METABOLOMIC ANDGENETIC PROFILING Svetlana Lyamina, RU

09:00 - 09:00 P0372DIAGNOSTIC DELAY, EFFECTIVENESS AND SAFETYOUTCOMES IN A REAL-WORLD COHORT OF PATIENTSWITH CROHN’S DISEASE: DATA FROM ADMINISTRATIVEDATABASES IN TUSCANY, ITALY Lorenzo Bertani, IT

09:00 - 09:00 P0373COLON-INVOLVING VERSUS NON-COLON-INVOLVINGCROHN’S DISEASE CLASSIFICATION: IS THE MONTREALCLASSIFICATION OUTDATED? Tiago Lima Capela, PT

09:00 - 09:00 P0375WHAT IS THE ROLE OF ANTI-TNF Α IN CORRECTINGANEMIA IN CROHN'S DISEASE? Amani Hassine, TN

09:00 - 09:00 P0376SEXUAL DYSFUNCTION IN CHRONIC INFLAMMATORYBOWEL DISEASE: MYTH OR REALITY? Amani Hassine, TN

09:00 - 09:00 P0377SLEEP DISORDERS AND CHRONIC INFLAMMATORY BOWELDISEASE: WHAT'S THE CONNECTION? Amani Hassine, TN

09:00 - 09:00 P0378PREVALENCE AND RISK FACTORS FOR FATIGUE INCHRONIC INFLAMMATORY BOWEL DISEASE Amani Hassine, TN

09:00 - 09:00 P0379ARTIFICIAL INTELLIGENCE SURPASSESGASTROINTESTINAL EXPERTS IN THE CLASSIFICATION OFENDOSCOPIC SEVERITY AMONG ULCERATIVE COLITIS Bobby Lo, DK

09:00 - 09:00 P1122PSYCHOSOCIAL IMPACT OF THE COVID-19 PANDEMIC ONPATIENTS WITH INFLAMMATORY BOWEL DISEASE INSPAIN Alejandro Hernandez Camba, ES09:00 - 09:00 P0380ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUSIN A COHORT OF PATIENTS WITH CROHN’S DISEASE Olga Maria Nardone, IT

09:00 - 09:00 P0381INTESTINAL ULTRASOUND RESPONSE AND TRANSMURALREMISSION AFTER 48 WEEKS OF TREATMENT WITHUSTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIALSUBSTUDY RESULTS BY LINE OF TREATMENT ANDLOCATION Torsten Kucharzik, DE

09:00 - 09:00 P0382REAL-TIME USE OF ARTIFICIAL INTELLIGENCE DURINGCOLONOSCOPY PREDICTS RELAPSE OF ULCERATIVECOLITIS: A PROSPECTIVE STUDY Yasuharu Maeda, JP

09:00 - 09:00 P0383FLUORINE18-FLUORODEOXYGLUCOSE LABELEDAUTOLOGOUS LEUCOCYTES POSITRON EMISSIONTOMOGRAPHY-COMPUTED TOMOGRAPHYENTEROGRAPHY: A NOVEL NON-INVASIVE METHOD FOREVALUATING THE EXTENT AND ACTIVITY OF CROHN’SDISEASE Pankaj Kumar, IN

09:00 - 09:00 P0384BASELINE HYPERTROPHY OF THE SUBMUCOSA ATINTESTINAL ULTRASOUND PREDICTS FAILURE OFTREATMENT IN PATIENTS WITH ULCERATIVE COLITIS Floris de Voogd, NL

09:00 - 09:00 P0385IBUS-SAS FOR THE EVALUATION OF CROHN’S DISEASEULTRASOUND ACTIVITY: DEFINING THE OPTIMAL CUT-OFFSCORE Gabriele Dragoni, IT

09:00 - 09:00 P0386EFFECT OF OZANIMOD TREATMENT ANDDISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNTIN PATIENTS WITH MODERATELY TO SEVERELY ACTIVEULCERATIVE COLITIS: RESULTS FROM A PHASE 3RANDOMIZED TRIAL Geert R. D'Haens, NL

09:00 - 09:00 P0387EVALUATION OF THE EFFICACY OF TOFACITINIB ASMAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVECOLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINEENDOSCOPIC SUBSCORE Krisztina Barbara Gecse, NL




09:00 - 09:00 P0388EVALUATION OF A COMPUTATIONAL PLATFORM FORPREDICTING TEMPORAL PROGRESSION OF MUCOSALDAMAGE AND HEALING IN PATIENTS WITH CROHN’SDISEASE Ryuichi Iwakiri, JP09:00 - 09:00 P0389QINGCHANG WENZHONG DECOCTION ACCELERATESINTESTINAL MUCOSAL HEALING THROUGH MODULATIONOF DYSREGULATED GUT MICROBIOTA IN DSS-INDUCEDCOLITIS MICE Tangyou Mao, CN

09:00 - 09:00 P0390PHARMACOKINETICS, SAFETY, AND TOLERABILITY OFETRASIMOD (APD334) IN SUBJECTS WITH MILD,MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY Caroline A. Lee, US

09:00 - 09:00 P0391IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITORFAILURE AND PRIOR CORTICOSTEROID USE ON THEMAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWINGDOSE REDUCTION IN PATIENTS WITH ULCERATIVECOLITIS WHO WERE IN STABLE REMISSION: 6-MONTHDATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETINGSTUDY William J. Sandborn, US

09:00 - 09:00 P0392NON-INVASIVE PREDICTORS OF MAINTAINING REMISSIONIN PATIENTS WITH MODERATELY TO SEVERELY ACTIVEULCERATIVE COLITIS TREATED WITH TOFACITINIB WHODOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILYTO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY Geert R. D'Haens, NL

09:00 - 09:00 P0393ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIORDURATION OF REMISSION IN PATIENTS WITH ULCERATIVECOLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY(BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID:6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISEDRIVETING STUDY Joana Torres, PT

09:00 - 09:00 P0394ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTSTREATED WITH TOFACITINIB IN THE ULCERATIVE COLITISCLINICAL PROGRAMME Christina Ha, US

09:00 - 09:00 P0395USTEKINUMAB FOR ULCERATIVE COLITIS A REAL-WORLDEXPERIENCE - RETROSPECTIVE DATA ANALYSIS OF THEIBD COHORT ORDENSKLINIKUM LINZ Dominik Ecker, AT

09:00 - 09:00 P0396ALICAFORSEN ENEMA IN CHRONIC POUCHITIS: RESULTSOF A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO-CONTROLLED TRIAL Nermeen Varawalla09:00 - 09:00 P0397CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATEDWITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICALPROGRAMME Alessandro Armuzzi, IT

09:00 - 09:00 P0398PREDICTORS OF CLINICAL RESPONSE ANDINFLAMMATORY BOWEL DISEASE QUESTIONNAIREIMPROVEMENT WITH GOLIMUMAB IN PATIENTS WITHMODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS INTHE PURSUIT-MAINTENANCE STUDY Cindy LJ Weinstein, US

09:00 - 09:00 P0399DOSE ESCALATION AND DISCONTINUATION RATES DIFFERDUE TO LOSS OF RESPONSE IN OLDER AND YOUNGER IBDCOHORTS TREATED WITH INFLIXIMAB Ian McDonald, IE

09:00 - 09:00 P0400COMPARISON OF DAIRY FOODS INTOLERANCE BETWEENINFLAMMATORY BOWEL DISEASE PATIENTS AND GENERALPOPULATION: A MULTINATIONAL CROSS SECTIONALSTUDY Pezhman Alavi Nejad, IR

09:00 - 09:00 P0401LONGITUDINAL DYNAMICS OF GUT MICROBIOME ANDMETABOLOME AFTER BIOLOGICAL THERAPY ININFLAMMATORY BOWEL DISEASES Mohamed Ahmed, DE

09:00 - 09:00 P0402EARLY PRO-2 SYMPTOM REMISSION FOLLOWINGGUSELKUMAB INDUCTION TREATMENT: RESULTSTHROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY Walter Reinisch, AT

09:00 - 09:00 P0403PATIENT-REPORTED OUTCOMES OF RESPONSE ANDREMISSION FOLLOWING GUSELKUMAB INDUCTIONTREATMENT AS MEASURED BY THE INFLAMMATORYBOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGHWEEK 12 OF THE PHASE 2 GALAXI 1 STUDY Julian Panés, ES

09:00 - 09:00 P0404CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATEDPATIENTS WITH RHEUMATOID ARTHRITIS Alessandra Oortwijn, NL

09:00 - 09:00 P0405ADALIMUMAB 80MG EVERY OTHER WEEK ININFLAMMATORY BOWEL DISEASE: TREATMENTINTENSIFICATION OUTCOMES IN REAL LIFE CLINICALPRACTICE Marta Isabel Calvo Moya, ES




09:00 - 09:00 P0406ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITHMODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTSFROM THE PHASE 2 OASIS TRIAL AND OPEN-LABELEXTENSION Michael Chiorean, US09:00 - 09:00 P0407IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVECOMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: AMULTICENTRE STUDY OF GETECCU Maria Jose Garcia, ES

09:00 - 09:00 P0408PERFUSE: A FRENCH NON-INTERVENTIONAL COHORTSTUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONEDPATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2;ANALYSIS OF 24-MONTH DATA Yoram Bouhnik, FR

09:00 - 09:00 P0409CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORYBOWEL DISEASE AND A PRIOR NON-DIGESTIVEMALIGNANCY ACCORDING TO THE IMMUNOMODULATORYTHERAPY: A MULTICENTER COHORT STUDY Florian Poullenot, FR

09:00 - 09:00 P0410REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESSAND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY Alessandro Armuzzi, IT

09:00 - 09:00 P0411OPTIMIZING THE POSITION OF VEDOLIZUMAB INTREATMENT SEQUENCES FOR CROHN’S DISEASE:RESULTS FROM A MARKOV MODEL SIMULATION USINGREAL-WORLD EVIDENCE Alessandro Armuzzi, IT

09:00 - 09:00 P0412OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USEIN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROMA EUROPEAN REAL-WORLD STUDY Alessandro Armuzzi, IT

09:00 - 09:00 P0413PROLONGED REMISSION OF ULCERATIVE COLITIS USINGFAECAL MICROBIOTA TRANSPLANTATION - A CASE SERIES

Thomas J. Borody, AU

09:00 - 09:00 P0414A SYSTEMATIC REVIEW AND META-ANALYSIS OF THEEFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMABIN PATIENTS WITH INFLAMMATORY BOWEL DISEASE Laurent Peyrin-Biroulet, FR

09:00 - 09:00 P0415SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGSDURING PREGNANCY AND BREASTFEEDING: MOTHERSAND BABIES’ OUTCOMES (DUMBO REGISTRY) María Chaparro, ES

09:00 - 09:00 P0416COMPARATIVE EFFICACY AND SAFETY OF ORAL FERRICMALTOL IN INFLAMMATORY BOWEL DISEASE PATIENTSWITH MILD-TO-MODERATE VS. MORE SEVERE IRONDEFICIENCY ANAEMIA Ian Jacob09:00 - 09:00 P0417EFFECTS OF USTEKINUMAB INDUCTION ANDMAINTENANCE THERAPY ON DISEASE CLEARANCE IN THEUNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS Silvio Danese, IT

09:00 - 09:00 P0418VEDOLIZUMAB IN REAL PRACTICE: EXPERIENCE IN ATERTIARY HOSPITAL María Carmen Fernández-Cano, ES

09:00 - 09:00 P0419VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THETREATMENT OF POSTOPERATIVE RECURRENCE OFCROHN’S DISEASE Fabio Salvatore Macaluso, IT

09:00 - 09:00 P0420THE IMPACT OF NON-MEDICAL SWITCHING FROMORIGINATOR TO BIOSIMILAR INFLIXIMAB VS CONTINUINGON ORIGINATOR IN INFLAMMATORY BOWEL DISEASE:RESULTS OF PROJECT NORTH Per Martin Hellström, SE

09:00 - 09:00 P0421AN AUDIT OF PROACTIVE THERAPEUTIC DRUGMONITORING OF PATIENTS WITH INFLAMMATORY BOWELDISEASE ON BIOLOGICS Kee Bin Ng, IE

09:00 - 09:00 P0422EFFECTS OF COVID-19 ON TREATMENT AND PATIENTMANAGEMENT IN INFLAMMATORY BOWEL DISEASE:FINDINGS FROM A REAL-WORLD SURVEY IN EUROPE Fritha Hennessy

09:00 - 09:00 P0423LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULACOMPLICATING CROHN’S DISEASE: ECUFIT STUDY FROMGETECCU Iago Rodríguez-Lago, ES

09:00 - 09:00 P0424SERUM INFLIXIMAB CONCENTRATIONS DURINGINDUCTION PREDICT SHORT-TERM TREATMENTRESPONSE IN PATIENTS WITH INFLAMMATORY BOWELDISEASE Anja Eberl, FI

09:00 - 09:00 P0425EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTSWITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM APHASE 2 RANDOMISED CONTROLLED TRIAL Remo Panaccione, CA




09:00 - 09:00 P0426REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUSTO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCETREATMENT FOR INFLAMMATORY BOWEL DISEASE Adriaan Volkers, NL09:00 - 09:00 P0427RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSALHEALING AND BASELINE CHARACTERISTICS IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE ULCERATIVECOLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3SELECTION STUDY Jean-Frederic Colombel, US

09:00 - 09:00 P0428REAL-WORLD TREATMENT PATTERNS AND HEALTHCARECOSTS AMONG US COMMERCIALLY INSURED ADULTSINITIATING BIOLOGICS FOR ULCERATIVE COLITIS Doug Wolf, US

09:00 - 09:00 P0429A REAL-WORLD EVALUATION OF TOFACITINIB FORULCERATIVE COLITIS IN UK AND IRELAND Richard Howard

09:00 - 09:00 P0430AGE MAY NOT IMPACT BIOLOGIC TREATMENT FAILURE AT12 MONTHS FOR INFLAMMATORY BOWEL DISEASE: A REALLIFE RETROSPECTIVE SINGLE CENTRE COHORT STUDY Jonathan Bruce, UK

09:00 - 09:00 P0431TASTY&AMP;HEALTHY IS A DIETARY APPROACH FORINDUCING AND MAINTAINING REMISSION IN CROHN'SDISEASE: A PROSPECTIVE CASE SERIES Luba Plotkin, IL

09:00 - 09:00 P0432EFFECTIVENESS AND SAFETY OF ON-DEMAND FERRICCARBOXYMALTOSE INFUSION STRATEGY FOR IRONDEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASEPATIENTS Mauro Grova, IT

09:00 - 09:00 P0433NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANDINFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW Murat Toruner, TR

09:00 - 09:00 P0434FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNFDOSE INTENSIFICATION IN INFLAMMATORY BOWELDISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS Laura Guberna, ES

09:00 - 09:00 P0435COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGHLEVELS BETWEEN POINT-OF-CARE TESTING ANDCURRENT STANDARD OF CARE (ENZYME LINKEDIMMUNOSORBENT ASSAY) IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Brigida Barberio, IT

09:00 - 09:00 P0436A PILOT STUDY ON THE USE OF USTEKINUMAB INREFRACTORY PERIANAL CROHN’S DISEASE Federica Crispino, IT09:00 - 09:00 P0437MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEDFATIGUE IN PATIENTS WITH MODERATELY TO SEVERELYACTIVE CROHN’S DISEASE Miguel Regueiro, US

09:00 - 09:00 P0438CHARACTERISTICS AND REAL WORLD TREATMENTHISTORY OF PATIENTS TREATED WITH TOFACITINIB FORULCERATIVE COLITIS IN EUROPE Alessandro Armuzzi, IT

09:00 - 09:00 P0440EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANALCROHN’S DISEASE Philip Smith

09:00 - 09:00 P0441SAFETY OF CONCURRENT ADMINISTRATION OFOZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS INPATIENTS WITH ULCERATIVE COLITIS Jean-Frederic Colombel, US

09:00 - 09:00 P0442LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITHMODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS(UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS)STUDIES Silvio Danese, IT

09:00 - 09:00 P0443IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGICMEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2STUDY OF PATIENTS WITH MODERATELY TO SEVERELYACTIVE CROHN’S DISEASE Rish Pai, US

09:00 - 09:00 P0444PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB INULCERATIVE COLITIS POTENTIALLY INCREASES THEACCURACY OF DISEASE MONITORING AND HELPS TOACHIEVE THERAPEUTIC TARGET Kata Judit Szántó, HU

09:00 - 09:00 P0445A RANDOMIZED, PLACEBO CONTROLLED, DOUBLEBLINDED, CROSS OVER FODMAP PROVOCATION INPATIENTS WITH ULCERATIVE COLITIS AND IRRITABLEBOWEL SYNDROME ON A LOW FODMAP DIET Anne Lund Krarup, DK

09:00 - 09:00 P0446ATTITUDE OF PATIENTS WITH IBD TOWARD COVID-19VACCINE IN SAUDI ARABIA Dimah Alaskar, SA




09:00 - 09:00 P0447RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPYFOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONGPATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATAFROM A PROSPECTIVE COHORT Jacob Ollech, IL09:00 - 09:00 P0448EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMABFOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OFTHE PHASE 4 EARNEST TRIAL Simon Travis

09:00 - 09:00 P0449LOCAL MESENCHYMAL STEM CELLS INJECTION INCROHN’S DISEASE STRICTURES: A PHASE I-II CLINICALSTUDY Sophie Vieujean, BE

09:00 - 09:00 P0450GROUP-BASED TRAJECTORY ANALYSIS OF WEIGHTCHANGE IN AN INFLIXIMAB-TREATED COHORT OFINFLAMMATORY BOWEL DISEASE PATIENTS Zhi Xin Tan, AU

09:00 - 09:00 P0451THERAPEUTIC TARGETS IN PAEDIATRIC IBD: ARETROSPECTIVE ANALYSIS OF INTERMEDIATE GOALSBASED ON UPDATED STRIDE-II (SELECTING THERAPEUTICTARGETS IN INFLAMMATORY BOWEL DISEASE)RECOMMENDATIONS Hannes Hölz, DE

09:00 - 09:00 P0452RESULTS FROM A LARGE SURVEY EXPLORING PATIENTPREFERENCES FOR TREATMENT ATTRIBUTES ININFLAMMATORY BOWEL DISEASE ACROSS 7 COUNTRIES INEUROPE Nawal Bent-Ennakhil, CH

09:00 - 09:00 P0453A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMABDOES NOT ENHANCE MODULATION OF DOWNSTREAMBLOOD MOLECULAR MARKERS IN PATIENTS WITHMODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE ORULCERATIVE COLITIS: RESULTS FROM THE SERENE-CDAND SERENE-UC STUDIES Marc Ferrante, BE

09:00 - 09:00 P0454REAL-LIFE DATA OF TREATMENT PERSISTENCE INPATIENTS WITH LONG-STANDING CROHN'S DISEASETREATED WITH BIOLOGICS: RESULTS FROM A CROATIANTERTIARY CENTER Filip Babić, HR

09:00 - 09:00 P0455ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARENOT ASSOCIATED WITH BIOCHEMICAL REMISSION INPATIENTS WITH CROHN’S DISEASE Jose Luis Rueda García, ES

09:00 - 09:00 P0456OBSERVATIONAL STUDY ON THE EFFECTIVENESS ANDSAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITISPOPULATION COMPRISED BY BIO-NAÏVE PATIENTS ANDPATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF(EVOLVE-IB STUDY) Francisco Casellas, ES09:00 - 09:00 P0457CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITHULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POSTHOC ANALYSIS OF SELECTION William J. Sandborn, US

09:00 - 09:00 P0458REAL WORLD EFFECTIVENESS AND SAFETY OFVEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS AFIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUSANTI-TNF (EVOLVE-IB STUDY) Fernando Muñoz, ES

09:00 - 09:00 P0459PHARMACOKINETICS, IMMUNOGENICITY, ANDEXPOSURE–RESPONSE RELATIONSHIPS OFUSTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’SDISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGETVS STANDARD OF CARE ANALYSIS OF THE STARDUSTSTUDY Geert R. D'Haens, NL

09:00 - 09:00 P0460INFLAMMATORY COMPLICATIONS OF THE POUCH, ANDTHERAPEUTIC REQUIREMENTS AFTER COLECTOMY INPATIENTS WITH ULCERATIVE COLITIS. RESULTS FROMTHE RESERVO STUDY OF GETECCU Francisco Mesonero, ES

09:00 - 09:00 P0461RATES OF TREATMENT FAILURE AMONG PATIENTS WITHULCERATIVE COLITIS TREATED WITH FIRST-LINEADVANCED TREATMENTS Komal Gupte-Singh, US

09:00 - 09:00 P0462ACCEPTANCE OF SWITCH, PATIENT SATISFACTION ANDADVERSE EVENTS AFTER SWITCH FROM ADALIMUMABORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING Thomas De Somer, BE

09:00 - 09:00 P0463CANNABIS INDUCES SIGNIFICANT CLINICAL AND QOLIMPROVEMENT IN CHRONIC POUCHITIS Timna Naftali, IL

09:00 - 09:00 P0464EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS ANDOTHER INFLAMMATORY COMPLICATIONS OF THE POUCH,AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OFGETECCU. Francisco Mesonero, ES




09:00 - 09:00 P0465INTRAABDOMINAL ABSCESSES IN CROHN'S DISEASE:TREATMENT AND OUTCOMES Salma Souissi, TN09:00 - 09:00 P0466PHARMACOKINETIC AND NONCLINICAL SAFETYEVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, INNON-HUMAN PRIMATES Jay Tibbitts, US

09:00 - 09:00 P0467COMPARISON OF COMBINATION SUBCUTANEOUSINFLIXIMAB AND AN IMMUNOMODULATOR VERSUSSUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOCANALYSIS OF A RANDOMISED CLINICAL TRIAL Shomron Ben-Horin, IL

09:00 - 09:00 P0468TREATMENT OPTIMIZATION WITH VEDOLIZUMAB INTREATMENT-REFRACTORY PATIENTS WITH ULCERATIVECOLITIS AND CROHN’S DISEASE – A REAL-WORLD TWO-CENTER COHORT STUDY Mohamed Attauabi, DK

09:00 - 09:00 P0469MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE CROHN'SDISEASE Edward V. Loftus, US

09:00 - 09:00 P0470REAL-WORLD IMPACT OF BIOLOGICAL THERAPIES ONWORK IMPAIRMENT AND QUALITY OF LIFE ININFLAMMATORY BOWEL DISEASE PATIENTS Pepijn Thomas, NL

09:00 - 09:00 P0471DE-ESCALATION OF BIOLOGICAL THERAPY ININFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWINGPRIOR ESCALATION Pepijn Thomas, NL

09:00 - 09:00 P0472SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUSINFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORYBOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POSTSWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISEDCONTROLLED PIVOTAL TRIAL Walter Reinisch, AT

09:00 - 09:00 P0473SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLYIBD PATIENTS: A REAL-LIFE MULTICENTRIC COHORTSTUDY Cara De Galan, BE

09:00 - 09:00 P0474MRI FOLLOW UP IN ACTIVE PERIANAL FISTULIZINGCROHN’S DISEASE REFRACTORY TO ANTI-TUMORNECROSIS FACTOR THERAPY RECEIVING USTEKINUMAB Nicolas Richard, FR

09:00 - 09:00 P0475IS LONGER TIME BETWEEN IBD DIAGNOSIS AND FIRSTBIOLOGIC INITIATION LEADING TO HIGHER DISEASESEVERITY AND MORE HOSPITALIZATIONS IN ITALY ANDTHE UNITED KINGDOM? A COMPARISON TO SIMILARMETRICS IN THE UNITED STATES Eric John, US09:00 - 09:00 P0476RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLYSYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN ANDSTOOL FREQUENCY IN PATIENTS WITH MODERATE TOSEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3INDUCTION STUDIES Jean-Frederic Colombel, US

09:00 - 09:00 P0477VEDOLIZUMAB AS THE FIRST LINE OF BIOLOGIC THERAPYFOR ULCERATIVE COLITIS AND CROHN’S DISEASE - ASYSTEMATIC REVIEW WITH META-ANALYSIS Mohamed Attauabi, DK

09:00 - 09:00 P0478PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSALHEALING RATES IN CROHN'S DISEASE Marko Brinar, HR

09:00 - 09:00 P0479INFLUENCE OF COVID-19 ON INFLAMMATORY BOWELDISEASE PATIENTS AND BIOLOGICAL TREATMENT María Carmen Fernández-Cano, ES

09:00 - 09:00 P0480SAFETY, TOLERABILITY AND PHARMACOKINETICS OFNX-13 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY IN NORMAL HEALTHYVOLUNTEERS Andrew Leber, US

09:00 - 09:00 P0481AUDIT: IS CO-TRIMOXAZOLE PROPHYLAXIS NECESSARYFOR INFLAMMATORY BOWEL DISEASE PATIENTSRECEIVING TRIPLE IMMUNOSUPPRESSION? Claudia Moore-Gillon

09:00 - 09:00 P0482DRUG MONITORING OF BIOTHERAPIES IN CHRONICINFLAMMATORY BOWEL DISEASES Ghada Gharbi, TN

09:00 - 09:00 P0483LOCALLY INJECTED ALLOGENEIC BONE MARROW-DERIVEDMESENCHYMAL STROMAL CELLS FOR THE TREATMENT OFREFRACTORY PROCTITIS: PRELIMINARY RESULTS OF APHASE IIA TRIAL Laura F. Ouboter, NL

09:00 - 09:00 P0484BROAD HOST RANGE BACTERIOPHAGE THERAPY FORREDUCTION OF KLEBSIELLA PNEUMONIAE AS A POTENTIALTREATMENT IN IBD Ariel Cohen, IL




09:00 - 09:00 P0485HISTOLOGICAL INFLAMMATION PREDICTS LOSS OFREMISSION AMONG CROHN’S PATIENTS WITHENDOSCOPIC REMISSION: A US COHORT ANALYSIS Harris Ahmad, US09:00 - 09:00 P0486PATIENT PREFERENCES REGARDING TREATMENT WITHADVANCED THERAPIES IN ULCERATIVE COLITIS: ADISCRETE-CHOICE EXPERIMENT Stefan Schubert, DE

09:00 - 09:00 P0487LONG-TERM OUTCOMES FOLLOWING A SWITCH FROMORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5(IMRALDI) IN IBD Lauranne Derikx

09:00 - 09:00 P0488PERFUSE: A FRENCH NON-INTERVENTIONAL COHORTSTUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONEDPATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5;BASELINE RESULTS Yoram Bouhnik, FR

09:00 - 09:00 P0489A MATCHING-ADJUSTED INDIRECT COMPARISON OFMAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUSVEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVEULCERATIVE COLITIS James Lindsay, UK

09:00 - 09:00 P0490SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTSWITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OFCLINICAL REMISSION WHEN INITIATING VEDOLIZUMABVERSUS ANTI-TNFΑ THERAPIES: ANALYSIS OF EVOLVESTUDY DATA Gerassimos J. Mantzaris, GR

09:00 - 09:00 P0491SERUM PREVALENCE OF SARS-COV2 ANTIBODIES INPATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFOREVACCINATION María Hernández Pérez, ES

09:00 - 09:00 P0492FAECAL MICROBIAL TRANSPLANTATION VERSUS 5-ASAENEMA FOR TREATMENT OF ACTIVE LEFT-SIDEDULCERATIVE COLITIS – RESULTS FROM RANDOMIZEDCONTROL TRIAL FACTU Jan Březina, CZ

09:00 - 09:00 P0493PROPENSITY SCORE ADJUSTED REAL WORLDEFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF INBIOLOGIC-NAÏVE ULCERATIVE COLITIS PATIENTS:INDUCTION PHASE RESULTS FROM THE PROSPECTIVE,OBSERVATIONAL VEDOIBD STUDY IN GERMANY Bernd Bokemeyer, DE

09:00 - 09:00 P0494SYSTEMATIC REVIEW ON THE USE OF ENTERAL NUTRITIONFOR THE INDUCTION OF REMISSION IN PAEDIATRICCROHN’S DISEASE Gigi Veereman, BE09:00 - 09:00 P0495BENEFICIAL EFFECTS OF NATURAL MINERAL WATERS ONINTESTINAL INFLAMMATION AND THE MUCOSA-ASSOCIATED MICROBIOTA Nicolas Barnich, FR

09:00 - 09:00 P0496A 12-WEEK TAILORED PHYSICAL TRAINING PROGRAMINCLUDING DIETARY ADVICE IN CHILDREN WITHINFLAMMATORY BOWEL DISEASE: A RANDOMIZEDCROSSOVER TRIAL Linda Elisabeth Scheffers, NL

09:00 - 09:00 P0497UPADACITINIB TREATMENT IMPROVES HEALTH-RELATEDQUALITY OF LIFE AMONG PATIENTS WITH MODERATELYTO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTSFROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE ANDU-ACCOMPLISH Julian Panés, ES

09:00 - 09:00 P0498IN CONTRAST TO ORAL IRON THERAPY, INTRAVENOUSIRON THERAPY IS NEITHER INFLUENCED BY, NOR DOES ITEXACERBATE, SYSTEMIC INFLAMMATION IN PATIENTSWITH INFLAMMATORY BOWEL DISEASE Aysegül Aksan, DE

09:00 - 09:00 P0499BIOMARKERS AND BOWEL URGENCY IN RESPONSE TOMIRIKIZUMAB FOR ULCERATIVE COLITIS Marla C. Dubinsky, US

09:00 - 09:00 P0500REAL-LIFE EFFECTIVENESS AND SAFETY OF USTEKINUMABINDUCTION THERAPY FOR KOREAN PATIENTS WITHCROHN’S DISEASE: A KASID PROSPECTIVE MULTICENTERSTUDY Hee Seung Hong, KR

09:00 - 09:00 P0501PROPENSITY SCORE ADJUSTED REAL WORLDEFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF INBIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS:INDUCTION PHASE RESULTS FROM THE PROSPECTIVE,OBSERVATIONAL VEDOIBD STUDY IN GERMANY Bernd Bokemeyer, DE

09:00 - 09:00 P0502IDENTIFYING PATIENTS WITH INFLAMMATORY BOWELDISEASES UNDER SUBCUTANEOUS BIOTHERAPY USING AMEDICATION DISPENSE DATABASE: FEASIBILITY, ANDIMPACT OF COVID-19 Matthieu Allez, FR




09:00 - 09:00 P0503TOFACITINIB IN ULCERATIVE COLITIS: SHORT TERMOUTCOMES IN REAL WORLD EXPERIENCE IN THE SOUTHOF SPAIN Alvaro Hernández Martínez, ES09:00 - 09:00 P0504SAFETY OF REDUCED CLINICAL MONITORING IN PATIENTSWITH STABLE INFLAMMATORY BOWEL DISEASE ONMAINTENANCE THIOPURINE THERAPY Fenna Minke Jansen, NL

09:00 - 09:00 P0505BOTH SINGLE AND MULTIPLE SWITCHING BETWEENINFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE INIBD: REAL WORLD OUTCOMES FROM THE EDINBURGH IBDUNIT Rachael Barrett

09:00 - 09:00 P0506BIOLOGICS AND SMALL MOLECULES COMBOTHERAPIES:PROMISING EXPERIENCE IN REFRACTORY IBD PATIENTS Maude Martinho, CH

09:00 - 09:00 P0507EVALUATION OF TROUGH LEVEL AND DISEASE ACTIVITYAFTER SWITCH FROM ADALIMUMAB ORIGINATOR TOBIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWELDISEASE Nele Deprez, BE

09:00 - 09:00 P0508ADHERENCE TO MESALAZINE AND IDENTIFICATION OFPATIENTS WITH ULCERATIVE COLITIS IN HEALTHCAREADMINISTRATIVE DATABASES OF TUSCANY (ITALY) Lorenzo Bertani, IT

09:00 - 09:00 P0509THE EFFECT OF TREATMENT WITH TNF-Α INHIBITORS ONBONE TURNOVER AND BONE MINERAL DENSITY (BMD) INPATIENTS WITH INFLAMMATORY BOWEL DISEASES Rafał Filip, PL

09:00 - 09:00 P0510MEDICATION ADHERENCE IN INFLAMMATORY BOWELDISEASES IN THE ERA OF BIOTHERAPIES Amani Hassine, TN

09:00 - 09:00 P0511DEFINITION OF A MICROBIAL SIGNATURE AS A PREDICTOROF POST-SURGICAL RECURRENCE IN PATIENTS WITHCROHN'S DISEASE Lia Oliver, ES

09:00 - 09:00 P0512PREVALENCE OF FIRST TIME SURGERY AMONGSTINFLAMMATORY BOWEL DISEASE PATIENTS AT A DISTRICTGENERAL HOSPITAL: A 25 YEAR RETROSPECTIVE REVIEW John Wye, UK

09:00 - 09:00 P0513REDO-SURGERY IN IBD PATIENTS: WHAT IS THE TIMEINTERVAL AND IS THIS EFFECTED BY SPECIFIC RISKFACTORS ? John Wye, UK09:00 - 09:00 P0514DOES THE TYPE OF SURGERY OR DISEASE LOCATIONPREDICT THE NEED FOR SUBSEQUENT SURGERIES, IN IBDPATIENTS John Wye, UK

09:00 - 09:00 P0515THE CHANGING TRENDS SEEN WITH SURGERY INPATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER A25 YEAR REVIEW PERIOD John Wye, UK

09:00 - 09:00 P0516MANAGEMENT AND OUTCOME OF POSTOPERATIVECROHN’S DISEASE IN THE ELDERLY AS COMPARED TOYOUNG ADULTS: DATA FROM ENEIDA REGISTRY Miriam Mañosa Ciria, ES

09:00 - 09:00 P0517IMPACT OF APPENDECTOMY ON THE NATURAL HISTORYOF CROHN'S DISEASE Fatima Zahra Ajana, MA

09:00 - 09:00 P0518SURGICAL TREATMENT IN PATIENTS WITH ULCERATIVECOLITIS: CLINICAL ASPECTS AND ASSOCIATED FACTORS Sandro da Costa Ferreira, BR

09:00 - 09:00 P0519INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRINGSURGERY CAN BE TREATED IN REFERRAL CENTRESREGARDLESS OF THE COVID-19 STATUS OF THEHOSPITAL: RESULTS OF A MULTICENTRIC EUROPEANSTUDY DURING THE FIRST COVID-19 OUTBREAK (COVIBD-SURG) Gianluca Pellino, IT

09:00 - 09:00 P0520CAN THE LEMANN INDEX AT DIAGNOSIS PREDICT THE RISKOF EARLY SURGERY IN CROHN'S DISEASE? Amani Hassine, TN

09:00 - 09:00 P0521COLECTOMY PREDICTIVE FACTORS IN ACUTE SEVERECOLITIS Hajar Koulali, MA

09:00 - 09:00 P0522MANAGEMENT AND OUTCOME OF ABDOMINAL SURGERYIN COMPLICATED CROHN'S DISEASE Mihaela Topala, RO

E-Poster Session

09:00 – 19:00 Poster ExhibitionClinical cases




09:00 - 09:00 CC001A RARE AND SYMPTOMATIC CASE: LOCALIZED GASTRICAND DUODENAL AMYLOIDOSIS Mahnoor Khan, US09:00 - 09:00 CC002A RARE CASE OF COLLAGENOUS GASTRITIS IN A 16 YEAROLD MALE PATIENT Corinna Lang-Schwarz, DE

09:00 - 09:00 CC003NON-CELIAC GLUTEN ENTEROPATHY-ASSOCIATEDLYMPHOCYTIC GASTROENTERITIS Marcus Brillantes, PH

09:00 - 09:00 CC004A CASE OF GASTRIC GRANULOMATOSIS IN ANIMMUNOCOMPETENT PATIENT - THE GREAT IMITATOR Luísa Martins Figueiredo, PT

09:00 - 09:00 CC005CMV DUODENITIS – A RARE CAUSE OF DUODENALULCERATION IN IMMUNE-COMPETENT HOST Muhammad Khan, QA

09:00 - 09:00 CC006ESOPHAGEAL-PULMONARY FISTULA AS THE INITIALPRESENTATION OF TUBERCULOSIS Mariel Dianne Velasco, PH

09:00 - 09:00 CC007CYTOMEGALOVIRUS INFECTION PRESENTING AS GASTRICOUTLET OBSTRUCTION - AN UNUSUAL PRESENTATION Ashish Gandhi, IN

09:00 - 09:00 CC008ENDOSCOPIC DIAGNOSIS OF A PRIMARYAORTOESOPHAGEAL FISTULA: AN EXTREMELY RARECAUSE OF ACUTE UPPER GASTROINTESTINAL BLEEDING Lorena Carballo-Folgoso, ES

09:00 - 09:00 CC010ESOPHAGEAL SQUAMOUS CELL PAPILLOMA. A RARECAUSE FOR DYSPHAGIA AND DYSPEPSIA Asmaa Gameel, EG

09:00 - 09:00 CC011THE UNDERRATED SIDE OF ACHALASIA Inês Pestana, PT

09:00 - 09:00 CC012SARS-COV2. POSSIBLE ACHALASIA TRIGGER? Gabriela Saldana, ES

09:00 - 09:00 CC013A CASE OF EOSINOPHILIC OESOPHAGITIS WITH CLASSICALRADIOLOGICAL AND ENDOSCOPIC FEATURES Dipal Juthani, UK

09:00 - 09:00 CC014SLOUGHING ESOPHAGITIS Anahita Sadeghi, IR

09:00 - 09:00 CC015PRIMARY DEDIFFERENTIATED LIPOSARCOMA OF THEESOPHAGUS Maryam Alahmad, AE09:00 - 09:00 CC016PRIMARY GASTRIC ADENOSQUAMOUS CARCINOMA: ARARE VARIANT OF GASTRIC CANCER Joaquín García Márquez, ES

09:00 - 09:00 CC017TESTICULAR SEMINOMA: A RARE CAUSE OF METASTATICDISEASE IN THE STOMACH Maria Azevedo Silva, PT

09:00 - 09:00 CC018A RARE ASSOCIATION OF TYPE III GASTRICNEUROENDOCRINE TUMOR WITH CRYPTOGENICCIRRHOSIS AND DIABETES MELLITUS, PRESENTING ASCHRONIC NON RESOLVING DIARRHEA Faiza Sadaqat Ali, PK

09:00 - 09:00 CC019GURVITS SYNDROME IN A YOUNG PATIENT WITH POORLYCONTROLLED DIABETES AND COCAINE USE María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC020CHRONIC MESENTERIC ISCHEMIA MIMICKING GASTRICCANCER Jana Jarosova, CZ

09:00 - 09:00 CC021MASSIVE ASCITES AS THE INITIAL PRESENTATION OFSYSTEMIC LUPUS ERYTHEMATOSUS Maryam Alahmad, AE

09:00 - 09:00 CC022A CASE OF COELIAC DISEASE AND COMMON VARIABLEIMMUNODEFICIENCY Gonzalo Trigo, ES

09:00 - 09:00 CC023TERMINAL ILEITIS AFTER ORTHOPEDIC SURGERY: HOW TOMANAGE IT? Margarida Gomes Gonçalves, PT

09:00 - 09:00 CC024SEVERE GASTROINTESTINAL AL AMYLOIDOSIS AS THEINITIAL MANIFESTATION OF MULTIPLE MYELOMA - ADIAGNOSTIC CHALLENGE Edgar Afecto, PT

09:00 - 09:00 CC025HENOCH-SCHÖNLEIN PURPURA IN AN OLDER PATIENTPRESENTING AS DIFFUSE SMALL BOWEL INVOLVEMENTAND MASSIVE GASTROINTESTINAL BLEEDING Edgar Afecto, PT

09:00 - 09:00 CC026LETHAL INTESTINAL SUBOCCLUSION Olga Neva López-García, ES




09:00 - 09:00 CC027GASTROINTESTINAL AMYLOIDOSIS: THE TONGUE GIVESTHE ANSWER Pedro Antunes, PT09:00 - 09:00 CC030WHIPPLE DISEASE: A CASE REPORT Vaidota Maksimaityte, LT

09:00 - 09:00 CC031LOOK BEYOND THE STOOL - WHEN CAPSULE ENDOSCOPYIS THE KEY FOR THE DIAGNOSIS OF TAPEWORMINFECTION Marta Freitas, PT

09:00 - 09:00 CC032COLONIC ULCERATION AND STRICTURING COMPLICATINGREFRACTORY COELIAC DISEASE TYPE II Andrea Vella Baldacchino, MT

09:00 - 09:00 CC033TRANSIENT SMALL BOWEL INTUSSUSCEPTIONUNMASKING ADULT CELIAC DISEASE Maryam Alahmad, AE

09:00 - 09:00 CC034CELIAC CRISIS – A RARE AND LIFE-THREATENINGPRESENTATION Isabel Garrido, PT

09:00 - 09:00 CC035HOW MANY CALORIES ARE ENOUGH? Zrinka Šmuljić, HR

09:00 - 09:00 CC036UNEXPECTED SMALL BOWEL FINDING IN OVERT-OBSCUREGASTROINTESTINAL BLEEDING IN A PATIENT WITHNEUROFIBROMATOSIS TYPE 1 AND CROHN’S DISEASE Ana Catarina Gomes, PT

09:00 - 09:00 CC037SMALL BOWEL ADENOCARCINOMA MIMICKING A CROHN’SATTACK Arda Yavuz, TR

09:00 - 09:00 CC038PRIMARY DUODENAL MELANOMA: A CASE REPORT Suzanne Cauchi, MT

09:00 - 09:00 CC039ILEAL DIEULAFOY’S LESION : A RARE CAUSE OF GASTRO-INTESTINAL BLEEDING Chifaa Belkhayat, MA

09:00 - 09:00 CC040HENOCH-SCHÖNLEIN PURPURA AS A MIMICKER OFCROHN’S DISEASE Sofia Silva Mendes, PT

09:00 - 09:00 CC041AN ALTERNATIVE METHOD FOR TREATING DUMPINGSYNDROME USING HEMOCLIPS Arda Yavuz, TR

09:00 - 09:00 CC042ENDOSCOPIC BAND LIGATION FOR WEIGHT LOSS: SHORT-TERM RESULTS Mohamed Abeid, EG09:00 - 09:00 CC043MIGRATED PEG BALLOON CAUSING ACUTE PANCREATITIS Muhammad Omar Saeed

09:00 - 09:00 CC044INTESTINAL SPIROCHETOSIS – AN ENTITY TO BERECOGNIZED IN A DEVELOPED COUNTRY Ana Catarina Gomes, PT

09:00 - 09:00 CC045HOW MANY BECHET DISEASE ARE WE TREATING LIKECROHN’S? Daniele Brinch, IT

09:00 - 09:00 CC046GANGRENOUS PYODERMA IN ULCERATIVE COLITIS - ANEXUBERANT AND PAINFUL COMPLICATION Margarida Gomes Gonçalves, PT

09:00 - 09:00 CC047SEVERE LOWER GASTROINTESTINAL BLEEDING IN APATIENT WITH CROHN'S DISEASE: A RARE CASE REPORT Isabel Garrido, PT

09:00 - 09:00 CC048SPONTANEOUS PNEUMOMEDIASTINUM: A RARECOMPLICATION OF ACUTE SEVERE ULCERATIVE COLITIS Emanuel Dias, PT

09:00 - 09:00 CC049SEVERE RECURRENT PERIANAL DISEASE: AMULTIDISCIPLINARY APPROACH TO A CHALLENGINGDIFFERENTIAL DIAGNOSIS Daniela Falcão, PT

09:00 - 09:00 CC050A CASE OF ISOLATED GASTRIC CROHN'S DISEASESUCCESSFULLY MANAGED WITH USTEKINUMABMONOTHERAPY ACHIEVING COMPLETE MUCOSALHEALING IN SIX MONTHS Fadwa Adel Elshahat Ibrahim, EG

09:00 - 09:00 CC051CARDIOTOXICITY AFTER ADMISSION OF MESALAZINE –CASE REPORT Tanja Elger, DE

09:00 - 09:00 CC052WERNICKE’S ENCEPHALOPATHY IN ULCERATIVE COLITIS Fabiana Castiglione, IT

09:00 - 09:00 CC053HEPATOTOXICITY IN INFLAMMATORY BOWEL DISEASE:MESALAZINE, THE FORGOTTEN DRUG! Isabel Garrido, PT




09:00 - 09:00 CC054ASSOCIATION BETWEEN CROHN'S DISEASE ANDCOLORECTAL CANCER IN A YOUNG PATIENT: CASEREPORT Rafael Luporini, BR09:00 - 09:00 CC055IMMUNE-MEDIATED COLITIS Mirza Faisal Anwar Baig

09:00 - 09:00 CC056BEHÇET'S DISEASE ASSOCIATED WITH CHRONIC MYELOIDLEUKEMIA - A CASE REPORT Marta Moreira, PT

09:00 - 09:00 CC057SEVERE COLITIS FOLLOWING RITUXIMAB THERAPY: ARARE ENTITY Joana Revés, PT

09:00 - 09:00 CC058PROCTITIS IN MEN HAVING SEX WITH MEN, ANYTHINGELSE YOU CAN THINK OF? María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC059FRESH RECTAL BLEEDING WITH A RARE HIDDENHISTOPATHOLOGIC DIAGNOSIS Anastasios Koutsoumourakis, GR

09:00 - 09:00 CC060RECTAL DIEULAFOY LESION - DIAGNOSTIC ANDTHERAPEUTIC CHALLENGE Ivo Klarin, HR

09:00 - 09:00 CC061SMALL AND TERRIBLE: A CASE REPORT ON RECURRENTMASSIVE LOWER GASTROINTESTINAL BLEEDING DUE TORECTAL DIEULAFOY’S LESION Nikko Theodore Raymundo, PH

09:00 - 09:00 CC062INFERIOR VENA CAVA ANOMALIES: A RARE CASE OFLOWER GASTROINTESTINAL BLEEDING AND INGVINALPAIN Katja Grubelic Ravic, HR

09:00 - 09:00 CC063EPCAM FAMILY WITH A PECULIAR PHENOTYPE: AREEXTRACOLONIC TUMORS THAT UNCOMUN IN EPCAMLYNCH SYNDROME? Joana Alves da Silva, PT

09:00 - 09:00 CC064ANAL SQUAMOUS CELL CARCINOMA IN HIV PATIENTSWITH HPV-16 CONDYLOMAS: A SERIOUS COMPLICATIONIN IMMUNOCOMPROMISED PATIENTS Miriam Celada Sendino, ES

09:00 - 09:00 CC065CECAL MALT LYMPHOMA: A CHALLENGING DIAGNOSIS Sofia Silva Mendes, PT

09:00 - 09:00 CC066DIFFUSE GASTROINTESTINAL MALT LYMPHOMA IN APATIENT WITH ULCERATIVE COLITIS IN REMISSION 09:00 - 09:00 CC067PRIMARY COLONIC LYMPHOMA : A CASE REPORT Hajar Koulali, MA

09:00 - 09:00 CC068MULTIFOCALMUCOSA-ASSOCIATED LYMPHOID TISSUELYMPHOMA INVOLVING THE DUODENUM, COLON ANDNASOPHARYNX: A RARE CLINICAL ENTITY: ACASE REPORT Ben youssef Hela, TN

09:00 - 09:00 CC069ANAL LYMPHOMA IN A PATIENT WITH HIDRADENITISSUPPURATIVA Maria Inês Canha, PT

09:00 - 09:00 CC070NEUROMUSCULAR AND VASCULAR HAMARTOMA: ANUNUSUAL HAMARTOMATOUS LESION OF THEGASTROINTESTINAL TRACT Simona Gurzu, RO

09:00 - 09:00 CC071SOLITARY RECTAL ULCER SYNDROME WITH RECTALPROLAPSE :A CASE REPORT Mohammed Adil Kaddouri, MA

09:00 - 09:00 CC072PAPILLOMA VS CONDYLOMA: AN IMPORTANT SUBTLEDISTINCTION Antonio Oliveira, PT

09:00 - 09:00 CC073ATYPICAL PRESENTATION OF A COMMON INFECTIOUSAGENT Isabel Garrido, PT

09:00 - 09:00 CC074GLYCOGENIC HEPATOPATHY: A RARE DIAGNOSIS OR ANUNDERDIAGNOSED ENTITY? Renato Medas, PT

09:00 - 09:00 CC075DRUG-INDUCED LIVER INJURY SECONDARY TODOXYCYCLINE Mahnoor Khan, US

09:00 - 09:00 CC076NODULAR REGENERATIVE HYPERPLASIA AFTERTREATMENT WITH TRASTUZUMAB EMTANSINE – A CASEREPORT Isabel Garrido, PT

09:00 - 09:00 CC077METFORMIN INDUCED TOXIC HEPATITIS - A CASE REPORT Marta Moreira, PT

09:00 - 09:00 CC078TREATMENT OF REFRACTORY HEPATIC HYDROTHORAXWITH TERLIPRESSIN Fhadidja Saidani, DZ




09:00 - 09:00 CC079ACUTE E HEPATITIS IN AN AUTOIMMUNITYENVIRONMENT Luísa Martins Figueiredo, PT09:00 - 09:00 CC080A RARE CASE OF ACUTE LIVER INJURY SECONDARY TOCONCURRENT HEPATITIS A VIRUS INFECTION ANDDENGUE VIRUS INFECTION IN AN IMMUNOCOMPROMISEDPATIENT Nikko Theodore Raymundo, PH

09:00 - 09:00 CC081A CASE OF SEVERE HEPATITIS E TREATED WITHRIBAVIRIN Maria Azevedo Silva, PT

09:00 - 09:00 CC082SUCCESSFUL TREATMENT OF HEPATITIS C IN A PATIENTWITH CONGENITAL SPHEROCYTOSIS BY RIBAVIRIN-FREEDIRECT-ACTING ANTIVIRALS REGIMEN: A CASE STUDY Ahmed Mansour, EG

09:00 - 09:00 CC084PEMBROLIZUMAB-INDUCED PANCREATIC EXOCRINEINSUFFICIENCY COMPLICATED BY SEVERE HEPATICSTEATOSIS Alex S Hong

09:00 - 09:00 CC085CHARACTERISTICS OF IMMUNOGLOBULIN G4-RELATEDAUTOIMMUNE HEPATITIS: A CASE REPORT AND REVIEW OFLITERATURE Siyu Jiang, CN

09:00 - 09:00 CC086TRANSVENOUS OBLITERATION PROCEDURE IN THEMANAGEMENT OF PARASTOMAL VARICEAL BLEEDING – ACASE REPORT João Estorninho, PT

09:00 - 09:00 CC087METASTATIC YOLK SAC TUMOR MASQUERADING AS MULTI-FOCAL HCC IN A YOUNG ADULT PATIENT Kamran Mushtaq, QA

09:00 - 09:00 CC088PRIMARY HEPATIC LEIOMYOSARCOMA – A CASE REPORT Isabel Garrido, PT

09:00 - 09:00 CC089HEPATIC NODULE: A CHALLENGING DIAGNOSIS Inês Costa-Santos, PT

09:00 - 09:00 CC090HNF1B DEFICIENCY IN A PEDIATRIC PATIENT WITHHISTORY OF HEPATOCELLULAR CARCINOMA: A CASEREPORT AND REVIEW OF LITERATURE Michele Pinon, IT

09:00 - 09:00 CC092CORONA AGAIN? – SECONDARY SCLEROSINGCHOLABGITIS AFTER SEVERE COVID-INFECTION Benno Arnstadt, DE

09:00 - 09:00 CC093DIGESTIVE INVOLVEMENT IN RENDU OSLER WEBERDISEASE : A CASE REPORT Najoua Elmoutaoukil, MA09:00 - 09:00 CC094ECTOPIC PAPILLA OF VATER IN THE GASTRIC ANTRUM Aikaterini Pappa, GR

09:00 - 09:00 CC095BOUVERET SYNDROME; CHOLEDOCHODUODENALFISTULA: A CASE REPORT Ahmed Alzamzamy, EG

09:00 - 09:00 CC096SECONDARY SCLEROSING CHOLANGITIS IN A CRITICALLY-ILL PATIENT PRECIPITATED BY SARS-COV2 INFECTION Bárbara Morão, PT

09:00 - 09:00 CC097GALLSTONE ILEUS: A RARE CAUSE OF BOWELOBSTRUCTION IN A LIVER TRANSPLANT PATIENT Tiago Ribeiro, PT

09:00 - 09:00 CC098UNUSUAL APPEARANCE OF CHOLANGIOCARCINOMA:SOLID- CYSTIC LESION; A CASE REPORT Montri Gururatsakul, AU

09:00 - 09:00 CC099GROOVE PANCREATITIS SUCCESSFULLY TREATED WITHLONG ACTING SOMATOSTATİN ANALOGUE-OCTREOTIDE:A CASE REPORT Kübra Akan, TR

09:00 - 09:00 CC100UNUSUAL EXTRAPULMONARY MANIFESTATION OFCOVID-19: ACUTE SEVERE PANCREATITIS Milena Peruhova, BG

09:00 - 09:00 CC101THE POSSIBLE ROLE OF OBESITY IN PEDIATRIC ACUTEPANCREATITIS: A CASE REPORT Mária Földi, HU

09:00 - 09:00 CC102THORACIC COMPLICATIONS OF PANCREATITIS:PANCREATICO-PLEURAL FISTULA María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC103SCURVY DUE TO FOOD RESTRICTION Артем Попов, RU

09:00 - 09:00 CC104APPENDICULAR MUCOCELE ASSOCIATED TOIGG4-RELATED PANCREATITIS AND CHOLANGITIS Alexey Okhlobystin, RU

09:00 - 09:00 CC105IGG4-RELATED PACHYMENINGITIS IN A PATIENT WITHLIVER AND PANCREAS PSEUDOTUMORS Alexey Okhlobystin, RU




09:00 - 09:00 CC106A RARE CAUSE OF OBSTRUCTIVE JAUNDICE Diana Ramos Silva, PT09:00 - 09:00 CC107A CASE OF UNRESECTABLE LOCALLY ADVANCEDPANCREATIC CANCER IN WHICH RO RESECTION WASACHIEVED BY COMBINING CHEMOTHERAPY AND HIFUTHERAPY Atsushi Sofuni, JP

09:00 - 09:00 CC108PANCREATIC MASS REVEALING A B CELL LYMPHOMA Hajar Koulali, MA

09:00 - 09:00 CC109AN EUS DIAGNOSIS OF A PANCREATIC NEUROENDOCRINETUMOUR: A RARE CASE OF OBSTRUCTIVE CHOLESTASISOVERLAPPING WITH CHOLEDOCHOLITHIASIS Rui de Sousa Magalhaes, PT

09:00 - 09:00 CC110GASTRIC BAROTRAUMA INDUCED BY SELLICK MANEUVERPERFORMED TO ENABLE ENDOSCOPIC SUBMUCOSALDISSECTION Daniela Falcão, PT

09:00 - 09:00 CC111AN ENDOSCOPIC APPROACH TO POST-OESOPHAGECTOMYBRONCHIAL OESOPHAGEAL FISTULA (BOF) Zahra Muhammad Iftikhar, UK

09:00 - 09:00 CC112DOWNHILL ESOPHAGEAL VARICES IN A PATIENT WITHRECURRENT HEMODIALYSIS PERMACATH THROMBOSIS Wafa Aldhaleei, AE

09:00 - 09:00 CC113TWO STEP ENDOSCOPIC TREATMENT OF APEDUNCULATED MUCOSA-ASSOCIATED LYMPHOID TISSUE(MALT) LYMPHOMA CAUSING GASTRIC OUTLETOBSTRUCTION Elena Resina Sierra, ES

09:00 - 09:00 CC114ESOPHAGOPLEURAL FISTULA DUE TO NECESSITANSEMPYEMA - AN ANCIENT AND SILENT CULPRIT Margarida Gomes Gonçalves, PT

09:00 - 09:00 CC115LARGE SUPERFICIAL SQUAMOUS CELL CARCINOMA IN THESETTING OF ACHALASIA TREATED BY ENDOSCOPICSUBMUCOSAL DISSECTION (ESD): PARTICULAR FEATURESOF SUPERFICIAL CARCINOMA ON STASIS RELATEDESOPHAGEAL HYPERKERATOSIS Lauriane Mesureur, BE

09:00 - 09:00 CC116LATERALLY SPREADING ESOPHAGEAL ADENOCARCINOMATREATED BY CIRCUMFERENTIAL ENDOSCOPICSUBMUCOSAL DISSECTION (ESD): A RARE PRESENTATIONOF SUPERFICIAL NEOPLASIA Lauriane Mesureur, BE

09:00 - 09:00 CC117“METALLIC TULIP-BUNDLE” TECHNIQUE AS RESCUEHEMOSTATIC THERAPY AFTER ENDOSCOPIC MUCOSALRESECTION OF A GASTRIC LESION Ana Catarina Gomes, PT09:00 - 09:00 CC118CLOSURE OF A JEJUNAL STUMP LEAK WITH AN OVER-THE-SCOPE-CLIP Ana Catarina Gomes, PT

09:00 - 09:00 CC119SUSPECTED MALIGNANT DEGENERATION IN A ZENKER’SDIVERTICULUM: SHOULD WE BIOPSY IT? Raquel Muñoz González, ES

09:00 - 09:00 CC120DUODENAL-TYPE FOLLICULAR LYMPHOMA Fernanda Lago, BR

09:00 - 09:00 CC121UPPER GASTROINTESTINAL BLEEDING IN LIVERCIRRHOSIS: GASTROESOPHAGEAL VARICES ARE NOTALWAYS TO BLAME Emanuel Dias, PT

09:00 - 09:00 CC122CRONKHITE-CANADA SYNDROME: A CASE REPORT FROMEGYPT Ahmed Alzamzamy, EG

09:00 - 09:00 CC123SUCCESSFUL TREATMENT OF ENTEROCUTANEOUSFISTULA BY ENDOSCOPIC-VACUUM THERAPY INCHILDREN Paula Peruzzi Elia, BR

09:00 - 09:00 CC124AN UNUSUAL CAUSE OF VOMITING AFTER SLEEVEGASTRECTOMY MANAGED ENDOSCOPICALLY WITH THELUSO-COR® ESOPHAGEAL STENT Filipe Damião, PT

09:00 - 09:00 CC125ENDOSCOPIC CLOSURE OF A PERSISTENT POST-PERCUTANEOUS ENDOSCOPIC GASTROSTOMY FISTULA Diana Ramos Silva, PT

09:00 - 09:00 CC126NEW ENDOSCOPIC SOLUTIONS IN MANAGINGPHLEGMONOUS ESOPHAGITIS Ana Luísa Santos, PT

09:00 - 09:00 CC127RECURRENT MELENA DUE TO DUODENAL INTRAMURALPSEUDO-DIVERTICULOSIS (SWISS CHEESE DUODENUM) INPATIENT WITH H PYLORI Omar AbdAllah, EG

09:00 - 09:00 CC128CECUM PERFORATION BY BAROTRAUMA DURINGCOLONOSCOPY PROCEDURE USING CO2 INSTILLATION Sónia Barros, PT




09:00 - 09:00 CC129INTESTINAL AMYLOIDOSIS PRESENTING AS A SOLITARYULCER OF THE CAECUM: A CASE REPORT Federica Crispino, IT09:00 - 09:00 CC130RECTAL ULCERATIONS IN PATIENT WITH PERIANALHERPES SIMPLEX VIRUS TYPE 1 Lourdes Carreira Guillán, ES

09:00 - 09:00 CC131TWO STEP ENDOSCOPIC MUCOSAL RESECTION AND FULL-THICKNESS RESECTION FOR ENDOSCOPIC TREATMENT OFA LARGE ADENOMATOUS RECURRENCE Raquel Muñoz González, ES

09:00 - 09:00 CC132EXTENSIVE ACUTE OCCLUSIVE MESENTERIC ISCHEMIAWITH SEVERE ISCHEMIC COLITIS PRECIPITATED BYSEVERE CLOSTRIDIOIDES DIFFICILE INFECTION, A CASEREPORT Ana Ordonez Vazquez, MX

09:00 - 09:00 CC133EXTENDED GASTROINTESTINAL MANTLE LYMPHOMA Ángela Martina Montero Moretón, ES

09:00 - 09:00 CC134COLONOSCOPY GUIDED MECHANICAL LITHOTRIPSY FORSUCCESSFUL MANAGEMENT OF GALL STONE SIGMOIDILEUS Ashish Gandhi, IN

09:00 - 09:00 CC135DIFFUSE INTESTINAL HEMANGIOMATOSIS: A RARE CAUSEOF GASTROINTESTINAL HEMORRHAGE Ricardo Rios Crespo, PT

09:00 - 09:00 CC136A RARE CAUSE FOR A RARE COMPLICATION Rachel Gingold-Belfer, IL

09:00 - 09:00 CC137A CASE REPORT OF FOUR COLONOSCOPIES USINGARTIFICIAL INTELLIGENCE (AI) FOR THE SCREENING OFCOLORECTAL CANCER - THE FIRST EXPERIENCE INBRAZIL Ivan David Arciniegas Sanmartin, BR

09:00 - 09:00 CC138CONE BEAM CT CAN GUIDE PRESENT AND FUTURE ERCPPROCEDURES : A CASE REPORT Ivan David Arciniegas Sanmartin, BR

09:00 - 09:00 CC139UNCOMMON COMPLICATION AFTER ENDOSCOPICULTRASOUND: GASTRIC COLLECTION IN FISTULOUSTRACT AFTER FINE NEEDLE ASPIRATION OF PANCREATICCYST María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC140ENDOSCOPY, RADIOLOGY AND PATHOLOGY: WHEN THEPIECES DON’T MATCH Ana Catarina Carvalho, PT09:00 - 09:00 CC141UNUSUAL CASE OF HEAD OF PANCREAS MASS:METASTATIC PROSTATE CANCER Montri Gururatsakul, AU

09:00 - 09:00 CC142PANCREATIC LYMPHOMA AS A CAUSE OF MALIGNANTOBSTRUCTIVE JAUNDICE, ROLE OF ENDOSCOPICULTRASOUND Mohammed Gouda, EG

09:00 - 09:00 CC143ENDOSCOPIC ULTRASOUND OF MENETRIER’S DISEASE,RARE CAUSE OF RESISTANT ANEMIA Mohammed Gouda, EG

09:00 - 09:00 CC144PRIMARY EXTRA-NODAL PELVIC LYMPHOMA DIAGNOSEDBY ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLEBIOPSY (EUS-FNB) Omar AbdAllah, EG

09:00 - 09:00 CC145RETROPERITONEAL PARAGANGLIOMA REVEALED BYENDOSONOGRAPHY AND FINE NEEDLE ASPIRATION Ouiam Elmqaddem, MA

09:00 - 09:00 CC147SUCCESSFUL RETRIEVAL OF A RETAINED JEJUNOSTOMYTUBE USING DOUBLE BALLOON ENTEROSCOPY Mariel Dianne Velasco, PH

09:00 - 09:00 CC148BALLOON-ASSISTED ENTEROSCOPY IN DIFFERENCIALDIAGNOSIS BETWEEN SMALL BOWEL CROHN`S DISEASEAND LYMPHOMA Fernando Berdugo-Hurtado, ES

09:00 - 09:00 CC149IS INTESTINAL DIVERTICULOSIS A CONTRAINDICATIONFOR CAPSULE ENDOSCOPY? María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC150PSEUDOCYSTOCOLONIC FISTULA: WHEN CAPSULEENDOSCOPY TAKES AN UNEXPECTED JOURNEY Vítor Macedo Silva, PT

09:00 - 09:00 CC151A DUBIOUS PELVIC ABSCESS IN A PATIENT WITH FAMILIALADENOMATOUS POLYPOSIS Joana Lemos Garcia, PT

09:00 - 09:00 CC152BILIARY OBSTRUCTION FOLLOWING TIPS PLACEMENT IN APATIENT AFTER LIVER TRANSPLANTATION: A CASEREPORT AND REVIEW OF THE LITERATURE Peter Macinga, CZ




09:00 - 09:00 CC153ENDOSCOPIC TREATMENT BY RENDEZVOUS PROCEDUREAND STENT INSERTION TO REOPENING A SEVEREESOPHAGEAL STRICTURE IN YOUNG CHILD Paula Peruzzi Elia, BR

E-Poster Session

09:00 – 19:00 Poster ExhibitionOesophageal, gastric and duodenal disorders

09:00 - 09:00 P0001THE FIRST REPORT ON THE NUCLEOTIDE ECTO-ENZYMEMETABOLIC PATTERN IN THE RAT GASTRIC AND COLONICMUCOSA UNDER THE CONDITIONS OFCYCLOOXYGENASE-1/-2 BLOCKAGE WITH INDOMETHACIN Christina Nasadyuk, UA

09:00 - 09:00 P0003ROLE OF MAFB TRANSCRIPTION FACTOR IN HUMANINTESTINAL METAPLASIA AND GASTRIC CANCERBIOPSIES Rachel Gingold-Belfer, IL

09:00 - 09:00 P0004ZONULIN ASSAY IN CAPILLARY BLOOD ADSORBED ONDRIED BLOOD DEVICES Nicola Volpi, IT

09:00 - 09:00 P0005HYDROGEN SULFIDE (H2S)-RELEASING AP-39 MODULATESGASTRIC MUCOSAL MITOCHONDRIAL ACTIVITYPREVENTING THE OXIDATIVE ISCHEMIA/REPERFUSION(I/R)-INDUCED GASTRIC MUCOSAL INJURY Marcin Magierowski, PL

09:00 - 09:00 P0006EXPRESSION OF THERAPEUTIC TARGETS INGASTROESOPHAGEAL NEUROENDOCRINE CARCINOMA:COMPARISON WITH COEXISTING ADENOCARCINOMA ANDSQUAMOUS CELL CARCINOMA COMPONENTS Satoshi Yamashita, JP

09:00 - 09:00 P0007ABERRANT MUC13 EXPRESSION AS PROGNOSTIC MARKERFOR GASTRIC CANCER Baptiste Oosterlinck, BE

09:00 - 09:00 P0008ELEVATED EPIDERMAL GROWTH FACTOR RECEPTORLEVELS IN BARRETT'S ESOPHAGUS Tereza Deissová, CZ

09:00 - 09:00 P0009 HYPERPLASIC GASTRIC POLYPS : ABOUT 63CASES Walid Sellami, TN

09:00 - 09:00 P0010METAGENOMIC AND METATRANSCRIPTOMIC ANALYSIS OFTHE STOMACH ANTRUM VS CORPUS BIOPSY MICROBIOTAIN PATIENTS WITH GASTROINTESTINAL SYMPTOMS Elena Kupriyanova, RU

09:00 - 09:00 P0011CLOSTRIDIOIDES DIFFICILE INFECTION AFTER VARICEALBLEEDING, A RISK TO BE CONSIDERED Bogdan Ungureanu, RO09:00 - 09:00 P0012SYSTEMATIC REVIEW WITH META-ANALYSIS: INFLUENCEOF INDIVIDUAL PROTON PUMP INHIBITORS ON CLINICALOUTCOMES IN PATIENTS RECEIVING CLOPIDOGRELFOLLOWING PERCUTANEOUS CORONARY INTERVENTION Beom Jin Kim, KR

09:00 - 09:00 P0013UPPER GASTROINTESTINAL BLEEDING IN VERY OLDPATIENTS. RISK FACTORS FOR IN-HOSPITAL AND DELAYEDMORTALITY Rita Jiménez-Rosales, ES

09:00 - 09:00 P0014USE OF INTRAVENOUS IRON REDUCES MORTALITY,HOSPITAL RE-ATTENDANCE AND READMISSION AFTERACUTE PEPTIC ULCER BLEEDING Ting Ting Chan, HK

09:00 - 09:00 P0015HIBAG SCORING SYSTEM: A NEW DYNAMIC RISKASSESSMENT MODEL THAT ACCURATELY PREDICTS THEMORTALITY OF ACUTE UPPER GASTROINTESTINALBLEEDING: A PROSPECTIVE REAL-WORLD STUDY INCHINA Shuang Liu, CN

09:00 - 09:00 P0016TIMING OF ENDOSCOPY FOR UPPER GASTROINTESTINALBLEEDING IN PATIENTS WITH CIRRHOSIS: IS URGENTENDOSCOPY REALLY NECESSARY? Marta Freitas, PT

09:00 - 09:00 P0017PERFORMANCE OF A DEEP LEARNING ALGORITHM FORAUTOMATIC DETECTION OF BLOOD IN THE GASTRICLUMEN USING CAPSULE ENDOSCOPY IMAGES Tiago Ribeiro, PT

09:00 - 09:00 P0018THE UTILITY OF CT ANGIOGRAPHY IN IDENTIFICATION OFACUTE GASTROINTESTINAL BLEEDING SOURCE ANDPREDICTORS OF A POSITIVE EXAMINATION

09:00 - 09:00 P0019DOES HEMOSPRAY HAVE A ROLE TO PLAY AS ACOMBINATION TREATMENT THERAPY FOR UPPER ANDLOWER GASTROINTESTINAL BLEEDS? Mohamed Hussein

09:00 - 09:00 P0020OUR ENDOSCOPY RESULTS IN UPPER GASTROINTESTINALBLEEDING IN COVID-19: SINGLE CENTER EXPERIENCE Oyku Tayfur Yurekli, TR

09:00 - 09:00 P0021ACUTE ESOPHAGEAL NECROSIS: A 10-YEARRETROSPECTIVE SINGLE-CENTER STUDY Emanuel Dias, PT




09:00 - 09:00 P0022ACUTE UPPER GASTROINTESTINAL BLEEDING INPATIENTS USING ANTICOAGULANTS: DOES THE TIMING OFENDOSCOPY AFFECT OUTCOMES? Tiago Lima Capela, PT09:00 - 09:00 P0023MODERN ANTICOAGULATION WITH FACTOR XAINHIBITORS IN ONCOLOGY: IS THE GASTROINTESTINALBLEEDING RATE (ALSO) DECISIVE? Martin Raithel, DE

09:00 - 09:00 P0024OVERLAPPING OF IRRITABLE BOWEL SYNDROME ANDUNINVESTIGATED DYSPEPSIA IN THE ADMINISTRATIVECENTER OF EASTERN SIBERIA Vladislav Tsukanov, RU

09:00 - 09:00 P0025THE YIELD OF ENDOSCOPIC ASSESSMENT OF DYSPEPSIAAND THE EFFECT OF ETHNICITY, AGE AND ALARM SIGNSON ENDOSCOPIC OUTCOMES: A LARGE RETROSPECTIVEPOPULATION STUDY FROM ISRAEL Fadi Abu Baker, IL

09:00 - 09:00 P0026VALIDATION OF SF-LEEDS DYSPEPSIA QUESTIONAIRE INPAKISTAN AND ITS CONVERSION INTO LOCAL LANGUAGE Dheeraj Kumar, PK

09:00 - 09:00 P0027QUANTITATIVE MAGNETIC RESONANCE IMAGING INPATIENTS WITH UNEXPLAINED UPPERGASTROINTESTINAL SYMPTOMS: A RETROSPECTIVESTUDY TO ASSESS INTER-READER AGREEMENT AND THEEFFECT OF USER DEFINED REGION OF INTEREST ONGASTRIC MOTILITY INDEX Heather Evelyn Fitzke, UK

09:00 - 09:00 P0028PLACEBO RESPONSE IN PHARMACOLOGICAL TRIALS INPATIENTS WITH FUNCTIONAL DYSPEPSIA – A SYSTEMATICREVIEW AND META-ANALYSIS Michelle Bosman, NL

09:00 - 09:00 P0029POSTPRANDIAL DISTURBANCES OF AUTONOMICNERVOUS SYSTEM AND GASTRIC ACTIVITY IN PATIENTSWITH FUNCTIONAL DYSPEPSIA Agata Furgała, PL

09:00 - 09:00 P0030ARE THERE CHANGES IN GASTRIC EMPTYING OFDIGESTIBLE SOLIDS IN PROFESSIONAL CYCLISTS DURINGEXERCISE? A PRELIMINARY STUDY Antonio M Caballero-Mateos, ES

09:00 - 09:00 P0031Β-ENDORPHINS DO NOT IMPROVE THE BASAL DELAYEDGASTRIC EMPTYING OF DIGESTIBLE SOLIDS INPROFESSIONAL CYCLISTS Antonio M Caballero-Mateos, ES

09:00 - 09:00 P0032THE PARAVENTRICULAR HYPOTHALAMIC NUCLEUS ISINVOLVED IN EXENDIN-4-INDUCED EMESIS ANDINHIBITION OF FOOD AND WATER INTAKE IN SUNCUSMURINUS Sze Wa Chan, HK09:00 - 09:00 P0033DEXTRAN SODIUM SULPHATE-INDUCEDGASTROINTESTINAL INJURY FURTHER AGGRAVATES THEIMPACT OF GALANTAMINE ON THE GASTRIC MYOELECTRICACTIVITY IN EXPERIMENTAL PIGS Jan Bures, CZ

09:00 - 09:00 P0034ADHESION OF GASTRIC CANCER CELLS TO THE ENTERICNERVOUS SYSTEM IN A NEWLY DEVELOPED CO-CULTUREMODEL: COMPARISON BETWEEN THE INTESTINAL ANDDIFFUSE TYPE OF GASTRIC CANCER Nicolas Chapelle, FR

09:00 - 09:00 P0035EVALUATION OF FORCEFUL INSPIRATORY SUCTION ANDSWALLOW TO TERMINATE TRANSIENT HICCUPS Mark Fox, CH

09:00 - 09:00 P0036WORLDWIDE PREVALENCE AND BURDEN OFGASTROPARESIS-LIKE SYMPTOMS: RESULTS FROM AGLOBAL EPIDEMIOLOGY INTERNET STUDY I-Hsuan Huang, BE

09:00 - 09:00 P0037GUIDEWIRE-ASSISTED PROBE PLACEMENT FOR WATER-PERFUSED HIGH-RESOLUTION MANOMETRY IN PATIENTSWITH ACHALASI Corinne Delbaen, BE

09:00 - 09:00 P0038FROM CHICAGO CLASSIFICATION VERSION 3 TO VERSION4: CHANGES IN DIAGNOSIS AND CLINICAL IMPLICATIONS Sabine Roman, FR

09:00 - 09:00 P0039ESOPHAGEAL MOTOR DISORDERS ACROSS AGES Matteo Ghisa, IT

09:00 - 09:00 P0040THE INTERPLAY BETWEEN STRESS AND FULLNESS INFUNCTIONAL DYSPEPSIA AND HEALTHY CONTROLS: ANEXPLORATORY EXPERIENCE SAMPLING METHOD STUDY Tim Klaassen, NL

09:00 - 09:00 P0041NEUROPSYCHIATRIC EXTRAINTESTINAL MANIFESTATIONSOF THE FUNCTIONAL GASTROINTESTINAL DISORDERS Marija Marjanovic-Haljilji, RS




09:00 - 09:00 P0042A DIAGNOSTIC DELAY OF TEN YEARS IN THE DANEOECOHORT CALLS FOR FOCUS ON EDUCATION - APOPULATION-BASED STUDY OF INCIDENCE, DIAGNOSTICPROCESS AND COMPLICATIONS OF EOSINOPHILICOESOPHAGITIS IN THE NORTH DENMARK REGION Anne Lund Krarup, DK09:00 - 09:00 P0043SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASEACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE INADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OFA NATIONWIDE PROSPECTIVE COHORT STUDY Philipp Schreiner, CH

09:00 - 09:00 P0044EFFICACY OF STEPPED THERAPY WITH PROTON PUMPINHIBITORS IN ADULT PATIENTS WITH EOSINOPHILICESOPHAGITIS AFTER 12 MONTHS OF FOLLOW UP IN OURHEALTHCARE AREA Lucía Madero, ES

09:00 - 09:00 P0045EOSINOPHILIC ESOPHAGITIS – OUR CLINICAL EXPERIENCEWITH ORODISPERSIBLE TABLET FORMULATIONBUDESONIDE (BOT) Michael Ding

09:00 - 09:00 P0046DUPILUMAB IN PAEDIATRIC PATIENTS WITHEOSINOPHILIC OESOPHAGITIS – DESIGN OF ARANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLEDSTUDY TO INVESTIGATE THE EFFICACY AND SAFETY OFDUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVEEOSINOPHILIC OESOPHAGITIS Mirna Chehade, US

09:00 - 09:00 P0047DIETARY ELIMINATION THERAPY AND PROTON-PUMPINHIBITORS IN PAEDIATRIC EOSINOPHILIC GASTRITIS:EFFICACY AND FACTORS INFLUENCING HISTOLOGICREMISSION IN ASIAN CHILDREN Lay Queen Ng, SG

09:00 - 09:00 P0048EOSINOPHILIC OESOPHAGITIS: INCREASING PREVALENCEOVER TWO DECADES AT AN IRISH TERTIARY REFERRALCENTRE Thomas Matthews, IE

09:00 - 09:00 P0049CAN HISTOLOGIC ACTIVITY AND EXPERTISE AFFECT THEACCURACY OF ENDOSCOPIC REFERENCE SCORE (EREFS)? Renato Medas, PT

09:00 - 09:00 P0050A SURVEY BASED ASSESSMENT OF MANAGEMENT OFESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE Philipp Schreiner, CH

09:00 - 09:00 P0051ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTSWITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVEOF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY Philipp Schreiner, CH09:00 - 09:00 P0052SYMPTOM AND QUALITY OF LIFE BURDEN AMONGPATIENTS WITH EOSINOPHILIC OESOPHAGITIS IN A REAL-WORLD SETTING Alain M. Schoepfer, CH

09:00 - 09:00 P0053COMPLIANCE FOR THE PROSE DAILY DIARY: MEASURINGCOMPLETION RATES OF A NEW INSTRUMENT TO MEASUREDYSPHAGIA EPISODES IN PATIENTS WITH EOSINOPHILICESOPHAGITIS Stella Karantzoulis, US

09:00 - 09:00 P0054EOSINOPHILIC ESOPHAGITIS IS FREQUENTLY ASSOCIATEDWITH DISORDERS OF PERISTALSIS AT HIGH-RESOLUTIONMANOMETRY: A PROSPECTIVE SINGLE-CENTRE CASE-CONTROL STUDY Pierfrancesco Visaggi, IT

09:00 - 09:00 P0055THE PREVALENCE OF GASTROESOPHAGEAL REFLUXDISEASE AND ITS ASSOCIATION WITH LIFESTYLE Said Farhat, LB

09:00 - 09:00 P0056COMPARISON OF REFLUX PATTERNS AND ESOPHAGEALMUCOSAL IMPAIRMENT BETWEEN PATIENTS WITH NON-EROSIVE REFLUX DISEASE WITH AND WITHOUT HIATUSHERNIA Akinari Sawada

09:00 - 09:00 P0057REFLUX CHARACTERISTICS TRIGGERING POST-REFLUXSWALLOW-INDUCED PERISTALTIC WAVE (PSPW) INPATIENTS WITH GERD SYMPTOMS Mentore Ribolsi, IT

09:00 - 09:00 P0058DIAGNOSIS AND TREATMENT PATTERNS OF EROSIVEESOPHAGITIS IN CHINA: A SUBGROUP ANALYSIS FROM ARETROSPECTIVE REAL-WORLD STUDY Xiaoyun Yu, CN

09:00 - 09:00 P0059ANALYSIS OF QUALITY OF LIFE BY GASTOINTESTINALQUALITY OF LIFE INDEX GIQLI IN PATIENTS WITH GERD Karl Hermann Fuchs, DE

09:00 - 09:00 P0060THE INCIDENCE OF BARRETT’S OESOPHAGUS AT A DGHENDOSCOPY UNIT, AND ITS ASSOCIATED CONVERSIONRATE TOWARDS OESOPHAGEAL CANCER: A 10YRETROSPECTIVE REVIEW Matthew Johnson




09:00 - 09:00 P0061FOCAL C2 CRYOBALLOONTM ABLATION WITH 8SEC DOSEHAS SIMILAR EFFICACY AS 10SEC FOR TREATMENT OFBARRETT’S ESOPHAGUS RELATED NEOPLASIA. Charlotte N. Frederiks, NL09:00 - 09:00 P0062RISK OF BARRETT’S ESOPHAGUS AND ESOPHAGEALADENOCARCINOMA IN PATIENTS DIAGNOSED WITHBREAST CANCER – A NATIONWIDE STUDY Yonne Peters, NL

09:00 - 09:00 P0063INCREASED RISK OF BARRETT’S ESOPHAGUS ANDESOPHAGEAL ADENOCARCINOMA IN INDIVIDUALS WITH APOSITIVE FAMILY HISTORY Yonne Peters, NL

09:00 - 09:00 P0064HYBRID ARGON PLASMA COAGULATION IN THE ABLATIONTREATMENT OF BARRETT´S ESOPHAGUS - LONG TERMRESULTS Radek Kroupa, CZ

09:00 - 09:00 P0065SEATTLE PROTOCOL BIOPSIES OF NORMAL NEO-SQUAMOUS EPITHELIUM IN ERADICATED BARRETT’S WITHPRIOR DYSPLASIA HAVE MINIMAL VALUE, A PROSPECTIVESINGLE CENTRE STUDY Alexander Huelsen, AU

09:00 - 09:00 P0066USE OF ANTI-ANDROGENIC 5Α-REDUCTASE INHIBITORSAND RISK OF OESOPHAGEAL AND GASTRIC CANCER BYHISTOLOGICAL TYPE AND ANATOMICAL SUB-SITE Sirus Rabbani, SE

09:00 - 09:00 P0067ENDOSCOPIC RESECTION FOLLOWED BYCHEMORADIOTHERAPY: A NEW STRATEGY FOR ADVANCEDUNRESECTABLE ESOPHAGEAL SQUAMOUS CELLCARCINOMA Lihua Ren, CN

09:00 - 09:00 P0068STEPWISE HYBRID ENDOSCOPIC THERAPY FORCIRCUMFERENTIAL ESOPHAGEAL SQUAMOUS CELLNEOPLASIA: A CASE SERIES AND LITERATURE REVIEW Siyu Lei, CN

09:00 - 09:00 P0071ENDOSCOPIC PHOTODYNAMIC RECANALIZATION OFOBSTRUCTIVE ESOPHAGUS CANCER Evgeny Stranadko, RU

09:00 - 09:00 P0072THE EFFECTIVENESS AND SAFETY OF CIRCUMFERENTIALENDOSCOPIC SUBMUCOSAL DISSECTION FORESOPHAGEAL CANCER: A COMPARISON TOCONVENTIONAL ENDOSCOPIC SUBMUCOSAL DISSECTIONFROM THE PERSPECTIVE OF LONG-TERM OUTCOMES Takakazu Miyake, JP

09:00 - 09:00 P0073TUMOR THICKNESS IS ASSOCIATED WITH METASTASIS INSUBMUCOSAL INVASIVE ADENOCARCINOMA OF THEESOPHAGOGASTRIC JUNCTION Nobuhisa Minakata, JP09:00 - 09:00 P0074A SYMPTOM AND RISK FACTOR QUESTIONNAIREACCURATELY PREDICTS UPPER GASTROINTESTINALCANCER Kai Man Alexander Ho

09:00 - 09:00 P0075ANASTOMOTIC LEAK IN ESOPHAGOGASTRIC ONCOLOGICSURGERY: MANAGEMENT WITH FULLY COVERED SELF-EXPANDABLE METALLIC STENTS Daniel Conceição, PT

09:00 - 09:00 P0076PREVALENCE AND PREDICTORS OF MALNUTRITION INPATIENTS WITH ESOPHAGEAL CANCER- A SINGLE CENTERPROSPECTIVE STUDY Prachi Patil, IN

09:00 - 09:00 P0077CHARACTERISTICS OF GASTRIC MUCOSAL INJURIES INPATIENTS TAKING CLOPIDOGREL Yuji Shimada, JP

09:00 - 09:00 P0078GASTROPROTECTIVE ACTION OF APELIN/AJP SYSTEMAGAINST ISCHEMIA-REPERFUSION INJURY. ROLE OFOXIDATIVE STRESS, NITRIC OXIDE AND SENSORYNEUROPEPTIDES Marcin Magierowski, PL

09:00 - 09:00 P0079THE EFFICACY AND SAFETY OF H008 COMPARED WITHLANSOPRAZOLE IN PATIENTS WITH DUODENAL ULCER(DU): A PHASE II, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL MULTICENTER STUDY IN CHINA Yinglian Xiao, CN

09:00 - 09:00 P0080APPROPRIATENESS OF PROTON PUMP INHIBITORPRESCRIPTIONS IN CLINICAL PRACTICE Lieke Maria Koggel, NL

09:00 - 09:00 P0081RISK FACTORS AND CLINICAL OUTCOMES OF POST-GASTRECTOMY SARCOPENIA NEWLY DEVELOPED AFTERCURATIVE RESECTION FOR GASTRIC CANCER Beom Jin Kim, KR

09:00 - 09:00 P0082SERUM PEPSINOGENS COMBINED WITH NEWBIOMARKERS MEASURED BY CHEMILUMINESCENTENZYME IMMUNOASSAY FOR NON-INVASIVE DIAGNOSISOF ATROPHIC GASTRITIS: A PROSPECTIVE MULTICENTERSTUDY Nicolas Chapelle, FR




09:00 - 09:00 P0083HYPERGASTRINEMIA IS NOT ASSOCIATED WITHINCREASED MORTALITY IN GASTRIC ADENOCARCINOMA Eivind Ness-Jensen, NO09:00 - 09:00 P0084LAUREN-TYPE GASTRIC CANCER VARIABLE BY AGE ANDSEX Hyeong Ho Jo, KR

09:00 - 09:00 P0085QUALITY OF LIFE IS ASSOCIATED WITH SURVIVAL INGASTRIC CANCER PATIENTS: RESULTS FROM THE CRITICSTRIAL Romy van Amelsfoort, NL

09:00 - 09:00 P0086PERSONALITY TRAITS ARE STRONGLY ASSOCIATED WITHGASTROINTESTINAL CANCER PATIENTS’ PSYCHOSOCIALBURDEN: AN ONGOING STUDY Christos Sotiropoulos, GR

09:00 - 09:00 P0087IMPORTANCE OF ENDOSCOPIC DIAGNOSIS FROM THEVIEWPOINT OF THE DISEASE STATE OF BURKITTLYMPHOMA Hiroyuki Aoyagi, JP

09:00 - 09:00 P0088USE OF PROTON PUMP INHIBITORS IS ASSOCIATED WITHINCREASED RISK OF GASTRIC CANCER IN COMMUNITYDWELLING ELDERLY Rachel Gingold-Belfer, IL

09:00 - 09:00 P0089SAFETY, EFFICACY, CLOSURE TECHNIQUES AND MEDIUM-TERM OUTCOMES OF ENDOSCOPIC FULL-THICKNESSRESECTION – A DECADE LONG EXPERIENCE FROM ATERTIARY CARE CENTER Ashish Gandhi, IN

09:00 - 09:00 P0090UNDIFFERENTIATED-PREDOMINANT MIXED-TYPE EARLYGASTRIC CANCER IS MORE AGGRESSIVE THAN PUREUNDIFFERENTIATED-TYPE: A META-ANALYSIS Xiaoyong Wang, CN

09:00 - 09:00 P0091COMPARISON OF ENDOSCOPIC PAPILLECTOMYOUTCOMES IN PATIENTS WITH SPORADIC AND FAMILIALADENOMATOUS POLYPOSIS ASSOCIATED LESIONS. Mateusz Szmit, PL

E-Poster Session

09:00 – 19:00 Poster ExhibitionHealth economics / Digitalisation in GI / Education In GI /Gender and diversity

09:00 - 09:00 P1102COSTS SAVINGS ASSOCIATED WITH FERRIC MALTOL ANDTHE REDUCED USE OF INTRAVENOUS IRON BASED ONREAL WORLD DATA Stefanie Howaldt, DE09:00 - 09:00 P1103A 7 YEAR RETROSPECTIVE REVIEW OF IRON DEFICIENCYANAEMIA IN A CATCHMENT OF 330,000, DEMONSTRATINGTHE NEED FOR A DEDICATED ANAEMIA SERVICE Matthew Johnson

09:00 - 09:00 P1104INAPPROPRIATE PRESCRIPTION OF PROTON PUMPINHIBITORS IN AN INTERNAL MEDICINE SERVICE – ARETROSPECTIVE STUDY Pedro Campelo, PT

09:00 - 09:00 P1105CAN ARTIFICIAL INTELLIGENCE INCREASE THE EFFICIENCYIN REFERRALS FROM PRIMARY TO SPECIALIZED CARE? Marta Tejedor, ES

09:00 - 09:00 P1106TELEMEDICINE CONSULTATIONS DURING THE COVID-19PANDEMIC ARE ASSOCIATED WITH A HIGH DEGREE OFSATISFACTION AND REDUCED ANXIETY IN PATIENTS WITHDISORDERS OF GUT-BRAIN INTERACTION Radislav Nakov, BG

09:00 - 09:00 P1107AN EARLY EVALUATION OF PARTICIPANT RECRUITMENTAND COMPLIANCE FOLLOWING THE VIRTUALISATION OFTHE RELIEVE IBS-D TRIAL Cho Ee Ng

09:00 - 09:00 P1108PATIENT PERSPECTIVES ON VIRTUAL OUTPATIENTCLINICS DURING THE COVID-19 PANDEMIC IN GENERALSURGERY George Averill

09:00 - 09:00 P1109NUTRITIONAL THERAPY FOR IRRITABLE BOWELSYNDROME – DO PATIENTS BENEFIT FROM APP-ASSISTEDLOW-FODMAP THERAPY? Leonie Geigis, DE

09:00 - 09:00 P1110ACCURACY AND APPLICABILITY OF THE ARTIFICIALINTELLIGENCE INTEGRATED SOFTWARE IN Z-LINESEGMENTATION Hang Dao, VN

09:00 - 09:00 P1111RATE OF INAPPROPRIATE PROTON PUMP INHIBITORSPRESCRIPTION AT DISCHARGE FROM INTERNAL MEDICINEDEPARTMENTS ACCORDING TO A DEVELOPEDALGORITHM Orly Sneh-Arbib, IL




09:00 - 09:00 P1112ONLINE EDUCATION SIGNIFICANTLY IMPROVEDGASTROENTEROLOGISTS' KNOWLEDGE OF CROHNDISEASE MANAGEMENT Elaine Bell09:00 - 09:00 P1113ONLINE EDUCATION SIGNIFICANTLY IMPROVESGASTROENTEROLOGISTS' KNOWLEDGE OF URGENCY AS AKEY CONCERN FOR PATIENTS WITH ULCERATIVE COLITIS Elaine Bell

09:00 - 09:00 P1114BARRIERS TO INFORMED CONSENT IN THERAPEUTICENDOSCOPY: EXPERIENCE IN A LARGE TEACHINGHOSPITAL George Sismey, UK

09:00 - 09:00 P1115LEARNING CURVES IN SMALL BOWEL CAPSULEENDOSCOPY Anders Bo Nielsen, DK

09:00 - 09:00 P1117READY STEADY GO TRANSITION PROGRAM FOR GREEKADOLESCENTS WITH INFLAMMATORY BOWEL AND CELIACDISEASE Antonios Theodorakopoulos, GR

09:00 - 09:00 P1118NEW POSSIBILITIES OF TRAINING FLEXIBLE ENDOSCOPY -INNOVATIVE, HYGIENIC, ALWAYS AVAILABLE Benedikt Mothes, DE

09:00 - 09:00 P1119SCOPING THE ROLE AND CONTENT OF A SIMULATOR-BASED ENDOSIM CURRICULUM Catherine Eley

09:00 - 09:00 P1120HOSPITAL COMPOUND LEVEL ENDOSCOPY TRAININGQUALITY PERFORMANCE: SCOPING THE SPECTRUM Catherine Eley

09:00 - 09:00 P1121VIRTUAL REALITY IMPLEMENTATION FOR PHYSICIANS ANDNURSES ENDOSCOPY TRAINING: RESULTS FROM ANINTERNATIONAL SURVEY Alexander Hann, DE

E-Poster Session

09:00 – 19:00 Poster ExhibitionOther lower GI disorders

09:00 - 09:00 P0523NP/LHB RATIO (NEUTROPHILS XPLATELETS/LYMPHOCYTES X HEMOGLOBIN) AS APOTENTIAL PROGNOSTIC AND DIAGNOSTIC MARKER OFCOLORECTAL CANCER Maria Hernandez Ainsa, ES

09:00 - 09:00 P0524IS ANTI-PD1-INDUCED COLITIS A DISTINCT HISTOLOGICALSUBTYPE? Stratigoula Sakellariou, GR09:00 - 09:00 P0525GUT BACTERIA FUNCTIONALITY PROFILES AND DIVERSITYINDEX DETECTED BY THE GA-MAP® DYSBIOSIS TEST LX Kristin Gravdal, NO

09:00 - 09:00 P0527STUDYING THE MUTUAL INTERACTION BETWEEN THEHUMAN GUT EPITHELIUM AND THE PREDOMINANTLYANAEROBIC GUT MICROBIOME IN HOXBAN-STOOL Raphael Fagundes Rosa, NL

09:00 - 09:00 P0529COVID-19 INFECTION AND CORRELATION OFCLOSTRIDIUM DIFFICILE COLITIS IN ELDERLY PATIENTS Carmen-Rodica Anton, RO

09:00 - 09:00 P0530UTILITY OF FOLLOW-UP ENDOSCOPY/IMAGING TODOCUMENT POST-THERAPY HEALING/RESOLUTION INPEDIATRIC ABDOMINAL TUBERCULOSIS Vignesh V, IN

09:00 - 09:00 P0531THE ESTABLISHMENT OF KLEBSIELLA QUASIPNEUMONIAEGASTROINTESTINAL MICE MODEL AND ERADICATION OFPATHOGEN BY ORAL DELIVERY OF ENCAPSULATEDKLEBICIN KVARIA Indre Karaliute, LT

09:00 - 09:00 P0532EFFICACY OF COMBINATION THERAPY OF EPINEPHRINELOCAL INJECTION AND HEMOSTATIC CLIP ON ACTIVEDIVERTICULAR BLEEDING Akira Teramoto, JP

09:00 - 09:00 P0533BMI &GT; 30 DOES NOT PREDICT NEGATIVE OUTCOMES INPATIENTS WHO EXPERIENCED GI BLEEDING IN AN URBANINPATIENT SETTING Muddasir Ayaz, US

09:00 - 09:00 P0534ABC SCORE TO PREDICT LOWER GASTROINTESTINALBLEEDING SEVERITY: A STEP IN THE RIGHT DIRECTION Joana Revés, PT

09:00 - 09:00 P0535ROLE OF URGENT CONTRAST-ENHACED COMPUTEDTOMOGRAPHY FOR ACUTE LOWER GASTROINTESTINALBLEEDING BEFORE COLONOSCOPY AND EVALUATION OFPREDICTORS FOR EXTRAVASATION POSITIVE SIGN FROMJAPANESE MULTICENTER STUDY (CODE BLUE J- STUDY) Takashi Ikeya, JP

09:00 - 09:00 P0536RISK OF BLEEDING AFTER COLORECTAL ENDOSCOPICRESECTION IN PATIENTS WITH CONTINUED USE OFWARFARIN Katsuaki Inagaki, JP




09:00 - 09:00 P0537MORTALITY FROM COLORECTAL CANCER IN THEPOPULATION INVITED TO A POPULATION-BASEDSCREENING PROGRAM USING THE FAECAL OCCULTBLOOD TEST Gemma Ibáñez-Sanz, ES09:00 - 09:00 P0538IS THERE A PLACE FOR SIGMOIDOSCOPY INCONTEMPORARY ENDOSCOPIC SCREENING FORCOLORECTAL CANCER? Vasileios Panteris, GR

09:00 - 09:00 P0539RISK ASSESSMENT OF COLORECTAL CARCINOMAS IN CO-INFECTED HEPATITIS B PATIENTS-REVIEW WITH META-ANALYSIS Ertugrul Giray Guven, BG

09:00 - 09:00 P0540CLINICAL SIGNIFICANCE OF INCIDENTAL COLONIC FOCAL 18F-FDG PET/CT UPTAKE. THE EXPERIENCE OF A CANCERCENTER Polyxeni Kevrekidou, GR

09:00 - 09:00 P0541PREVALENCE OF ADENOMAS IN LYNCH SYNDROME: GENE-SPECIFIC ANALYSIS AND COMPARISON WITH AVERAGEAND FAMILIAL CRC RISK POPULATIONS Ariadna Sanchez, ES

09:00 - 09:00 P05423 YEAR EVALUATION OF FAECAL IMMUNOCHEMICAL TEST(FIT) FOR PRIORITISATION OF URGENT COLORECTALCANCER REFERRAL IN SYMPTOMATIC PATIENTS James Bailey

09:00 - 09:00 P0543RISKS AND HISTOPATHOLOGIC CHARACTERISTICS OFEARLY-ONSET COLORECTAL CANCER: A SINGLE CENTERSTUDY Elif Sitre Koç, TR

09:00 - 09:00 P0544KRAS MUTATION: A RISK FACTOR FOR THE DEVELOPMENTOF ADVANCED METACHRONOUS ADENOMAS INSURVEILLANCE COLONOSCOPY Alejandro Martinez-Roca, ES

09:00 - 09:00 P0545ADENOMA DETECTION RATES, CANCER RATES, ANDCOMFORT SCORES OF WHITE AND SOUTH ASIANPOPULATIONS IN THE UK BOWEL CANCER SCREENINGPROGRAMME Ajay M Verma

09:00 - 09:00 P0546IDENTIFICATION OF ATF6-DRIVEN GENE-SIGNATURE WITHPROGNOSTIC VALUE IN COLORECTAL CANCER Sandra Bierwirth, DE

09:00 - 09:00 P0547TOLL-LIKE RECEPTOR-4-DRIVEN MACROPHAGEPOLARIZATION IN COLORECTAL CANCER IS MODULATEDBY THE ECM MOLECULE EMILIN2 Eva Andreuzzi, IT09:00 - 09:00 P0548INTERLEUKIN 33 IS A NEGATIVE REGULATOR OF THETUMOUR SUPPRESSOR PROTEIN P53 IN A MODEL OFCOLORECTAL ADENOCARCINOMA Maximilian Wellenhofer, DE

09:00 - 09:00 P0549APPENDICEAL LESIONS IN SERRATED POLYPOSISPATIENTS: HIGHLY PREVALENT BUT LOW MALIGNANTPOTENTIAL David van Toledo, NL

09:00 - 09:00 P0550NANOMOLAR EP4 RECEPTOR POTENCY IN NORMALAPPEARING COLONIC MUCOSA FROM PATIENTS WITHCOLORECTAL NEOPLASIA Ulrike Ries Feddersen, DK

09:00 - 09:00 P0551NEW MUTATIONS IN THE APC GENE IN BELARUSIANFAMILIES WITH FAMILIAL ADENOMATOUS POLYPOSIS:CLINICAL MANIFESTATIONS AND GENETIC ASPECTS Natalyia Lagodich, BY

09:00 - 09:00 P0552COMBINED USE OF FINDINGS OF LEVELS OF FATTY ACIDSIN ERYTHROCYTE MEMBRANES AND BLOOD SERUM ASWELL AS ELECTRIC, VISCOELASTIC PARAMETERS OFERYTHROCYTES INCREASES ACCURACY OF DIAGNOSIS OFPRE-CANCER AND EARLY COLORECTAL CANCER Margarita Vitalievna Kruchinina, RU

09:00 - 09:00 P0553MAGE-A10 CANCER/TESTIS ANTIGEN IS HIGHLYEXPRESSED IN AGGRESSIVE SUB-TYPE OF COLORECTALCANCER Vedran Tomasic, HR

09:00 - 09:00 P0554PKHD1 MUTATION AS A POTENTIAL PROGNOSTIC FACTORAND A POSITIVE PREDICTOR OF RESPONSE TO IMMUNECHECKPOINT INHIBITORS IN PATIENTS WITH COLONCANCER Weijun Tian, CN

09:00 - 09:00 P0555COLORECTAL CANCER SCREENING IN THE ELDERLY - DOESINCREASED PREVALENCE NECESSITATE TIGHTERSURVEILLANCE? Mohamad Suki, IL

09:00 - 09:00 P0556TELEMEDICINE IN THE COVID ERA, A REAL-LIFEEXPERIENCE IN THE COLORECTAL CANCER DIAGNOSIS Rita Jiménez-Rosales, ES




09:00 - 09:00 P0557FAECAL IMMUNOCHEMICAL TEST (FIT) IN SECONDARYCARE: PRIORITISING LOWER GI TWO WEEK WAIT PATIENTSDURING THE COVID19 PANDEMIC Christopher Kearsey09:00 - 09:00 P0558THE EFFICACY OF MAGNIFIED ENDOSCOPIC OBSERVATIONWITH NARROW BAND IMAGING AND BLUE LASER IMAGINGFOR DIAGNOSING COLORECTAL SERRATED LESIONS Reo Kobayashi, JP

09:00 - 09:00 P0559HIGH EXPRESSION OF BROTHER OF THE REGULATOR OFTHE IMPRINTED SITE (BORIS) CYTOPLASM-LOCALIZEDPROTEIN IS NOT ASSOCIATED WITH HIGH-RISK FEATURESOF COLORECTAL CANCER Petra Ćaćić, HR

09:00 - 09:00 P0560PREMALIGNANT POLYPS, COLORECTAL CANCER AND THE'SCOPE' FOR COLORECTAL CANCER SCREENING IN CYSTICFIBROSIS: A 10 YEAR EXPERIENCE FROM A UK CENTRE Karuna Sapru

09:00 - 09:00 P0561PCCRC CASES IDENTIFIED USING POPULATION-BASEDDATA MAY BE RE-CLASSIFIED AS DETECTED CANCERSWHEN LOCAL DATA IS USED TO PERFORM A ROOT CAUSEANALYSIS Ahmir Ahmad

09:00 - 09:00 P0562CLINICOPATHOLOGICAL AND SURVIVAL FEATURES OFCOLORECTAL LYMPHOMAS: A RETROSPECTIVE SINGLE-CENTER STUDY OF 31 PATIENTS Emanuel Dias, PT

09:00 - 09:00 P0563BOWEL LUMEN LAVAGE FLUID AS BIOLOGICAL SAMPLEFOR CHARACTERIZATION AND ANALYSIS OFEXTRACELLULAR VESICLES IN COLORECTAL CANCERPATIENTS Marina Alorda-Clara, ES

09:00 - 09:00 P0564USE OF THE FAECAL IMMUNOCHEMICAL TEST FORPATIENTS WITH LOWER RISK SYMPTOMS OF COLORECTALCANCER IN PRIMARY CARE: A PRAGMATIC PROSPECTIVESTUDY IN THE EAST OF ENGLAND Fiona M. Walter, UK

09:00 - 09:00 P0565IS CRUSH CYTOLOGY EFFECTIVE IN DIAGNOSING LUMINALGASTROINTESTINAL MALIGNANCY? Anto Gnana Delasalle, IN

09:00 - 09:00 P0566DIAGNOSTIC YIELD USING A FIT-BASED RISK MODEL WASNOT BETTER THAN FIT ONLY: A RANDOMIZEDCONTROLLED TRIAL IN THE SECOND ROUND OF THEDUTCH COLORECTAL CANCER SCREENING PROGRAMME Tim Kortlever, NL

09:00 - 09:00 P0567THE IMPACT OF THE FAECAL IMMUNOHISTOCHEMICALTEST IN THE PROGNOSIS OF SYMPTOMATIC PATIENTSWITH COLORECTAL CANCER Jesús Daniel Fernández de Castro, ES09:00 - 09:00 P0568AGE, BODY MASS INDEX (BMI) AND DIABETESSIGNIFICANTLY AFFECTS ADEQUACY OF BOWELPREPARATION AND POLYP DETECTION IN SCREENINGCOLONOSCOPY: A PROSPECTIVE OBSERVATIONAL STUDY Alexandros Ioannou, GR

09:00 - 09:00 P0569DIAGNOSTIC PERFORMANCE OF MAGNETIC RESONANCETO ASSESS COMPLETE RESPONSE AFTER NEOADJUVANTCHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTALCANCER Pedro Campelo, PT

09:00 - 09:00 P0570THE CLINICOPATHOLOGICAL DIFFERENCES OF ADENOMASAND INTRAMUCOSAL CANCERS DETECTED BETWEEN THECOLON AND THE RECTUM Seiji Kimura, JP

09:00 - 09:00 P0571COMPARISON OF 1-L PEG PLUS ASCORBIC ACID WITHLINACLOTIDE VERSUS SENNOSIDE FOR COLON CLEANINGIN CONSTIPATED PATIENTS Natsumi Maeda, JP

09:00 - 09:00 P0572BACTERIAL SIGNATURE TO OPTIMIZE ENDOSCOPICSURVEILLANCE IN PATIENTS WITH HIGH-RISK OFDEVELOPING ADVANCED COLORECTAL NEOPLASIA Mireia López Sánchez-Vizcaino, ES

09:00 - 09:00 P0573CLASSIFICATION OF METASTATIC COLORECTAL CANCER:DOES UICC MISS THE MARK? Martin Flatz, DE

09:00 - 09:00 P0574THE IMPACT OF COVID-19 IN COLORECTAL CANCER CARE Sofia Saraiva, PT

09:00 - 09:00 P0575ENDOSCOPIC MANAGEMENT TARGETING COLORECTALLESIONS &GT;5MM ALONG WITH STRICT SURVEILLANCE INFAMILIAL ADENOMATOUS POLYPOSIS: SINGLE CENTEREXPERIENCE Tatsuro Murano, JP

09:00 - 09:00 P0577IS METFORMIN ASSOCIATED WITH A LOWER PREVALENCEOF POLYPS, ADENOMAS AND COLORECTAL CARCINOMA INPATIENTS WITH DIABETES MELLITUS? Maria Inês Canha, PT




09:00 - 09:00 P0578FIRST-LINE PALLIATIVE SYSTEMIC THERAPY ALTERNATEDWITH ELECTROSTATIC PRESSURIZED INTRAPERITONEALAEROSOL CHEMOTHERAPY (OXALIPLATIN) FOR ISOLATEDUNRESECTABLE COLORECTAL PERITONEAL METASTASES:A MULTICENTRE, SINGLE-ARM, PHASE II STUDY (CRC-PIPAC-II). Paulien Rauwerdink, NL09:00 - 09:00 P0580IDENTIFICATION OF AN AT-RISK SUBPOPULATION WITHHIGH IMMUNE INFILTRATION BASED ON PEROXISOMEPATHWAY AND TIM3 IN COLORECTAL CANCER Jinwen Yin, CN

09:00 - 09:00 P0581AN EVALUATION OF THE FULLY ROBOTIC ANTERIORRESECTION LEARNING CURVE AND SHORT-TERM CLINICALOUTCOMES Seung Yeop Oh, KR

09:00 - 09:00 P0582DIMETHYL FUMARATE AND BCL-2 INHIBITOR ABT-199INDUCE CELL DEATH AND INHIBIT CELL PROLIFERATIONIN COLORECTAL CANCER CELLS Simon Wagner, DE

09:00 - 09:00 P0583FLUORESCENCE MOLECULAR ENDOSCOPY USINGCETUXIMAB-800CW TO EVALUATE THE RESPONSE TONEOADJUVANT CHEMORADIOTHERAPY IN LOCALLYADVANCED RECTAL CANCER: PRELIMINARY RESULTS Anne M. van der Waaij, NL

09:00 - 09:00 P0584GASTROENTEROLOGIST AGAINST THE MACHINE –OPPORTUNITIES AND LIMITATIONS OF MACHINELEARNING FOR PREDICTION OF ADVANCED ADENOMA Georg Semmler, AT

09:00 - 09:00 P0587EVALUATION OF BASELINE CHARACTERISTICS ANDEVOLUTION OF PATIENTS UNDERWENT ENDOSCOPICPLACEMENT OF SELF-EXPANDABLE METALLIC COLONICSTENT IN A TERTIARY CENTRE Lorena Carballo-Folgoso, ES

09:00 - 09:00 P0588MANAGEMENT OF PREOPERATIVE ANEMIA WITH IRONTHERAPY IN COLORECTAL CANCER PATIENTS- ASYSTEMATIC REVIEW AND META-ANALYSIS Sangara Narayanan Narayanasamy

09:00 - 09:00 P0589PREOPERATIVE THERAPY SELECTION ON LOCALADVANCED RECTAL CANCER: DECISIONS DURINGUNCERTAIN TIMES Paula Marques, PT

09:00 - 09:00 P0590GLUTEN INTAKE AND GASTROINTESTINAL SYMPTOMS INPATIENTS WITH IRRITABLE BOWEL SYNDROME Joost Algera, SE

09:00 - 09:00 P0591PREVALENCE AND QUALITY OF LIFE IMPACT OF GAS-RELATED SYMPTOMS IN THE GENERAL POPULATION:FINDINGS FROM A SURVEY OF THE UNITED STATES (US),UNITED KINGDOM (UK) AND MEXICO Olafur S. Palsson, US09:00 - 09:00 P0592IRRITABLE BOWEL SYNDROME: PREVALENCE ANDASSOCIATED FACTORS OF THE BIOPSYCHOSOCIAL MODELDURING THE CORONAVIRUS DISEASE-19 PANDEMIC.CROSS-SECTIONAL STUDY Angel Daniel Trujillo Leija, MX

09:00 - 09:00 P0593IS THERE A LINK BETWEEN SYMPTOMS, BACTERIALFERMENTATION, FECAL SHORT-CHAIN FATTY ACIDS, ANDGLUTEN IN IRRITABLE BOWEL SYNDROME? Joost Algera, SE

09:00 - 09:00 P0594THE ROLE OF ABUSE HISTORY IN IRRITABLE BOWELSYNDROME: RELATIONSHIP WITH GASTROINTESTINALAND EXTRAINTESTINAL SYMPTOM SEVERITY Chloé Melchior, FR

09:00 - 09:00 P0595IMPACT OF PRENATAL STRESS ON VISCERALHYPERSENSITIVITY AND GUT MICROBIOTA INADULTHOOD. Camille Petitfils, FR

09:00 - 09:00 P0596CHARACTERISING PSYCHOMORBIDITY AND QUALITY OFLIFE IN PATIENTS WITH HYPERMOBILE EHLERS-DANLOSSYNDROME STRATIFIED ACCORDING TO FUNCTIONALGASTROINTESTINAL DISEASE Anisa Choudhary

09:00 - 09:00 P0597EFFECT OF COVID RELATED RESTRICTIONS ON IRRITABLEBOWEL SYNDROME PSYCHOLOGICAL WELL-BEING. ACOMPARATIVE STUDY WITH ULCERATIVE COLITIS Ariadna Aguilar, ES

09:00 - 09:00 P0598THE RELATIONSHIP BETWEEN HOSPITAL ADMISSIONSFOR CONSTIPATION AND OPIOID PRESCRIBING: A 20 YEARCORRELATION STUDY Shivam Chauhan, UK

09:00 - 09:00 P0599INTERMITTENT COLONIC EXOPERISTALSIS DEVICE FORTHE TREATMENT OF CHRONIC CONSTIPATION IN SPINALCORD INJURED PATIENTS. A LONG-TERM EVALUATION INHOME CARE USE Immaculada Herrero-Fresneda, ES

09:00 - 09:00 P0600RETROSPECTIVE OBSERVATIONAL STUDY ASSESSINGDOSE CHANGES AMONG LONG-TERM BISACODYL USERSBASED ON THE THIN FRENCH DATABASE Robert Lange, DE




09:00 - 09:00 P0601DIAGNOSIS OF INTESTINAL MOTOR DYSFUNCTION USINGHIGH-RESOLUTION JEJUNAL MANOMETRY Luis Alcala, ES09:00 - 09:00 P0602NON-PHARMACOLOGICAL TREATMENT FOR CHILDRENWITH FUNCTIONAL CONSTIPATION: A SYSTEMATICREVIEW AND META-ANALYSIS Carrie A.M. Wegh, NL

09:00 - 09:00 P0603MANOMETRIC PATTERN AND IMPORTANCE OF THEALTERATION IN THE DEFECTION IN THE ANAL FISSURE Guiomar Moral Villarejo, ES

09:00 - 09:00 P0604DIAGNOSTIC RECOGNITION AND PREVALENCE OF ROME IVIRRITABLE BOWEL SYNDROME AND FUNCTIONALDYSPEPSIA IN THE ADULT GENERAL POPULATION OFGIBRALTAR Dénes Botond Kovács, GI

09:00 - 09:00 P0605EPIDEMIOLOGY OF IRRITABLE BOWEL SYNDROME INALBANIA Adelina Nicoleta Galica, RO

09:00 - 09:00 P0606PREVALENCE AND RISK FACTORS OF CONSTIPATIONAMONG PATIENTS UNDERGOING COLONOSCOPY: ASINGLE-CENTER CROSS-SECTIONAL STUDY Shiori Komori, JP

09:00 - 09:00 P0607IMPACT OF ENVIRONMENTAL CHANGES FORCED BYPANDEMIC RESTRICTIVE MEASURES ON THEDEVELOPMENT AND COURSE OF IRRITABLE BOWELSYNDROME Stefano Kayali, IT

09:00 - 09:00 P0608ASSESSMENT OF SERUM ZONULIN AS A MARKER OFINTESTINAL PERMEABILITY AND IRRITABLE BOWELSYNDROME DIAGNOSIS Maria Raffaella Barbaro, IT

09:00 - 09:00 P0609PRIMARY AND SECONDARY BILE ACID DIARRHOEA AREHIGHLY PREVALENT IN PATIENTS WITH SYMPTOMSCOMPATIBLE WITH ROME IV IRRITABLE BOWELSYNDROME-DIARRHOEA AND FUNCTIONAL DIARRHOEA Mohamed G. Shiha, UK

09:00 - 09:00 P0610COLONOIDS AS A MODEL TO STUDY HOST-MICROBIOTA-METABOLITE CROSSTALK AT THE INTESTINALEPITHELIUM POTENTIALLY REFLECTING EPITHELIALEVENTS ASSOCIATED WITH IBSPATHOPHYSIOLOGY Cristina Iribarren, SE

09:00 - 09:00 P0611EFFECT OF BIFIDOBACTERIUM LONGUM 35624 ON DISEASESEVERITY AND QUALITY OF LIFE IN PATIENTS WITHIRRITABLE BOWEL SYNDROME: RESULTS OF THEFLORAVIE STUDY Jean Marc Sabate, FR09:00 - 09:00 P0612RESPONSES TO FAECAL MICROBIOTA TRANSPLANTATIONIN FEMALE AND MALE PATIENTS WITH IRRITABLE BOWELSYNDROME Magdy El-Salhy, NO

09:00 - 09:00 P0613EFFICACY OF FAECAL MICROBIOTA TRANSPLANTATIONFOR PATIENTS WITH IRRITABLE BOWEL SYNDROME THREEYEARS AFTER TRANSPLANTATION Magdy El-Salhy, NO

09:00 - 09:00 P0614A TRIAL-BASED ECONOMIC EVALUATION OF PEPPERMINTOIL FOR THE TREATMENT OF IRRITABLE BOWELSYNDROME Zsa Zsa Weerts, NL

09:00 - 09:00 P0615ENHANCED THERAPEUTIC SUCCESS BY LONG-TERMPROBIOTIC TREATMENT WITH LACTOBACILLUSPLANTARUM 299V: A NON-INTERVENTIONAL STUDY OFPATIENTS WITH IRRITABLE BOWEL SYNDROME Heiner Krammer, DE

09:00 - 09:00 P0616THE GLUCAGON-LIKE PEPTIDE 1 ANALOGUE LIRAGLUTIDEIS SUPERIOR TO THE BILE ACID SEQUESTRANTCOLESEVELAM IN REDUCING STOOL FREQUENCY IN BILEACID MALABSORPTION Martin L. Kårhus, DK

09:00 - 09:00 P0617EVALUATING THE EFFICACY OF A NATURAL THERAPEUTICCONTAINING XYLOGLUCAN, PEA PROTEIN AND CHIASEEDS EXTRACT ON A MURINE MODEL OF CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME Irene Paterniti, IT

09:00 - 09:00 P0618THE MANAGEMENT OF IRRITABLE BOWEL SYNDROME:WHAT ARE THE PREFERENCES OF PATIENTS? Rosel Sturkenboom, NL

09:00 - 09:00 P0619GENDER AND SUBTYPE-BASED DIFFERENCES IN FECALSHORT-CHAIN FATTY ACIDS IN IRRITABLE BOWELSYNDROME (IBS) Piyush Patel, SE

09:00 - 09:00 P0620MANIPULATING REGIONAL COLONIC FERMENTATIONTHROUGH A COMBINATION OF MINIMALLY- AND SLOWLY-FERMENTED FIBRES IN PATIENTS WITH IRRITABLE BOWELSYNDROME INITIATED ON A LOW FODMAP DIET Daniel So, AU




09:00 - 09:00 P0621EFFECT OF HUMAN MILK OLIGOSACCHARIDES ON GUTMICROBIOTA AND METABOLITE PROFILE AND HOSTRESPONSE IN IRRITABLE BOWEL SYNDROME Cristina Iribarren, SE09:00 - 09:00 P0623MACHINE LEARNING MODEL FOR OUTCOME PREDICTIONOF PATIENTS SUFFERING FROM ACUTE DIVERTICULITISARRIVING AT THE EMERGENCY DEPARTMENT - A PROOFOF CONCEPT STUDY Adi Lahat, IL

09:00 - 09:00 P0624THE IMPACT OVERWEIGHT ON DIVERTICULAR DISEASE: ACASE CONTROL MULTICENTER STUDY

09:00 - 09:00 P0625CHRONIC CONSTIPATION IS NEGATIVELY ASSOCIATEDWITH COLONIC DIVERTICULA Natsumi Maeda, JP

09:00 - 09:00 P0626THE YIELD OF FOLLOW-UP COLONIC INVESTIGATIONSFOLLOWING AN EPISODE OF ACUTE DIVERTICULITIS: ATERTIARY SINGLE CENTRE EXPERIENCE Lauren Chong

09:00 - 09:00 P0627DO PATIENTS WITH CONSTIPATION REQUIRE A SPECIALBOWEL PREPARATION PRIOR TO A COLONOSCOPY? CASESERIES FROM A SPANISH TERTIARY HOSPITAL Gonzalo López Roldán, ES

09:00 - 09:00 P0628A MORPHOMETRIC ANALYSIS OF PATHOLOGICALALTERATIONS IN HAEMORRHOIDAL DISEASE VERSUSNORMAL CONTROLS: A CONTROLLED TRIAL Sara Z Kuiper, NL

09:00 - 09:00 P0629FOAM VERSUS LIQUID POLIDOCANOL SCLEROTHERAPY INTHE MANAGEMENT OF LOW-GRADE HEMORRHOIDALDISEASE: TOWARDS A GREATER SYMPTOMATICIMPROVEMENT Vítor Macedo Silva, PT

09:00 - 09:00 P0630EVALUATING THE MUCOADHESIVE PROPERTIES OF ATHERAPEUTIC CONTAINING A COMBINATION OFXYLOGLUCAN, RETICULATED PROTEINS ANDXYLOOLLIGOSACCHARIDES ON THE RESTORATION OFINTESTINAL BARRIER FUNCTION IN RATS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME Emanuela Esposito, IT

Recorded only

10:00 – 10:30 Hall 2From guidelines to clinical practice: Lower GImalignancies

10:00 - 10:10 IP027Guideline on advanced imaging for detection anddifferentiation of CR neoplasia Raf Bisschops, BE10:10 - 10:20 IP028Guideline on endoscopic management of Lynch syndromeand familial risks of CRC Francesc Balaguer, ES

10:20 - 10:30 IP029Guideline on endscopic management of polyposissyndromes in the young (ESPGHAN) Warren Hyer, UK

Industry Symposia Live

10:00 – 11:00 Industry HallIS-01 Going Beyond Eosinophils in EosinophilicEsophagitis (EoE): The Importance of Type 2Inflammation and Evolving Approaches to ClinicalManagement

Live Case-based Discussion

10:30 – 11:30 TV StudioManagement of fundoplication failuresChairs: André Smout, NL

Guido Costamagna, ITPhilip Wai Yan Chiu, HKJutta Keller, DE

10:30 - 10:35Introduction André Smout, NL

10:35 - 10:45 IP030A female patient with post-fundoplication dysphagia Jutta Keller, DE


10:55 - 11:05 IP031A man with recurrence of reflux symptoms afterfundoplication Philip Wai Yan Chiu, HK


11:28 - 11:30Summary and closing André Smout, NL





10:30 – 11:30 Hall 1IBD: Clinical trials IChairs: Bram Verstockt, BE

Joana Torres, PT

10:30 - 10:42 OP016EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AMATCHED COHORT OF ELDERLY AND YOUNG IBDPATIENTS – LIVE STUDY-GROUP Daniela Pugliese, IT

10:42 - 10:54 OP017EFFICACY OF UPADACITINIB INDUCTION THERAPY INPATIENTS WITH MODERATELY TO SEVERELY ACTIVEULCERATIVE COLITIS BY BIOLOGIC INADEQUATERESPONDER STATUS: RESULTS FROM TWO RANDOMIZEDPHASE 3 STUDIES Severine Vermeire, BE

10:54 - 11:06 OP018VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMESTHAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVECOLITIS REFRACTORY TO TREATMENT WITHADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBDBIORESOURCE OUTCOMES Christina Kapizioni

11:06 - 11:18 OP019OUTCOMES OF FIRST-LINE BIOLOGICALS IN AMULTICENTER PROSPECTIVE COHORT OF BIOLOGICAL-NAÏVE IBD PATIENTS – THE DANISH IBD BIOBANKPROJECT Mirabella Zhao, DK

11:18 - 11:30 OP020DECREASED IMMUNE RESPONSE TO COVID-19 MRNAVACCINE IN PATIENTS WITH INFLAMMATORY BOWELDISEASES TREATED WITH ANTI TNFΑ: A PROSPECTIVE,CONTROLLED, MULTI-CENTER ISRAELI STUDY Hadar Edelman-Klapper, IL

Moderated Poster

10:30 – 11:30 Hall 2IBD: Cross-sectionalChairs: Johan Burisch, DK

Joana Roseira, PT

10:30 - 10:40 MP001DIMINISHED SOMATIC PAIN IN ADULT PATIENTS WITHMILD-MODERATE CROHN'S DISEASE AFTER COGNITIVEBEHAVIORAL AND MINDFULNESS-BASED STRESSREDUCTION Shirley Regev, IL

10:40 - 10:50 MP002HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMABVERSUS ADALIMUMAB FOR INDUCTION ANDMAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTSWITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ INTHE SEAVUE STUDY Silvio Danese, IT10:50 - 11:00 MP003CROHN’S DISEASE REAL WORLD THERAPY IN PREVALENTCD-PATIENTS IN GERMANY - THERE IS STILL A GREATBURDEN OF DISEASE Andras Borsi

11:00 - 11:10 MP004OUTCOMES OF CORONAVIRUS DISEASE 2019 AMONGPATIENTS WITH INFLAMMATORY BOWEL DISEASES ANDTHE INFLUENCE OF IBD-RELATED MEDICATIONS– ADANISH PROSPECTIVE POPULATION-BASED COHORTSTUDY Mohamed Attauabi, DK

11:10 - 11:20 MP005BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN’SPATIENTS ON BIOLOGICS: A PROMISING TOOL TOPREDICT ENDOSCOPIC OUTCOMES Federica Crispino, IT

11:20 - 11:30 MP006SHOULD WE EXPECT AN INCREMENTAL CLINICAL BENEFITFROM ACHIEVING HISTOLOGIC REMISSION IN PATIENTSWITH ULCERATIVE COLITIS IN ENDOSCOPIC REMISSION? Polyxeni Kevrekidou, GR

Live Late Breaking Abstracts

10:30 – 11:30 Hall 3Late-breaking Abstracts I: EndoscopyChairs: Mario Dinis-Ribeiro, PT

10:30 - 10:42 LB01THE ACCURACY OF HUMAN DETECTION OF SUBMUCOSALINVASIVE CANCER– ANALYSIS OF 739 INDIVIDUALASSESSMENTS OF LARGE NON-PEDUNCULATEDCOLORECTAL POLYPS (LNPCPS) USING A NOVEL CLINICALDECISION SUPPORT TOOL Lynn Debels, BE

10:42 - 10:54 LB02ENDOSCOPIC SUBMUCOSAL DISSECTION WITH ADIAGNOSTIC INTENT FOR COLORECTAL LESIONSPRESENTING A LIMITED AREA &LT; 15 MM OF DEEPINVASIVE PIT OR VASCULAR PATTERNS Mathieu Pioche, FR

10:54 - 11:06 LB03MOTORIZED SPIRAL ENTEROSCOPY: RESULTS OF ANINTERNATIONAL, MULTICENTER, PROSPECTIVE CLINICALTRIAL (SAMISEN) INCLUDING PATIENTS WITHPOSTSURGICAL/ALTERED ANATOMY Torsten Beyna, DE




11:06 - 11:18 LB04EUS-GUIDED GASTROJEJUNOSTOMY SHOWS HIGHERCLINICAL SUCCESS AND LOWER DYSFUNCTION RATEVERSUS DUODENAL STENTS IN MALIGNANT GASTRICOUTLET OBSTRUCTION: AN INTERNATIONALMULTICENTER PROPENSITY SCORE MATCHEDCOMPARISON Rogier P. Voermans, NL11:18 - 11:30 LB05NATIONWIDE PRACTICE AND DIAGNOSTIC ACCURACY OFEUS- GUIDED TISSUE ACQUISITION PRIOR TO RESECTIONOF PANCREATIC CARCINOMA Rutger Quispel, NL

Live Nurse Programme

10:30 – 11:30 Hall 4ESGENA 25th Anniversary - Opening sessionChairs: Marjon De Pater-Godhelp, NL

Wendy Jo Waagenes, DK

10:30 - 10:50 IP03325 years of ESGENA: Meet pioniers of endoscopy nursing Ulrike Beilenhoff, DE

10:50 - 11:10 IP034Ethics in gastroenterology Christiane Neumann, UK

11:10 - 11:30 IP035How have advanced roles changed Endoscopy andGastroenterology Helen Griffiths, UK

Moderated Poster

10:30 – 11:30 Hall 5Basic aspects of GI neoplasiaChairs: Marcis Leja, LV

Joep Grootjans, NL

10:30 - 10:40 MP007DEFECT IN MIR-497 CONTRIBUTES THE TUMORIGENESISAND PROGRESSION OF GASTRIC CANCER VIA REGULATINGCDC42/ITGB1/FAK/PXN/AKT SIGNALING Lihui Zhang, CN

10:40 - 10:50 MP008ATM MUTATIONS AS A POTENTIAL BIOMARKER FORIMMUNE CHECKPOINT THERAPY IN GASTRIC CANCER Haiyan Liao, CN

10:50 - 11:00 MP009GENETIC CLONAL DIVERSITY IN GASTRIC CANCERSURVEILLANCE BIOPSIES OF PROGRESSORS AND NON-PROGRESSORS William Waddingham

11:00 - 11:10 MP010AN OBJECTIVE RISK PREDICTION ASSAY ACCURATELYRISK STRATIFIES BARRETT’S ESOPHAGUS PATIENTS WITHLOW-GRADE DYSPLASIA Amir M. Khoshiwal, NL11:10 - 11:20 MP011PROTEOMICS SIGNATURE OF AUTOIMMUNE ATROPHICGASTRITIS: TOWARDS A LINK WITH GASTRIC CANCER Ombretta Repetto, IT

11:20 - 11:30 MP012INHIBITORY EFFECT OF SLOW H2S-RELEASING DONOR(GYY4137) ON THE DEVELOPMENT OF BARRETT’SMETAPLASIA-SPECIFIC MOLECULAR PROFILE ANDINFLAMMATORY SIGNALING Marcin Magierowski, PL

Live Session

10:30 – 11:30 Hall 6Stool tests for gastroenterologists and patientsChairs: Britta Siegmund, DE

10:30 - 10:50 IP036Calprotectin: Love the point (of care) or point to the lab? Bella Ungar, IL

10:50 - 11:10 IP037Molecular stool tests and their place in colorectal cancersurveillance Gerrit Meijer, NL

11:10 - 11:30 IP038Stool tests in nutrition-adjust the test to the disease-andpatient James Lindsay, UK

Moderated Poster

10:30 – 11:30 Hall 7Pancreatic cancerChairs: Philippe Ruszniewski, FR

10:30 - 10:40 MP013THE PORCINE URINARY BLADDER FUNCTIONS AS ANINNOVATIVE IN VITRO MODEL FOR THE INVESTIGATION OFHUMAN PANCREATIC DEVELOPMENT ANDCARCINOGENESIS IN A PLURIPOTENT STEM CELL-BASEDAPPROACH Michael Karl Melzer, DE

10:40 - 10:50 MP014CELL-FREE DNA BIOMARKERS PREDICT OVERALL ANDPROGRESSION-FREE SURVIVAL IN PANCREATICADENOCARCINOMA – A SYSTEMATIC REVIEW AND META-ANALYSIS Stefania Bunduc, RO




10:50 - 11:00 MP015IS ATM DEFICIENCY PROVIDE A BENEFIT TO PANCREATICTUMOR CELLS IN A METABOLIC STRESS CONTEXT? Elodie Roger, DE11:00 - 11:10 MP016DECIPHERING THE MOLECULAR DIALOGUE BETWEENCANCER-ASSOCIATED FIBROBLASTS AND TUMOR CELLS INATM-DEFICIENT PANCREATIC CANCER Elodie Roger, DE

11:10 - 11:20 MP017DEFINING AND PREDICTING RECURRENCE IN PATIENTSUNDERGOING PANCREATECTOMY AFTER NEOADJUVANTTREATMENT FOR PANCREATIC DUCTALADENOCARCINOMA Sara Nobile, IT

11:20 - 11:30 MP018FOLFOX-BEVACIZUMAB CHEMOTHERAPY IN PATIENTSWITH PROGRESSIVE METASTATIC NEUROENDOCRINETUMORS Caroline Lacombe, FR

Moderated Poster

10:30 – 11:30 Hall 8Biliopancreatic endoscopyChairs: Livia Archibugi, IT

10:30 - 10:40 MP019ARTIFICIAL INTELLIGENCE AND DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY: AUTOMATICIDENTIFICATION OF NEOPLASTIC BILIARY NODULES INPATIENTS WITH INDETERMINATE BILIARY STENOSIS. Tiago Ribeiro, PT

10:40 - 10:50 MP020ARTIFICIAL INTELLIGENCE FOR AUTOMATIC DIAGNOSIS OFBILIARY STRICTURES MALIGNANCY STATUS IN SINGLE-OPERATOR CHOLANGIOSCOPY: A PILOT STUDY Miguel Jose Mascarenhas Saraiva, PT

10:50 - 11:00 MP021ARTIFICIAL INTELLIGENCE MODEL FOR THECHARACTERIZATION OF BILIARY STRICTURES DURINGREAL-TIME DIGITAL CHOLANGIOSCOPY: A PILOT STUDY Roberto Oleas, EC

11:00 - 11:10 MP022REGULATION OF THE CYSTIC FIBROSIS TRANSMEMBRANECONDUCTANCE REGULATOR (CFTR) BY THE NUCLEAR BILEACID RECEPTOR, FARNESOID X RECEPTOR: A NEW TARGETFOR NUTRACEUTICAL TREATMENT OF DIARRHOEALDISEASES Jessica S Smyth, IE

11:10 - 11:20 MP023INTRADUCTAL FULLY COVERED SELF-EXPANDING METALSTENTS IN THE MANAGEMENT OF POST LIVERTRANSPLANT ANASTOMOTIC STRICTURES; A UK WIDEEXPERIENCE Wafaa Ahmed11:20 - 11:30 MP024FEASIBILITY AND SAFETY OF A NEW DEDICATED BILIARYSTENT FOR TRANSMURAL EUS-GUIDED HEPATICO-GASTROSTOMY: THE FIT STUDY Alessandro Fugazza, IT

Live Demo

10:30 – 11:30 Live Demo RoomSurgical cases: ColorectalChairs: Alberto Arezzo, IT

Nader K Francis, UK

10:30 - 10:50 IP039TAMIS Eloy Espin Basany, ES

10:50 - 11:10 IP040TA procedures for IBD Roel Hompes, NL


myUEG Community Programme

10:30 – 11:00 myUEG CommunityProgramme Hall

Tasty takeaways: The power of questions with CristinaCuerdaChairs: Carolina Ciacci, IT

Cristina Cuerda, ES


11:30 – 12:30 Industry HallIS-02 Practice makes perfect: a holistic approach toremission in the clinic

Vienna Live Session

12:00 – 13:00 TV StudioCase closed? Live expert lunch IChairs: Mario Dinis-Ribeiro, PT

Pradeep Bhandari, UKMathieu Pioche, FREmmanuel Coron, FR




12:00 - 12:04 IP041Case presentation 1 Pradeep Bhandari, UK12:04 - 12:09Panel discussion

12:09 - 12:13 IP042Case presentation 2 Mathieu Pioche, FR


12:18 - 12:22 IP043Case presentation 3 Emmanuel Coron, FR


12:27 - 12:31 IP044Case presentation 4 Pradeep Bhandari, UK


12:36 - 12:40 IP045Case presentation 5 Mathieu Pioche, FR


12:45 - 12:49 IP046Case presentation 6 Emmanuel Coron, FR


Live Session

12:00 – 13:00 Hall 1Highlights in microscopic colitisChairs: Stephan Miehlke, DE

Gian Eugenio Tontini, IT

12:00 - 12:20 IP047Results from the PRO-MC collaboration Bas Verhaegh, NL

12:20 - 12:40 IP048What's new in pathology? Anne-Marie Kanstrup Fiehn, DK

12:40 - 13:00 IP049Treatment with focus on budesonide-refcratory cases Andreas Münch, SE


12:00 – 13:00 Hall 2Patient outcomes in IBD trialsChairs: Maria T. Abreu, US

Paolo Giuffrida, UK

12:00 - 12:12 OP021PATIENTS WITH ULCERATIVE COLITIS REPORTIMPROVEMENTS IN ABDOMINAL PAIN, BOWEL URGENCY,AND FATIGUE WITH 8-WEEK UPADACITINIB TREATMENT INTWO PHASE 3 TRIALS: U-ACHIEVE AND U-ACCOMPLISH Silvio Danese, IT

12:12 - 12:24 OP022SURGICAL DOWNGRADING OF INFLAMMATORY BURDEN INCROHN’S DISEASE OPTIMISES ANTI-TNFPHARMACOKINETICS Susanna Meade

12:24 - 12:36 OP023PATIENT-REPORTED OUTCOME IMPROVEMENT WITHTOFACITINIB IN THE ULCERATIVE COLITIS OCTAVECLINICAL PROGRAMME David P. Hudesman, US

12:36 - 12:48 OP024MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OFDISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY INPATIENTS WITH MODERATELY TO SEVERELY ACTIVECROHN’S DISEASE David T. Rubin, US

12:48 - 13:00 OP025THE IMPACT OF GROUP COGNITIVE BEHAVIORAL THERAPYON IBD PATIENTS’ PSYCHOSOCIAL FUNCTIONING,INFLAMMATION AND DISEASE SEVERITY INDICES: ARANDOMIZED CONTROLLED STUDY Christos Sotiropoulos, GR

Live Session

12:00 – 13:00 Hall 3Challenges in functional disordersChairs: Jutta Keller, DE

Jordi Serra, ES

12:00 - 12:20 IP050Individualised management of globus Nathalie Rommel, BE

12:20 - 12:40 IP051Predictors of response to therapy in functional dyspepsiaand gastroparesis Guillaume Gourcerol, FR

12:40 - 13:00 IP052Rome IV functional gastrointestinal disorders;prevalance, associations, and clinical conundrums Imran Aziz, UK





12:00 – 13:00 Hall 4Management of duodenal tumors: All you want to know!Chairs: Marianna Arvanitakis, BE

12:00 - 12:12 OP026IDENTIFICATION OF RISK FACTORS FOR THEOCCURRENCE OF AMPULLARY TUMORS: A CASE-CONTROLSTUDY Piera Zaccari, IT

12:12 - 12:24 OP027AMPULLARY ADENOMAS IN PATIENTS WITH FAMILIALADENOMATOUS POLYPOSIS (FAP): BIOPSY,MANAGEMENT, RISK ASSESSMENT Robert Hüneburg, DE

12:24 - 12:36 OP028COLD SNARE POLYPECTOMY FOR SUPERFICIAL NON-AMPULLARY DUODENAL EPITHELIAL TUMOR: AMULTICENTER PROSPECTIVE CONFIRMATORY TRIAL (D-COP TRIAL) Kohei Takizawa, JP

12:36 - 12:48 OP029USEFULNESS OF ENDOCYTOSCOPIC IMAGES OFSUPERFICIAL NON-AMPULLARY DUODENAL EPITHELIALTUMORS AS OPTICAL BIOPSY Marina Kubo, JP

12:48 - 13:00 OP030LONG OVERALL SURVIVAL AND LOW DISEASERECURRENCE IN PATIENTS WITH DUODENALNEUROENDOCRINE TUMOURS Oddry Folkestad, NO

Live Session

12:00 – 13:00 Hall 5Newly diagnosed PDAC: What are the next steps?Chairs: Vinciane Rebours, FR

Lydi van Driel, NL

12:00 - 12:20 IP053The best imaging for local staging Giulia Zamboni, IT

12:20 - 12:40 IP054Biopsy of the primary tumour is crucially needed Irene Esposito, DE

12:40 - 13:00 IP055Optimal preoperative management Thomas M. Gress, DE


12:00 – 13:00 Hall 6Endoscopic diagnosis of oesophageal neoplasiaChairs: Roos E. Pouw, NL

Raf Bisschops, BE

12:00 - 12:12 OP031GASTROESOPHAGEAL REFLUX DISEASE AND DE NOVOINCIDENCE OF BARRETT’S ESOPHAGUS ≥5 YEARS AFTERLAPAROSCOPIC SLEEVE GASTRECTOMY OR ROUX-Y-GASTRIC BYPASS Mark Fox, CH

12:12 - 12:24 OP032ENDOCYTOSCOPIC IDENTIFICATION OF DYSPLASIA IN THEBARRETT’S OESOPHAGUS USING ARTIFICIALINTELLIGENCE AS A SECOND ASSESSOR: A PROSPECTIVEASSESSMENT OF THE INTERACTION BETWEENGASTROENTEROLOGISTS AND A CONVOLUTIONALNEURAL NETWORK ALGORITHM Jouke van der Laan, NL

12:24 - 12:36 OP033OPTICAL BIOPSY FOR ESOPHAGEAL SQUAMOUS CELLNEOPLASIA BY USING ENDOCYTOSCOPY Yoshihiko Shimoda, JP

12:36 - 12:48 OP034COMPUTER AIDED DIAGNOSIS NETWORK FOR THECHARACTERISATION OF BARRETT’S DYSPLASIA ONMAGNIFICATION I-SCAN IMAGES Mohamed Hussein

12:48 - 13:00 OP035IDENTIFICATION AND VALIDATION OF NOVEL TARGETSFLUORESCENCE MOLECULAR ENDOSCOPY FORNEOPLASIA DETECTION IN BARRETT’S ESOPHAGUS Xiaojuan Zhao, NL

Live Session

12:00 – 13:00 Hall 7Highlights from UEG JournalChairs: Joost P.H. Drenth, NL

12:00 - 12:02Introduction to the first paper on: IBD Iago Rodríguez-Lago, ES

12:02 - 12:20 IP057Vedolizumab is effective and safe in elderly inflammatorybowel disease patients: a binational, multicenter,retrospective cohort study Nitsan Maharshak, IL

12:20 - 12:22Introduction to the second paper on: Pancreas Livia Archibugi, IT




12:22 - 12:40 IP059Pancreatic exocrine insufficiency and pancreatic enzymereplacement therapy in patients with advancedpancreatic cancer: A systematic review and meta-analysis Enrique de-Madaria, ES12:40 - 12:42Introduction to the third paper on: Endoscopy Diogo Libânio, PT

12:42 - 13:00 IP061Proximal retroflexion versus second forward view of theright colon during screening colonoscopy: A multicentrerandomized controlled trial Henar Núñez Rodríguez, ES


12:00 – 13:00 Hall 8Advanced endoscopic therapy in lower GIChairs: Helmut Messmann, DE

Roberta Maselli, IT

12:00 - 12:12 OP036DEVELOPMENT AND VALIDATION OF AN AI SYSTEM TORISK-STRATIFICATION DIAGNOSE OF COLORECTALNEOPLASIA Xu Youming, CN

12:12 - 12:24 OP037LESS IS MORE: THE IMPACT OF 2020 ESGE GUIDELINE ONPOST PIECEMEAL EMR SURVEILLANCE Catarina Nascimento, PT

12:24 - 12:36 OP039IMPACT OF PROPHYLACTIC ENDOSCOPIC CLIPPLACEMENT ON CLINICALLY SIGNIFICANT POSTENDOSCOPIC MUCOSAL RESECTION BLEEDING IN THERIGHT COLON - A RANDOMIZED CONTROLLED TRIAL Sunil Gupta, AU

12:36 - 12:48 OP040SPYGLASS-A NEW INNOVATION FOR ENDOSCOPICRETROGRADE APPENDICITIS THERAPY Lingjian Kong, CN

Live Demo

12:00 – 13:00 Live Demo RoomSurgical cases: HPBChairs: Mustapha Adham, FR

Helmut Friess, DE

12:00 - 12:20 IP062Biliary tract and duodenum preserving pancreatectomy Julie Perinel, FR

12:20 - 12:30 IP063Laparoscopic liver resection Gregor Stavrou, DE12:30 - 13:00Panel discussion

Recorded only

13:00 – 13:30 Hall 5From guidelines to clinical practice: Biliary, liver,pancreas

13:00 - 13:10 IP064Gallstone disease: Guidelines versus real life practice Monica Acalovschi, RO

13:10 - 13:20 IP065Hepatitis: Current guideline recommendations Pietro Lampertico, IT

13:20 - 13:30 IP066NASH guideline: Are we up to date? Lawrence Serfaty, FR


13:00 – 14:00 Industry HallIS-03 Planning the patient’s journey to success in Crohn’sdisease


13:30 – 14:30 TV StudioSmall intestinal Crohn’s disease: Luminal andextraluminal inflammationChairs: Hannah Gordon, UK

Charlie Lees, UKMarietta Iacucci, UKChristian Maaser, DEJaap Stoker, NL

13:30 - 13:40 IP067Abscess or inflammatory mass? How to optimise andwhen to operate Christian Maaser, DE


13:50 - 14:00 IP068Stricturing small bowel disease in a patient with an activepregnancy wish Jaap Stoker, NL





14:10 - 14:20 IP069Interactive endoscopic videos: Dilatation of small bowelstrictures Marietta Iacucci, UK14:20 - 14:30Panel discussion


13:30 – 14:30 Hall 1IBD: Clinical trials II (small molecules)Chairs: Laurent Peyrin-Biroulet, FR

Ailsa L Hart, UK

13:30 - 13:42 OP041EARLY ACHIEVEMENT OF PARTIAL MAYO SCOREREMISSION AND IBDQ NORMALIZATION IN PATIENTS WITHULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THEPHASE 2B/3 SELECTION STUDY Marc Ferrante, BE

13:42 - 13:54 OP042CORTICOSTEROID-FREE REMISSION OF ULCERATIVECOLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POSTHOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY Severine Vermeire, BE

13:54 - 14:06 OP043RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIBINDUCTION THERAPY IN PATIENTS WITH MODERATELY TOSEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROMTWO RANDOMIZED PHASE 3 STUDIES Edward V. Loftus, US

14:06 - 14:18 OP044MAINTENANCE OF REMISSION WITH TOFACITINIB INPATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OFA SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL,LONG-TERM EXTENSION STUDY, OCTAVE OPEN Walter Reinisch, AT

14:18 - 14:30 OP045ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITHMODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: DATAFROM THE VIBRATO UMBRELLA STUDY William J. Sandborn, US

Moderated Poster

13:30 – 14:30 Hall 2IBD: Basic pathophysiologyChairs: Sebastian Zeissig, DE

Carolina Ciacci, IT

13:30 - 13:40 MP025ROLE OF SUCNR1 IN INFLAMMASOME ACTIVATION OFINTESTINAL EPITHELIAL CELLS: RELEVANCE INULCERATIVE COLITIS Cristina Bauset, ES

13:40 - 13:50 MP026MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATIONDISCRIMINATES COLLAGENOUS FROM LYMPHOCYTICCOLITIS Tenghao Zheng, AU13:50 - 14:00 MP027LIPID PEROXIDATION FUELS INTESTINAL INFLAMMATIONVIA A TLR2-JNK AXIS Lisa Mayr, AT

14:00 - 14:10 MP028CYTOKINELINK: A NOVEL BIOINFORMATIC TOOL TO MAPCYTOKINE-MEDIATED INTERCELLULAR COMMUNICATIONIN INFLAMMATORY BOWEL DISEASE John P Thomas, UK

14:10 - 14:20 MP029SZN-1326, A WNT SIGNAL ACTIVATOR, IS MOREEFFICACIOUS THAN CYCLOSPORINE A IN AN ACUTE DSSMODEL Liqin Xie, US

14:20 - 14:30 MP030SZN-1326 PROMOTES COLONIC MUCOSAL HEALING IN ANACUTE INJURY MODEL OF IBD BY EXPANDING THEPROGENITOR POOL AND ACCELERATINGDIFFERENTIATION Russell B Fletcher, US


13:30 – 14:30 Hall 3Late-breaking Abstracts II: Upper GI and IBDChairs: Kaija-Leena Kolho, FI

Timon Adolph, AT

13:30 - 13:42 LB06ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASEPREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTSUNDERGOING GLUTEN CHALLENGE Detlef Schuppan, DE

13:42 - 13:54 LB07DAVID AGAINST GOLIATH: DIRECT COMPARISON OF HAND-HELD BOWEL SONOGRAPHY AND MAGNETIC RESONANCEENTEROGRAPHY FOR DIAGNOSIS OF CROHN’S DISEASE Antonio Rispo, IT

13:54 - 14:06 LB08TREATMENT OF PERIANAL FISTULAS IN CROHN’S DISEASE:ANTI-TNF WITH SURGICAL CLOSURE VERSUS ANTI-TNFALONE (PISA-II) - A PATIENT PREFERENCE RCT Elise Maria Meima-van Praag, NL

14:06 - 14:18 LB09DEVELOPMENT OF A CORE DESCRIPTOR SET FORCROHN’S ANAL FISTULA - THE ENIGMA CODE STUDY Kate Williams, UK




14:18 - 14:30 LB10DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS INADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILICESOPHAGITIS: RESULTS FROM PART A AND C OF ARANDOMIZED, PLACEBO-CONTROLLED, THREE-PART,PHASE 3 LIBERTY EOE TREET STUDY Evan S Dellon, US


13:30 – 14:30 Hall 4The future becomes daily routine?Chairs: Björn Fehrke, CH

Siiri Maasen, EE

13:30 - 13:50 IP070Artificial intelligence in endoscopy: How will AI changeour diagnosis & therapy Helmut Neumann, DE

13:50 - 14:10 IP071Green endoscopy: Managing sustainibility andenvironmental impact Leigh Donnelly, UK

14:10 - 14:30 IP072Robots in endoscope reprocessing Hans-Dieter Allescher, DEMartin Mangold, DE

Moderated Poster

13:30 – 14:30 Hall 5Novel insights in a new disease: EosinophilicoesophagitisChairs: Alex Straumann, CH

Ulrike von Arnim, DE

13:30 - 13:40 MP031ENDOSCOPIC AND HISTOLOGICAL FINDINGS BEYONDEOSINOPHIL COUNT HELP TO ASSESS HISTOLOGICALREMISSION IN PAEDIATRIC EOSINOPHILIC ESOPHAGITIS Nuria Puente Ubierna, ES

13:40 - 13:50 MP032BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TOMAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPICREMISSION IN ADULT PATIENTS WITH EOSINOPHILICESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLINDEOS-2 TRIAL Alex Straumann, CH

13:50 - 14:00 MP033BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLYEFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION INRELAPSING ADULT PATIENTS WITH EOSINOPHILICESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL Christoph Schlag, DE

14:00 - 14:10 MP034DYSPHAGIA DAYS AS A CLINICAL MARKER OF EOETREATMENT RESPONSE Ikuo Hirano, US14:10 - 14:20 MP035DIAGNOSTIC DELAY REDUCES AND DIAGNOSTICPRECISION INCREASES ALONG TIME FOR EOSINOPHILICESOPHAGITIS: AN ANALYSIS FROM THE EOE CONNECTREGISTRY ON THE IMPACT ON CLINICAL PRACTICEGUIDELINES TO IMPROVE DISEASE AWARENESS INEUROPE M Pilar Navarro Sánchez, ES

14:20 - 14:30 MP036NOVEL SEROLOGICAL BIOMARKERS FOR MONITORINGDISEASE PROGRESSION IN ADULT EOSINOPHILICESOPHAGITIS PATIENTS Martin Pehrsson, DK


13:30 – 14:30 Hall 6Challenges in developing drugs for NASHChairs: Alessio Aghemo, IT

Michael Trauner, AT

13:30 - 13:50 IP073NASH: Novel insights in pathophysiology Helena Cortez-Pinto, PT

13:50 - 14:10 IP074Microbiota in NASH: Friends or foes? Herbert Tilg, AT

14:10 - 14:30 IP075Treatment of NASH: What is in the pipeline? Jean-François Dufour, CH

Moderated Poster

13:30 – 14:30 Hall 7Acute and chronic pancreatitisChairs: Matthias Löhr, SE

Irene Esposito, DE

13:30 - 13:40 MP037THE TRANSCRIPTION FACTOR TBX3 FOSTERSREGENERATION FROM ACUTE PANCREATITIS AND SHOWSSWITCHING EXPRESSION PATTERNS IN THE EMBRYONICPANCREAS Michael Karl Melzer, DE

13:40 - 13:50 MP038LONG-TERM FOLLOW-UP OUTCOMES OF AN ENDOSCOPICVERSUS SURGICAL STEP-UP APPROACH FOR INFECTEDNECROTIZING PANCREATITIS (EXTENSION) Anke Onnekink, NL




13:50 - 14:00 MP039THE ROLE OF ORAI1 CA2+ CHANNEL IN THE PANCREATICDUCTAL EPITHELIAL CELLS UNDER PATHOPHYSOLOGICALCONDITIONS József Maléth, HU14:00 - 14:10 MP040PANCREATIC ENZYME TREATMENT IN CHRONICPANCREATITIS: QUALITY OF MANAGEMENT ANDADHERENCE TO GUIDELINES. Trond Engjom, NO

14:10 - 14:20 MP041AZATHIOPRINE IMPAIRS PANCREATIC DUCTAL CHLORIDEAND BICARBONATE SECRETION BY DISRUPTING CFTRPLASMA MEMBRANE RETENTION IN MICE Bálint Tél, HU

14:20 - 14:30 MP042EARLY PHASE OF CHRONIC PANCREATITIS: RESULTS OF A2-YEAR FOLLOW-UP OF THE FIRST 133 PATIENTS OF THEGOULASH-PLUS CLINICAL TRIAL Alexandra Miko, HU

Moderated Poster

13:30 – 14:30 Hall 8Advanced endoscopyChairs: Lars Aabakken, NO

Arnaud Lemmers, BE

13:30 - 13:40 MP043IS MAGNETIC COMPRESSION ANASTOMOSIS TECHNIQUE AGOOD TREATMENT OPTION FOR PATIENTS WITHCOMPLETE BENIGN BILIARY STENOSIS? Batuhan Başpınar, TR

13:40 - 13:50 MP044AN INTERNATIONAL EXPERIENCE WITH SINGLE-OPERATOR CHOLANGIOPANCREATOSCOPY IN PATIENTSWITH ALTERED ANATOMY Shruti Mony, US

13:50 - 14:00 MP045EUS GUIDED CYSTO-DUODENOSTOMY IN PANCREATICFLUID COLLECTIONS WITH BILIARY COMPRESSION: ATERTIARY CENTRE EXPERIENCE Sonam Mathur, IN

14:00 - 14:10 MP046SAFETY AND EFFICACY OF DOUBLE EUS-BYPASS VERSUSSURGICAL HEPATICOJEJUNOSTOMY ANDGASTROJEJUNOSTOMY Jonas Lauwereys, BE

14:10 - 14:20 MP047EUS-GUIDED GALLBLADDER DRAINAGE USING LUMEN-APPOSING METAL STENT AS RESCUE TREATMENT FORMALIGNANT DISTAL BILIARY OBSTRUCTION: A LARGEMULTICENTER EXPERIENCE Cecilia Binda, IT

14:20 - 14:30 MP048DOES A THIRD “EXTRA” CLIP ON THE CYSTIC DUCT AFFECTBILIARY LEAKAGE RATES IN LAPAROSCOPICCHOLECYSTECTOMY? Arvid Gustafsson, SE

Live Demo

13:30 – 14:30 Live Demo RoomSurgical cases: Upper GIChairs: Richard Van Hillegersberg, NL

Bas P.L. Wijnhoven, NL

13:30 - 13:50 IP076Minimally invasive oesophagectomy Mark Ivo van Berge Henegouwen, NL

13:50 - 14:10 IP077Robotic minimally invasive resection for CARDIA junctioncancer Richard Van Hillegersberg, NL


Recorded only

14:30 – 15:00 Hall 8From guidelines to clinical practice: Guidelines forsurgical and interventional procedures

14:30 - 14:40 IP078AGREE II extension for surgical guidelines Stavros Antoniou, CY

14:40 - 14:50 IP079Implementation of quality indicators in endoscopy Ian Mark Gralnek, IL

14:50 - 15:00 IP080Current application of the European evidence-basedguidelines on pancreatic cystic tumours Giovanni Marchegiani, IT


14:30 – 15:30 Industry HallIS-04 Targeting inflammation to improve long-termoutcomes in UC

Vienna Live Session

15:00 – 16:00 TV StudioGut Talk: Lessons learned IChairs: Britta Siegmund, DE




15:00 - 15:20 IP081The role of MRI in outlining treatment strategies Andrea Laghi, IT15:20 - 15:30 IP082What is important for the surgeon? Christianne Johanna Buskens, NL

15:30 - 15:40 IP083What is the impact for the gastroenterologist Lieven Pouillon, BE



15:00 – 16:00 Hall 1Basic science in IBDChairs: Sebastian Zeissig, DE

Bella Ungar, IL

15:00 - 15:12 OP046PRECLINICAL IN VITRO AND IN VIVO INVESTIGATION OFTHE FIRST-IN-CLASS SELECTIVE SIK2/SIK3 INHIBITORGLPG3970 IN EXPERIMENTAL MODELS OF IBD Steve De Vos, BE

15:12 - 15:24 OP047ER STRESS AS A RHEOSTAT OF LIPID-INDUCEDMETABOLIC ENTERITIS IN CROHN’S DISEASE Julian Schwärzler, AT

15:24 - 15:36 OP048PRECLINICAL MECHANISTIC INVESTIGATION OF THE FIRST-IN-CLASS SIK2/SIK3 INHIBITOR GLPG3970 IN ANEXPERIMENTAL MODEL OF IBD Steve De Vos, BE

15:36 - 15:48 OP049REDUCED EXPRESSION OF GATA6-AS1 LNCRNA IN GUTEPITHELIA ATTENUATE MITOCHONDRIAL RESPIRATIONAND MAY ACCOUNT IN PART FOR THE EPITHELIALDYSFUNCTION SEEN IN INFLAMMATORY BOWEL DISEASE(IBD) Katya Sosnovski, IL

15:48 - 16:00 OP050EPITHELIAL ELASTASE ELA2 DELAYS WOUND HEALING IN AMURINE MODEL OF INFLAMMATORY BOWEL DISEASE Marion Demeurs, FR

Live Session

15:00 – 16:00 Hall 2Improving the diagnosis of gastrointestinal pain for abetter treatmentChairs: Qasim Aziz, UK

Jutta Keller, DE

15:00 - 15:20 IP084Disorders of the gut-brain interaction: How to improveaccuracy of symptom assassment Daniel Keszthelyi, NL15:20 - 15:40 IP085Which investigations are necessary in patients withabdominal pains? Tim Vanuytsel, BE

15:40 - 16:00 IP086Pharmacological management of abdominal pain Asbjørn Mohr Drewes, DK


15:00 – 16:00 Hall 3Biomarkers and basic concepts in lower GI oncologyChairs: Lior H Katz, IL

15:00 - 15:12 OP051SCG2 IS A PROGNOSTIC BIOMARKER ASSOCIATED WITHIMMUNE INFILTRATION AND MACROPHAGEPOLARIZATION IN COLORECTAL CANCER Hao Wang, CN

15:12 - 15:24 OP052COLIBACTIN-PRODUCING ESCHERICHIA COLI INDUCE THEFORMATION OF INVASIVE CARCINOMAS IN A CHRONICINFLAMMATION-ASSOCIATED MOUSE MODEL Laurène Salesse, FR

15:24 - 15:36 OP053MUCOSA-ADHERENT MUCISPIRILLUM SPP. DRIVEATF6-DEPENDENT COLORECTAL TUMOURIGENESIS INMURINE MODELS Adam Sorbie, DE

15:36 - 15:48 OP054IN-SILICO LYNCH SYNDROME-RELATED NEOANTIGENSPREDICTION FOR A DENDRITIC-CELL BASED CANCERPREVENTION VACCINE Cristina Bayó, ES

15:48 - 16:00 OP055FECAL MICRO RNA'S: A PROMISING TOOL FORCOLORECTAL CANCER SCREENING Filippo Scevola, IT


15:00 – 16:00 Hall 4Gastric and oesophageal preneoplastic lesions: Diagnosisand treatmentChairs: Diogo Libânio, PT

Oliver Pech, DE




15:00 - 15:12 OP056CYTOSPONGE-TFF3 TESTING CAN DETECT PRE-CANCEROUS MUCOSAL CHANGES OF THE STOMACH Andreas V Hadjinicolaou15:12 - 15:24 OP057SIMPLE CYTOSPONGE-BIOMARKER TECHNOLOGY TOPRIORITIZE ENDOSCOPIC BARRETT’S ESOPHAGUSSURVEILLANCE Nastazja Pilonis

15:24 - 15:36 OP058UTILISATION OF THE CYTOSPONGE DEVICE AS A TOOLFOR RISK STRATIFICATION IN PATIENTS WITH BARRETT’SOESOPHAGUS WHO ARE OVERDUE ENDOSCOPICSURVEILLANCE DUE TO THE COVID-19 PANDEMIC Vinay Sehgal

15:36 - 15:48 OP059NEAR-INFRARED FLUORESCENCE MOLECULARENDOSCOPY SHOWS PROMISING RESULTS IN DETECTINGDYSPLASTIC ESOPHAGEAL LESIONS USING TOPICALLYADMINISTERED BEVACIZUMAB-800CW: THE PRELIMINARYRESULTS OF A PHASE 2 STUDY Ruben Yannick Gabriëls, NL

15:48 - 16:00 OP060ENDOSCOPIC SUBMUCOSAL DISSECTION AS FIRST LINETHERAPY FOR NEOPLASTIC BARRETT’S ESOPHAGUS WITHVISIBLE LESIONS Masami Omae, SE

Live Session

15:00 – 16:00 Hall 5Interventional management of chronic pancreatitisChairs: Juan Enrique Dominguez-Munoz, ES

Matthias Löhr, SE

15:00 - 15:20 IP087Stones, strictures and pseudocysts: Novel approaches inendotherapy? Marianna Arvanitakis, BE

15:20 - 15:40 IP088Optimal timing of surgery Helmut Friess, DE

15:40 - 16:00 IP089Surgery, islet autotransplant for chronic pancreatitis Marc G.H. Besselink, NL

Live Session

15:00 – 16:00 Hall 6How to start a research project from scratchChairs: Julia Mayerle, DE

Pedro M. Rodrigues, ES

15:00 - 15:20 IP090The quest for an excellent research question Roos E. Pouw, NL15:20 - 15:40 IP091You have an idea! How to convince funding bodies/bossesto support you Pilar Acedo, UK

15:40 - 16:00 IP092Research on a shoe string: How to do a research project ina non-university setting Alex Straumann, CH

Live Session

15:00 – 16:00 Hall 7Current management of benign liver lesionsChairs: Jan IJzermans, NL

Jessica Zucman-Rossi, FR

15:00 - 15:20 IP093Current imaging approach to incidental lesions in thehealthy liver: Key diagnostic recommendation Federica Vernuccio, IT

15:20 - 15:40 IP094Focal nodular hyperplasia and hepatocellular adenomas:Pathology perspective Valerie Paradis, FR

15:40 - 16:00 IP095Key management recommendation of benign liverdieseases Minneke J. Coenraad, NL

Live Session

15:00 – 16:00 Hall 8When is upper GI endoscopy mandatory?Chairs: Raf Bisschops, BE

Thierry Ponchon, FR

15:00 - 15:20 IP096Dyspepsia: To scope or not to scope? Niek J. De Wit, NL

15:20 - 15:40 IP098Upper GI endoscopy in hereditary syndromes Maria Pellisé Urquiza, ES

15:20 - 15:40 IP097Reflux: To scope or not to scope? Radu Tutuian, CH




Live Demo

15:00 – 16:00 Live Demo RoomSurgical cases: Inflammatory condition of the colonChairs: Emma V. Carrington, UK

Nuha A. Yassin, UK

15:00 - 15:20 IP099Managmenent of small bowel Crohn's as this will bring insurgery, gastroenterology, radiology, endoscopy andnutrition Nuha A. Yassin, UK

15:20 - 15:40 IP100Laparoscopic diverticulitis and lavage/drainage:Definitive treatment or bridge to surgery? Dorin Eugen Popa, SE




A melting pot: Inclusive research opportunities forEastern Europeans & beyondChairs: Marcis Leja, LV

Juozas Kupcinskas, LTAnna Voseckova, CZSilver Toomla, EE

Recorded only

16:00 – 16:30 Hall 1Best of DDW I

16:00 - 16:10 IP101Best of celiac disease and gluten related disorders Julio Bai, AR

16:10 - 16:20 IP102Best of neurogastroenterology Michael Camilleri, US

16:20 - 16:30 IP103Best of IBD Aline Charabaty, US


16:00 – 17:00 Industry HallIS-05 Raising the Bar for Diagnosis and Management ofGastroparesis


16:30 – 17:30 TV StudioEndoscopic management of bariatric complicationsChairs: Jacques Deviere, BE

Ivo Boskoski, ITPaola Iovino, ITRoberta Maselli, IT

16:30 - 16:40 IP104Endoscopic management of early and delayed leaks Ivo Boskoski, IT


16:50 - 17:00 IP105Stenoses and angulations after sleeve gastrectomy:Which role for endoscopy? Roberta Maselli, IT


17:10 - 17:20 IP106GERD after bariatric surgery Paola Iovino, IT



16:30 – 17:30 Hall 1IBD prediction and prognosisChairs: Iris Dotan, IL

Matthieu Allez, FR

16:30 - 16:42 OP061CIRCULATING INFLAMMATORY PROTEIN AND CELLULARPROFILES AT TIME OF DIAGNOSIS CLASSIFYINFLAMMATORY BOWEL DISEASE PATIENTS ACCORDINGTO THEIR UNDERLYING IMMUNE RESPONSE AND CLINICALDISEASE COURSE Maud Heredia, NL

16:42 - 16:54 OP062SERUM INFLAMMATORY PROTEIN PROFILING TOCORROBORATE SELECTION OF THERAPY NAÏVEMODERATE-TO-SEVERE PAEDIATRIC CROHN’S DISEASEPATIENTS ELIGIBLE FOR FIRST-LINE INFLIXIMAB Janneke N Samsom, NL

16:54 - 17:06 OP063CAN WE PREDICT CMV COLITIS WITH HAEMOGRAM-BASEDINFLAMMATORY INDICES? Arda Yavuz, TR




17:06 - 17:18 OP065LOW FREQUENCIES OF CIRCULATING INHIBITORYTIGIT+CD38+ EFFECTOR T CELLS IDENTIFY ANIMMUNOLOGICALLY DISTINCT SUBGROUP OF PEDIATRICPATIENTS WITH SEVERE CROHN’S DISEASE Maud Heredia, NL

Live Session

16:30 – 17:30 Hall 2IBS: What's new in 2021?Chairs: Chloé Melchior, FR

Hans Törnblom, SE

16:30 - 16:50 IP107Food-induced abdominal pain Guy E. Boeckxstaens, BE

16:50 - 17:10 IP108Histamine producing bacterial strains in IBS Premysl Bercik, CA

17:10 - 17:30 IP109New drugs in the pipeline Giovanni Barbara, IT

Live Session

16:30 – 17:30 Hall 3Multidisciplinary approaches in mesenteric ischemiaChairs: Marco J. Bruno, NL

Olivier Corcos, FR

16:30 - 16:50 IP110Acute mesentric ischemia: Epidemiology and diagnosticwork up Desiree Leemreis- van Noord, NL

16:50 - 16:55 IP112Multidisciplinary management: Role of the radiologist Maxime Ronot, FR

16:55 - 17:00 IP111Multidisciplinary management: Role of the surgeon Olaf Jan Bakker, NL

17:00 - 17:10Q&A

17:10 - 17:30 IP113Challenges in the management of short bowel syndrome Johane Allard, CA


16:30 – 17:30 Hall 4H.pylori: Extra-digestive manifestations and therapyChairs: Gianluca Ianiro, IT

Colm O'Morain, IE

16:30 - 16:42 OP066ASSESSMENT OF PATIENTS AT-RISK FOR HELICOBACTERPYLORI INFECTION USING MEDICAL INSURANCE CLAIMSDATA AND MACHINE LEARNING Maxime Coriou, CH

16:42 - 16:54 OP067RISKS OF MAJOR OSTEOPOROTIC FRACTURE IN PATIENTSWHO FAILED H. PYLORI ERADICATION THERAPY: APOPULATION-BASED STUDY Ka Shing Cheung, HK

16:54 - 17:06 OP068DIABETES LEADS TO A DECREASE IN THE ERADICATIONRATE OF HELICOBACTER PYLORI Xiaoyong Wang, CN

17:06 - 17:18 OP069EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE:RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG) Olga Perez Nyssen, ES

17:18 - 17:30 OP070TIMING OF PREVIOUS EXPOSURE TO ANTIBIOTICS ANDFAILURE OF CLARITHROMYCIN-CONTAINING TRIPLETHERAPY FOR HELICOBACTER PYLORI: A POPULATION-BASED STUDY Wai K Leung, CN

Live Session

16:30 – 17:30 Hall 5Pancreatic diseases: What's new in 2021?Chairs: Marianna Arvanitakis, BE

Juan Enrique Dominguez-Munoz, ES

16:30 - 17:00 IP114Acute pancreatitis Gabriele Capurso, IT

17:00 - 17:30 IP115Chronic pancreatitis Laszlo Czako, HU

Live Session

16:30 – 17:30 Hall 6Inflammation-mediated liver diseaseChairs: Sven Francque, BE

Frank Tacke, DE




16:30 - 16:50 IP117B-cell depletion strategies in hepatology in the future? Michael Manns, DE16:50 - 17:10 IP118Quantification of hepatic inflammation using AI on liverhistology Pinelopi Manousou, UK

17:10 - 17:30 IP119From hepatic inflammation to cancer Jean Charles Nault, FR

Live Session

16:30 – 17:30 Hall 7Influence of gender in the pathophysiology, prognosisand treatment of liver diseasesChairs: Patrizia Burra, IT

Jörn Schattenberg, DE

16:30 - 16:50 IP120Impact of gender in liver disease Helena Cortez-Pinto, PT

16:50 - 17:10 IP121Clinical trials: Study design & enrolment. Are femalesdisadvantaged? Erica Villa, IT

17:10 - 17:30 IP122Gender disparities in liver transplantations Marina Berenguer, ES

Live Session

16:30 – 17:30 Hall 8Screening endoscopy for upper GI: What's new in 2021?Chairs: Cesare Hassan, IT

Thierry Ponchon, FR

16:30 - 16:50 IP123Squamous oesophageal neoplasia Tsuneo Oyama, JP

16:50 - 17:10 IP124Non-invasive screening for Barrett's oesophagus Rebecca Clare Fitzgerald, UK

17:10 - 17:30 IP125Early gastric cancer: Is it time for a tailored approach? Pedro Pimentel-Nunes, PT



The future of journals: Add social media and mix wellwith scientific publishingChairs: Katarzyna Monika Pawlak, PL

Iago Rodríguez-Lago, ESAlexander Meining, DE

Recorded only

17:30 – 18:00 Hall 1Best of DDW II

17:30 - 17:40 IP126Best of liver Jasmohan S. Bajaj, US

17:40 - 17:50 IP127Best of pancreatic disorders Christopher J. DiMaio, US

17:50 - 18:00 IP128Best of oesophageal, gastric and duodenal disorders Ikuo Hirano, US


17:30 – 18:30 Industry HallIS-06 Breaking the ‘therapeutic ceiling’ in themanagement of Crohn’s disease: hype or hope?


18:00 – 19:00 TV StudioManagement of patients with advanced fibrosis andcirrhosis in chronic viral hepatitisChairs: Heiner Wedemeyer, DE

Stefano Gitto, ITSabela Lens, ESFrancesco Negro, CH

18:00 - 18:10 IP129Hepatocellular carcinoma and HCV: A complexrelationship Stefano Gitto, IT


18:20 - 18:30 IP130Management and treatment of HBV/HDV coinfection incirrhosis: When and how? Sabela Lens, ES




18:30 - 18:40Panel discussion 18:40 - 18:50 IP131A difficult-to-treat hepatitis C case Francesco Negro, CH


Expert Encore

18:00 – 19:30 Hall 1Placing novel treatment strategies in IBD algorithmsChairs: Matthieu Allez, FR

Iris Dotan, IL

18:00 - 18:20 IP132Where to place novel JAK inhibitors Severine Vermeire, BE

18:20 - 18:40 IP133Novel integrin strategies Julian Panés, ES

18:40 - 19:00 IP134Anti-IL23 and more Raja Atreya, DE

19:00 - 19:30In-depth discussion with the experts

Live Session

18:00 – 19:00 Hall 2Prevention of lower GI diseasesChairs: Jean-Frederic Colombel, US

Elizabeth E Half, IL

18:00 - 18:20 IP135IBD: Strategies for prevention Joana Torres, PT

18:20 - 18:40 IP136CT colonography: Advantages and limitations as ascreening test Andrew Plumb, UK

18:40 - 19:00 IP137Prevention of colorectal neoplasia: Update on organisedprograms Jaroslaw Regula, PL

Expert Encore

18:00 – 19:30 Hall 3Refractory GORD: Insights from new ESNM and ANMSconsensus reportChairs: C Prakash Gyawali, US

Sabine Roman, FR

18:00 - 18:20 IP138Definition and diagnostic work up Frank Zerbib, FR

18:20 - 18:40 IP139PPIs, more PPIs and side-effects of acid suppression Rena Yadlapati, US

18:40 - 19:00 IP140Interventional antireflux therapies Salvatore Tolone, IT


Moderated Poster

18:00 – 19:00 Hall 5Health economical aspect in GI disordersChairs: Christos D Lionis, GR

Cristina Carretero, ES

18:00 - 18:10 MP049THE FIRST UK DIETITIANS PROVIDING ADVANCEDPRACTITIONER GI SERVICES Christian Shaw

18:10 - 18:20 MP050COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD ANDADALIMUMAB IN PATIENTS WITH MODERATELY TOSEVERELY ACTIVE ULCERATIVE COLITIS Marla C. Dubinsky, US

18:20 - 18:30 MP051ESTIMATING THE BURDEN AND ECONOMIC IMPACT OFINPATIENT ADMISSIONS FOR DIGESTIVE DISEASESACROSS EUROPE, 2021–2035 Tanith Rose, UK

18:30 - 18:40 MP052COST-BENEFIT ANALYSIS OF THE INNOVATIVEGASTROENTEROLOGICAL INTERPROFESSIONAL TRAININGWARD REGENSBURG (A-STAR) Sophie Schlosser, DE

18:40 - 18:50 MP054THE IMPACT OF ENDOSCOPIC ACTIVITY ONMUSCULOSKELETAL DISORDERS OF PRACTICINGGASTROENTEROLOGISTS IN GERMANY Benjamin Walter, DE





18:00 – 19:00 Hall 6Immunomodulatory treatment in cancer: Pros and consChairs: Michel Ducreux, FR

Eric Van Cutsem, BE

18:00 - 18:20 IP141Mapping the human peritoneal immune system toidentify novel immunomodulatory targets for thetreatment of peritoneal metastasised cancer Joep Grootjans, NL

18:20 - 18:40 IP142Colon cancer and inhibitory checkpoints: Targets fortreatment Michel Ducreux, FR

18:40 - 19:00 IP143How to deal with severe GI and hepatic toxicity Franck Carbonnel, FR

Expert Encore

18:00 – 19:30 Hall 7Advances in the multidisciplinary management ofhepatocellular carcinomaChairs: Peter Robert Galle, DE

Lorenza Rimassa, IT

18:00 - 18:20 IP144Molecular strategies in HCC Jean Charles Nault, FR

18:20 - 18:40 IP145Curative therapies for HCC Gonzalo Sapisochin Cantis, CA

18:40 - 19:00 IP146Immunotherapy: Challenges and opportunities forpatients with hepatocellular carcinoma David James Pinato, UK




Tasty takeaways: The power of questions with VincianeReboursChairs: Dina Tiniakos, UK

Vinciane Rebours, FR

Vienna Live Session

19:00 – 19:30 TV StudioThe UEG Week Tonight Show IChairs: Axel Dignass, DE

Michael Farthing, UKRebecca Clare Fitzgerald, UKHenriette Heinrich, CHMagnus Simrén, SE


19:00 – 20:00 Industry HallIS-07 TNF inhibition in the evolving IBD landscape: anenduring cornerstone of care?



UEG Week Final Programme Monday, October 4, 2021

Scientific Programme by DayMonday, October 4, 2021

Vienna Live Session

08:00 – 09:00 TV StudioUEG Week Digested IChairs: Herbert Tilg, AT

Mario Dinis-Ribeiro, PTBritta Siegmund, DEMagnus Simrén, SEJoost P.H. Drenth, NL

Live Session

09:00 – 10:00 TV StudioMistakes in...IIChairs: Charles Murray, UK

09:00 - 09:10 IP147Mistakes in pouchitis Ailsa L Hart, UK

09:10 - 09:20 IP148Mistakes in jejunal feeding Ashley Bond, UK

09:20 - 09:30 IP149Mistakes in pregnancy and IBD C. Janneke van der Woude, NL



09:00 – 10:00 Hall 1IBD diagnostics and biomarkersChairs: Konstantinos Papamichail, US

Michael Scharl, CH

09:00 - 09:12 OP071NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTINDERIVED FROM HUMAN NEUTROPHIL ELASTASE(CPA9-HNE) IS A NOVEL SERUM CALPROTECTINBIOMARKER OF INFLAMMATION AND DISEASE ACTIVITYFOR IBD Joachim Høg Mortensen, DK

09:12 - 09:24 OP072EARLY PREDICTORS OF SURGERY IN PATIENTS WITHACUTE SEVERE ULCERATIVE COLITIS: RESULTS OF ANINTERNATIONAL COHORT STUDY Matteo Frasson, ES

09:24 - 09:36 OP073PERIPHERAL BLOOD DNA METHYLATION PROFILESPREDICT RESPONSE TO USTEKINUMAB AND SHOWSTABILITY DURING BOTH INDUCTION AND MAINTENANCETREATMENT IN CROHN’S DISEASE Vincent Joustra, NL09:36 - 09:48 OP074INCREASED EXPRESSION OF SERPIN E1, A POTENTIALNEW ACTIVITY MARKER, REFLECTS ENDOSCOPIC ACTIVITYAND THERAPEUTIC NON-RESPONSE IN INFLAMMATORYBOWEL DISEASE Boldizsár Jójárt, HU

09:48 - 10:00 OP075RISK AND PREDICTORS OF SURGERY IN A NEWLYDIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGICERA: RESULTS FROM THE EPIDEMIBD STUDY María Chaparro, ES

Live Session

09:00 – 10:00 Hall 2Management of functional constipationChairs: Jordi Serra, ES

Jan Tack, BE

09:00 - 09:20 IP150Evaluation of colonic motility and ano-rectal function:How and for whom? Henriette Heinrich, CH

09:20 - 09:40 IP151Pharmacological treatment Maura Corsetti, UK

09:40 - 10:00 IP152When should the surgeon step in? Eloy Espin Basany, ES


09:00 – 10:00 Hall 3A 360° look on lower GI oncologyChairs: Thomas Seufferlein, DE

Irit Ben-Aharon, IL

09:00 - 09:12 OP076INTERNATIONAL MULTICENTRE RANDOMIZEDCONTROLLED TRIAL COMPARINGFERRIC(III)CARBOXYMALTOSE INFUSION WITH ORAL IRONSUPPLEMENTATION IN THE TREATMENT OFPREOPERATIVE ANAEMIA IN COLORECTAL CANCERPATIENTS: THE FIT-TRIAL Kevin Talboom, NL




09:12 - 09:24 OP077ENDOSCOPIC INTERMUSCULAR DISSECTION (EID) FORDEEP SUBMUCOSAL INVASIVE CANCER IN THE RECTUM- ANEW ENDOSCOPIC APPROACH Leon M.G. Moons, NL09:24 - 09:36 OP078INTRAVENOUS INJECTION OF COLON CANCEREXTRACELLULAR VESICLES SUPPRESSES TUMOR GROWTHWITH DAMPENING REGULATORY T CELL PHENOTYPE Sanshiro Kobayashi, JP

09:36 - 09:48 OP079BREATH TESTING FOR COLORECTAL CANCER ANDADENOMATOUS POLYPS - THE COLORECTAL BREATHANALYSIS1 STUDY (COBRA1) Georgia Woodfield

09:48 - 10:00 OP080LONG-TERM RISK OF METACHRONOUS ADVANCEDADENOMA DURING 10 YEARS FOR SUBJECTS WITHNEGATIVE COLONOSCOPY Seiji Kimura, JP


09:00 – 10:00 Hall 4Diverse intestinal disordersChairs: Antonio Di Sabatino, IT

Sibylle Koletzko, DE

09:00 - 09:12 OP081BLINDED ORAL CHALLENGES WITH LACTOSE ANDPLACEBO ACCURATELY DIAGNOSE LACTOSEINTOLERANCE: A REAL-LIFE STUDY Costantino Sgamato, IT

09:12 - 09:24 OP082A BLOOD TEST FOR COELIAC DISEASE DIAGNOSIS ON AGLUTEN-FREE DIET Maria Corzo, ES

09:24 - 09:36 OP083APOB-48 LEVELS ARE RELATED TO PARENTERALNUTRITION DEPENDENCE IN PATIENTS WITH SHORTBOWEL SYNDROME: A POTENTIAL BIOMARKER OFINTESTINAL FAILURE Salma Fourati, FR

09:36 - 09:48 OP084ASYMPTOMATIC HUMORAL IMMUNE RESPONSE TOGLUTEN INTAKE IN EARLY INFANCY IS MISSING IN HLA-DQ2.5 HOMOZYGOUS SUBJECTS: LACK OF PRIMARYTOLEROGENIC RESPONSE? Ilma Korponay-Szabo, HU

09:48 - 10:00 OP085PREDICTING THE RISK OF SIGNIFICANT LESIONS ONCAPSULE ENDOSCOPY IN PATIENTS WITH SUSPECTEDSMALL BOWEL BLEEDING – EXTERNAL VALIDATION OF THESSB CAPSULE DX SCORE Tiago Lima Capela, PT

Live Session

09:00 – 10:00 Hall 5Controversies in liver transplantation and MELDChairs: Jean-François Dufour, CH

Ruben Ciria, ES

09:00 - 09:20 IP153Timing of liver transplantation: Pitfalls of the MELDsystem Francois Durand, FR

09:20 - 09:40 IP154Liver transplantation at the edge (of guidelines) Salvatore Gruttadauria, IT

09:40 - 10:00 IP155Difficulties of getting organ donations Beatriz Domínguez-Gil, ES


09:00 – 10:00 Hall 6Endoscopy on a different trackChairs: Marianna Arvanitakis, BE

Ivo Boskoski, IT

09:00 - 09:12 OP086POWERSPIRAL ENTEROSCOPY DELIVERS AN IMPRESSIVEPERFORMANCE AND ACHIEVING TOTAL ENTEROSCOPYEVEN IN ALTERED GASTROINTESTINAL ANATOMY.MULTICENTRE PROSPECTIVE STUDY Abdulbaqi Al-toma, NL

09:12 - 09:24 OP087MOTORIZED SPIRAL ENTEROSCOPY-ASSISTED ERCP INALTERED GASTROINTESTINAL ANATOMY: FIRST CLINICALSERIES Markus Schneider, DE

09:24 - 09:36 OP088COMPARATIVE EFFICACY OF DIFFERENT METHODS FORDIFFICULT BILIARY CANNULATION IN ENDOSCOPICRETROGRADE CHOLANGIOPANCREATOGRAPHY: ASYSTEMATIC REVIEW AND A NETWORK META-ANALYSIS Paraskevas Gkolfakis, BE

09:36 - 09:48 OP089EUS-GUIDED CHOLEDOCHODUODENOSTOMY USING ALUMEN-APPOSING METAL STENT FOR MALIGNANT DISTALBILIARY OBSTRUCTION: A RETROSPECTIVE MULTICENTERANALYSIS Alessandro Fugazza, IT




09:48 - 10:00 OP090EFFICACY AND SAFETY OF EUS GUIDED TRANSMURALGALLBLADDER DRAINAGE IN MALIGNANT BILIARYOBSTRUCTION USING AN ELECTROCAUTERY-ENHANCEDLUMEN APPOSING METAL STENT: A MULTICENTER STUDY Thomas Lambin, FR


09:00 – 10:00 Hall 7Clinical hepatology: Evolving issuesChairs: Sven Francque, BE

Andreas E. Kremer, CH

09:00 - 09:12 OP091EFFICACY AND SAFETY OF GIVOSIRAN IN PATIENTS WITHACUTE HEPATIC PORPHYRIA: 24-MONTH INTERIMANALYSIS OF THE PHASE 3 ENVISION RANDOMIZEDCLINICAL TRIAL Herbert L. Bonkovsky, US

09:12 - 09:24 OP092RECENT AUSTRIAN EPIDEMIOLOGICAL DATA ONHEPATITIS D VIRUS Mathias Jachs, AT

09:24 - 09:36 OP093EARLY SARS-COV-2-RELATED MORTALITY OF LIVERCANCER PATIENTS: CANCER STAGE MATTERS Sergio Muñoz-Martinez, ES

09:36 - 09:48 OP094PREGNANCY AFTER LIVER TRANSPLANTATION: A SURVEYFROM ITALIAN LIVER TRANSPLANTS CENTRES Salvatore Stefano Sciarrone, IT

09:48 - 10:00 OP095LIFESTYLE CHANGES OF CURED HEPATITIS C PATIENTS INA NURSE-LED LIVER CANCER SCREENING PROGRAM Núria Granel, ES

Live Session

09:00 – 10:00 Hall 8Is per oral endoscopic myotomy (POEM) the newstandard?Chairs: Paul Fockens, NL

Jan Martinek, CZ

09:00 - 09:10 IP156POEM for Zenker Roberta Maselli, IT

09:10 - 09:20 IP157POEM for non achalasia disorders Bas L.A.M. Weusten, NL

09:20 - 09:30 IP158GORD after POEM Haruhiro Inoue, JP


Live Demo

09:00 – 10:00 Live Demo RoomUltrasound Course I - Ultrasound of the liverChairs: Thomas Müller, DE

Alina Popescu, RO

09:00 - 09:15 IP159Ultrasound examination of the abdomen with specialfocus on liver (ultrasound demonstration) Dieter Nürnberg, DE

09:15 - 09:30 IP160Diffuse liver pathology: The role of ultrasound,elastography and attenuating imaging Ioan Sporea, RO

09:30 - 09:45 IP161Focal liver lesions – the role of ultrasound and contrastenhanced ultrasound Alina Popescu, RO


E-Poster Session

09:00 – 19:00 Poster ExhibitionE-Poster Sessions

E-Poster Session









09:00 - 09:00 P0096CORRELATION BETWEEN THE INTENSITY OFHELICOBACTER PYLORI COLONIZATION AND SEVERITY OFGASTRITIS: RESULTS OF A PROSPECTIVE STUDY Salma Souissi, TN09:00 - 09:00 P0097THE ANATOMIC DISTRIBUTION AND FREQUENCY OFPREMALIGNANT LESIONS OF STOMACH RELATED TOHELICOBACTER PYLORI INFECTION IN MIDDLE-AGED ANDOLDER PATIENTS Cundullah Torun, TR




09:00 - 09:00 P0101FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPYIN EUROPE: RESULTS FROM 30,000 CASES OF THEEUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG) Olga P. Nyssen, ES

09:00 - 09:00 P0102EMPIRICAL FIRST-LINE TREATMENT USE ANDEFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) Olga Perez Nyssen, ES



09:00 - 09:00 P0105ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTERPYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2020:ANALYSIS OF THE EUROPEAN REGISTRY ON H.PYLORI MANAGEMENT (HP-EUREG) Luis Bujanda, ES09:00 - 09:00 P0106EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN426 PATIENTS FROM THE EUROPEAN REGISTRY ON H.PYLORI MANAGEMENT (HP-EUREG) Olga P. Nyssen, ES




09:00 - 09:00 P0111DIAGNOSIS, TREATMENT PATTERNS, AND EFFECTIVENESSOF HELICOBACTER PYLORI ERADICATION IN CHINA: STUDYDESIGN FOR A RETROSPECTIVE REAL-WORLD STUDY Fang Zhou, CN

09:00 - 09:00 P0112FIRST LINE ERADICATION THERAPY FOR HELICOBACTERPYLORI GUIDED BY MOLECULAR ANALYSIS OF GENOTYPICRESISTANCES ON STOOLS: A PILOT STUDY Giuseppe Losurdo, IT







09:00 - 09:00 P0116FIRST-LINE HELICOBACTER PYLORI ERADICATION RATE INDAILY CLINICAL PRACTICE IN TWO SPANISH MEDICALCENTERS: 2010-2019 Inés Ariño Pérez, ES09:00 - 09:00 P0117MANAGEMENT OF HELICOBACTER PYLORI INFECTIONDURING THE LAST DECADE: TEMPORAL PRESCRIPTIONTRENDS FOR THE FIRST-LINE OF NON-ALLERGICPATIENTS AND ITS ADEQUACY TO CLINICAL GUIDELINES Inés Ariño Pérez, ES




09:00 - 09:00 P0125LONG-TERM RISK OF UPPER GASTROINTESTINALBLEEDING AFTER HELICOBACTER PYLORI ERADICATION: APOPULATION-BASED COHORT STUDY Fang Jiang, CN

09:00 - 09:00 P0126PRIMARY RESISTANCE OF HELICOBACTER PYLORI TOCLARITHROMYCIN IN TUNISIA Manel Moalla, TN




E-Poster Session







09:00 - 09:00 P0636LIVER TRANSAMINASES, LEPTIN AND INTERLEUKIN-6LEVEL IN PATIENTS WITH NON-ALCOHOLICSTEATOHEPATITIS COMBINED WITH OBESITY ANDARTERIAL HYPERTENSION DURING TREATMENT WITHURSODEOXYCHOLIC ACID, STATINS AND SARTANS Olesia Bochar, UA

09:00 - 09:00 P0637UNDERSTANDING THE TRANSCRIPTOMIC CHANGES OFMAFLD IN HIGH FAT DIET MURINE MODELS AND ITSREVERSION BY ANTI-STEATOTIC TREATMENTS THROUGHMETA-ANALYSIS Nadezda Apostolova, ES







09:00 - 09:00 P0641HUMAN ALPHA-1-DEFENSIN IN PATIENTS WITHALCOHOLIC HEPATITIS AND LIVER CIRRHOSIS Viachaslau Pryshchepenka, BY09:00 - 09:00 P0642RELATIONSHIP BETWEEN INTESTINAL DYSBIOSIS ANDOBESITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVERDISEASE. Yana Nikiforova, UA




09:00 - 09:00 P0646HYPOADIPONECTINEMIA AS A MARKER OF INCREASEDCARDIOVASCULAR RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: CORRELATION WITHALBUMIN/CREATININE RATIO Mona Ahmed Amin, EG

09:00 - 09:00 P0647THE IMPACT OF PNPLA3 RS738409 RISK G ALLELES ONHEPATIC STEATOSIS, THE METABOLIC SYNDROME ANDPORTAL HYPERTENSION IN ADVANCED FATTY LIVERDISEASE Antonina Antonenko, AT




09:00 - 09:00 P0651METABOLIC ASSOCIATED FATTY LIVER DISEASE IN THECHRONIC HEPATITIS C PATIENTS Yasser Fouad, EG09:00 - 09:00 P0652DIETARY PATTERNS IN PATIENTS WITH SIMPLE STEATOSISAND NON-ALCOHOLIC STEATOHEPATITIS: PROSPECTIVECOMPARATIVE TRIAL Sergey Morozov, RU




09:00 - 09:00 P0656DISTINCTIVE CLINICAL FEATURES OF NON-ALCOHOLICAND MIXED FATTY LIVER DISEASE Nicolau Vallejo-Senra, ES

09:00 - 09:00 P0659NOVEL PATHOGENIC ALG8 VARIANTS AND EVIDENCE FORSOMATIC LOSS OF HETEROZYGOSITY IN 199 AUTOSOMALDOMINANT POLYCYSTIC LIVER DISEASE PATIENTS Melissa M. Boerrigter, NL







09:00 - 09:00 P0663FAST IS NOT SUPERIOR TO LSM FOR NONINVASIVEDIAGNOSIS OF FIBROSIS STAGE OR ‘ACTIVE FIBROTICNASH’ IN NONALCOHOLIC FATTY LIVER DISEASE Rudolf Stauber, AT09:00 - 09:00 P0664COLONIC DIVERTICULOSIS AND NON-ALCOHOLIC FATTYLIVER DISEASE: IS THERE A CONNECTION? Ivana Pantic, RS





09:00 - 09:00 P0669VITAMIN D DEFICIENCY IS ASSOCIATED WITH SIGNIFICANTSTEATOSIS, ADVANCED FIBROSIS AND NON-ALCOHOLICSTEATOHEPATITIS (NASH), IN NON-ALCOHOLIC FATTYLIVER DISEASE (NAFLD) Khellaf Amalou, DZ

09:00 - 09:00 P0670EFFECT OF CHOLECYSTECTOMY ON HEPATIC STEATOSISAND INSULIN RESISTANCE ASSESSED BY CONTROLLEDATTENUATION PARAMETER (CAP) AND MRI IN NON-ALCOHOLIC FATTY LIVER (NAFLD) ALGERIAN PATIENTS: APILOT STUDY Khellaf Amalou, DZ



09:00 - 09:00 P0674FEATURES OF THE SERUM LONG-CHAIN FREE FATTY ACIDSCONTENT IN CHILDREN WITH NON-ALCOHOLIC FATTYLIVER DISEASE Natalia Zavhorodnia, UA09:00 - 09:00 P0675INSULIN LEVELS ARE ASSOCIATED TO LIVER FUNCTIONTEST AND LIVER DISEASE IN COHORTS WITH UP TO 24YEARS OF FOLLOW-UP Andreas Schult, SE





09:00 - 09:00 P0680OUTCOMES OF PATIENTS WITH ALCOHOLIC LIVERDISEASE AFFECTED WITH THE METABOLIC SYNDROME Leore Cohen Mendel, IL

09:00 - 09:00 P0681ALCOHOL USE DISORDER AND ALCOHOL RELATED LIVERDISEASE: TIME FOR SCREENING? Camelia Gianina Foncea, RO






09:00 - 09:00 P0684DIP THE TAP - IMPROVING NEEDLE TO DIAGNOSIS TIME INSPONTANEOUS BACTERIAL PERIOTINITIS: A RENEWEDSCREENING ROLE FOR BEDSIDE LEUCOCYTE ESTERASETEST KITS - DURING COVID 19 PANDEMIC A MULTISITESTUDY Flora Kokwaro09:00 - 09:00 P0685CAN SERUM FERRITIN PREDICT 30 DAYS MORTALITY INPATIENTS WITH DECOMPENSATED CIRRHOSIS? Sahar Nasr, TN






09:00 - 09:00 P0693QUALITY OF LIFE IMPROVEMENT IS A TOP-RATED BUTRARELY ASSESSED OUTCOME IN EUROPEAN ANDAUSTRALIAN PATIENTS WITH HEPATICENCEPHALOPATHY: QUALITY OF LIFE TARGETING ANDMONITORING NEEDS TO BE PRIORITISED Juha Halonen

09:00 - 09:00 P0694PROCALCITONIN AS A PROGNOSTIC TOOL IN THEMANAGEMENT OF REFRACTORY ASCITES Margarida Gomes Gonçalves, PT


09:00 - 09:00 P0696WHAT IS THE CLINICAL IMPACT OF ASCITES CHOLESTEROLAND PROBNP LEVELS IN OUR ROUTINE PRACTICE FOR THEDIFFERENTIAL DIAGNOSIS OF ASCITES ETIOLOGY? Filiz Akyuz, TR09:00 - 09:00 P0697INTERNATIONAL FRENCH-SPEAKING MULTICENTREPRACTICE SURVEY ON HEPATIC HYDROTHORAX (HH) :RESULTS OF THE "HEP HEP" STUDY AMONG 529HEPATOGASTROENTEROLOGIST (HG) OR PNEUMOLOGIST(PN) RESPONDENTS Jean-François David Cadranel, FR






09:00 - 09:00 P0703PREDICTORS OF BLEEDING AFTER PROPHYLACTICENDOSCOPIC VARICEAL LIGATION Renato Medas, PT

09:00 - 09:00 P0704PREDICTIVE FACTORS OF BACTERIAL INFECTION INPATIENTS WITH LIVER CIRRHOSIS: EXPERIENCE OF THEHEPATO-GASTROENTEROLOGY DEPARTMENTCASABLANCA UNIVERSITY HOSPITAL Sara Nacer, MA





09:00 - 09:00 P0706THE SPECTRUM OF DECOMPENSATED CIRRHOSIS: WHICHSCORES PERFORM THE BEST IN PREDICTINGMORTALITY? Inês Costa-Santos, PT09:00 - 09:00 P0707A DEEP LEARNING-BASED SYSTEM FOR PREDICTING THERISK OF HEMORRHAGE OF GASTROESOPHAGEAL VARICESQUANTITATIVELY UNDER ENDOSCOPY Jing Wang, CN







09:00 - 09:00 P0714THE SUBPOPULATION COMPOSITION OF BLOOD T-KILLERS AND THE FREQUENCY OF SEVERE LIVER FIBROSISDIFFER IN PATIENTS WITH VIRAL HEPATITIS C WITHGENOTYPES 1 AND 3 IN THE INDUSTRIAL CENTER OFEASTERN SIBERIA Vladislav Tsukanov, RU

09:00 - 09:00 P0715THE SHIFT IN PREVALENCE, INCIDENCE, AND MORTALITYRATES OF VIRAL HEPATITIS TYPES A, B, C AND D INBRAZILIAN CITIZENS BETWEEN 1999 AND 2019 Lucas Monteiro, BR

09:00 - 09:00 P0716RETRIEVAL OF LOST PATIENTS IN THE SYSTEM FORHEPATITIS C MICROELIMINATION: A SINGLE-CENTERRETROSPECTIVE STUDY Hsu-Heng Yen, TW09:00 - 09:00 P0717CHRONIC HEPATITIS B UNDER TENOFOVIR OR ENTECAVIR:PERFORMANCE OF THE PAGE-B SCORE TO PREDICTHEPATOCELLULAR CARCINOMA Daniela Falcão, PT







09:00 - 09:00 P0725CHRONIC HEPATITIS B GENOTYPE E: A REALITY IN ADISTRICT HOSPITAL IN PORTUGAL Bárbara Morão, PT

09:00 - 09:00 P0726DIABETES MELLITUS DOES NOT INCREASE THE RISK OFRECURRENT HEPATOCELLULAR CARCINOMA AFTERDIRECT-ACTING ANTIVIRAL TREATMENT FOR HEPATITIS C:SYSTEMATIC REVIEW WITH META-ANALYSIS Szilárd Váncsa, HU




09:00 - 09:00 P0727CHRONIC HEPATITIS B GENOTYPE E: CLINICALCHARACTERISTICS AND RESPONSE TO ANTI-VIRALAGENTS Bárbara Morão, PT09:00 - 09:00 P0728SEROPREVALENCE OF HEPATITIS B AND C VIRUSES INCHILDREN ABOVE THE AGE OF 3 YEARS: AN EGYPTIANHOSPITAL-BASED CROSS-SECTIONAL SURVEY STUDY Muhammad Abdel-Gawad, EG







09:00 - 09:00 P0737PREVALENCE OF INSULIN RESISTANCE IN PATIENTSBEFORE AND AFTER LIVER TRANSPLANTATION, AND ITSPROGRESSION DURING THE FOLLOW-UP. A PROSPECTIVESTUDY Irena Mikova, CZ

09:00 - 09:00 P0738DRUG INDUCED LIVER INJURY: ROLE OF CIRCULATINGLIVER-SPECIFIC MICRORNAS AND KERATIN-18 Giacomo Germani, IT


09:00 - 09:00 P0740ULTRASOUND VISCOELASTIC LIVER MEASUREMENTS ANDFACTORS THAT INFLUENCE THEM Roxana Sirli, RO09:00 - 09:00 P0741THE ROLE OF VASCULARIZATION PARAMETERSQUANTIFICATION FOR THE ASSESSMENTS OFINCONCLUSIVE FOCAL LIVER LESIONS CHARACTERIZED BYCEUS Tudor Voicu Moga, RO






09:00 - 09:00 P0747COMPARISON BETWEEN ACOUSTIC RADIATION FORCEIMPULSE (ARFI) ELASTOGRAPHY AGAINST TRANSIENTELASTOGRAPHY (FIBROSCAN) IN NON-ALCOHOLIC FATTYLIVER DISEASE (NAFLD) Thazin Min

09:00 - 09:00 P0748TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) INPATIENTS WITH UNRESECTABLE HEPATOCELLULARCARCINOMA: EXPERIENCE OF A TUNISIAN CENTER Amani Hassine, TN





09:00 - 09:00 P0750MICRORNA-122 CONJUGATED POLYMER NANOPARTICLESAS A PROTECTIVE TOOL AGAINST DEVELOPMENT OFHEPATOCELLULAR CARCINOMA IN AN EXPERIMENTALMODEL Eman EL-Ahwany, EG09:00 - 09:00 P0751DISTINCT EFFECTS OF IGFBP2 ON VIABILITY OFHEPATOMA CELLS – A MATTER OF DOSE Frederik Kolligs, DE






09:00 - 09:00 P0758THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIESPATIENTS WITH ADVERSE CLINICAL OUTCOME FROMIMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA Ambreen Muhammed

09:00 - 09:00 P0759NEW TOOLS FOR PREDICTING SURVIVAL IN PATIENTSWITH HEPATOCELLULAR CARCINOMA TREATED WITHSORAFENIB Alexandra Pires, PT


09:00 - 09:00 P0761NURSE INTERVENTION OPTIMIZES THE CARE OF PATIENTSWITH HEPATOCELLULAR CARCINOMA UNDERSECOND/THIRD-LINE TREATMENTS Gemma Iserte Fort, ES09:00 - 09:00 P0762FAILURE OF ULTRASOUND-BASED SURVEILLANCE FORHEPATOCELLULAR CARCINOMA IN PATIENTS AT RISK ISFREQUENT AND ASSOCIATED WITH DETECTION AT LATERTUMOR STAGES, NON-CURATIVE TREATMENT OPTIONSAND REDUCED SURVIVAL. RESULTS FROM A GERMANMULTI-CENTER RETROSPECTIVE COHORT STUDY Christoph Schramm, DE






09:00 - 09:00 P0769DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABELUSE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS) Georg Semmler, AT

09:00 - 09:00 P0770NATURAL HISTORY OF PATIENTS WITH NON-CIRRHOTICPORTAL HYPERTENSION Joel Silva, PT






09:00 - 09:00 P0773HEPATOCELLULAR CARCINOMA (HCC) AWARENESS ANDSURVEILLANCE IN PATIENTS WITH CHRONIC LIVERDISEASES (CLD) FOLLOWED IN TERTIARY GREEK LIVERCENTERS Paraskevi Fytili, GR09:00 - 09:00 P0775PREVALENCE OF PERIODONTAL DISEASE IN PATIENTSWITH LIVER CIRRHOSIS AND ITS INFLUENCE ON THESHORT-TERM OUTCOME OF THE DISEASE Srinivas Reddy Thummala, IN




09:00 - 09:00 P0779DIABETES MELLITUS WAS ASSOCIATED WITH A HIGHERRATE OF ACUTE CHOLANGITIS AMONG PATIENTS WITHCOMMON BILE DUCT STONE Tawfik Khoury, IL

09:00 - 09:00 P0780THREE-MONTHS DURATION OF FULLY-COVERED METALSTENT FOR REFRACTORY DOMINANT EXTRA-HEPATICBILIARY STRICTURE AMONG PRIMARY SCLEROSINGCHOLANGITIS PATIENTS: EFFICACY AND SAFETY Tawfik Khoury, IL

09:00 - 09:00 P0781ROLE OF ENDOSCOPIC ULTRASOUND IN EVALUATION OFBILE DUCT DILATATION: EXPERIENCE OF A TERTIARYCENTER Marta Librero Jiménez, ES

09:00 - 09:00 P0782ERCP IN BILROTH-II CASES. EXPERIENCE, TIPS ANDTRICKS Aleksandr Filin, RU


E-Poster Session


09:00 - 09:00 P0859DOES ANTIBIOTIC PROPHYLAXIS REDUCE THE INFECTIONRATE IN CHILDREN AFTER PERCUTANEOUS ENDOSCOPICGASTROSTOMY INSERTION? Oana Belei, RO

09:00 - 09:00 P0860I-SCAN ENDOSCOPIC PATTERNS OF HELICOBACTERPYLORI-INDUCED GASTRITIS Ahmed Altonbary, EG


09:00 - 09:00 P0862ME-BLI TO JUDGE THE DEPTH OF INVASION OF EARLYESOPHAGEAL CANCER WITH TYPE B2 BLOOD VESSELSAND ANALYSIS OF RELATED FACTORS Wei Ning, CN

09:00 - 09:00 P0863A PROMISING METHOD FOR ACCURATELY CALCULATINGTHE PERCENTAGE OF GASTRIC INTESTINAL METAPLASIAAREA Ning Wei, CN








09:00 - 09:00 P0868THE SWEDISH STANDARDIZED COURSE OF CARE FORUPPER GI CANCER – CANCER PREVALENCE ANDPREDICTIVE VALUES OF ENTRY CRITERIA Michiel Van Nieuwenhoven, SE09:00 - 09:00 P0869DELIBERATE FOREIGN BODY SWALLOWING IN PATIENTSWITH UNDERLYING MENTAL HEALTH DISEASE: ARETROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY Warren Seow, AU

09:00 - 09:00 P0870SAFETY AND EFFICACY OF DUAL EMISSION ENDOSCOPICLASER TREATMENT IN PATIENTS WITH UPPER OR LOWERGASTRO-INTESTINAL VASCULAR LESIONS CAUSINGCHRONIC ANAEMIA: RESULTS FROM THE FIRST MULTI-CENTRE COHORT STUDY Alessandro Rimondi, IT


09:00 - 09:00 P0872DIAGNOSTIC OUTCOMES AFTER CANCELLEDGASTROSCOPY: RESULTS OF TELEPHONE VETTING&GT;600 PATIENTS DURING THE COVID-19 PANDEMIC Ella Mozdiak

09:00 - 09:00 P0873THE ROLE OF COMPUTED TOMOGRAPHY IN FISH BONEIMPACTION IN ESOPHAGUS AND ACCURACY OF PATIENT'SCOMPLAINING LOCATION COMPARED WITH THEIMPACTION LOCATION: A RETROSPECTIVE, SINGLE-CENTER STUDY Gyu Man Oh, KR




09:00 - 09:00 P0877CLINICAL UTILITY OF DUODENAL BIOPSIES IN THEDIAGNOSIS OF IRON DEFICIENCY ANEMIA. ARETROSPECTIVE STUDY Theodoros Voulgaris, GR09:00 - 09:00 P0878REAL-TIME USE OF ARTIFICIAL INTELLIGENCE FORDIAGNOSING EARLY GASTRIC CANCER BY ENDOSCOPY: AMULTICENTER, DIAGNOSTIC STUDY Xinqi He, CN

09:00 - 09:00 P0879DOES IMAGE ENHANCED ENDOSCOPY IMPROVEDETECTION OF NEOPLASIA IN BARRETT’S OESOPHAGUSSURVEILLANCE: A NETWORK META ANALYSIS Chun Wai Sin



09:00 - 09:00 P0882GASTROINTESTINAL RESIDUE REMOVAL USING ABALLOON OVERTUBE UNDER ULTRATHIN ENDOSCOPICNAVIGATION: AN EXPERIMENTAL ANIMAL STUDY Kazuhiro Kozuka, JP

09:00 - 09:00 P0883WAFER PAPER AND RING-MOUNTED POLYGLYCOLIC ACIDSHEET METHOD FOR SHIELDING ULCER AFTER GASTRICENDOSCOPIC SUBMUCOSAL DISSECTION Nobuya Kobayashi, JP







09:00 - 09:00 P0887AZITHROMYCIN VERSUS ERYTHROMYCIN IN INTRAVENOUSINFUSION IN UPPER GASTROINTESTINAL BLEEDING:PRELIMINARY RESULTS OF A NON-INFERIOR,PROSPECTIVE, RANDOMIZED, DOUBLE-BLINDCONTROLLED CLINICAL TRIAL Maria Boquera Ferrer, ES09:00 - 09:00 P0888IMPACT ON AEROSOL GENERATION OF A MOUTHPIECEDESIGNED TO REDUCE DROPLET SPREAD OF COVID-19DURING UPPER GASTROINTESTINAL ENDOSCOPY, ASINGLE CENTER RANDOMIZED CONTROLLED TRIAL Pieter Sinonquel, BE

09:00 - 09:00 P0889ENDOSCOPIC GRADING OF GASTRIC INTESTINALMETAPLASIA IN PATIENTS WITH AUTOIMMUNE GASTRITIS:PSEUDOPYLORIC METAPLASIA MUDDIES THE WATERS Emanuele Dilaghi, IT



09:00 - 09:00 P0892PILLCAM ESO CAPSULE: AN ALTERNATIVE DIAGNOSTICTOOL DURING THE COVID-19 PANDEMIC. FIRST IRISHEXPERIENCE Mary Nwaezeigwe, IE

09:00 - 09:00 P0893DIRECT AND NON-DIRECT COSTS IN DIRECT-TO-TESTUPPER GASTROINTESTINAL ENDOSCOPY: NURSEENDOSCOPISTS VERSUS DOCTORS Ahaan Gupta



09:00 - 09:00 P0896EMERGENCY ENDOSCOPY IN CHILDREN DURING SARS-COV-2 PANDEMIC IN A TERTIARY CENTER – A CHANGINGPATTERN? Ana Sofia Vilardouro, PT09:00 - 09:00 P0897DIFFERENTIAL DIAGNOSTICS AND LONG-TERMPROGNOSIS OF NON-ATROPHIC DUODENAL CHANGES INCHILDREN UNDERGOINGESOPHAGOGASTRODUODENOSCOPY WITH SYSTEMATICBIOPSY SAMPLING Sofia Kröger, FI

09:00 - 09:00 P0898ARTIFICIAL INTELLIGENT CHRONIC ATROPHIC GASTRITISDIAGNOSTIC SYSTEM: AN EFFECTIVE GASTRICPRECANCEROUS RISK-SURVEILLANCE ASSISTED TOOL Yijie Zhu, CN




09:00 - 09:00 P0902PREMEDICATION WITH SIMETHICONE FOR IMPROVINGTHE QUALITY OF GASTRIC MUCOSAL VISUALISATIONDURING UPPER GASTROINTESTINAL ENDOSCOPY: ADOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL Léo Duez, BE

09:00 - 09:00 P0903TREATMENT OF DUODENAL ULCER BLEEDING - EFFICACYOF TRAUMATIC AND ATRAUMATIC OVER-THE-SCOPE-CLIPS (OTSC) – A MULTICENTER RETROSPECTIVEANALYSIS Marcus Hollenbach, DE






09:00 - 09:00 P0908DIAGNOSIS AND MANAGEMENT OF HYPERPLASTICGASTRIC POLYPS Salma Souissi, TN09:00 - 09:00 P0909THE DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCEAND COMPUTER-AIDED DIAGNOSIS FOR THE DETECTIONAND CHARACTERISATION OF COLORECTAL POLYPS: ASYSTEMATIC REVIEW AND META-ANALYSIS Scarlet Nazarian

09:00 - 09:00 P0910ENDOSCOPIC RETROGRADE APPENDICITIS THERAPY: ANEW THERAPEUTIC METHOD FOR ACUTE APPENDICITIS INCHILDREN WITH LEUKEMIA Jiyu Zhang, CN




09:00 - 09:00 P0914ACETO-ELECTRIC CHROMOENDOSCOPY FOR EVALUATINGTHE PIT PATTERN IN COLORECTAL POLYPS Shunsuke Yamamoto, JP

09:00 - 09:00 P0915THE ROLE OF CROSS-SECTIONAL IMAGING IN THEMANAGEMENT OF PATIENTS WITH COMPLEX COLORECTALPOLYPS Clare Westwood, UK



09:00 - 09:00 P0918INCREMENTAL YIELD OF ARTIFICIAL INTELLIGENCE INFOLLOW-UP SCREENING COLONOSCOPIES – AN INTERIMANALYSIS ON 432 PATIENTS Sebastian Manuel Milluzzo, IT09:00 - 09:00 P0919A NOVEL ONE-DAY VIRTUAL-LIVE HYBRID TRAININGCOURSE IS FEASIBLE AND HAS A POSITIVE IMPACT ONCOLONOSCOPY KEY PERFORMANCE INDICATORS OFEXPERIENCED ENDOSCOPY TRAINEES Louise Krott, BE

09:00 - 09:00 P0920SURVEILLANCE INTERVAL OF PATIENTS WITH HIGH-RISKADENOMAS REMOVED DURING SCREENINGCOLONOSCOPY Thomas Yuen Tung Lam, HK




09:00 - 09:00 P0925ESD KNIVES FEATURE COMPARISON - WHICH KNIFE TOUSE FOR ESD? Kota Momose, JP

09:00 - 09:00 P0926ENDOSCOPIC THERMAL DYNAMICS FOR EVALUATING THELESION WITH INFLAMMATION OR CANCER CORRELATESTO THE HISTOLOGICAL FINDINGS Hidetoshi Ohta, JP






09:00 - 09:00 P0929ENDOSCOPY AND RADIOLOGY IN THE EVALUATION OFRESPONSE TO CHEMORADIOTHERAPY IN LOW RECTALCANCER Pedro Currais, PT09:00 - 09:00 P0930ENDOSCOPIC SUBMUCOSAL DISSECTION FOR LESIONSINVOLVING ILEOCECAL VALVE WITH/WITHOUT EXTENSIONINTO TERMINAL ILEUM: A MULTICENTER 10-YEAR STUDY Hidenori Tanaka, JP

09:00 - 09:00 P0931EFFICACY OF SINGLE-BALLOON OVERTUBE FORENDOSCOPIC SUBMUCOSAL DISSECTION IN THEPROXIMAL COLON: A PROPENSITY SCORE MATCHEDANALYSIS Hidenori Tanaka, JP




09:00 - 09:00 P0935ARTIFICIAL INTELLIGENCE FOR POLYP DETECTIONDURING COLONOSCOPY – AN IN-DEPTH ANALYSIS OF ACOMMERCIALLY AVAILABLE SYSTEM Joel Troya, DE

09:00 - 09:00 P0936BOWEL PREPARATION QUALITY AND ITS IMPACT ONCOLONOSCOPY SCREENING INTERVAL AFTER A NEGATIVECOLONOSCOPY Lisa-Maria Rockenbauer, AT




09:00 - 09:00 P0940CHARACTERISTICS OF DEPRESSED TYPE COLORECTALNEOPLASMS IN MAGNIFYING ENDOSCOPY ANDENDOCYTOSCOPY Shinei Kudo, JP09:00 - 09:00 P0941AN ARTIFICIAL INTELLIGENCE-BASED QUALITYIMPROVEMENT SYSTEM SIGNIFICANTLY IMPROVED THEEFFICACY OF COMPUTER-AIDED DETECTION SYSTEM INCOLONOSCOPY: A 2*2 FACTORIAL ANALYSIS Lihui Zhang, CN

09:00 - 09:00 P0942NEW COMPUTER-AIDED POLYP DETECTION SYSTEM(ENDO-AID) INCREASED THE 5-10MM ADENOMADETECTION RATE IN JUNIOR ENDOSCOPISTS DURINGCOLONOSCOPIES – A PILOT STUDY Ho Shing Louis Lau, HK




09:00 - 09:00 P0946EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSEBOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATEWITH SODIUM PICOSULFATE IN SPECIAL GROUPS OFPATIENTS Tamás Molnár, HU

09:00 - 09:00 P0947ARTIFICIAL INTELLIGENCE IN ENDOSCOPIC SCREENINGFOR COLORECTAL CANCER – EXPENSIVE ADD-ON OR COSTSAVING? Stephan Döring, DE






09:00 - 09:00 P0950REAL-TIME ARTIFICIAL INTELLIGENCE-AIDEDCOLONOSCOPY EXPERIENCE: THE IMPACT ON ROUTINECLINICAL PRACTICE IN A HIGH-VOLUME CENTER -PRELIMINARY DATA Costanza Alvisi, IT09:00 - 09:00 P0951PATIENT ACCEPTABILITY OF OPTICAL DIAGNOSIS FORDIMINUTIVE POLYPS WITH A RESECT AND DISCARDSTRATEGY IN BOWEL CANCER SCREENINGCOLONOSCOPY Ahmir Ahmad

09:00 - 09:00 P0952HIGH CONFIDENCE OPTICAL DIAGNOSIS OF SMALLPOLYPS AT COLONOSCOPY VERSUS HISTOPATHOLOGY:MOVING TOWARDS A NEW GOLD STANDARD? Ahmir Ahmad




09:00 - 09:00 P0956NO SURVEILLANCE INTERVAL CHANGE WITH OPTICALDIAGNOSIS OF SMALL POLYPS DURING BOWEL CANCERSCREENING COLONOSCOPY Ahmir Ahmad

09:00 - 09:00 P0957CLINICAL USEFULNESS OF THE “HOLD-AND-DRAG”CLOSURE USING SB CLIP FOR LARGE MUCOSAL DEFECTSAFTER COLORECTAL ENDOSCOPIC SUBMUCOSALDISSECTION Kenjiro Shigita, JP



09:00 - 09:00 P0960HIGH FREQUENCY OF COLORECTAL POLYPS IN PATIENTSOF SPORADIC ADENOMAS OR ADENOCARCINOMAS OF THEPAPILLA OF VATER: A PROPENSITY SCORE MATCHINGSTUDY Fan Zhou, CN09:00 - 09:00 P0961INCOMPLETE RESECTION RATES OF 4-20MM NON-PEDUNCULATED COLORECTAL POLYPS WHEN USINGROUTINE SUBMUCOSAL INJECTION Leslie Motchum, CA

09:00 - 09:00 P0962INFLUENCE OF SEDATION TYPE ON POLYP DETECTIONRATE IN DIAGNOSTIC AND SCREENING COLONOSCOPIES:A TERTIARY CARE CENTER EXPERIENCE Fady Daniel, LB




09:00 - 09:00 P0966TECHNICAL OUTCOMES AND RISK OF STRICTURE AFTERENDOSCOPIC SUBMUCOSAL DISSECTION FOR LARGECOLORECTAL LESIONS Roberta Maselli, IT

09:00 - 09:00 P0967HOT AVULSION VERSUS ARGON PLASMA COAGULATIONFOR THE MANAGEMENT OF THE NON-LIFTING POLYP: AMULTICENTRE, RANDOMISED CONTROLLED TRIAL Chloe Attree, AU






09:00 - 09:00 P0970DEVELOPMENT AND COMPARISON OF THE POLYPDETECTION SYSTEM ENDOMIND WITH A COMMERCIALLYAVAILABLE CADE SYSTEM Alexander Hann, DE09:00 - 09:00 P097210-YEAR PREVALENCE OF OVERALL COLONOSCOPY ANDSCREENING COLONOSCOPY USE IN GERMANY: A CLAIMSDATA ANALYSIS Michel Hornschuch, DE

09:00 - 09:00 P0973EFFICACY OF ARGON PLASMA COAGULATION INPREVENTION OF BLEEDING RECURRENCE FROMGASTROINTESTINAL ANGIODYSPLASIA Sahar Nasr, TN





09:00 - 09:00 P0978ENDOSCOPIC MANAGEMENT OF SIGMOID COLONVOLVULUS - A RETROSPECTIVE COHORT OF 76 CASES Maria Inês Canha, PT

09:00 - 09:00 P0979PROSPECTIVE OBSERVATIONAL STUDY OF 1L NER1006COMPARED TO 2L POLYETHYLENE GLYCOL IN INPATIENTSAND OUTPATIENTS Marcus Hollenbach, DE



09:00 - 09:00 P0983AUGMENTATION OF BOWEL PREPARATION FOR REPEATCOLONOSCOPY : WHAT IS THE BEST APPROACH? Thomas Archer, UK09:00 - 09:00 P0985STRICTURE FORMATION FOLLOWING ENDOSCOPICRESECTION FOR LARGE NON-PEDUNCULATEDCOLORECTAL POLYPS Sunil Gupta, AU

09:00 - 09:00 P0986IS THIS THE TIP OF THE ICEBERG? SIX MONTH OUTCOMESFOR PATIENTS DECLINING ENDOSCOPIC INVESTIGATION Thomas Archer, UK





09:00 - 09:00 P0991DOES COMBINING EUS-GUIDED TISSUE ACQUISITIONWITH ERCP IN PATIENTS WITH DISTAL BILIARYOBSTRUCTION INCREASE THE RISK OF PANCREATITIS? Myrte Gorris, NL

09:00 - 09:00 P0993SAFETY AND EFFICACY OF DIRECT PERORALCHOLANGIOPANCREATOSCOPY IN ELDERLY PATIENTS: ACASE-CONTROL STUDY Marcantonio Gesualdo, IT






09:00 - 09:00 P0996TIMING OF ADMISSION AND ENDOSCOPIC DRAINAGE INPATIENTS WITH ACUTE CHOLANGITIS: WEEKDAY VERSUSWEEKEND Bogdan Miutescu, RO09:00 - 09:00 P0997THE USEFULNESS OF ERCP BILE ASPIRATED CULTURE INPATIENTS WITH ACUTE CHOLANGITIS Bogdan Miutescu, RO

09:00 - 09:00 P0998USE OF FULLY COVERED SELF-EXPANDING METAL STENTSFOR MANAGEMENT OF BENIGN BILIARY STRICTURE: ASYSTEMATIC REVIEW AND META-ANALYSIS Arthur Schmidt, DE




09:00 - 09:00 P1002AUTOMATIC DETECTION OF BILIARY MASSES IN PATIENTSWITH INDETERMINATE BILIARY STENOSIS: THE FUTUREOF ARTIFICIAL INTELLIGENCE IN SINGLE-OPERATORCHOLANGIOSCOPY João Afonso, PT

09:00 - 09:00 P1004ENDOSCOPIC PAPILLECTOMY: RESULTS OF A TERTIARYREFERRAL CENTER EXPERIENCE Francesca Aprile, IT



09:00 - 09:00 P1009MORPHOLOGICAL CLASSIFICATION IN CHOLANGIOSCOPY:MORE OBJECTIVITY, MORE ACCURACY? Ana Luísa Santos, PT09:00 - 09:00 P1010IS URGENT ERCP THE BEST CHOICE FOR ACUTE BILIARYPANCREATITIS? Sorin Alexandru Coman, RO

09:00 - 09:00 P1011ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY WASNOT MORE COST-EFFECTIVE THAN FINE NEEDLEASPIRATION WITH RAPID ON-SITE EVALUATION INGASTROINTESTINAL LESIONS DIAGNOSIS Tawfik Khoury, IL

09:00 - 09:00 P1012ANXIETY AND CANCEROPHOBIA IN PATIENTS WITH SMALLGASTROINTESTINAL SUBEPITHELIAL LESIONS ANDTUMOURS: BASELINE RESULTS OF A PROSPECTIVE STUDY(QUALI-BANDING-SET) Francesc Bas-Cutrina, ES




09:00 - 09:00 P1016LUMEN-APPOSING METAL STENTS FOR EUS-GUIDEDDRAINAGE OF WALLED-OFF PANCREATIC NECROSIS:RESULTS OF A LARGE MULTICENTER COHORT Arnaldo Amato, IT

09:00 - 09:00 P1017ENDOSCOPIC ULTRASOUND GUIDED ELASTOGRAPHY FORTHE DIAGNOSIS OF MALIGNANCY IN RESECTABLEPANCREATIC TUMORS Julio Iglesias-Garcia, ES





09:00 - 09:00 P1019POSSIBILITIES OF ENDOSCOPIC ULTRASONOGRAPHY ANDOTHER MODERN ENDOSCOPIC TECHNIQUES ININFLAMMATORY BOWEL DISEASES Anastasia Titaeva, RU09:00 - 09:00 P1020APPLICATION OF ARTIFICIAL INTELLIGENCE FOR REAL-TIME ANATOMICAL RECOGNITION DURING ENDOSCOPICULTRASOUND EVALUATION: A PILOT STUDY Roberto Oleas, EC

09:00 - 09:00 P1021WET SUCTION TECHNIQUE: THE CORNERSTONE OF EUS-GUIDED SAMPLING OF SOLID LESIONS? Inês Marques de Sá, PT

09:00 - 09:00 P1022EUS AND PET-CT RESTAGING FOR ESOPHAGEAL ANDGASTRIC ADENOCARCINOMA.COMPARED PERFORMANCEAND SURVIVAL PREDICTION Eduardo Redondo-Cerezo, ES




09:00 - 09:00 P1026CREATION OF A PATIENT REPORTED EXPERIENCEMEASURE TOOL TO EVALUATE PATIENTS’ EXPERIENCEDURING ENDOSCOPIC ULTRASONOGRAPHY (EUS): PREUSSTUDY. Laura Apadula, IT

09:00 - 09:00 P1027DEEP LEARNING-BASED NAVIGATION SYSTEM FORPANCREATIC ENDOSCOPIC ULTRASONOGRAPHY Huiling Wu, CN


09:00 - 09:00 P1029DYNAMIC CONTRAST HARMONIC IMAGING BYENDOSCOPIC ULTRASOUND ANDIMMUNOHISTOCHEMICAL ANALYSIS IN GASTRIC CANCER-A FEASIBILITY STUDY Victor-Mihai Sacerdotianu, RO09:00 - 09:00 P1030ENDOSCOPIC ULTRASOUND-GUIDED ETHANOL ANDRADIOFREQUENCY ABLATION OF FUNCTIONINGINSULINOMAS: A SYSTEMATIC LITERATURE REVIEW Ghassan El-Sayed

09:00 - 09:00 P1031ELECTROCAUTERY-ENHANCED DELIVERY SYSTEM OFLUMEN APPOSING METAL STENT FOR EUS-GUIDEDBILIARY AND GALLBLADDER DRAINAGE: A SINGLE-CENTRESTUDY Martha Arevalo-Mora, EC

09:00 - 09:00 P1032ENDOSCOPIC ULTRASOUND SHARE-WAVE ELASTOGRAPHYOF THE RIGHT AND LEFT HEPATIC LOBE PREDICTS LIVERCIRRHOSIS: A DIAGNOSTIC TRIAL Miguel Puga-Tejada, EC




09:00 - 09:00 P1036CLINICAL PRACTICE OF SPIRAL ENTEROSCOPY (SPE) INTHE LEARNING PHASE OF A REAL-WORLD SETTING Martin Raithel, DE

09:00 - 09:00 P1037PERCEPTION AND EXPECTATIONS TOWARDS ARTIFICIALINTELLIGENCE IN CAPSULE ENDOSCOPY Romain Leenhardt, FR





09:00 - 09:00 P1039MAGNETIC-ASSISTED CAPSULE ENDOSCOPY IN CHILDREN:PRELIMINARY REPORT ON FEASIBILITY, SAFETY ANDIMPACT ON GASTRIC TRANSIT TIME. Letizia Zenzeri, IT09:00 - 09:00 P1040USEFULNESS OF ENDOSCOPIC DELIVERY METHOD FORPATIENTS WITH CAPSULE ENDOSCOPY STAGNATION INTHE STOMACH Akihiko Sumioka, JP

09:00 - 09:00 P1041THE DIAGNOSTIC PERFORMANCE OF PAN-ENTERICCAPSULE ENDOSCOPY AND MAGNETIC RESONANCEENTEROCOLONOGRAPHY IN PATIENTS WITH SUSPECTEDCROHN’S DISEASE Jacob Broder Brodersen, DK

09:00 - 09:00 P1042GUIDED CAPSULE FOR UPPER AND MIDGASTROINTESTINAL BLEEDING Jean-Francois Rey, FR





09:00 - 09:00 P1047ARTIFICIAL INTELLIGENCE AND CAPSULE ENDOSCOPY:AUTOMATIC DETECTION OF GASTRIC PROTRUDINGLESIONS USING A CONVOLUTIONAL NEURAL NETWORK João Afonso, PT

09:00 - 09:00 P1048PERFORMANCE OF A DEEP LEARNING SYSTEM FORAUTOMATIC DIAGNOSIS OF PROTRUDING LESIONS INCOLON CAPSULE ENDOSCOPY: A MULTICENTRIC STUDY Pedro Cardoso, PT

09:00 - 09:00 P1049AUTOMATIC DETECTION OF COLONIC ULCERS ANDEROSIONS IN COLON CAPSULE ENDOSCOPY IMAGESUSING A CONVOLUTIONAL NEURAL NETWORK João Afonso, PT09:00 - 09:00 P1050AUTOMATIC DETECTION OF ULCERS AND EROSIONS IN PILLCAM™ CROHN’S CAPSULE USING A CONVOLUTIONALNEURAL NETWORK João Afonso, PT

09:00 - 09:00 P1051A PROSPECTIVE COMPARISON OF TWO HEADED ANDSINGLE HEADED CAPSULES FOR THE INVESTIGATION OFSUSPECTED SMALL BOWEL BLEEDING. ARE TWO HEADSBETTER THAN ONE? Eilís M. McCarthy, IE

09:00 - 09:00 P1052ARTIFICIAL INTELLIGENCE AND CAPSULE ENDOSCOPY:AUTOMATIC DETECTION OF GASTRIC VASCULAR LESIONSUSING A CONVOLUTIONAL NEURAL NETWORK Miguel Jose Mascarenhas Saraiva, PT





09:00 - 09:00 P1057MODIFIED ENDOSCOPIC VACUUM THERAPY FOR THETREATMENT OF GASTROINTESTINAL FISTULAS ANDPERFORATIONS: EXPERIENCE FROM A BRAZILIANTERTIARY CARE CENTER Danielle Queiroz Bonilha, BR

09:00 - 09:00 P1058PROPHYLACTIC TRANSCATHETER ARTERIALEMBOLIZATION IS ASSOCIATED WITH LOWER ODDS OFREBLEEDING IN NON-VARICEAL UPPERGASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEWAND META-ANALYSIS Eszter Boros, HU




E-Poster Session


09:00 - 09:00 P1102COSTS SAVINGS ASSOCIATED WITH FERRIC MALTOL ANDTHE REDUCED USE OF INTRAVENOUS IRON BASED ONREAL WORLD DATA Stefanie Howaldt, DE

09:00 - 09:00 P1103A 7 YEAR RETROSPECTIVE REVIEW OF IRON DEFICIENCYANAEMIA IN A CATCHMENT OF 330,000, DEMONSTRATINGTHE NEED FOR A DEDICATED ANAEMIA SERVICE Matthew Johnson








09:00 - 09:00 P1111RATE OF INAPPROPRIATE PROTON PUMP INHIBITORSPRESCRIPTION AT DISCHARGE FROM INTERNAL MEDICINEDEPARTMENTS ACCORDING TO A DEVELOPEDALGORITHM Orly Sneh-Arbib, IL09:00 - 09:00 P1112ONLINE EDUCATION SIGNIFICANTLY IMPROVEDGASTROENTEROLOGISTS' KNOWLEDGE OF CROHNDISEASE MANAGEMENT Elaine Bell

09:00 - 09:00 P1113ONLINE EDUCATION SIGNIFICANTLY IMPROVESGASTROENTEROLOGISTS' KNOWLEDGE OF URGENCY AS AKEY CONCERN FOR PATIENTS WITH ULCERATIVE COLITIS Elaine Bell








E-Poster Session





09:00 - 09:00 P0001THE FIRST REPORT ON THE NUCLEOTIDE ECTO-ENZYMEMETABOLIC PATTERN IN THE RAT GASTRIC AND COLONICMUCOSA UNDER THE CONDITIONS OFCYCLOOXYGENASE-1/-2 BLOCKAGE WITH INDOMETHACIN Christina Nasadyuk, UA09:00 - 09:00 P0003ROLE OF MAFB TRANSCRIPTION FACTOR IN HUMANINTESTINAL METAPLASIA AND GASTRIC CANCERBIOPSIES Rachel Gingold-Belfer, IL








09:00 - 09:00 P0011CLOSTRIDIOIDES DIFFICILE INFECTION AFTER VARICEALBLEEDING, A RISK TO BE CONSIDERED Bogdan Ungureanu, RO

09:00 - 09:00 P0012SYSTEMATIC REVIEW WITH META-ANALYSIS: INFLUENCEOF INDIVIDUAL PROTON PUMP INHIBITORS ON CLINICALOUTCOMES IN PATIENTS RECEIVING CLOPIDOGRELFOLLOWING PERCUTANEOUS CORONARY INTERVENTION Beom Jin Kim, KR

09:00 - 09:00 P0013UPPER GASTROINTESTINAL BLEEDING IN VERY OLDPATIENTS. RISK FACTORS FOR IN-HOSPITAL AND DELAYEDMORTALITY Rita Jiménez-Rosales, ES09:00 - 09:00 P0014USE OF INTRAVENOUS IRON REDUCES MORTALITY,HOSPITAL RE-ATTENDANCE AND READMISSION AFTERACUTE PEPTIC ULCER BLEEDING Ting Ting Chan, HK




09:00 - 09:00 P0018THE UTILITY OF CT ANGIOGRAPHY IN IDENTIFICATION OFACUTE GASTROINTESTINAL BLEEDING SOURCE ANDPREDICTORS OF A POSITIVE EXAMINATION Tawfik Khoury, IL




09:00 - 09:00 P0022ACUTE UPPER GASTROINTESTINAL BLEEDING INPATIENTS USING ANTICOAGULANTS: DOES THE TIMING OFENDOSCOPY AFFECT OUTCOMES? Tiago Lima Capela, PT




09:00 - 09:00 P0023MODERN ANTICOAGULATION WITH FACTOR XAINHIBITORS IN ONCOLOGY: IS THE GASTROINTESTINALBLEEDING RATE (ALSO) DECISIVE? Martin Raithel, DE09:00 - 09:00 P0024OVERLAPPING OF IRRITABLE BOWEL SYNDROME ANDUNINVESTIGATED DYSPEPSIA IN THE ADMINISTRATIVECENTER OF EASTERN SIBERIA Vladislav Tsukanov, RU








09:00 - 09:00 P0032THE PARAVENTRICULAR HYPOTHALAMIC NUCLEUS ISINVOLVED IN EXENDIN-4-INDUCED EMESIS ANDINHIBITION OF FOOD AND WATER INTAKE IN SUNCUSMURINUS Sze Wa Chan, HK

09:00 - 09:00 P0033DEXTRAN SODIUM SULPHATE-INDUCEDGASTROINTESTINAL INJURY FURTHER AGGRAVATES THEIMPACT OF GALANTAMINE ON THE GASTRIC MYOELECTRICACTIVITY IN EXPERIMENTAL PIGS Jan Bures, CZ09:00 - 09:00 P0034ADHESION OF GASTRIC CANCER CELLS TO THE ENTERICNERVOUS SYSTEM IN A NEWLY DEVELOPED CO-CULTUREMODEL: COMPARISON BETWEEN THE INTESTINAL ANDDIFFUSE TYPE OF GASTRIC CANCER Nicolas Chapelle, FR








09:00 - 09:00 P0042A DIAGNOSTIC DELAY OF TEN YEARS IN THE DANEOECOHORT CALLS FOR FOCUS ON EDUCATION - APOPULATION-BASED STUDY OF INCIDENCE, DIAGNOSTICPROCESS AND COMPLICATIONS OF EOSINOPHILICOESOPHAGITIS IN THE NORTH DENMARK REGION Anne Lund Krarup, DK




09:00 - 09:00 P0043SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASEACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE INADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OFA NATIONWIDE PROSPECTIVE COHORT STUDY Philipp Schreiner, CH09:00 - 09:00 P0044EFFICACY OF STEPPED THERAPY WITH PROTON PUMPINHIBITORS IN ADULT PATIENTS WITH EOSINOPHILICESOPHAGITIS AFTER 12 MONTHS OF FOLLOW UP IN OURHEALTHCARE AREA Lucía Madero, ES







09:00 - 09:00 P0051ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTSWITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVEOF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY Philipp Schreiner, CH

09:00 - 09:00 P0052SYMPTOM AND QUALITY OF LIFE BURDEN AMONGPATIENTS WITH EOSINOPHILIC OESOPHAGITIS IN A REAL-WORLD SETTING Alain M. Schoepfer, CH

09:00 - 09:00 P0053COMPLIANCE FOR THE PROSE DAILY DIARY: MEASURINGCOMPLETION RATES OF A NEW INSTRUMENT TO MEASUREDYSPHAGIA EPISODES IN PATIENTS WITH EOSINOPHILICESOPHAGITIS Stella Karantzoulis, US09:00 - 09:00 P0054EOSINOPHILIC ESOPHAGITIS IS FREQUENTLY ASSOCIATEDWITH DISORDERS OF PERISTALSIS AT HIGH-RESOLUTIONMANOMETRY: A PROSPECTIVE SINGLE-CENTRE CASE-CONTROL STUDY Pierfrancesco Visaggi, IT







09:00 - 09:00 P0061FOCAL C2 CRYOBALLOONTM ABLATION WITH 8SEC DOSEHAS SIMILAR EFFICACY AS 10SEC FOR TREATMENT OFBARRETT’S ESOPHAGUS RELATED NEOPLASIA. Charlotte N. Frederiks, NL

09:00 - 09:00 P0062RISK OF BARRETT’S ESOPHAGUS AND ESOPHAGEALADENOCARCINOMA IN PATIENTS DIAGNOSED WITHBREAST CANCER – A NATIONWIDE STUDY Yonne Peters, NL




09:00 - 09:00 P0063INCREASED RISK OF BARRETT’S ESOPHAGUS ANDESOPHAGEAL ADENOCARCINOMA IN INDIVIDUALS WITH APOSITIVE FAMILY HISTORY Yonne Peters, NL09:00 - 09:00 P0064HYBRID ARGON PLASMA COAGULATION IN THE ABLATIONTREATMENT OF BARRETT´S ESOPHAGUS - LONG TERMRESULTS Radek Kroupa, CZ







09:00 - 09:00 P0073TUMOR THICKNESS IS ASSOCIATED WITH METASTASIS INSUBMUCOSAL INVASIVE ADENOCARCINOMA OF THEESOPHAGOGASTRIC JUNCTION Nobuhisa Minakata, JP

09:00 - 09:00 P0074A SYMPTOM AND RISK FACTOR QUESTIONNAIREACCURATELY PREDICTS UPPER GASTROINTESTINALCANCER Kai Man Alexander Ho

09:00 - 09:00 P0075ANASTOMOTIC LEAK IN ESOPHAGOGASTRIC ONCOLOGICSURGERY: MANAGEMENT WITH FULLY COVERED SELF-EXPANDABLE METALLIC STENTS Daniel Conceição, PT09:00 - 09:00 P0076PREVALENCE AND PREDICTORS OF MALNUTRITION INPATIENTS WITH ESOPHAGEAL CANCER- A SINGLE CENTERPROSPECTIVE STUDY Prachi Patil, IN







09:00 - 09:00 P0083HYPERGASTRINEMIA IS NOT ASSOCIATED WITHINCREASED MORTALITY IN GASTRIC ADENOCARCINOMA Eivind Ness-Jensen, NO

09:00 - 09:00 P0084LAUREN-TYPE GASTRIC CANCER VARIABLE BY AGE ANDSEX Hyeong Ho Jo, KR




09:00 - 09:00 P0085QUALITY OF LIFE IS ASSOCIATED WITH SURVIVAL INGASTRIC CANCER PATIENTS: RESULTS FROM THE CRITICSTRIAL Romy van Amelsfoort, NL09:00 - 09:00 P0086PERSONALITY TRAITS ARE STRONGLY ASSOCIATED WITHGASTROINTESTINAL CANCER PATIENTS’ PSYCHOSOCIALBURDEN: AN ONGOING STUDY Christos Sotiropoulos, GR






E-Poster Session



09:00 - 09:00 P0524IS ANTI-PD1-INDUCED COLITIS A DISTINCT HISTOLOGICALSUBTYPE? Stratigoula Sakellariou, GR

09:00 - 09:00 P0525GUT BACTERIA FUNCTIONALITY PROFILES AND DIVERSITYINDEX DETECTED BY THE GA-MAP® DYSBIOSIS TEST LX Kristin Gravdal, NO09:00 - 09:00 P0527STUDYING THE MUTUAL INTERACTION BETWEEN THEHUMAN GUT EPITHELIUM AND THE PREDOMINANTLYANAEROBIC GUT MICROBIOME IN HOXBAN-STOOL Raphael Fagundes Rosa, NL

































































































09:00 - 09:00 P0624THE IMPACT OVERWEIGHT ON DIVERTICULAR DISEASE: ACASE CONTROL MULTICENTER STUDY Tawfik Khoury, IL







E-Poster Session


09:00 - 09:00 P0784THE OBESTATIN/GPR39 SYSTEM REGULATES THESYNTHESIS AND SECRETION OF PANCREATIC ENZYMESFORM ACINAR CELLS Yolanda Pazos-Randulfe, ES09:00 - 09:00 P0785OPTIMIZATION OF DOSE LEVELS OF ORALLYADMINISTERED PANCREATIC ENZYME SUPPLEMENTS INTHE DYNAMIC IN-VITRO GASTROINTESTINAL MODEL TINY-TIM Mª Luisa Orera-Peña, ES

09:00 - 09:00 P0786CHARACTERIZATION OF HCO3






09:00 - 09:00 P0791FATTY PANCREAS REPRESENTS A RISK FACTOR FORACUTE PANCREATITIS: A PILOT STUDY Tawfik Khoury, IL







09:00 - 09:00 P0796HOW TO PREDICT MICROLITHIASIS IN IDIOPATHICPANCREATITIS – A MACHINE LEARNING DERIVED TOOL Michal Zorniak, DE09:00 - 09:00 P0797MACHINE LEARNING MODEL FOR EARLY PREDICTION OFNECROTISING PANCREATITIS: A COHORT ANALYSIS Szabolcs Kiss, HU

09:00 - 09:00 P0798THE CHARACTERISTICS AND THE POTENTIALPROGNOSTIC ROLE OF ACUTE ABDOMINAL ON-ADMISSIONPAIN IN ACUTE PANCREATITIS: A PROSPECTIVE COHORT-ANALYSIS OF 1432 CASES Mária Földi, HU









09:00 - 09:00 P0807THE ROLE OF CFTR MUTATIONS IN ACUTE BILIARYPANCREATITIS Ágnes Rita Martonosi, HU09:00 - 09:00 P0808METABOLIC ASSOCIATED FATTY LIVER DISEASE ISASSOCIATED WITH A MORE SEVERE ACUTE PANCREATITIS:A PROSPECTIVE COHORT ANALYSIS OF 2053 CASES Szilárd Váncsa, HU

09:00 - 09:00 P0809PREVALENCE OF GASTROINTESTINAL BLEEDING INPANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Marie Anne Engh, HU












09:00 - 09:00 P0819COMMON CASR POLYMORPHISMS DO NOT INCREASECHRONIC PANCREATITIS RISK Amanda Takáts, HU09:00 - 09:00 P0821BICARBONATE DEFECTIVE CFTR VARIANTS IN CHRONICPANCREATITIS: A META-ANALYSIS Gergő Berke, HU

09:00 - 09:00 P0822OPEN LABEL, RANDOMIZED, CROSSOVER CLINICAL TRIALTO ASSESS THE EFFICACY OF INCREASING DOSES OFPANCREATIC ENZYMES, WITH OR WITHOUT INHIBITION OFGASTRIC ACID SECRETION, IN PATIENTS WITHPANCREATIC EXOCRINE INSUFFICIENCY SECONDARY TOCHRONIC PANCREATITIS Daniel De la Iglesia-Garcia, ES








09:00 - 09:00 P0830SYSTEMATIC REVIEW AND META-ANALYSIS OFOBSERVATIONAL STUDIES ON BD-IPMNS RISK OFPROGRESSION TO HIGH-RISK LESIONS Alberto Balduzzi, IT09:00 - 09:00 P0831INTERNATIONAL EXTERNAL VALIDATION OF ASTRATIFICATION TOOL TO IDENTIFY BRANCH-DUCTINTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS ATLOWEST RISK OF PROGRESSION Kasper A. Overbeek, NL

09:00 - 09:00 P0832NEW KID ON THE BLOCK: PANCREATIC CYST FLUIDGLUCOSE IS AN ACCURATE, BEDSIDE, LOW COSTDIAGNOSTIC TEST OF MUCINOUS CYSTS Dana Ben-Ami Shor, IL












09:00 - 09:00 P0841RNA-SEQUENCING OF PANCREATIC CANCER FROM EUS-ACQUIRED TISSUE IS USEFUL TO DEFINE MOLECULARSUBTYPES AND PROGNOSIS Livia Archibugi, IT09:00 - 09:00 P0842IMMUNOMODULATION INDUCED BY ENDOSCOPICULTRASOUND-GUIDED ABLATION WITH THEHYBRIDTHERM PROBE IN LOCALLY ADVANCED ANDBORDERLINE RESECTABLE PANCREATIC CANCER:RESULTS FROM A PHASE II RANDOMIZED CONTROLLEDTRIAL Sabrina Gloria Giulia Testoni, IT

09:00 - 09:00 P0843DISCRIMINATION BETWEEN PANCREATIC CANCER,PANCREATITIS AND HEALTHY CONTROLS USING URINARYPOLYAMINE PANEL Samuli Nissinen, FI








09:00 - 09:00 P0854CAUSES OF DEATH IN PATIENTS WITH METASTATICDIGESTIVE NEUROENDOCRINE TUMOURS Juliette Beringer, FR09:00 - 09:00 P0855SOMATOSTATIN ANALOGS IN PATIENTS WITH ZOLLINGERELLISON SYNDROME (ZES): AN OBSERVATIONAL STUDY Sara Massironi, IT

09:00 - 09:00 P0856QUANTITATIVE CONTRAST-ENHANCED ENDOSCOPICULTRASOUND IN PANCREATIC DUCTALADENOCARCINOMA AND PANCREATIC NEUROENDOCRINETUMORS: CAN WE PREDICT SURVIVAL USING PERFUSIONPARAMETERS? Alina Liliana Constantin, RO



E-Poster Session










09:00 - 09:00 P0227THERAPEUTIC POTENTIAL OF TNK1 IN PREVENTION ANDHEALING OF INTESTINAL BARRIER BREACH Hongxia Li, DE09:00 - 09:00 P0228THE VARIATIONS OF GUT MICROBIOME FROM ULCERATIVECOLITIS PATIENTS ARE NOT AS GREAT AS EXPECTED Chen Li, CN




09:00 - 09:00 P0232IS VITAMIN D DEFICIENCY RELATED TO FATMALABSORPTION OR INFLAMMATION IN INFLAMMATORYBOWEL DISEASE? PRELIMINARY RESULTS FROM THE FAT-D STUDY Aysegül Aksan, DE

09:00 - 09:00 P0233SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORINGEPITHELIAL INTEGRITY AND MITIGATING COLITIS IN ACHRONIC DSS MODEL Priya Handa, US




09:00 - 09:00 P0237ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OFPERSISTENT HISTOLOGICAL ACTIVITY DESPITEENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITHBIOLOGICS Vedran Tomasic, HR09:00 - 09:00 P0238HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZELUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS Sarit Cohen-Kedar, IL




09:00 - 09:00 P0242CROHN’S DISEASE ASSOCIATED FIBROSIS MODULATESTHE EXPRESSION OF COLLAGEN RECEPTORS Cristina Bauset, ES

09:00 - 09:00 P0243SUCCINATE RECEPTOR (SUCNR1) MEDIATES LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS INDUCED BY TNFΑ Cristina Bauset, ES







09:00 - 09:00 P0247EXPRESSION PROFILING OF WNT PATHWAY GENES INCOLON BIOPSIES OF PATIENTS WITH ULCERATIVE COLITISAND CROHN’S DISEASE Chenggang Lu, US09:00 - 09:00 P0248FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINALMUCOSAL HEALTH VIA HIF1Α-INDUCED EPITHELIALPRODUCTION OF IL-18 Raphael Fagundes Rosa, NL





09:00 - 09:00 P0253IMPACT OF EXCLUSIVE ENTERAL NUTRITION ONINTESTINAL HOMEOSTASIS IN A MOUSE MODEL OFCOLITIS Kawthar Boumessid, FR

09:00 - 09:00 P0254ROLE OF P2X7 IN INTESTINAL FIBROSIS ANDINFLAMMASOME ACTIVATION: RELEVANCE IN CROHN´SDISEASE Cristina Bauset, ES



09:00 - 09:00 P0257CHARACTERIZATION OF CYTOKINE AND DRUGCONCENTRATIONS IN SERUM, MUCOSA AND FAECESDURING INDUCTION TREATMENT OF SEVERE ULCERATIVECOLITIS WITH INFLIXIMAB Joep van Oostrom, NL09:00 - 09:00 P0258VOLUNTARY EXERCISE COMBINED WITH CONCOMITANTALKALINE PHOSPHATASE TREATMENT RESOLVESEXPERIMENTAL COLITIS IN OBESE MICE BY IMPROVINGCOLONIC MICROCIRCULATION AND ATTENUATINGINFLAMMATION, OXIDATIVE STRESS, AND RESTORATIONOF ADIPONECTIN/LEPTIN RATIO Marcin Magierowski, PL





09:00 - 09:00 P0264VACCINATION STRATEGIES IN INFLAMMATORY BOWELDISEASE PATIENTS: PERSPECTIVE OF PHYSICIANS ANDPATIENTS. Rocío Ferreiro-Iglesias, ES

09:00 - 09:00 P0265SARS-COV-2 VACCINE ACCEPTANCE AMONGGASTROENTEROLOGIST AND INFLAMMATORY BOWELDISEASE PATIENTS: VACUNEII PROJECT Alejandro Hernandez Camba, ES





09:00 - 09:00 P0267INFLAMMATORY BOWEL DISEASE (IBD) ANDIMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSISOF COVID-19. RESULTS FROM THE ENEIDA PROJECT OFGETECCU Yamile Zabana Abdo, ES09:00 - 09:00 P0268COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTORBUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASETHE RISK OF COVID-19 IN INFLAMMATORY BOWELDISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROLSTUDY Yamile Zabana Abdo, ES






09:00 - 09:00 P0274THE ASSOCIATION BETWEEN FAECAL SHORT-CHAIN FATTYACIDS CONCENTRATION AND THE CLINICAL ACTIVITY OFULCERATIVE COLITIS AND CROHN’S DISEASE -PRELIMINARY STUDY Olga Kaczmarczyk, PL

09:00 - 09:00 P0275SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS ARISK FACTOR FOR SEVERE COVID-19: DATA FROM THESICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE(SN-IBD) Fabio Salvatore Macaluso, IT


09:00 - 09:00 P0277VACCINATION AGAINST SARS-COV-2 IN IBD: ACCEPTANCEAND CONCERNS IN A COHORT FROM SOUTHERN ITALY Federica Crispino, IT09:00 - 09:00 P0278INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION INPATIENTS WITH INFLAMMATORY BOWEL DISEASE INSOUTHERN SPAIN (ANDALUSIA) Beatriz Gros Alcalde, ES






09:00 - 09:00 P0284CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADICINFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERAOF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROMTHE ENEIDA REGISTRY Carlos González-Muñoza, ES

09:00 - 09:00 P0285ANTIOXIDANT VITAMINS AND ELECTROLYTES INCREASEDINTAKE IS ASSOCIATED WITH LOWER DISEASE ACTIVITYAND BETTER QUALITY OF LIFE IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Ioanna Pefkianaki, GR





09:00 - 09:00 P0287IMPACT OF INFLAMMATORY BOWEL DISEASES ON THEPHENOTYPE AND SEVERITY OF PRIMARY SCLEROSINGCHOLANGITIS - A SYSTEMATIC REVIEW WITH META-ANALYSIS Mohamed Attauabi, DK09:00 - 09:00 P0288CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWELDISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME Marta Vernero, IT






09:00 - 09:00 P0294PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOULDBE VACCINATED AGAINST PNEUMOCOCCUS ANDINFLUENZA DESPITE IMMUNOSUPPRESSIVE THERAPY Dóra Dohos, HU

09:00 - 09:00 P0295PREDICCT COHORT BASELINE HABITUAL NUTRIENTINTAKE BY IBD PATIENTS Janet Kyle


09:00 - 09:00 P0297TRANSFORMATION OF FECAL MICROBIOTA COMPOSITIONDUE TO BOWEL PREPARATION WITH MAGNESIUM-OXIDAND SODIUM PICOSULFATE AMONGST PATIENTS WITHINFLAMMATORY BOWEL DISEASE Mariann Rutka, HU09:00 - 09:00 P0298NON-IBD CHANGES IN THE ORAL MUCOSA IN PATIENTSWITH INFLAMMATORY BOWEL DISEASES. A CROSSSECTIONAL STUDY IN POLISH PATIENTS Rafał Filip, PL






09:00 - 09:00 P0304THE APA I POLYMORPHISM IN THE VITAMIN D RECEPTORGENE IS ASSOCIATED WITH A STRICTURING BEHAVIOUR INCROHN´S DISEASE PATIENTS Cristina Bauset, ES

09:00 - 09:00 P0305PECULIARITIES OF FATTY ACID PROFILES OFERYTHROCYTE MEMBRANES AND BLOOD SERUMDEPENDING ON ACTIVITY RATE OF CROHN’S DISEASE Margarita Vitalievna Kruchinina, RU




09:00 - 09:00 P0306COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITHLOWER DISABILITY THAN PARTIAL MUCOSAL HEALING INCROHN’S DISEASE: A PROSPECTIVE MULTICENTRICSTUDY. Clara Yzet, FR09:00 - 09:00 P0307TELEDERMA: TELEMEDICINE SYSTEM FORDERMATOLOGICAL LESIONS IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Marta Ramos Alonso, ES







09:00 - 09:00 P0314CORRELATION OF EX VIVO MUCOSAL CYTOKINE PROFILESWITH CLINICAL AND ENDOSCOPIC SCORES IN ULCERATIVECOLITIS Vesna Eraković Haber, HR

09:00 - 09:00 P0315IMPACT OF INFLAMMATORY BOWEL DISEASE IN PEDIATRICPATIENTS AND THEIR FAMILIES ACCORDING TO DISEASECONTROL Laura María Palomino Pérez, ES

09:00 - 09:00 P0316THE USE OF PANENTERIC CROHN’S CAPSULES TO ASSESSTREATMENT OUTCOME OF VEDOLIZUMAB IN IBDPATIENTS: A 1 YEAR PROOF OF CONCEPT STUDY Matthew Johnson09:00 - 09:00 P0317THE OUTCOME OF COLONOSCOPIC SURVEILLANCE ANDSURGERY IN A COHORT OF INFLAMMATORY BOWELDISEASE PATIENTS WHO DEVELOPED COLO-RECTALCANCER OVER A 12 YEAR REVIEW PERIOD AT A DISTRICTGENERAL HOSPITAL John Wye, UK







09:00 - 09:00 P0325CORRELATION OF THE FIRST LATERAL FLOW-BASEDPOINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITHTHE REFERENCE ELISA TECHNIQUE M. Begoña Ruiz-Argüello, ES




09:00 - 09:00 P0326THERAPEUTIC DRUG MONITORING: PERFORMANCE OFTHE FIRST LATERAL FLOW-BASED POINT OF CARE TESTFOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGERPRICK Amagoia Ametzazurra, ES09:00 - 09:00 P0327NON-INVASIVE BIOMARKERS OF TYPE III COLLAGENCROSS-LINKING REFLECT FIBROLYSIS IN CROHN'SDISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR Martin Pehrsson, DK








09:00 - 09:00 P0335COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGHLEVELS BETWEEN POINT-OF-CARE TESTING ANDCURRENT STANDARD OF CARE (ENZYME LINKEDIMMUNOSORBENT ASSAY) IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Ilaria Marsilio, IT

09:00 - 09:00 P0336PEDIATRIC INFLAMMATORY BOWEL DISEASE AFFECTS THEPATIENTS AND THEIR FAMILIES IN DIFFERENT WAYSDEPENDING ON THE AGE AT DIAGNOSIS Marta Velasco Rodríguez-Belvís, ES09:00 - 09:00 P0337INCIDENCE AND RISK FACTORS FOR NEOPLASIA ININFLAMMATORY BOWEL DISEASE Joana Lemos Garcia, PT







09:00 - 09:00 P0344TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTSAND THE TYPE IV COLLAGEN FORMATION/DEGRADATIONRATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING(MONTREAL B2) CROHN'S DISEASE Arno R. Bourgonje, NL

09:00 - 09:00 P0345TYPE IV COLLAGEN FORMATION/DEGRADATION RATIOPREDICTS RESPONSE TO INFLIXIMAB INDUCTIONTHERAPY IN PATIENTS WITH ULCERATIVE COLITIS Arno R. Bourgonje, NL




09:00 - 09:00 P0346INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITHRESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’SDISEASE Jose Luis Rueda García, ES09:00 - 09:00 P0347COMPARATIVE ASSESSMENT C-REACTIVE PROTEINBETWEEN A POINT-OF-CARE TESTING AND CURRENTSTANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING)

Greta Lorenzon, IT







09:00 - 09:00 P0354PSYCHOLOGICAL MORBIDITY PREDICTS MALADAPTIVEDECISION-MAKING IN PEOPLE WITH INFLAMMATORYBOWEL DISEASE Lydia Grinsted Tate

09:00 - 09:00 P0355COLORECTAL CANCER SURVEILLANCE IN COMPLEX IBDPATIENTS WITH STRICTURES Alexander Kokrashvili, UK


09:00 - 09:00 P0357HUMAN NEUTROPHIL ELASTASE DERIVED FRAGMENT OFCALPROTECTIN (S100A9) IS A SERUM BIOMARKER(CPA9-HNE) FOR MONITORING OF ANTI-TNFΑ TREATMENTRESPONSE IN CROHN’S DISEASE Joachim Høg Mortensen, DK09:00 - 09:00 P0358WATCH OUT FOR SIGNS OF ANXIETY AND DEPRESSION INIBD PATIENTS DURING AN ACUTE FLARE-UP Jochen Gerhard Klaus, DE






09:00 - 09:00 P0365COVID-19 PANDEMIC PSYCHOLOGICAL EFFECTS ONPATIENTS WITH INFLAMMATORY BOWEL DISEASE INTUNISIA Sahar Nasr, TN

09:00 - 09:00 P0366DIAGNOSTIC WORK-UP OF CHILDREN AND ADOLESCENTSWITH INFLAMMATORY BOWEL DISEASE: EVOLUTION IN APOPULATION-BASED COHORT OVER A 26-YEAR PERIOD(1988-2014). Dominique Turck, FR





09:00 - 09:00 P0368DEEP REMISSION IN CROHN’S DISEASE ON BIOLOGICTHERAPY: TOWARDS A NEW DEFINITION Fabiana Castiglione, IT09:00 - 09:00 P0369FEATURES OF THE COURSE OF COVID-19 ININFLAMMATORY BOWEL DISEASE PATIENTS WITHHERPESVIRUS LESIONS Gulustan Babayeva, AZ







09:00 - 09:00 P0377SLEEP DISORDERS AND CHRONIC INFLAMMATORY BOWELDISEASE: WHAT'S THE CONNECTION? Amani Hassine, TN

09:00 - 09:00 P0378PREVALENCE AND RISK FACTORS FOR FATIGUE INCHRONIC INFLAMMATORY BOWEL DISEASE Amani Hassine, TN


09:00 - 09:00 P1122PSYCHOSOCIAL IMPACT OF THE COVID-19 PANDEMIC ONPATIENTS WITH INFLAMMATORY BOWEL DISEASE INSPAIN

09:00 - 09:00 P0380ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUSIN A COHORT OF PATIENTS WITH CROHN’S DISEASE Olga Maria Nardone, IT09:00 - 09:00 P0381INTESTINAL ULTRASOUND RESPONSE AND TRANSMURALREMISSION AFTER 48 WEEKS OF TREATMENT WITHUSTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIALSUBSTUDY RESULTS BY LINE OF TREATMENT ANDLOCATION Torsten Kucharzik, DE





09:00 - 09:00 P0386EFFECT OF OZANIMOD TREATMENT ANDDISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNTIN PATIENTS WITH MODERATELY TO SEVERELY ACTIVEULCERATIVE COLITIS: RESULTS FROM A PHASE 3RANDOMIZED TRIAL Geert R. D'Haens, NL

09:00 - 09:00 P0387EVALUATION OF THE EFFICACY OF TOFACITINIB ASMAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVECOLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINEENDOSCOPIC SUBSCORE Krisztina Barbara Gecse, NL

09:00 - 09:00 P0388EVALUATION OF A COMPUTATIONAL PLATFORM FORPREDICTING TEMPORAL PROGRESSION OF MUCOSALDAMAGE AND HEALING IN PATIENTS WITH CROHN’SDISEASE Ryuichi Iwakiri, JP




09:00 - 09:00 P0389QINGCHANG WENZHONG DECOCTION ACCELERATESINTESTINAL MUCOSAL HEALING THROUGH MODULATIONOF DYSREGULATED GUT MICROBIOTA IN DSS-INDUCEDCOLITIS MICE Tangyou Mao, CN09:00 - 09:00 P0390PHARMACOKINETICS, SAFETY, AND TOLERABILITY OFETRASIMOD (APD334) IN SUBJECTS WITH MILD,MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY Caroline A. Lee, US



09:00 - 09:00 P0393ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIORDURATION OF REMISSION IN PATIENTS WITH ULCERATIVECOLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY(BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID:6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISEDRIVETING STUDY Joana Torres, PT

09:00 - 09:00 P0394ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTSTREATED WITH TOFACITINIB IN THE ULCERATIVE COLITISCLINICAL PROGRAMME Christina Ha, US


09:00 - 09:00 P0396ALICAFORSEN ENEMA IN CHRONIC POUCHITIS: RESULTSOF A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO-CONTROLLED TRIAL Nermeen Varawalla

09:00 - 09:00 P0397CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATEDWITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICALPROGRAMME Alessandro Armuzzi, IT09:00 - 09:00 P0398PREDICTORS OF CLINICAL RESPONSE ANDINFLAMMATORY BOWEL DISEASE QUESTIONNAIREIMPROVEMENT WITH GOLIMUMAB IN PATIENTS WITHMODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS INTHE PURSUIT-MAINTENANCE STUDY Cindy LJ Weinstein, US




09:00 - 09:00 P0402EARLY PRO-2 SYMPTOM REMISSION FOLLOWINGGUSELKUMAB INDUCTION TREATMENT: RESULTSTHROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY Walter Reinisch, AT

09:00 - 09:00 P0403PATIENT-REPORTED OUTCOMES OF RESPONSE ANDREMISSION FOLLOWING GUSELKUMAB INDUCTIONTREATMENT AS MEASURED BY THE INFLAMMATORYBOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGHWEEK 12 OF THE PHASE 2 GALAXI 1 STUDY Julian Panés, ES






09:00 - 09:00 P0406ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITHMODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTSFROM THE PHASE 2 OASIS TRIAL AND OPEN-LABELEXTENSION Michael Chiorean, US09:00 - 09:00 P0407IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVECOMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: AMULTICENTRE STUDY OF GETECCU Maria Jose Garcia, ES




09:00 - 09:00 P0411OPTIMIZING THE POSITION OF VEDOLIZUMAB INTREATMENT SEQUENCES FOR CROHN’S DISEASE:RESULTS FROM A MARKOV MODEL SIMULATION USINGREAL-WORLD EVIDENCE Alessandro Armuzzi, IT

09:00 - 09:00 P0412OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USEIN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROMA EUROPEAN REAL-WORLD STUDY Alessandro Armuzzi, IT





09:00 - 09:00 P0416COMPARATIVE EFFICACY AND SAFETY OF ORAL FERRICMALTOL IN INFLAMMATORY BOWEL DISEASE PATIENTSWITH MILD-TO-MODERATE VS. MORE SEVERE IRONDEFICIENCY ANAEMIA Ian Jacob09:00 - 09:00 P0417EFFECTS OF USTEKINUMAB INDUCTION ANDMAINTENANCE THERAPY ON DISEASE CLEARANCE IN THEUNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS Silvio Danese, IT




09:00 - 09:00 P0421AN AUDIT OF PROACTIVE THERAPEUTIC DRUGMONITORING OF PATIENTS WITH INFLAMMATORY BOWELDISEASE ON BIOLOGICS Kee Bin Ng, IE

09:00 - 09:00 P0422EFFECTS OF COVID-19 ON TREATMENT AND PATIENTMANAGEMENT IN INFLAMMATORY BOWEL DISEASE:FINDINGS FROM A REAL-WORLD SURVEY IN EUROPE Fritha Hennessy







09:00 - 09:00 P0426REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUSTO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCETREATMENT FOR INFLAMMATORY BOWEL DISEASE Adriaan Volkers, NL09:00 - 09:00 P0427RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSALHEALING AND BASELINE CHARACTERISTICS IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE ULCERATIVECOLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3SELECTION STUDY Jean-Frederic Colombel, US




09:00 - 09:00 P0431TASTY&AMP;HEALTHY IS A DIETARY APPROACH FORINDUCING AND MAINTAINING REMISSION IN CROHN'SDISEASE: A PROSPECTIVE CASE SERIES Luba Plotkin, IL

09:00 - 09:00 P0432EFFECTIVENESS AND SAFETY OF ON-DEMAND FERRICCARBOXYMALTOSE INFUSION STRATEGY FOR IRONDEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASEPATIENTS Mauro Grova, IT




09:00 - 09:00 P0436A PILOT STUDY ON THE USE OF USTEKINUMAB INREFRACTORY PERIANAL CROHN’S DISEASE Federica Crispino, IT09:00 - 09:00 P0437MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEDFATIGUE IN PATIENTS WITH MODERATELY TO SEVERELYACTIVE CROHN’S DISEASE Miguel Regueiro, US




09:00 - 09:00 P0442LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITHMODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS(UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS)STUDIES Silvio Danese, IT

09:00 - 09:00 P0443IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGICMEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2STUDY OF PATIENTS WITH MODERATELY TO SEVERELYACTIVE CROHN’S DISEASE Rish Pai, US







09:00 - 09:00 P0447RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPYFOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONGPATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATAFROM A PROSPECTIVE COHORT Jacob Ollech, IL09:00 - 09:00 P0448EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMABFOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OFTHE PHASE 4 EARNEST TRIAL Simon Travis



09:00 - 09:00 P0451THERAPEUTIC TARGETS IN PAEDIATRIC IBD: ARETROSPECTIVE ANALYSIS OF INTERMEDIATE GOALSBASED ON UPDATED STRIDE-II (SELECTING THERAPEUTICTARGETS IN INFLAMMATORY BOWEL DISEASE)RECOMMENDATIONS Hannes Hölz, DE

09:00 - 09:00 P0452RESULTS FROM A LARGE SURVEY EXPLORING PATIENTPREFERENCES FOR TREATMENT ATTRIBUTES ININFLAMMATORY BOWEL DISEASE ACROSS 7 COUNTRIES INEUROPE Nawal Bent-Ennakhil, CH




09:00 - 09:00 P0456OBSERVATIONAL STUDY ON THE EFFECTIVENESS ANDSAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITISPOPULATION COMPRISED BY BIO-NAÏVE PATIENTS ANDPATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF(EVOLVE-IB STUDY) Francisco Casellas, ES09:00 - 09:00 P0457CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITHULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POSTHOC ANALYSIS OF SELECTION William J. Sandborn, US


09:00 - 09:00 P0459PHARMACOKINETICS, IMMUNOGENICITY, ANDEXPOSURE–RESPONSE RELATIONSHIPS OFUSTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’SDISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGETVS STANDARD OF CARE ANALYSIS OF THE STARDUSTSTUDY Geert R. D'Haens, NL

09:00 - 09:00 P0460INFLAMMATORY COMPLICATIONS OF THE POUCH, ANDTHERAPEUTIC REQUIREMENTS AFTER COLECTOMY INPATIENTS WITH ULCERATIVE COLITIS. RESULTS FROMTHE RESERVO STUDY OF GETECCU Francisco Mesonero, ES








09:00 - 09:00 P0465INTRAABDOMINAL ABSCESSES IN CROHN'S DISEASE:TREATMENT AND OUTCOMES Salma Souissi, TN09:00 - 09:00 P0466PHARMACOKINETIC AND NONCLINICAL SAFETYEVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, INNON-HUMAN PRIMATES Jay Tibbitts, US


09:00 - 09:00 P0468TREATMENT OPTIMIZATION WITH VEDOLIZUMAB INTREATMENT-REFRACTORY PATIENTS WITH ULCERATIVECOLITIS AND CROHN’S DISEASE – A REAL-WORLD TWO-CENTER COHORT STUDY Mohamed Attauabi, DK

09:00 - 09:00 P0469MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE CROHN'SDISEASE Edward V. Loftus, US






09:00 - 09:00 P0475IS LONGER TIME BETWEEN IBD DIAGNOSIS AND FIRSTBIOLOGIC INITIATION LEADING TO HIGHER DISEASESEVERITY AND MORE HOSPITALIZATIONS IN ITALY ANDTHE UNITED KINGDOM? A COMPARISON TO SIMILARMETRICS IN THE UNITED STATES Eric John, US09:00 - 09:00 P0476RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLYSYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN ANDSTOOL FREQUENCY IN PATIENTS WITH MODERATE TOSEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3INDUCTION STUDIES Jean-Frederic Colombel, US

09:00 - 09:00 P0477VEDOLIZUMAB AS THE FIRST LINE OF BIOLOGIC THERAPYFOR ULCERATIVE COLITIS AND CROHN’S DISEASE - ASYSTEMATIC REVIEW WITH META-ANALYSIS Mohamed Attauabi, DK

09:00 - 09:00 P0478PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSALHEALING RATES IN CROHN'S DISEASE Marko Brinar, HR










09:00 - 09:00 P0485HISTOLOGICAL INFLAMMATION PREDICTS LOSS OFREMISSION AMONG CROHN’S PATIENTS WITHENDOSCOPIC REMISSION: A US COHORT ANALYSIS Harris Ahmad, US09:00 - 09:00 P0486PATIENT PREFERENCES REGARDING TREATMENT WITHADVANCED THERAPIES IN ULCERATIVE COLITIS: ADISCRETE-CHOICE EXPERIMENT Stefan Schubert, DE

09:00 - 09:00 P0487LONG-TERM OUTCOMES FOLLOWING A SWITCH FROMORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5(IMRALDI) IN IBD Lauranne Derikx

09:00 - 09:00 P0488PERFUSE: A FRENCH NON-INTERVENTIONAL COHORTSTUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONEDPATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5;BASELINE RESULTS Yoram Bouhnik, FR






09:00 - 09:00 P0494SYSTEMATIC REVIEW ON THE USE OF ENTERAL NUTRITIONFOR THE INDUCTION OF REMISSION IN PAEDIATRICCROHN’S DISEASE Gigi Veereman, BE09:00 - 09:00 P0495BENEFICIAL EFFECTS OF NATURAL MINERAL WATERS ONINTESTINAL INFLAMMATION AND THE MUCOSA-ASSOCIATED MICROBIOTA Nicolas Barnich, FR

09:00 - 09:00 P0496A 12-WEEK TAILORED PHYSICAL TRAINING PROGRAMINCLUDING DIETARY ADVICE IN CHILDREN WITHINFLAMMATORY BOWEL DISEASE: A RANDOMIZEDCROSSOVER TRIAL Linda Elisabeth Scheffers, NL

09:00 - 09:00 P0497UPADACITINIB TREATMENT IMPROVES HEALTH-RELATEDQUALITY OF LIFE AMONG PATIENTS WITH MODERATELYTO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTSFROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE ANDU-ACCOMPLISH Julian Panés, ES









09:00 - 09:00 P0503TOFACITINIB IN ULCERATIVE COLITIS: SHORT TERMOUTCOMES IN REAL WORLD EXPERIENCE IN THE SOUTHOF SPAIN Alvaro Hernández Martínez, ES09:00 - 09:00 P0504SAFETY OF REDUCED CLINICAL MONITORING IN PATIENTSWITH STABLE INFLAMMATORY BOWEL DISEASE ONMAINTENANCE THIOPURINE THERAPY Fenna Minke Jansen, NL

09:00 - 09:00 P0505BOTH SINGLE AND MULTIPLE SWITCHING BETWEENINFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE INIBD: REAL WORLD OUTCOMES FROM THE EDINBURGH IBDUNIT Rachael Barrett

09:00 - 09:00 P0506BIOLOGICS AND SMALL MOLECULES COMBOTHERAPIES:PROMISING EXPERIENCE IN REFRACTORY IBD PATIENTS Maude Martinho, CH







09:00 - 09:00 P0513REDO-SURGERY IN IBD PATIENTS: WHAT IS THE TIMEINTERVAL AND IS THIS EFFECTED BY SPECIFIC RISKFACTORS ? John Wye, UK09:00 - 09:00 P0514DOES THE TYPE OF SURGERY OR DISEASE LOCATIONPREDICT THE NEED FOR SUBSEQUENT SURGERIES, IN IBDPATIENTS John Wye, UK

09:00 - 09:00 P0515THE CHANGING TRENDS SEEN WITH SURGERY INPATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER A25 YEAR REVIEW PERIOD John Wye, UK

09:00 - 09:00 P0516MANAGEMENT AND OUTCOME OF POSTOPERATIVECROHN’S DISEASE IN THE ELDERLY AS COMPARED TOYOUNG ADULTS: DATA FROM ENEIDA REGISTRY Miriam Mañosa Ciria, ES







E-Poster Session





09:00 - 09:00 P0130SOLVING THE ENIGMA OF NON-IGE MEDIATEDGASTROINTESTINAL FOOD ALLERGY IN THE PEDIATRICAGE: RESULTS FROM THE NIGEFA STUDY Laura Carucci, IT09:00 - 09:00 P0131RELEVANCE AND OUTCOME OF NON-SPECIFIC ENTERITISDURING LONG-TERM FOLLOW-UP Ana Catarina Gomes, PT





09:00 - 09:00 P0136GEOGRAPHIC EVOLUTION OF PEDIATRIC INTESTINALFAILURE (PIF) MANAGEMENT IN THE UNITED STATES (US) David F Mercer, US

09:00 - 09:00 P0137SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROMEAND THERMAL FOOD PROCESSING PATTERN Vladimir Pilipenko, RU




09:00 - 09:00 P0141HLA RISK STRATIFICATION COULD BE USED TO TARGETSEROLOGICAL SCREENING OF CELIAC DISEASE AMONG AT-RISK RELATIVES Saana Paavola, FI09:00 - 09:00 P0142CHANGES IN BODY COMPOSITION AMONG PATIENTS WITHCOELIAC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS Zsófia Vereczkei, HU





09:00 - 09:00 P0147CONCOMITANT AUTOIMMUNITY IN CELIAC DISEASE:ASSOCIATION TO THE DISEASE FEATURES AND LONG-TERM TREATMENT OUTCOMES Riku Tauschi, FI

09:00 - 09:00 P0148WHAT IS THE ROLE OF MULTIPLE URINE GIPS INESTABLISHED COELIAC DISEASE? William Holland







09:00 - 09:00 P0153THE INCIDENCE OF CELIAC DISEASE AMONG PATIENTSWITH GASTROENTEROLOGICAL DISORDERS Svetlana Bykova, RU09:00 - 09:00 P0154MICRORNAS ARE POTENTIAL EARLY MARKERS OF COELIACDISEASE AND MAY REGULATE THE COELIAC DISEASE-SPECIFIC TRANSCRIPTIONAL CHANGES IN THE SMALLINTESTINE Ineke Tan, NL




09:00 - 09:00 P0158FUNCTIONAL STATUS OF DUODENAL MUCOSA IN CELIACDISEASE PATIENTS Olga Akhmadullina, RU

09:00 - 09:00 P0159NATURAL HISTORY OF CELIAC DISEASE: COMPARISONBETWEEN CHILDHOOD AND ADULT-ONSET DISEASE Hadrien Alric, FR





09:00 - 09:00 P0165SCREENING FOR ADULT COELIAC DISEASE IN THEGENERAL POPULATION Ina Lervåg Andersen, NO09:00 - 09:00 P0166PREDICTIVE FACTORS FOR LONG-TERM COMPLICATIONSIN CELIAC DISEASE: A LARGE RETROSPECTIVE STUDYFROM THE CELAC GROUP Hadrien Alric, FR





09:00 - 09:00 P0172INCREASED PREVALENCE OF CELIAC DISEASE IN PATIENTSWITH CYSTIC FIBROSIS: A SYSTEMATIC REVIEW ANDMETA–ANALYSIS Marcell Imrei, HU

09:00 - 09:00 P0174ADHERENCE TO CELIAC DIAGNOSTIC GUIDELINES:RESULTS FROM THE GERMAN CELIAC REGISTRY (GECER) Sibylle Koletzko, DE







09:00 - 09:00 P0178SHORT AND LONG-TERM OUTCOME OF COLDPOLYPECTOMY FOR SUPERFICIAL NON-AMPULLARYDUODENAL EPITHELIAL TUMORS Kenichiro Okimoto, JP09:00 - 09:00 P0179TIMING OF ENTEROSCOPY IN OVERT-OBSCUREGASTROINTESTINAL BLEEDING - A SYSTEMATIC REVIEWAND META-ANALYSIS Ana Catarina Gomes, PT





E-Poster Session



09:00 - 09:00 P1060COLORECTAL CANCER SURVIVAL AT DR. ORLANDO SMITHHOSPITAL, TORTOLA, BRITISH VIRGIN ISLANDS David Nelson, VG

09:00 - 09:00 P1061MORTALITY FOLLOWING APPENDICECTOMY IN PATIENTSWITH LIVER CIRRHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Adil Rashid

09:00 - 09:00 P1064FEATURES OF GUNSHOT COLON DAMAGE WITHEXPANSIVE BULLETS VS CONVENTIONAL BULLETS (DATAOF JOINT FORCES OPERATION AT THE EAST OF UKRAINE2014 - 2020 YY.) Kostiantyn Gumeniuk, UA09:00 - 09:00 P1065RECTAL DEFECT HEALING: EXPERIMENTAL ASSESSMENTSTUDY OF DIFFERENT REINFORCEMENT PROCEDURES Freddy Mboti, BE






09:00 - 09:00 P1071INCIDENCE, RISK FACTORS AND OUTCOMES OF MESHINFECTION AFTER INCISIONAL HERNIA REPAIR SURGERYIN THE UNITED STATES: A NATIONWIDE DATABASESTUDY Andrea Carolina Quiroga Centeno, CO

09:00 - 09:00 P1072ENDOSCOPIC TREATMENT OF GASTRO-BRONCHIAL ANDGASTRO-COLIC FISTULAS POST SLEEVE GASTRECTOMY Alessandra D'Alessandro, IT

09:00 - 09:00 P1073FEWER BRANCHES OF LEFT COLIC ARTERY AND THEIRIMPACTS ON LAPAROSCOPIC SURGERY IN PATIENTS WITHPERSISTENT DESCENDING MESOCOLON Hiroaki Nozawa, JP




09:00 - 09:00 P1074DEVELOPMENT OF GASTRIC ENDOSCOPIC FULL-THICKNESS RESECTION FOLLOWED BY BAND LIGATIONAND OVER-THE-SCOPE CLIP CLOSURE Hideki Kobara, JP09:00 - 09:00 P1075PERORAL ENDOSCOPIC SEPTOTOMY USING ALAPAROSCOPIC VESSEL-TISSUE SEALER FOR TREATMENTOF ZENKER’S DIVERTICULUM: FEASIBILITY AND SAFETY OFENDOSCOPIC SCISSORS TECHNIQUE Filippo Mocciaro, IT

E-Poster Session






09:00 - 09:00 P0188EFFICACY, SAFETY AND COST EFFECTIVENESS OFINTRAGASTRIC BALLOON THERAPY COMPARED TO AMULTIDISCIPLINARY WEIGHT LOSS PROGRAM IN A REAL-WORLD POPULATION – A PROPENSITY SCORE MATCHINGANALYSIS Jürgen Stein, DE

09:00 - 09:00 P0189REDO ENDOSCOPIC SLEEVE GASTROPLASTY: REPEATINGDOES NOT MEAN FAILING Maria Valeria Matteo, IT

09:00 - 09:00 P0190OBESITY TREATMENT BY GASTRIC ENDOSCOPY SLEEVEPLICATION: EFFICACY AND SAFETY AT 24 MONTHSFOLLOW-UP Carmen H. Bautista Altamirano, ES

09:00 - 09:00 P0191ENDOSCOPIC SLEEVE GASTROPLASTY AS NEW HOPE FORMILD OBESITY Maria Valeria Matteo, IT09:00 - 09:00 P0192HIGHER BODY MASS INDEX IS ASSOCIATED WITH BETTERCLINICAL OUTCOMES IN PATIENTS WITH CYSTICFIBROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF3100 PATIENTS Rita Nagy, HU






09:00 - 09:00 P0199PREVALENCE OF MICRONUTRIENT DEFICIENCY ANDRELATIONS WITH POLYENDOCRINE SYNDROME TYPE 3 INPATIENTS WITH CHRONIC AUTOIMMUNE ATROPHICGASTRITIS Safa Senel, TR

09:00 - 09:00 P0200EARLY CHILDHOOD FOOD ALLERGY IN FAMILIES WITHATOPY IN BULGARIA Silviya Kuneva, BG


09:00 - 09:00 P0202LACTOSE MALABSORPTION BY THIRD-GENERATIONHYDROGEN BREATH TEST: NEW DATA COLLECTION ANDTIME IMPLEMENTATION Filippo Scevola, IT




09:00 - 09:00 P0203NATIVE AND SATURATED BOVINE LACTOFERRINMODULATE THE EXPRESSION OF TOLL-LIKE RECEPTORS(TLRS) IN MICE TREATED WITH ANTIBIOTICS Andrea Bellés, ES09:00 - 09:00 P0204ASSESSMENT OF GUT MICROBIOTA IN IBS PATIENTSAFTER A 4-WEEK STARCH-AND SUCROSE-REDUCED DIETSHOWS INCREASED BETA DIVERSITY, UNALTERED ALPHADIVERSITY AND SPECIFIC CHANGES IN GENERA Clara Nilholm, SE





09:00 - 09:00 P0209ASSOCIATION OF IRRITABLE BOWEL SYNDROME ANDMICRONUTRIENTS: A SYSTEMATIC REVIEW Yao Neng Teo, SG

09:00 - 09:00 P0210INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITHFRUCTOSE Raphael Fagundes Rosa, NL


09:00 - 09:00 P0213VITAMIN D RECEPTOR ACTIVATION EXERTS ANTI-SECRETORY ACTIONS IN COLONIC EPITHELIAL CELLS Caitriona E. Curley, IE

09:00 - 09:00 P0214DIETARY PATTERNS AND GASTROESOPHAGEAL REFLUXES:CORRELATION ANALYSIS Sergey Morozov, RU09:00 - 09:00 P0216SAFE PATIENT SELECTION AND USE OF TRANSNASALENDOSCOPY(TNE) FOR PEG INSERTION IN MOTORNEURONE DISEASE(MND) Mohammed Shamsaldeen, UK


09:00 - 09:00 P0218SCHEDULED PERCUTANEOUS ENDOSCOPICGASTROSTOMY TUBE REPLACEMENT DID NOT REDUCEPEG RELATED COMPLICATIONS Tawfik Khoury, IL



E-Poster Session


09:00 - 09:00 CC001A RARE AND SYMPTOMATIC CASE: LOCALIZED GASTRICAND DUODENAL AMYLOIDOSIS Mahnoor Khan, US

09:00 - 09:00 CC002A RARE CASE OF COLLAGENOUS GASTRITIS IN A 16 YEAROLD MALE PATIENT Corinna Lang-Schwarz, DE






09:00 - 09:00 CC005CMV DUODENITIS – A RARE CAUSE OF DUODENALULCERATION IN IMMUNE-COMPETENT HOST Muhammad Khan, QA09:00 - 09:00 CC006ESOPHAGEAL-PULMONARY FISTULA AS THE INITIALPRESENTATION OF TUBERCULOSIS Mariel Dianne Velasco, PH

09:00 - 09:00 CC007CYTOMEGALOVIRUS INFECTION PRESENTING AS GASTRICOUTLET OBSTRUCTION - AN UNUSUAL PRESENTATION Ashish Gandhi, IN







09:00 - 09:00 CC015PRIMARY DEDIFFERENTIATED LIPOSARCOMA OF THEESOPHAGUS Maryam Alahmad, AE

09:00 - 09:00 CC016PRIMARY GASTRIC ADENOSQUAMOUS CARCINOMA: ARARE VARIANT OF GASTRIC CANCER Joaquín García Márquez, ES



09:00 - 09:00 CC019GURVITS SYNDROME IN A YOUNG PATIENT WITH POORLYCONTROLLED DIABETES AND COCAINE USE María del Mar Díaz Alcázar, ES09:00 - 09:00 CC020CHRONIC MESENTERIC ISCHEMIA MIMICKING GASTRICCANCER Jana Jarosova, CZ

09:00 - 09:00 CC021MASSIVE ASCITES AS THE INITIAL PRESENTATION OFSYSTEMIC LUPUS ERYTHEMATOSUS Maryam Alahmad, AE






09:00 - 09:00 CC027GASTROINTESTINAL AMYLOIDOSIS: THE TONGUE GIVESTHE ANSWER Pedro Antunes, PT

09:00 - 09:00 CC030WHIPPLE DISEASE: A CASE REPORT Vaidota Maksimaityte, LT






09:00 - 09:00 CC033TRANSIENT SMALL BOWEL INTUSSUSCEPTIONUNMASKING ADULT CELIAC DISEASE Maryam Alahmad, AE09:00 - 09:00 CC034CELIAC CRISIS – A RARE AND LIFE-THREATENINGPRESENTATION Isabel Garrido, PT

09:00 - 09:00 CC035HOW MANY CALORIES ARE ENOUGH? Zrinka Šmuljić, HR







09:00 - 09:00 CC042ENDOSCOPIC BAND LIGATION FOR WEIGHT LOSS: SHORT-TERM RESULTS Mohamed Abeid, EG

09:00 - 09:00 CC043MIGRATED PEG BALLOON CAUSING ACUTE PANCREATITIS Muhammad Omar Saeed



09:00 - 09:00 CC046GANGRENOUS PYODERMA IN ULCERATIVE COLITIS - ANEXUBERANT AND PAINFUL COMPLICATION Margarida Gomes Gonçalves, PT09:00 - 09:00 CC047SEVERE LOWER GASTROINTESTINAL BLEEDING IN APATIENT WITH CROHN'S DISEASE: A RARE CASE REPORT Isabel Garrido, PT

09:00 - 09:00 CC048SPONTANEOUS PNEUMOMEDIASTINUM: A RARECOMPLICATION OF ACUTE SEVERE ULCERATIVE COLITIS Emanuel Dias, PT






09:00 - 09:00 CC054ASSOCIATION BETWEEN CROHN'S DISEASE ANDCOLORECTAL CANCER IN A YOUNG PATIENT: CASEREPORT Rafael Luporini, BR

09:00 - 09:00 CC055IMMUNE-MEDIATED COLITIS Mirza Faisal Anwar Baig






09:00 - 09:00 CC058PROCTITIS IN MEN HAVING SEX WITH MEN, ANYTHINGELSE YOU CAN THINK OF? María del Mar Díaz Alcázar, ES09:00 - 09:00 CC059FRESH RECTAL BLEEDING WITH A RARE HIDDENHISTOPATHOLOGIC DIAGNOSIS Anastasios Koutsoumourakis, GR

09:00 - 09:00 CC060RECTAL DIEULAFOY LESION - DIAGNOSTIC ANDTHERAPEUTIC CHALLENGE Ivo Klarin, HR






09:00 - 09:00 CC066DIFFUSE GASTROINTESTINAL MALT LYMPHOMA IN APATIENT WITH ULCERATIVE COLITIS IN REMISSION Costantino Sgamato, IT

09:00 - 09:00 CC067PRIMARY COLONIC LYMPHOMA : A CASE REPORT Hajar Koulali, MA



09:00 - 09:00 CC070NEUROMUSCULAR AND VASCULAR HAMARTOMA: ANUNUSUAL HAMARTOMATOUS LESION OF THEGASTROINTESTINAL TRACT Simona Gurzu, RO09:00 - 09:00 CC071SOLITARY RECTAL ULCER SYNDROME WITH RECTALPROLAPSE :A CASE REPORT Mohammed Adil Kaddouri, MA

09:00 - 09:00 CC072PAPILLOMA VS CONDYLOMA: AN IMPORTANT SUBTLEDISTINCTION Antonio Oliveira, PT







09:00 - 09:00 CC079ACUTE E HEPATITIS IN AN AUTOIMMUNITYENVIRONMENT Luísa Martins Figueiredo, PT

09:00 - 09:00 CC080A RARE CASE OF ACUTE LIVER INJURY SECONDARY TOCONCURRENT HEPATITIS A VIRUS INFECTION ANDDENGUE VIRUS INFECTION IN AN IMMUNOCOMPROMISEDPATIENT Nikko Theodore Raymundo, PH





09:00 - 09:00 CC082SUCCESSFUL TREATMENT OF HEPATITIS C IN A PATIENTWITH CONGENITAL SPHEROCYTOSIS BY RIBAVIRIN-FREEDIRECT-ACTING ANTIVIRALS REGIMEN: A CASE STUDY Ahmed Mansour, EG09:00 - 09:00 CC084PEMBROLIZUMAB-INDUCED PANCREATIC EXOCRINEINSUFFICIENCY COMPLICATED BY SEVERE HEPATICSTEATOSIS Alex S Hong

09:00 - 09:00 CC085CHARACTERISTICS OF IMMUNOGLOBULIN G4-RELATEDAUTOIMMUNE HEPATITIS: A CASE REPORT AND REVIEW OFLITERATURE Siyu Jiang, CN







09:00 - 09:00 CC093DIGESTIVE INVOLVEMENT IN RENDU OSLER WEBERDISEASE : A CASE REPORT Najoua Elmoutaoukil, MA

09:00 - 09:00 CC094ECTOPIC PAPILLA OF VATER IN THE GASTRIC ANTRUM Aikaterini Pappa, GR


09:00 - 09:00 CC096SECONDARY SCLEROSING CHOLANGITIS IN A CRITICALLY-ILL PATIENT PRECIPITATED BY SARS-COV2 INFECTION Bárbara Morão, PT09:00 - 09:00 CC097GALLSTONE ILEUS: A RARE CAUSE OF BOWELOBSTRUCTION IN A LIVER TRANSPLANT PATIENT Tiago Ribeiro, PT

09:00 - 09:00 CC098UNUSUAL APPEARANCE OF CHOLANGIOCARCINOMA:SOLID- CYSTIC LESION; A CASE REPORT Montri Gururatsakul, AU








09:00 - 09:00 CC106A RARE CAUSE OF OBSTRUCTIVE JAUNDICE Diana Ramos Silva, PT

09:00 - 09:00 CC107A CASE OF UNRESECTABLE LOCALLY ADVANCEDPANCREATIC CANCER IN WHICH RO RESECTION WASACHIEVED BY COMBINING CHEMOTHERAPY AND HIFUTHERAPY Atsushi Sofuni, JP





09:00 - 09:00 CC109AN EUS DIAGNOSIS OF A PANCREATIC NEUROENDOCRINETUMOUR: A RARE CASE OF OBSTRUCTIVE CHOLESTASISOVERLAPPING WITH CHOLEDOCHOLITHIASIS Rui de Sousa Magalhaes, PT09:00 - 09:00 CC110GASTRIC BAROTRAUMA INDUCED BY SELLICK MANEUVERPERFORMED TO ENABLE ENDOSCOPIC SUBMUCOSALDISSECTION Daniela Falcão, PT







09:00 - 09:00 CC117“METALLIC TULIP-BUNDLE” TECHNIQUE AS RESCUEHEMOSTATIC THERAPY AFTER ENDOSCOPIC MUCOSALRESECTION OF A GASTRIC LESION Ana Catarina Gomes, PT

09:00 - 09:00 CC118CLOSURE OF A JEJUNAL STUMP LEAK WITH AN OVER-THE-SCOPE-CLIP Ana Catarina Gomes, PT


09:00 - 09:00 CC120DUODENAL-TYPE FOLLICULAR LYMPHOMA Fernanda Lago, BR09:00 - 09:00 CC121UPPER GASTROINTESTINAL BLEEDING IN LIVERCIRRHOSIS: GASTROESOPHAGEAL VARICES ARE NOTALWAYS TO BLAME Emanuel Dias, PT








09:00 - 09:00 CC129INTESTINAL AMYLOIDOSIS PRESENTING AS A SOLITARYULCER OF THE CAECUM: A CASE REPORT Federica Crispino, IT

09:00 - 09:00 CC130RECTAL ULCERATIONS IN PATIENT WITH PERIANALHERPES SIMPLEX VIRUS TYPE 1 Lourdes Carreira Guillán, ES





09:00 - 09:00 CC132EXTENSIVE ACUTE OCCLUSIVE MESENTERIC ISCHEMIAWITH SEVERE ISCHEMIC COLITIS PRECIPITATED BYSEVERE CLOSTRIDIOIDES DIFFICILE INFECTION, A CASEREPORT Ana Ordonez Vazquez, MX09:00 - 09:00 CC133EXTENDED GASTROINTESTINAL MANTLE LYMPHOMA Ángela Martina Montero Moretón, ES







09:00 - 09:00 CC140ENDOSCOPY, RADIOLOGY AND PATHOLOGY: WHEN THEPIECES DON’T MATCH Ana Catarina Carvalho, PT

09:00 - 09:00 CC141UNUSUAL CASE OF HEAD OF PANCREAS MASS:METASTATIC PROSTATE CANCER Montri Gururatsakul, AU


09:00 - 09:00 CC143ENDOSCOPIC ULTRASOUND OF MENETRIER’S DISEASE,RARE CAUSE OF RESISTANT ANEMIA Mohammed Gouda, EG09:00 - 09:00 CC144PRIMARY EXTRA-NODAL PELVIC LYMPHOMA DIAGNOSEDBY ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLEBIOPSY (EUS-FNB) Omar AbdAllah, EG









E-Poster Session





09:00 - 09:00 P1076AN ANALYSIS OF GI AND NON-GI MANIFESTATIONS OFCOVID-19 DURING THE FIRST WAVE OF THE COVID-19PANDEMIC IN DARLINGTON, UNITED KINGDOM Anjan Dhar09:00 - 09:00 P1077COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIANCASE-CONTROL DOUBLE-CENTER STUDY Maria Guarino, IT


09:00 - 09:00 P1079SUCCESSFUL ENDOSCOPY RECOVERY STRATEGY AFTERTHE FIRST WAVE OF THE COVID-19 PANDEMIC IN ANORTHEAST LONDON HOSPITAL Paolo Giuffrida, UK

09:00 - 09:00 P1080FREQUENCY AND OUTCOMES OF SARS-COV-2 INFECTIONIN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASINGLE TERTIARY CENTER EXPERIENCE Ilhami Yuksel, TR




09:00 - 09:00 P1084A NOVEL MICROBIOME FORMULA (SIM01) AS ANADJUVANT THERAPY FOR COVID-19: AN OPEN-LABELPILOT STUDY Lin Zhang, CN

09:00 - 09:00 P1085A PROSPECTIVE OBSERVATIONAL STUDY ON THEEVALUATION OF THE RISK OF TRANSMISSION DUE TODROPLETS AND AEROSOLS DURINGESOPHAGOGASTRODUODENOSCOPY AND THEUSEFULNESS OF EXTRAORAL SUCTION DEVICES Hironori Sunakawa, JP


09:00 - 09:00 P1087EVIDENCE-BASED SELECTION ON THE APPROPRIATE FITCUT-OFF POINT IN CRC SCREENING PROGRAMS IN THECOVID PANDEMIC Patricia Carrera-Lasfuentes, ES09:00 - 09:00 P1088HEPATOKINES AND COVID-19 SEVERITY Michał Kukla, PL


09:00 - 09:00 P1090EVALUATION OF LIVER ALTERATIONS IN PATIENTS WITHPOST-ACUTE COVID-19 SYNDROME - A PILOT STUDY Felix Bende, RO

09:00 - 09:00 P1091ELEVATED AMINOTRANSFERASES AT ADMISSION IS APREDICTOR OF ACUTE KIDNEY INJURY IN HOSPITALIZEDPATIENTS WITH COVID-19 Yulia Khruleva, RU



09:00 - 09:00 P1094IMPACT EVALUATION OF TELECONSULTATION ONGASTROENTEROLOGY DURING THE SARS-COV-2PANDEMIC Pedro Antunes, PT

09:00 - 09:00 P1095MAINTAINING ERCP CAPACITY AND HIGH QUALITY KEYPERFORMANCE QUALITY INDICATORS (KPIS) DURING THECHALLENGE OF COVID-19 RESTRICTIONS: WHAT HAVE WELEARNT? Ioannis Varmpompitis





09:00 - 09:00 P1097SATISFACTION WITH TELECONSULTATION ININFLAMMATORY BOWEL DISEASE PATIENTS DURING THECOVID-19 PANDEMIC Pedro Campelo, PT09:00 - 09:00 P1098DOES THE PRESENCE OF GASTROINTESTINAL SYMPTOMSPREDICT MILDER DISEASE IN COVID-19 PATIENTS ? – APROSPECTIVE EVALUATION jayanta Samanta, IN


09:00 - 09:00 P1100THE IMPACT OF THE COVID-19 PANDEMIC ON THEMANAGEMENT OF CIRRHOTIC PATIENTS Amani Hassine, TN

09:00 - 09:00 P1101OUTCOMES OF PATIENTS WITH DECOMPENSATEDCIRRHOSIS AND CORONAVIRUS DISEASE 19: MORTALITYAND SAFETY OF LIVER TRANSPLANTATION Ahad Eshraghian, IR

Recorded only

10:00 – 10:30 Hall 2From guidelines to clinical practice: Guidelines forconstipation, chronic and IBS-diarrhea and faecalincontinence

10:00 - 10:10 IP162European society of neurogastroenterology and motilityguidelines on functional constipation in adults Jordi Serra, ES

10:10 - 10:20 IP163Guideline on functional chronic diarrhea Edoardo Vincenzo Savarino, IT

10:20 - 10:30 IP164Guideline on faecal incontinence Sadé Assmann, NL


10:00 – 11:00 Industry HallIS-08 B cell Biology and IgG4-Related Disease


10:30 – 11:30 TV StudioMultidisciplinary approach to vascular liver diseasesChairs: Pierre-Emmanuel Rautou, FR

Annalisa Berzigotti, CHMarco Dioguardi Burgio, FRRoberto Miraglia, IT

10:30 - 10:32Introduction Pierre-Emmanuel Rautou, FR

10:32 - 10:42 IP165PSVD Annalisa Berzigotti, CH


11:02 - 11:12 IP166Portal cholangiopathy and treatment usinginterventionnal radiology Marco Dioguardi Burgio, FR


11:27 - 11:30Take-home messages


10:30 – 11:30 Hall 1IBD epidemiology and drug safetyChairs: Valerie Pittet, CH

Naila Arebi, UK

10:30 - 10:42 OP096NEW THERAPEUTIC STRATEGIES HAVE CHANGED THENATURAL HISTORY OF PAEDIATRIC INFLAMMATORYBOWEL DISEASES: RESULTS FROM A POPULATION-BASEDCOHORT OVER A 24-YEAR PERIOD (1988-2011) Delphine Ley, FR

10:42 - 10:54 OP097THE RISK OF ACUTE ARTERIAL EVENTS ASSOCIATED WITHANTI-TNF AND AZATHIOPRINE IN INFLAMMATORY BOWELDISEASES: A DANISH NATIONWIDE COHORT STUDY Daniel Ward, DK

10:54 - 11:06 OP098INCREASED INCIDENCE OF CANCER AND MORTALITY IN APEDIATRIC-ONSET IBD POPULATION-BASED COHORT OF1344 PATIENTS DIAGNOSED BETWEEN 1988 AND 2011:THE INSPIRED STUDY Claire Dupont-Lucas, FR




11:06 - 11:18 OP099SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVECOLITIS: RESULTS FROM THE PHASE 2B/3 SELECTIONSTUDY AND PHASE 3 SELECTION LTE LONG-TERMEXTENSION STUDY Stefan Schreiber, DE11:18 - 11:30 OP100USTEKINUMAB LEVELS IN PREGNANT WOMEN WITHINFLAMMATORY BOWEL DISEASE AND NEONATESEXPOSED IN-UTERO Ralley Prentice, AU

Moderated Poster

10:30 – 11:30 Hall 2IBD: Clinical trials poster IChairs: Iago Rodríguez-Lago, ES

João Sabino, BE

10:30 - 10:40 MP055EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACYAND SAFETY OF FILGOTINIB AND ITS METABOLITEGS-829845 IN PATIENTS WITH MODERATELY TO SEVERELYACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE2B/3 SELECTION STUDY Amy Meng, US

10:40 - 10:50 MP056PATIENTS WITH CROHN'S DISEASE HAVE IMPROVEDCOPING STRATEGIES AFTER A 3-MONTH COURSE OFCOGNITIVE BEHAVIORAL AND MINDFULNESS-BASEDSTRESS REDUCTION Ganit Goren, IL

10:50 - 11:00 MP057MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES INPATIENT BIOPSIES AT WEEK 12 ARE MAINTAINEDTHROUGH WEEK 52 IN PATIENTS WITH ULCERATIVECOLITIS Venkatesh Krishnan, US

11:00 - 11:10 MP058AGREEMENT BETWEEN LOCALLY AND CENTRALLYREVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFISTUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVECOLITIS: CORROBORATION WITH FECAL CALPROTECTINAND HISTOLOGY Walter Reinisch, AT

11:10 - 11:20 MP059GENE EXPRESSION PROFILING IN ULCERATIVE COLITISIDENTIFIES CHARACTERISTICS FOR ANTI-TNF RESPONSEAND TARGETS FOR ALTERNATIVE THERAPIES Marietta Iacucci, UK

11:20 - 11:30 MP060LONG-TERM TREATMENT WITH SUBCUTANEOUSVEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTSFROM THE VISIBLE OPEN-LABEL EXTENSION STUDY Silvio Danese, IT


10:30 – 11:30 Hall 3Late-breaking Abstracts III: Clinical trials in IBDChairs: Iris Dotan, IL

Britta Siegmund, DE

10:30 - 10:42 LB11EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCETHERAPY IN PATIENTS WITH MODERATELY TO SEVERELYACTIVE ULCERATIVE COLITIS: RESULTS FROM ARANDOMIZED PHASE 3 STUDY Remo Panaccione, CA

10:42 - 10:54 LB12ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURINGPHASE 2B INDUCTION AND MAINTENANCE TREATMENT OFULCERATIVE COLITIS PATIENTS Severine Vermeire, BE

10:54 - 11:06 LB13EFFICACY AND SAFETY OF RISANKIZUMAB ASMAINTENANCE THERAPY IN PATIENTS WITH CROHN'SDISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFYSTUDY Marc Ferrante, BE

11:06 - 11:18 LB14CLINICAL AND ENDOSCOPIC OUTCOMES WITHUSTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE:RESULTS FROM THE LONG-TERM EXTENSION PERIOD OFTHE STARDUST TRIAL Laurent Peyrin-Biroulet, FR

11:18 - 11:30 LB15THE PHARMACOKINETICS AND IMMUNOGENICITY OFUSTEKINUMAB AND ADALIMUMAB IN PATIENTS WITHMODERATE-TO-SEVERE CROHN’S DISEASE: RESULTSFROM THE SEAVUE STUDY Silvio Danese, IT


10:30 – 11:30 Hall 4New developments in nurse educationChairs: Ulrike Beilenhoff, DE


10:30 - 10:50 IP168Effect of university diploma on daily routine: Experiencesof French nurses Fanny Durand, FR

10:50 - 11:10 IP169VIGATU: Virtual learning in endoscopy. How can thiswork? Monika Engelke, DE




11:10 - 11:30 IP170Standardisation of nurses education in pneumology: Thenurses working group within the European RespirationSociety Andreja Sajnic, HR

Moderated Poster

10:30 – 11:30 Hall 5Upper GI bleedingChairs: Cesare Hassan, IT

Ian Mark Gralnek, IL

10:30 - 10:40 MP061FIRST-LINE THERAPY WITH OVER-THE-SCOPE-CLIPS ISSUPERIOR TO STANDARD ENDOSCOPIC TREATMENT INHIGH-RISK PATIENTS WITH ACUTE NON-VARICEAL UPPERGASTROINTESTINAL BLEEDING (STING-2 TRIAL) Benjamin Meier, DE

10:40 - 10:50 MP062THE ROLE OF HEMOSPRAY AS A MONOTHERAPYTREATMENT OF UPPER AND LOWER GASTROINTESTINALBLEEDS Mohamed Hussein

10:50 - 11:00 MP063COMPARISSION OF THE NEW ABC SCORE AND MAP(ASH)SCORE TO PREDICT MORTALITY IN UPPERGASTROINTESTINAL BLEEDING Rita Jiménez-Rosales, ES

11:00 - 11:10 MP064COMORBIDITIES AND REBLEEDING ARE ASSOCIATED WITHSIGNIFICANT MORTALITY IN NON-VARICEAL UPPERGASTROINTESTINAL BLEEDING (NVUGIB): A SYSTEMATICREVIEW AND META-ANALYSIS Eduard Ostarijas, HU

11:10 - 11:20 MP065CHANGE IN OUTCOMES OVER TIME IN PATIENTS TREATEDWITH HEMOSPRAY FOR UPPER GASTROINTESTINALBLEEDS: OUTCOMES FROM THE HEMOSPRAY REGISTRY Mohamed Hussein

11:20 - 11:30 MP066ANEMIA IS ASSOCIATED WITH POOR PROGNOSIS INPATIENTS TREATED WITH DUAL ANTI-PLATELET THERAPYAFTER CARDIAC CATHETERIZATION Sandra García Mateo, ES

Live Session

10:30 – 11:30 Hall 6Immunotherapy in GI cancersChairs: Zohar Levi, IL

Jean-Luc Van Laethem, BE

10:30 - 10:50 IP171Immunotherapy in GI cancers today and beyond Julien Taieb, FR10:50 - 11:10 IP172Tumour biology as a surrogate biomarker toimmunotherapy in the upper GI tract Irit Ben-Aharon, IL

11:10 - 11:30 IP173Immune biomarkers for treatment selection in GIcancers Jean-François Emile, FR

Moderated Poster

10:30 – 11:30 Hall 7Diseases of the bile ductChairs: Thomas Reiberger, AT

Michael Trauner, AT

10:30 - 10:40 MP067PERI-AMPULLARY DIVERTICULUM WAS ASSOCIATED WITHA HIGHER RATE OF ACUTE CHOLANGITIS AMONGPATIENTS WITH CHOLEDOCHOLITHIASIS Tawfik Khoury, IL

10:40 - 10:50 MP068PREDICTORS OF LONG-TERM OUTCOMES OF PRIMARYSCLEROSING CHOLANGITIS BASED ONCHOLANGIOSCOPIC FEATURES Sooraj Tejaswi, US

10:50 - 11:00 MP069BILE ACID MALABSORPTION AS A CONSEQUENCE OFCANCER TREATMENT: PREVALENCE AND MANAGEMENT INTHE NATIONAL LEADING CENTRE Darina Kohoutova

11:00 - 11:10 MP070EFFICACY AND SAFETY OF THE ENDOSCOPIC TREATMENTIN PATIENTS WITH IATROGENIC BILIARY INJURY Petko Karagyozov, BG

11:10 - 11:20 MP071SAME DAY ENDOSCOPIC ULTRASOUND FOLLOWED BYENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY FOR CHOLEDOCHOLITHIASIS ISFEASIBLE, SAFE AND COST-EFFECTIVE Tawfik Khoury, IL

11:20 - 11:30 MP072RELATION BETWEEN HELICOBACTER SPP. ISOLATED INBILE AND BILIARY TRACT MALIGNANCIES Beatriz Gros Alcalde, ES




Moderated Poster

10:30 – 11:30 Hall 8Advanced Imaging for screening colonoscopiesChairs: Giulio Antonelli, IT

Pradeep Bhandari, UK

10:30 - 10:40 MP073EFFECT OF LINKED-COLOR IMAGING ON THE DETECTIONOF ADENOMAS IN SCREENING COLONOSCOPIES Ivan David Arciniegas Sanmartin, BR

10:40 - 10:50 MP074NBI FOR THE DETECTION OF SESSILE SERRATED LESIONS:A RANDOMIZED CONTROLLED TRIAL Catarina Nascimento, PT

10:50 - 11:00 MP076DEVELOPMENT AND VALIDATION OF ANUNDERSTANDABLE AI SYSTEM TO COMPREHENSIVELYDIAGNOSE THE INVASION DEPTH OF CRC Zihua Lu, CN

11:00 - 11:10 MP077ARTIFICIAL INTELLIGENCE HELPS TO KEEP ADENOMADETECTION CONSTANT OVER THE DAY Jochen Weigt, DE

11:10 - 11:20 MP078MULTI-STEP VALIDATION OF A DEEP LEARNING BASEDSYSTEM FOR THE QUANTIFICATION OF BOWELPREPARATION: AN OBSERVATIONAL STUDY Liwen Yao, CN

Live Demo

10:30 – 11:30 Live Demo RoomUltrasound Course II - Ultrasound of the pancreas andbiliary systemChairs: Christian Jenssen, DE

Roxana Sirli, RO

10:30 - 10:45 IP174Ultrasound examination of the gallbladder, bile ducts andpancreas (ultrasound demonstration) Roxana Sirli, RO

10:45 - 11:00 IP175Ultrasound algorithm in acute pancreatitis Christian Jenssen, DE

11:00 - 11:15 IP176Ultrasound algorithm in obstructive jaundice Thomas Müller, DE




Tasty takeaways: The power of questions with MariannaArvanitakisChairs: Catalina Vladut, RO

Marianna Arvanitakis, BE

Recorded only

11:30 – 12:00 Hall 7Rising Stars in liver, biliary and pancreas from Europeand Japan - Part I

11:30 - 11:40 IP177Tips and tricks: How to become a UEG Rising Star Dan Lucian Dumitrascu, RO

11:40 - 11:50 IP178Presentation by JSGE Rising Star 2021 Takumu Hasebe, JP

11:50 - 12:00 IP179Presentation by UEG Rising Star 2021 Sabela Lens, ES


11:30 – 12:30 Industry HallIS-09 Walk this way: navigating the evolving UCtreatment pathway

Vienna Live Session

12:00 – 13:00 TV StudioCase closed? Live expert lunch IIChairs: Torsten Beyna, DE

Paolo Giorgio Arcidiacono, ITBalint Eross, HUJeanin E. van Hooft, NL

12:00 - 12:05Introduction Torsten Beyna, DE

12:05 - 12:12 IP180Case presentation 1 Jeanin E. van Hooft, NL

12:12 - 12:22Panel discussion: Biliary pancreatitis and anatomicalvariants




12:22 - 12:29 IP181Case presentation 2 Balint Eross, HU12:29 - 12:39Panel discussion: Metabolic, immune and hereditaryacute pancreatitis

12:39 - 12:46 IP182Case presentation 3 Paolo Giorgio Arcidiacono, IT

12:46 - 12:56Panel discussion: Acute and long term complications ofacute pancreatitis

12:56 - 13:00Closing remarks Torsten Beyna, DE


12:00 – 13:00 Hall 1Microbiota in IBDChairs: Konrad Aden, DE

James Lindsay, UK

12:00 - 12:12 OP101SACCHAROMYCES BOULARDII CNCM I-745SUPPLEMENTATION MODIFIES THE FECAL RESISTOMEDURING THE HELICOBACTER PYLORI ERADICATIONTHERAPY Sara Gabriela Cifuentes, EC

12:12 - 12:24 OP102COMPARISON OF FECAL TRANSPLANTATION, FECALTRANSPLANTATION WITH THE NOVEL UC DIET OR THE UCDIET ALONE FOR REFRACTORY MILD TO MODERATEACTIVE ULCERATIVE COLITIS: THE CRAFT UC RANDOMIZEDCONTROLLED TRIAL Arie Levine, IL

12:24 - 12:36 OP103FUNGAL AND BACTERIAL GUT MICROBIOTA IN PATIENTSWITH PAEDIATRIC ONSET INFLAMMATORY BOWELDISEASE INTRODUCED TO INFLIXIMAB Rebecka Ventin-Holmberg, FI

12:36 - 12:48 OP104SUCCESSFUL DIETARY THERAPY IN PEDIATRIC CROHN’SDISEASE CORRECTS COMPOSITIONAL DYSBIOSIS BYREDUCING PROTEOBACTERIA Charlotte M. Verburgt, NL

12:48 - 13:00 OP105DIET CONTROLS SEGMENTED FILAMENTOUS BACTERIA INDRIVING CROHN’S DISEASE-LIKE ILEO-COLONICINFLAMMATION IN TNFDELTAARE MICE Amira Metwaly, DE


12:00 – 13:00 Hall 2Intestinal pathophysiologyChairs: Marianne Rebecca Spalinger, CH

Timon Adolph, AT

12:00 - 12:12 OP106CHYMOTRYPSIN IN THE GUT: MORE THAN JUST A FOODDIGESTION ENZYME Simon Guignard, FR

12:12 - 12:24 OP107THE ROLE OF THE GUT SWEET TASTE RECEPTOR INREGULATING GUT HORMONE RELEASE IN RESPONSE TOTHE LOW-CALORIC SWEETENERS D-ALLULOSE ANDERYTHRITOL IN HUMANS: A RANDOMIZED, CONTROLLEDTRIAL Fabienne Teysseire, CH

12:24 - 12:36 OP108NUTRACEUTICAL TARGETING OF THE BILE ACIDRECEPTOR, FARNESOID X RECEPTOR, FOR INTESTINALDISEASE. Ciara M Fallon, IE

12:36 - 12:48 OP109STUDY ON THE EFFECT AND MECHANISM OF DECREASEDESTROGEN ON THE ABSORPTION OF GLUCOSE IN THEDUODENAL MUCOSA IN MENOPAUSAL FEMALES Weixi Shan, CN

12:48 - 13:00 OP110A NOVEL INGESTIBLE MECHANICAL PILL RELIABLYSAMPLES SMALL INTESTINAL LUMINAL CONTENT FORMICROBIOTA ANALYSIS: THE SIMBA CAPSULE Christopher N. Andrews, CA


12:00 – 13:00 Hall 3IBSChairs: Henriette Heinrich, CH

Magnus Simrén, SE

12:00 - 12:12 OP111EVALUATING THE EFFICACY OF XYLOGLUCAN AND PEAPROTEIN ON A MURINE MODEL OF ABDOMINAL PAIN ANDDISTENSION Michela Campolo, IT

12:12 - 12:24 OP112POST-INFECTIVE BOWEL DYSFUNCTION FOLLOWINGCAMPYLOBACTER ENTERITIS IS CHARACTERISED BYREDUCED MICROBIAL DIVERSITY AND PERSISTENTREDUCTION OF FIRMICUTES AND INCREASE OFPROTEOBACTERIA Jonna Jalanka, FI




12:24 - 12:36 OP113DIFFERENTIAL ENTERIC GLIAL CELL PHENOTYPE IN THEJEJUNUM OF DIARRHOEA-PRONE IRRITABLE BOWELSYNDROME AND ITS ASSOCIATION WITH CLINICALPHENOTYPE AND SYMPTOM SEVERITY Mercé Albert-Bayo, ES12:36 - 12:48 OP114ORO-ANAL TRANSIT IS ASSOCIATED WITH POSTPRANDIALSYMPTOMS, BREATH HYDROGEN AND METHANE INIRRITABLE BOWEL SYNDROME Joost Algera, SE

12:48 - 13:00 OP115EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLYACTING, HIGHLY SELECTIVE, FULL AGONIST OFCANNABINOID RECEPTOR 2, FOR THE TREATMENT OFABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWELSYNDROME: RESULTS FROM A PHASE 2B RANDOMIZEDSTUDY Lin Chang, US

Live Session

12:00 – 13:00 Hall 4Modern management of gastric cancer/premalignantlesionChairs: Florian Lordick, DE

Eric Van Cutsem, BE

12:00 - 12:20 IP183Gastric premalignant lesions: Detection and endoscopictreatment Mario Dinis-Ribeiro, PT

12:20 - 12:40 IP184Minimally invasive gastric cancer surgery Suzanne S. Gisbertz, NL

12:40 - 13:00 IP185New aspects of perioperative therapy: What and forwhom? Anna Dorothea Wagner, CH

Live Session

12:00 – 13:00 Hall 5Managing the obese liver patientChairs: Jude Oben, UK

Gabriella Par, HU

12:00 - 12:30 IP186Current concepts: The role of processed foods and life-style Shira Zelber-Sagi, IL

12:30 - 13:00 IP187Bariatric and metabolic endoscopy management of fattyliver disease Alia Hadefi, BE


12:00 – 13:00 Hall 6IBD: From genes to organoid modelsChairs: Arthur Kaser, UK

Edouard Louis, BE

12:00 - 12:20 IP189Phenotypic, genetic and immunologic diseaseclassification: More than CD and CU Britta Siegmund, DE

12:20 - 12:40 IP190Biomarkers and pathways in disease prediction James C. Lee, UK

12:40 - 13:00 IP191The evolution and benefit of organoid models Azucena Salas, ES

Live Session

12:00 – 13:00 Hall 7Progress in non-invasive biomarkers inhepatology/NAFLDChairs: Laurent Castera, FR

Helena Cortez-Pinto, PT

12:00 - 12:20 IP192Need to define patient pathways Jeffrey Lazarus, ES

12:20 - 12:40 IP193Moving beyond biopsy Quentin Anstee, UK

12:40 - 13:00 IP194Stratification of patients in NASH clinical trials: A pitfallfor trial success Javier Ampuero, ES

Live Session

12:00 – 13:00 Hall 8Quality in Endoscopy: How to raise the bar?Chairs: Michal Filip Kaminski, PL

Matt Rutter, UK

12:00 - 12:20 IP195ERCP Quality Indicators: Can we bring trainees to therequired levels? Gavin Johnson, UK

12:20 - 12:40 IP196Assuring quality and patient safety during corecurriculum training: Is there a price to pay? Siwan Thomas-Gibson, UK




12:40 - 13:00 IP197Colonoscopy: How to cure underperformance? Monika Ferlitsch, AT

Live Demo

12:00 – 13:00 Live Demo RoomUltrasound Course III - Ultrasound of the digestive tractChairs: Dieter Nürnberg, DE

Ioan Sporea, RO

12:00 - 12:15 IP198Ultrasound in acute inflammatory conditions:Diverticulitis, appendicitis Christian Jenssen, DE

12:15 - 12:30 IP199The role of ultrasound in inflammatory bowel diseases(IBD) Kim Nylund, NO

12:30 - 12:45 IP200Ultrasound in digestive tract emergency: Ileus andperforation Dieter Nürnberg, DE




Diversity is the spice of life: Career chat on equality ingrantsChairs: Maude le Gall, FR

Imam A Waked, EGMaria Pellisé Urquiza, ESNektarios Tavernarakis, GR

Recorded only

13:00 – 13:30 Hall 7Rising Stars in liver, biliary and pancreas from Europeand Japan - Part II

13:00 - 13:10 IP201How to become a Rising Star? Takanori Kanai, JP

13:10 - 13:20 IP202Presentation by UEG Rising Star 2021 Xavier Verhelst, BE

13:20 - 13:30 IP203Presentation by JSGE Rising Star 2021 Kenta Yamamoto, JP


13:00 – 14:00 Industry HallIS-10 ABX464, a novel anti-inflammatory drug-candidatefor the treatment of ulcerative colitis


13:30 – 14:30 TV StudioTreatment of refractory autoimmune hepatitis andpancreatitisChairs: Joost P.H. Drenth, NL

Laszlo Czako, HUEmma Culver, UKMarcial Sebode, DE

13:30 - 13:35Introduction Joost P.H. Drenth, NL

13:35 - 13:45 IP204When things go smooth: Autoimmune hepatitismanagement according to plan Emma Culver, UK


14:00 - 14:10 IP205When things go wrong: What to do when first linemanagement fails in autoimmune hepatitis? Christoph Schramm, DE


Live Session

13:30 – 14:30 Hall 1Extraintestinal manifestations of IBDChairs: Britta Siegmund, DE

Stephan Vavricka, CH

13:30 - 13:50 IP206Joint manifestations and their effect on treatmentoptions Gerassimos J. Mantzaris, GR

13:50 - 14:10 IP207PSC: Management and treatment options Martti A. Färkkila, FI

14:10 - 14:30 IP208How to choose therapy for a patient with IBD and skin orjoint comorbidity or both Charlotte R H Hedin, SE




Moderated Poster

13:30 – 14:30 Hall 2IBD: Clinical trials poster IIChairs: Raja Atreya, DE

C. Janneke van der Woude, NL

13:30 - 13:40 MP079LONG-TERM OUTCOMES OF BIOLOGIC THERAPY INCROHN’S DISEASE COMPLICATED WITH INTERNALFISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU Iago Rodríguez-Lago, ES

13:40 - 13:50 MP080PROACTIVE THERAPEUTIC DRUG MONITORING ISSUPERIOR TO STANDARD TREATMENT DURINGMAINTENANCE THERAPY WITH INFLIXIMAB; THERANDOMIZED NOR-DRUM PART B CLINICAL TRIAL Kristin Kaasen Jørgensen, NO

13:50 - 14:00 MP081VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY INELDERLY PATIENTS AND THOSE WITHCONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITHINFLAMMATORY BOWEL DISEASES Mohamed Attauabi, DK

14:00 - 14:10 MP082BENEFIT OF PROLONGED FILGOTINIB DOSING INPATIENTS WITH ULCERATIVE COLITIS WHO DID NOTRESPOND TO INDUCTION THERAPY: DATA FROM THESELECTION LONG-TERM EXTENSION STUDY Severine Vermeire, BE

14:10 - 14:20 MP083VEDOLIZUMAB THERAPEUTIC DRUG MONITORING ANDREAL-WORLD OUTCOMES IN INFLAMMATORY BOWELDISEASE Waqqas Afif, CA


13:30 – 14:30 Hall 4Challenges in daily routine of endoscopy unitsChairs: Tatjana Gjergek, SI


13:30 - 13:42 IP209Why are most colorectal cancers diagnosed in screeningeligible adults detected outside the screeningprogramme? A clinical audit of cases diagnosed at StMark’s Hospital between 2017 and 2020 Andrew Prentice, UK

13:42 - 13:54 IP210A nurses intervention in bowel preparation Maria Coelho, PT

13:54 - 14:06 IP211Nursing quality indicators – are they applicable forendoscopy? Filomena Laurinda Barbosa Da Silva Maia, PT14:06 - 14:18 IP212Endoscopy Nursing Education Programme in Portugal –how can the ESGENA Core Curriculum be adapted in anational education systems? Filomena Laurinda Barbosa Da Silva Maia, PT

14:18 - 14:30 IP213Liver nurses in Austria – how to establish advanced rolesin daily practise Denise Schäfer, AT

Moderated Poster

13:30 – 14:30 Hall 5Oesophageal motilityChairs: Edoardo Vincenzo Savarino, IT

Eivind Ness-Jensen, NO

13:30 - 13:40 MP085CHANGES IN ESOPHAGEAL BODY MOVEMENT AFTERPERORAL ENDOSCOPIC MYOTOMY IN TYPE III ACHALASIA Alex Kim, KR

13:40 - 13:50 MP086PERORAL ENDOSCOPIC MYOTOMY (POEM) FORACHALASIA 6 YEARS LATER: LONG-TERM EFFICACY ANDPOST-POEM REFLUX ANALYSIS IN A SINGLE CENTERSTUDY Zuzana Vackova, CZ

13:50 - 14:00 MP087NOVEL IMPEDANCE-PH PARAMETERS ARE ASSOCIATED TOPROTON PUMP INHIBITOR RESPONSE IN PATIENTS WITHINCONCLUSIVE DIAGNOSIS OF GERD ACCORDING TO LYONCONSENSUS Mentore Ribolsi, IT

14:00 - 14:10 MP088THE EFFECT OF WATER TEMPERATURE ON PRESSURERESPONSES TO THE RAPID DRINK CHALLENGE TESTUSING SOLID STATE SENSORS Claudia Barber Caselles, ES

14:10 - 14:20 MP089EVIDENCE FOR THE ROLE OF IMPAIRED MUCOSALINTEGRITY IN THE GENERATION OF ESOPHAGEAL PAINUSING CAPSAICIN IN HUMANS Annick Alleleyn, NL

14:20 - 14:30 MP090ABNORMAL ESOPHAGEAL ACID EXPOSURE AS A RISKFACTOR FOR ACUTE CORONARY SYNDROME Ji Hea Bang, KR





13:30 – 14:30 Hall 6Endoscopic treatment of upper GI neoplasiaChairs: Bas L.A.M. Weusten, NL

Alanna Ebigbo, DE

13:30 - 13:42 OP116ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'SRELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OFA NATIONWIDE COHORT OF 130 CASES Eva Verheij, NL

13:42 - 13:54 OP117ENDOSCOPIC RESECTION OF SUPERFICIAL ESOPHAGEALNEOPLASIA IN THE CONTEXT OF PORTAL HYPERTENSION:A MULTICENTER OBSERVATIONAL STUDY Mathilde Simonnot, FR

13:54 - 14:06 OP118ENDOSCOPIC LIGATION WITH O-RING CLOSUREINVOLVING MUSCLE LAYER FOR PREVENTING DELAYEDBLEEDING AFTER GASTRIC ENDOSCOPIC SUBMUCOSALDISSECTION UNDER ANTITHROMBOTIC THERAPY Noriko Nishiyama, JP

14:06 - 14:18 OP119ENDOSCOPIC SUBMUCOSAL DISSECTION FORMANAGEMENT OF GASTRIC NEUROENDOCRINE TUMOURS:EXPERIENCE FROM 11 INTERNATIONAL CENTERS Nikolaos Lazaridis

14:18 - 14:30 OP120ENDOSCOPIC BAND LIGATION WITHOUT RESECTION OFSMALL-SIZED SUBEPITHELIAL TUMOURS: RESULTS INLONG-TERM FOLLOW UP OF A MULTICENTREPROSPECTIVE STUDY (BANDING-SET) Francesc Bas-Cutrina, ES

Moderated Poster

13:30 – 14:30 Hall 7Aspects of cirrhosisChairs: Georg Semmler, AT

Christian Labenz, DE

13:30 - 13:40 MP091ANTIBIOTIC PROPHYLAXIS IN CIRRHOSIS PATIENTS WITHUPPER GASTROINTESTINAL BLEEDING: AN UPDATEDSYSTEMATIC REVIEW AND META-ANALYSIS Chin Kimg Tan, SG

13:40 - 13:50 MP092EFFECTIVE ALBUMIN AS A NOVEL BIOMARKER IN THEASSESSMENT OF CHILD-PUGH B AND C LIVER CIRRHOSIS Anastasia Turkina, RU

13:50 - 14:00 MP093SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) INPATIENTS WITH ADVANCED LIVER DISEASE Georg Semmler, AT14:00 - 14:10 MP094CLINICAL SIGNIFICANCE OF SUBSTANTIALLY ELEVATEDVON WILLEBRAND FACTOR ANTIGEN LEVELS IN PATIENTSWITH ADVANCED CHRONIC LIVER DISEASE Katharina Pomej, AT

14:10 - 14:20 MP095EPIDEMIOLOGY OF MULTIDRUG-RESISTANT INFECTIONSIN PATIENTS WITH CIRRHOSIS HOSPITALIZED IN AGASTROENTEROLOGY DEPARTMENT IN PORTUGAL Fátima Nélia Abreu, PT

14:20 - 14:30 MP096USE OF LIVER TRANSIENT ELASTOGRAPHY ON THEPREDICTION OF THE PRESENCE OF OESOPHAGEALVARICES IN PATIENTS WITH COMPENSATED ADVANCEDCHRONIC LIVER DISEASE: IS THE AETIOLOGY RELEVANT? Joana Revés, PT

Moderated Poster

13:30 – 14:30 Hall 8Outcomes in endoscopyChairs: Evelien Dekker, NL

Matt Rutter, UK

13:30 - 13:40 MP097POST-COLONOSCOPY COLORECTAL CANCER: INCIDENCE,CHARACTERISTICS AND PREDICTIVE FACTORS Sandra Baile Maxía, ES

13:40 - 13:50 MP098THE 1L POLYETHYLENE GLYCOL NER1006 BOWELPREPARATION ENABLES PROCEDURE TIME SAVINGS INPOLYP- AND ADENOMA-FREE PATIENTS UNDERGOINGSURVEILLANCE COLONOSCOPY Juha Halonen

13:50 - 14:00 MP099EFFECTIVENESS OF PERFORMING CONTRAST-ENHANCEDCOMPUTED TOMOGRAPHY PRIOR TO EARLYCOLONOSCOPY IN PATIENTS WITH COLONICDIVERTICULAR BLEEDING: A MULTICENTER RANDOMIZEDCONTROLLED TRIAL (CECT-DIVBLEED STUDY) Yuko Sakakibara, JP

14:00 - 14:10 MP100WHAT SIZE CUT-OFF LEVEL SHOULD BE USED TOIMPLEMENT OPTICAL POLYP DIAGNOSIS? Mahsa Taghiakbari, CA

14:10 - 14:20 MP101ENDOSCOPIC PAPILLECTOMY VS.PANCREATICODUODENECTOMY FOR AMPULLARYLESIONS: A PROPENSITY-SCORED MATCHING ANALYSISOF THE ESAP STUDY Marcus Hollenbach, DE




14:20 - 14:30 MP102ENDOCUFF DOES NOT IMPROVE THE RATE OF PATIENTSWITH MISSING POLYPS IN COLONOSCOPY Míriam Gómez Villagrá, ES

Live Demo

13:30 – 15:00 Live Demo RoomUltrasound Live Demo IChairs: Alina Popescu, RO

Roxana Sirli, RO



Feast your eyes: MDT (multidisciplinary team) imagetriviaChairs: Catalina Vladut, RO

Marianna Arvanitakis, BEChristoph Zech, CHDina Tiniakos, UK

Recorded only

14:30 – 15:00 Hall 6Horizon Europe: What is in it for GI Researchers?

14:30 - 14:40 IP214Conquering Cancer, Mission possible Marcis Leja, LV

14:40 - 14:50 IP215Innovative Health Initiative : Opportunity for public-private collaborations Magda Chlebus, BE

14:50 - 15:00 IP216Participation & opportunities for non-EU Countries Ruta Zarnauskaite, BE


14:30 – 15:30 Industry HallIS-11 Connecting the dots: Integrating mechanism ofaction into advanced treatment decisions in UC

Vienna Live Session

15:00 – 16:00 TV StudioGut talk: Lessons learned IIChairs: Marianna Arvanitakis, BE

Joost P.H. Drenth, NL

15:00 - 15:20 IP217When the stones start rolling: Clinical presentation anddiagnostic work up Fredrik Swahn, SE15:20 - 15:40 IP218ABC of endoscopic management Daniel Blero, BE

15:40 - 16:00 IP219When to call the surgeon? Valerio Lucidi, BE

Live Session

15:00 – 16:00 Hall 1Manipulating microbiota as therapeutic strategyChairs: Melanie Schirmer, DE

Harry Sokol, FR

15:00 - 15:20 IP220Can we prevent IBD by targeting the intestinalmicrobiota? Marla C. Dubinsky, US

15:20 - 15:40 IP221Role of microbiota in the treatment of IBD Konrad Aden, DE

15:40 - 16:00 IP222Targeting the microbiota in IBS: From pre- and probioticsto FMT Gerard Clarke, IE


15:00 – 16:00 Hall 2IBD: Clinical trials IIIChairs: Stavros Antoniou, CY

Christian Maaser, DE

15:00 - 15:12 OP121SAFETY, PHARMACOKINETICS, AND IMMUNOLOGICALEFFECTS OF OMILANCOR (BT-11) IN A PHASE 2RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLEDTRIAL OF PATIENTS WITH ULCERATIVE COLITIS Josep Bassaganya-Riera, US

15:12 - 15:24 OP122HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMABVERSUS ADALIMUMAB FOR INDUCTION ANDMAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTSWITH MODERATE-TO-SEVERE CROHN'S DISEASE:PROMIS-29 IN THE SEAVUE STUDY Matthieu Allez, FR




15:24 - 15:36 OP123PROGNOSTIC VALUE OF INTESTINAL ULTRASOUNDPARAMETERS FOR LONG-TERM OUTCOMES IN IBDPATIENTS – ONE YEAR INTERIM RESULTS OF THE TRUSTBEYOND STUDY Torsten Kucharzik, DE15:36 - 15:48 OP124ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISINGSYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, ANDMOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OFGB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR(HIF)-1Α STABILIZER, IN MILD-TO-MODERATE ULCERATIVECOLITIS Silvio Danese, IT

15:48 - 16:00 OP125AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPYINDUCES CLINICAL RESPONSE IN PATIENTS WITHMODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TOACHIEVE CLINICAL RESPONSE AFTER AN INITIALINDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWOPHASE 3 STUDIES Geert R. D'Haens, NL

Live Session

15:00 – 16:00 Hall 3Barrett's oesophagus: What's hot?Chairs: Oliver Pech, DE

Manon C.W. Spaander, NL

15:00 - 15:20 IP223Barrett's pathology and biomarkers: Towards a newstandard? Rebecca Clare Fitzgerald, UK

15:20 - 15:40 IP224Artificial intelligence in Barrett. Is this the future? Alanna Ebigbo, DE

15:40 - 16:00 IP225Endoscopic mucosal resection in Barrett: Indications andcontroversies Prateek Sharma, US


15:00 – 16:00 Hall 4Improving the understanding of oesophageal sensitivityand motilityChairs: C Prakash Gyawali, US

Henriette Heinrich, CH

15:00 - 15:12 OP126EVIDENCE FOR ENGAGEMENT OF THE NUCLEUS OF THESOLITARY TRACT IN PROCESSING INTESTINALCHEMONOCICEPTIVE INPUT IRRESPECTIVE OFCONSCIOUS PAIN RESPONSE IN HEALTHY HUMANS Bram Beckers, NL

15:12 - 15:24 OP127RNA SEQUENCING OF THE OESOPHAGEAL MUCOSA OFPATIENTS WITH HEARTBURN IDENTIFIES DENDRITIC CELLPOPULATION IN FUNCTIONAL HEARTBURN Ahsen Ustaoglu15:24 - 15:36 OP128GLOBAL PREVALENCE AND IMPACT OF RUMINATIONSYNDROME Axel Josefsson, SE

15:36 - 15:48 OP129RAPID DRINK CHALLENGE DURING HIGH RESOLUTIONMANOMETRY: A CLINICALLY USEFUL SURROGATE FORTIMED BARIUM EOPHAGOGRAM IN PREDICTINGESOPHAGEAL EMPTYING IN TREATED ACHALASIAPATIENTS Roberto Penagini, IT

15:48 - 16:00 OP130EGJ OUTFLOW OBSTRUCTION ACCORDING TO THE NEWCHICAGO CLASSIFICATION. HOW MANY DIAGNOSES MIGHTBE CONFIRMED? Pierfrancesco Visaggi, IT


15:00 – 16:00 Hall 5Improving the outcome of acute pancreatitisChairs: Gabriele Capurso, IT

Matthias Löhr, SE

15:00 - 15:12 OP131URGENT ENDOSCOPIC ULTRASOUND-GUIDED ERC INPREDICTED SEVERE ACUTE BILIARY PANCREATITIS(APEC-2): A MULTICENTER PROSPECTIVE STUDY Nora D Hallensleben, NL

15:12 - 15:24 OP132EFFECT OF ENDOSCOPIC TRANSPAPILLARY BILIARYDRAINAGE WITH/WITHOUT ENDOSCOPICSPHINCTEROTOMY ON POST-ENDOSCOPIC RETROGRADECHOLANGIOPANCREATOGRAPHY PANCREATITIS INPATIENTS WITH BILIARY STRICTURE (E-BEST): AMULTICENTER RANDOMIZED CONTROLLED TRIAL Shin Kato, JP

15:24 - 15:36 OP133LACTATED RINGER’S SOLUTION IN COMBINATION WITHRECTAL INDOMETHACIN PREVENTS EFFICIENTLY POST-ERCP PANCREATITIS IN PATIENTS AT HIGH-RISK : APROSPECTIVE RANDOMIZED, DOUBLE-BLINDED,CONTROLLED TRIAL Khellaf Amalou, DZ

15:36 - 15:48 OP134ORAL N-ACETYL CYSTEINE VERSUS RECTALINDOMETHACIN FOR PREVENTION OF POST ERCPPANCREATITIS: A MULTICENTER MULTINATIONALRANDOMIZED CONTROLLED TRIAL Omar Elshaarawy, UK




15:48 - 16:00 OP135PREDICTIVE SCORE OF DELAYED COMPLICATIONS INNECROTIZING ACUTE PANCREATITIS Maxime Gasperment, FR

Live Session

15:00 – 16:00 Hall 6Career beasts and how to cope with themChairs: Michael Farthing, UK

Catalina Vladut, RO

15:00 - 15:20 IP226First aid: Recognise a toxic work environment Omar Elshaarawy, UK

15:20 - 15:40 IP227Tame the beasts and put the palace in order Maria Sharkova, BG

15:40 - 16:00 IP228Effectively moving forward: Shining without diminishing Marla C. Dubinsky, US


15:00 – 16:00 Hall 7Liver diseases: From bench to bedsideChairs: Michele Vacca, IT

Pau Sancho-Bru, ES

15:00 - 15:15 OP136THE ROLES OF TUMOUR SELF-SEEDED CELLS IN LIVERCANCER PROGRESSION Haotian Yang, AU

15:15 - 15:30 OP137LONG NON-CODING MEG-3 CONJUGATEDNANOPARTICLES AS A NOVEL THERAPEUTIC TOOL IN AMURINE MODEL OF HEPATOCELLULAR CARCINOMA Mohamed Elzallat, EG

15:30 - 15:45 OP138THE NOVEL FARNESOID X RECEPTOR LIGAND TC-100PROTECTS FROM LIVER INJURY VIA MODULATION OF THEINTESTINAL MICROBIOTA Raffaella Gadaleta, IT

15:45 - 16:00 OP139TRANSCRIPTOME ANALYSIS OF HUMAN LIVERS EXPLANTSFROM ALCOHOL-ASSOCIATED LIVER DISEASESHIGHLIGHTS A LOSS OF PERICENTRAL ANDPROLIFERATION GENE EXPRESSION Helene Baribault, US

Live Session

15:00 – 16:00 Hall 8Endoscope contamination and patient infections: Burdenand measures for preventionChairs: Ulrike Beilenhoff, DE

Marco J. Bruno, NL

15:00 - 15:10 IP229How to contain the risk of re-usable scope contaminationwith optimal reprocessing Margreet C. Vos, NL

15:10 - 15:20 IP230Biofilm in re-usable endoscopy: Can it be dealt with? Axel Eickhoff, DE

15:20 - 15:30 IP231Disposable endoscopes are the solution to eliminate theissue of scope contamination Andrew S. Ross, US

Live Demo

16:00 – 17:30 Live Demo RoomUltrasound Live Demo IIChairs: Christian Jenssen, DE

Dieter Nürnberg, DEAlina Popescu, ROIoan Sporea, RO


16:00 – 17:00 Industry HallIS-12 Evolving treatment goals and unmet needs inulcerative colitis: how to address the gaps?


16:30 – 17:30 TV StudioLower GI symptoms in infectious diseaseChairs: Shomron Ben-Horin, IL

Franck Carbonnel, FRSibylle Koletzko, DEEls Van Nood, NL

16:30 - 16:32Introduction Shomron Ben-Horin, IL

16:32 - 16:41 IP232Case presentation 1 Sibylle Koletzko, DE





16:51 - 17:00 IP233Case presentation 2 Els Van Nood, NL17:00 - 17:10Panel discussion

17:10 - 17:14 IP234Case presentation 3 Franck Carbonnel, FR


Live Session

16:30 – 17:30 Hall 1IBD drug safety: Update 2021Chairs: Irit Avni-Biron, IL

Dana Duricova, CZ

16:30 - 16:40 IP235The ideal checklist: Addressing non-infectious drugcomplications in 2021 Marcus Harbord, UK

16:40 - 16:50 IP236The ideal checklist: Addressing infectious drugcomplications in 2021 Stephan Vavricka, CH

16:50 - 17:10Q&A

17:10 - 17:30 IP237COVID-19: Lessons learned Fernando Magro, PT

Live Session

16:30 – 17:30 Hall 2GI training and competence: What's new in 2021?Chairs: Henriette Heinrich, CH

Frank Tacke, DE

16:30 - 16:50 IP238"When I grow up, I want to be a pancreatologist!": Therole of continuous learning in gastroenterology Giovanni Marchegiani, IT

16:50 - 17:10 IP239In quest of abolishing gastroenterological surgerycomplications Ville Sallinen, FI

17:10 - 17:30 IP240Training in endoscopy Paraskevas Gkolfakis, BE

Live Session

16:30 – 17:30 Hall 3Dysphagia in benign disordersChairs: Tim Vanuytsel, BE

Rena Yadlapati, US

16:30 - 16:50 IP241Diagnostic approach: New insights Edoardo Vincenzo Savarino, IT

16:50 - 17:10 IP242Benign oesophageal stricture Manon C.W. Spaander, NL

17:10 - 17:15 IP243Achalasia: What is the best treatment? Dilatation? Guy E. Boeckxstaens, BE

17:15 - 17:20 IP244Achalasia: What is the best treatment? Myotomy? Thomas Rösch, DE

17:20 - 17:30Q&A

Live Session

16:30 – 17:30 Hall 4Upper GI bleeding: What's new in 2021?Chairs: Roberta Maselli, IT

Helmut Messmann, DE

16:30 - 16:50 IP245Variceal bleeding Lars Aabakken, NO

16:50 - 17:10 IP246Non variceal bleeding Ian Mark Gralnek, IL

17:10 - 17:30 IP247Role of radiology in diagnosis and treatment Kelvin Cortis, MT


16:30 – 17:30 Hall 5Pancreatic diseases: From bench to bedsideChairs: Pilar Acedo, UK

Vinciane Rebours, FR

16:30 - 16:42 OP141A PROSPECTIVE FEASIBILITY TRIAL TO CHALLENGEPATIENT-DERIVED PANCREATIC CANCER ORGANOIDS INPREDICTING TREATMENT RESPONSE Alica Katrin Beutel, DE




16:42 - 16:54 OP142ATM AND P53 AUTONOMOUS ROLES DURING PANCREATICCANCER TUMORIGENESIS Johann Gout, DE16:54 - 17:06 OP143INTERPLAY OF ORAI1 CA2+ CHANNEL AND CYSTIC FIBROSISTRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INEPITHELIAL PHYSIOLOGY Arpad Varga, HU

17:06 - 17:18 OP144IMPACTS OF SYSTEMIC BILE ACIDS IN ACUTEPANCREATITIS DEPEND ON THEIR HYDROPHOBICITY ANDMAY RESULT FROM THEIR INTERACTION WITH CCK1RECEPTOR Quang Trung Tran, DE

17:18 - 17:30 OP145ROBO1 SUPPORTS ACTIN RICH STRUCTURES INPANCREATIC TUMOR CELLS WITH PARTICULAR EFFECTSON RHOA ACTIVITY AT ADHERENS JUNCTIONS Ilse Rooman, BE

Live Session

16:30 – 17:30 Hall 6Metabolomics: Time to shine!Chairs: Jörn Schattenberg, DE

Eytan Wine, CA

16:30 - 16:50 IP248Road to metastasis beyond gene damage: Spotlight onEMT Luigi Andrea Laghi, IT

16:50 - 17:10 IP249Metabolites determine the effects of IBD diets and may bethe gate to specific therapy Lihi Godny, IL

17:10 - 17:30 IP250Functional implications of gut microbial metabolismalteration in PSC Johannes Roksund Hov, NO

Live Session

16:30 – 17:30 Hall 7Elimination of chronic viral hepatitis: What's new in2021?Chairs: Alessio Aghemo, IT

Stefan Zeuzem, UK

16:30 - 16:50 IP251Early HBV infection in infancy induces changes in thememory B cell compartment and HBV-specific B cellresponses Sabela Lens, ES

16:50 - 17:10 IP252Chronic hepatitis B and delta Heiner Wedemeyer, DE17:10 - 17:30 IP253Chronic hepatitis C Jean-Michel Pawlotsky, FR


16:30 – 17:30 Hall 8Endoscopic management of hereditary and inflammatoryconditionsChairs: Maria Pellisé Urquiza, ES

Matt Rutter, UK

16:30 - 16:42 OP146MUTYH-ASSOCIATED POLYPOSIS: GENOTYPE-PHENOTYPECORRELATIONS Pedro Currais, PT

16:42 - 16:54 OP147SIZE AND MULTIPLICITY ARE RISK FACTORS FOR THERECURRENCE OF HIGH-RISK ADENOMAS IN ACOLORECTAL CANCER SCREENING COHORT Jasmin Zessner-Spitzenberg, AT

16:54 - 17:06 OP148OUTCOMES FOLLOWING DUODENECTOMY IN PATIENTSWITH FAMILIAL ADENOMATOUS POLYPOSIS Isabel Martin

17:06 - 17:18 OP149RESPONSE TO BIOLOGICS IN IBD PATIENTS ASSESSED BYCOMPUTERIZED IMAGE ANALYSIS OF PROBE BASEDCONFOCAL LASER ENDOMICROSCOPY WITH MOLECULARLABELING Marietta Iacucci, UK

17:18 - 17:30 OP150DEVELOPMENT OF NOVEL COMPUTER-ASSISTEDDIAGNOSIS SYSTEM FOR ENDOSCOPIC DISEASE ACTIVITYIN PATIENTS WITH ULCERATIVE COLITIS Noriyuki Ogata, JP



Superfood for thought (prepping the future of education)Chairs: Charles Murray, UK

Sophia Eugenia Hodgkinson, ITHashem Al-Ghaili, DE





17:30 – 18:30 Industry HallIS-13 Targeting IL-12/23 in ulcerative colitis: fromevidence to bedside

Vienna Live Session

18:00 – 19:00 TV StudioUEG Research Prize 2021 SessionChairs: Rebecca Clare Fitzgerald, UK

Berthold Koletzko, DELuigi Ricciardiello, IT

18:00 - 18:12 LB16CELIACSHIELDTM GLUTEN-CHALLENGE STUDY –LATIGLUTENASE PROTECTS THE MUCOSA ANDATTENUATES SYMPTOMS IN CELIAC DISEASE PATIENTS Jennifer Sealey Voyksner, US

18:12 - 18:24 LB17INCREASED RATE OF COLORECTAL CANCER IN PATIENTSWITH ULCERATIVE COLITIS: A NATIONAL COHORT STUDYBETWEEN 1991-2020 Lianne Heuthorst, NL

18:24 - 18:44 IP254UEG Research Prize 2021: Repurposing mitochondria-protective targets for adjuvant IBD therapy Dirk Haller, DE

Expert Encore

18:00 – 19:30 Hall 1STRIDE 2.0: Treatment goals in IBDChairs: Axel Dignass, DE

Severine Vermeire, BE

18:00 - 18:20 IP257Transmural healing in small intestinal Crohn's disease Irit Avni-Biron, IL

18:20 - 18:40 IP255From STRIDE 1 to STRIDE 2: Evidence for changes Laurent Peyrin-Biroulet, FR

18:40 - 19:00 IP256Patient perspective: Optimal care Kay Greveson, UK


Live Session

18:00 – 19:00 Hall 4Multidisciplinary treatment of oesophageal cancerChairs: Suzanne S. Gisbertz, NL

Jean-Luc Van Laethem, BE

18:00 - 18:20 IP258Management of dysphagia and nutrition support prior totx Kinga Szczepanek, PL

18:20 - 18:40 IP259Management of early oesophageal cancer: Endoscopiceradication therapy and surveillance after endoscopictherapy Roos E. Pouw, NL

18:40 - 19:00 IP260Enhanced recovery after surgery (ERAS) afteresophagectomy Richard Van Hillegersberg, NL

Live Session

18:00 – 19:00 Hall 5Early strategies in acute pancreatitisChairs: Enrique de-Madaria, ES

Robert Sutton, UK

18:00 - 18:20 IP261Targeting inflammation in early AP: Are we ready forclinical trials? Julia Mayerle, DE

18:20 - 18:40 IP262Catabolism and prevention of infection: Strategies forearly nutrition Peter Hegyi, HU

18:40 - 19:00 IP263Endoscopic management of biliary pancreatitis: Timing ofERCP and role of EUS Marco J. Bruno, NL


18:00 – 19:00 Hall 6What is new in fibrosis?Chairs: Gerhard Rogler, CH

Detlef Schuppan, DE

18:00 - 18:20 IP264The fibroblast: Friend or foe? Fabio Marra, IT




18:20 - 18:40 IP265Intestinal fibrosis in IBD Florian Rieder, US18:40 - 19:00 IP266The fibrotic liver: Triggers and players Frank Tacke, DE

Expert Encore

18:00 – 19:30 Hall 7Rare liver diseasesChairs: Marco Carbone, IT

Ansgar W. Lohse, DE

18:00 - 18:20 IP267Management of Wilson's Disease Uta Merle, DE

18:20 - 18:40 IP268A paradigm shift towards personalised medicine inprimary biliary cholangitis Marco Carbone, IT

18:40 - 19:00 IP269Bile acid/phospholipid transporter defects Verena Keitel-Anselmino, DE


Expert Encore

18:00 – 19:30 Hall 8Therapy update: Upper GI interventional endoscopyChairs: Jacques Deviere, BE

Jeanin E. van Hooft, NL

18:00 - 18:20 IP270Bariatric interventions: Endoscopic procedures Ivo Boskoski, IT

18:20 - 18:40 IP271Barrett neoplasia: EMR or ESD? Pierre Henri Deprez, BE

18:40 - 19:00 IP272Full thickness resection Philip Wai Yan Chiu, HK




Tasty takeaways: The power of questions with IsabelleCleynenChairs: Iris Dotan, IL

Isabelle Cleynen, BE

Vienna Live Session

19:00 – 19:30 TV StudioThe UEG Week Tonight Show IIChairs: Magnus Simrén, SE

Joost P.H. Drenth, NLDirk Haller, DEWafaa Khannoussi, MALuigi Ricciardiello, ITNicolas Richard, FR


19:00 – 20:00 Industry HallIS-14 Weighing up treatment options in UC: how do weinterpret the evidence for JAK inhibition?



UEG Week Final Programme Tuesday, October 5, 2021

Scientific Programme by DayTuesday, October 5, 2021

Vienna Live Session

08:00 – 09:00 TV StudioUEG Week Digested IIChairs: Herbert Tilg, AT

Iris Dotan, ILHenriette Heinrich, CHJulia Mayerle, DEWafaa Khannoussi, MA

Live Session

09:00 – 10:00 TV StudioMistakes in...IIIChairs: Charles Murray, UK

09:00 - 09:10 IP273Mistakes in abnormal LFTs Joost P.H. Drenth, NL

09:10 - 09:20 IP274Mistakes in liver transplantation Patrizia Burra, IT

09:20 - 09:30 IP275Mistakes in cystic lesions of the pancreas Juan Enrique Dominguez-Munoz, ES



09:00 – 10:00 Hall 1IBD drug efficacy and safetyChairs: Silvio Danese, IT

Arthur Kaser, UK

09:00 - 09:12 OP151INTRAVENOUS ADMINISTRATION OF FLUORESCENTLYLABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCALDRUG DISTRIBUTION AND PHARMACODYNAMICS ININFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY Ruben Yannick Gabriëls, NL

09:12 - 09:24 OP152TOFACITINIB FOR THE TREATMENT OF ULCERATIVECOLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBALCLINICAL TRIALS Julian Panés, ES

09:24 - 09:36 OP153EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS INPATIENTS THROUGH 3 YEARS: UNIFI LONG-TERMEXTENSION David Rowbotham, NZ09:36 - 09:48 OP154RAPIDITY OF SYMPTOM IMPROVEMENTS DURINGFILGOTINIB INDUCTION THERAPY IN PATIENTS WITHULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE2B/3 SELECTION STUDY Silvio Danese, IT

09:48 - 10:00 OP155EFFICACY AND SAFETY OF ELECTIVE SWITCHING OFINFLAMMATORY BOWEL DISEASE PATIENTS FROMINTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY Philip Smith

Live Session

09:00 – 10:00 Hall 2Update on diverticulitis: Controversis and challengesChairs: Willem A. Bemelman, NL

09:00 - 09:20 IP276Is it time to adpot a non-antibiotic management? A lookat data, guidelines & more Nader K Francis, UK

09:20 - 09:40 IP277Abdominal pain and diverticulosis: SUDD, SCAD, orsmoldering diverticulitis Adi Lahat, IL

09:40 - 10:00 IP278Quality of life in uncomplicated recurred diverticulitis:When to operate? Dieter Hahnloser, CH


09:00 – 10:00 Hall 3Innovation in biliopancreatic endoscopyChairs: Paolo Giorgio Arcidiacono, IT

Paraskevas Gkolfakis, BE

09:00 - 09:12 OP156ARTIFICIAL INTELLIGENCE AND DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY: AUTOMATICIDENTIFICATION OF TUMOR VESSELS IN PATIENTS WITHINDETERMINATE BILIARY STRICTURES Tiago Ribeiro, PT




09:12 - 09:24 OP157COMPARISON OF THE DIAGNOSTIC ACCURACY OFCHOLANGIOSCOPY, CYTOLOGY, BIOPSIES AND ANCILLARYTECHNIQUES IN INDETERMINATE BILIARY STRICTURE: AMONOCENTRIC RETROSPECTIVE EXPERIENCE Marcantonio Gesualdo, IT09:24 - 09:36 OP158COMPARISON OF 19G VS 22G FRANSEEN-TIP-EUS-FNBDEVICE FOR PATIENT DERIVED ORGANOID (PDO) YIELDFROM PRIMARY PANCREATIC CANCER: A PROSPECTIVECONTROLLED STUDY Georg Beyer, DE

09:36 - 09:48 OP159ARTIFICIAL INTELLIGENCE AND DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY: AUTOMATICIDENTIFICATION OF PAPILLARY PROJECTIONS INPATIENTS WITH INDETERMINATE BILIARY STENOSIS Miguel Jose Mascarenhas Saraiva, PT

09:48 - 10:00 OP160BIO-DEGRADABLE STENTS IN BILIARY AND PANCREATICDISEASE Andreas Maieron, AT


09:00 – 10:00 Hall 4Gastric cancer spreading: What are the risks?Chairs: Tamara Matysiak-Budnik, FR

Marcis Leja, LV

09:00 - 09:12 OP161INCREASED RISK OF GASTRIC AND PANCREATICADENOCARCINOMA ASSOCIATED TO HEREDITARY BREASTAND OVARIAN CANCER SYNDROME Joan Llach, ES

09:12 - 09:24 OP162GENOTYPE-PHENOTYPE ASSOCIATIONS PROVIDE ARATIONAL TO IDENTIFY POTENTIALLY ACTIONABLE VUS José García Peláez, PT

09:24 - 09:36 OP163RISK FACTORS FOR METACHRONOUS CANCER IN THEREMNANT STOMACH AMONG 3,706 PATIENTS WHORECEIVED GASTRIC CANCER SURGERY IN KOREA Yonghoon Choi, KR

09:36 - 09:48 OP164ABERRANT DNA METHYLATION MAKER FOR PREDICTINGMETACHRONOUS RECURRENCE AFTER ENDOSCOPICRESECTION OF GASTRIC NEOPLASMS Cheol-Min Shin, KR

09:48 - 10:00 OP165RISK FACTORS OF METACHRONOUS PERITONEALMETASTASIS AFTER POTENTIALLY CURATIVE GASTRICCANCER RESECTION IN THE CRITICS TRIAL Irene A. Caspers, NL

Live Session

09:00 – 10:00 Hall 5Therapy update: Prevention of severe acute pancreatitisChairs: Marianna Arvanitakis, BE

Albrecht Neesse, DE

09:00 - 09:20 IP279How to predict the severity of AP: Is it time to use artificialintelligence? Peter Hegyi, HU

09:20 - 09:40 IP280Fluid resustitation and nutrition: When, what and howmuch? Enrique de-Madaria, ES

09:40 - 10:00 IP281Which patients benefit from early ERCP? Nicolien Schepers, NL


09:00 – 10:00 Hall 6Biomarkers and improved medical managementChairs: Raja Atreya, DE

09:00 - 09:20 IP282Barrett's oesophageal CA Sheila Krishnadath, BE

09:20 - 09:40 IP283Predictors of response IBD Severine Vermeire, BE

09:40 - 10:00 IP284Biomarkers for early pancreatic cancer Patrick Michl, DE


09:00 – 10:00 Hall 7Endoscopy and surgery outcomesChairs: Ian Mark Gralnek, IL

09:00 - 09:12 OP166SINGLE DOSE VERSUS NO ANTIBIOTIC PROPHYLAXIS INTHE TREATMENT OF ACUTE CHOLECYSTITIS (PEANUTS II):MULTICENTER RANDOMIZED NON-INFERIORITY TRIAL Willemieke G van Braak, NL

09:12 - 09:24 OP167PERITUMORAL MICROENVIRONMENT AS A PREDICTOR OFANASTOMOTIC LEAK AFTER SURGERY FOR RECTALCANCER Ottavia De Simoni, IT




09:24 - 09:36 OP168THE PRESENCE OF ON-CALL ENDOSCOPY NURSESDECREASES 30-DAY MORTALITY IN PATIENTS WHOREQUIRE OUT-OF-OFFICE HOUR EMERGENCYESOPHAGOGASTRODUODENOSCOPY (EGD) Shannon Chan, HK09:36 - 09:48 OP169COLORECTAL CANCER INCIDENCE WITHIN 10 YEARSAMONG ONE MILLION PERSONS UNDERGOING SCREENINGCOLONOSCOPY: A CLAIMS DATA ANALYSIS Sarina Schwarz, DE

09:48 - 10:00 OP170PRIORITISATION OF LOWER GASTROINTESTINALENDOSCOPY DURING THE COVID-19 PANDEMIC:OUTCOMES OF A NOVEL TRIAGE PATHWAY Thomas Archer, UK

Live Session

09:00 – 10:00 Hall 8A changing view on nutritional approachChairs: Cristina Cuerda, ES

Loris Pironi, IT

09:00 - 09:20 IP285Nutrition status affects COVID-19 patient outcomes Ioav Cabanchik, IL

09:20 - 09:40 IP286Nutrition and physical activity: The best supportive carein cancer? Cindy Neuzillet, FR

09:40 - 10:00 IP287A place for prebiotics and probiotics in obese patients ? Nathalie Delzenne, BE

Live Demo

09:00 – 10:00 Live Demo RoomLive Endoscopy IChairs: Mario Dinis-Ribeiro, PT

Haruhiro Inoue, JPMaria Pellisé Urquiza, ESLars Aabakken, NOUlrike Walburga Denzer, DECesare Hassan, ITHelmut Messmann, DEManuel Pérez-Miranda, ESJulius Spicak, CZJan Martinek, CZOndrej Urban, CZZuzana Vackova, CZ

E-Poster Session







09:00 - 09:00 P0227THERAPEUTIC POTENTIAL OF TNK1 IN PREVENTION ANDHEALING OF INTESTINAL BARRIER BREACH Hongxia Li, DE

09:00 - 09:00 P0228THE VARIATIONS OF GUT MICROBIOME FROM ULCERATIVECOLITIS PATIENTS ARE NOT AS GREAT AS EXPECTED Chen Li, CN







09:00 - 09:00 P0232IS VITAMIN D DEFICIENCY RELATED TO FATMALABSORPTION OR INFLAMMATION IN INFLAMMATORYBOWEL DISEASE? PRELIMINARY RESULTS FROM THE FAT-D STUDY Aysegül Aksan, DE09:00 - 09:00 P0233SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORINGEPITHELIAL INTEGRITY AND MITIGATING COLITIS IN ACHRONIC DSS MODEL Priya Handa, US




09:00 - 09:00 P0237ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OFPERSISTENT HISTOLOGICAL ACTIVITY DESPITEENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITHBIOLOGICS Vedran Tomasic, HR

09:00 - 09:00 P0238HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZELUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS Sarit Cohen-Kedar, IL




09:00 - 09:00 P0242CROHN’S DISEASE ASSOCIATED FIBROSIS MODULATESTHE EXPRESSION OF COLLAGEN RECEPTORS Cristina Bauset, ES09:00 - 09:00 P0243SUCCINATE RECEPTOR (SUCNR1) MEDIATES LEUKOCYTE-ENDOTHELIAL CELL INTERACTIONS INDUCED BY TNFΑ Cristina Bauset, ES




09:00 - 09:00 P0247EXPRESSION PROFILING OF WNT PATHWAY GENES INCOLON BIOPSIES OF PATIENTS WITH ULCERATIVE COLITISAND CROHN’S DISEASE Chenggang Lu, US

09:00 - 09:00 P0248FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINALMUCOSAL HEALTH VIA HIF1Α-INDUCED EPITHELIALPRODUCTION OF IL-18 Raphael Fagundes Rosa, NL








09:00 - 09:00 P0253IMPACT OF EXCLUSIVE ENTERAL NUTRITION ONINTESTINAL HOMEOSTASIS IN A MOUSE MODEL OFCOLITIS Kawthar Boumessid, FR09:00 - 09:00 P0254ROLE OF P2X7 IN INTESTINAL FIBROSIS ANDINFLAMMASOME ACTIVATION: RELEVANCE IN CROHN´SDISEASE Cristina Bauset, ES



09:00 - 09:00 P0257CHARACTERIZATION OF CYTOKINE AND DRUGCONCENTRATIONS IN SERUM, MUCOSA AND FAECESDURING INDUCTION TREATMENT OF SEVERE ULCERATIVECOLITIS WITH INFLIXIMAB Joep van Oostrom, NL

09:00 - 09:00 P0258VOLUNTARY EXERCISE COMBINED WITH CONCOMITANTALKALINE PHOSPHATASE TREATMENT RESOLVESEXPERIMENTAL COLITIS IN OBESE MICE BY IMPROVINGCOLONIC MICROCIRCULATION AND ATTENUATINGINFLAMMATION, OXIDATIVE STRESS, AND RESTORATIONOF ADIPONECTIN/LEPTIN RATIO Marcin Magierowski, PL





09:00 - 09:00 P0264VACCINATION STRATEGIES IN INFLAMMATORY BOWELDISEASE PATIENTS: PERSPECTIVE OF PHYSICIANS ANDPATIENTS. Rocío Ferreiro-Iglesias, ES09:00 - 09:00 P0265SARS-COV-2 VACCINE ACCEPTANCE AMONGGASTROENTEROLOGIST AND INFLAMMATORY BOWELDISEASE PATIENTS: VACUNEII PROJECT Alejandro Hernandez Camba, ES


09:00 - 09:00 P0267INFLAMMATORY BOWEL DISEASE (IBD) ANDIMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSISOF COVID-19. RESULTS FROM THE ENEIDA PROJECT OFGETECCU Yamile Zabana Abdo, ES

09:00 - 09:00 P0268COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTORBUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASETHE RISK OF COVID-19 IN INFLAMMATORY BOWELDISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROLSTUDY Yamile Zabana Abdo, ES









09:00 - 09:00 P0274THE ASSOCIATION BETWEEN FAECAL SHORT-CHAIN FATTYACIDS CONCENTRATION AND THE CLINICAL ACTIVITY OFULCERATIVE COLITIS AND CROHN’S DISEASE -PRELIMINARY STUDY Olga Kaczmarczyk, PL09:00 - 09:00 P0275SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS ARISK FACTOR FOR SEVERE COVID-19: DATA FROM THESICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE(SN-IBD) Fabio Salvatore Macaluso, IT


09:00 - 09:00 P0277VACCINATION AGAINST SARS-COV-2 IN IBD: ACCEPTANCEAND CONCERNS IN A COHORT FROM SOUTHERN ITALY Federica Crispino, IT

09:00 - 09:00 P0278INCIDENCE AND EVOLUTION OF SARS-COV2 INFECTION INPATIENTS WITH INFLAMMATORY BOWEL DISEASE INSOUTHERN SPAIN (ANDALUSIA) Beatriz Gros Alcalde, ES






09:00 - 09:00 P0284CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADICINFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERAOF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROMTHE ENEIDA REGISTRY Carlos González-Muñoza, ES09:00 - 09:00 P0285ANTIOXIDANT VITAMINS AND ELECTROLYTES INCREASEDINTAKE IS ASSOCIATED WITH LOWER DISEASE ACTIVITYAND BETTER QUALITY OF LIFE IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Ioanna Pefkianaki, GR


09:00 - 09:00 P0287IMPACT OF INFLAMMATORY BOWEL DISEASES ON THEPHENOTYPE AND SEVERITY OF PRIMARY SCLEROSINGCHOLANGITIS - A SYSTEMATIC REVIEW WITH META-ANALYSIS Mohamed Attauabi, DK

09:00 - 09:00 P0288CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWELDISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME Marta Vernero, IT









09:00 - 09:00 P0294PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOULDBE VACCINATED AGAINST PNEUMOCOCCUS ANDINFLUENZA DESPITE IMMUNOSUPPRESSIVE THERAPY Dóra Dohos, HU09:00 - 09:00 P0295PREDICCT COHORT BASELINE HABITUAL NUTRIENTINTAKE BY IBD PATIENTS Janet Kyle


09:00 - 09:00 P0297TRANSFORMATION OF FECAL MICROBIOTA COMPOSITIONDUE TO BOWEL PREPARATION WITH MAGNESIUM-OXIDAND SODIUM PICOSULFATE AMONGST PATIENTS WITHINFLAMMATORY BOWEL DISEASE Mariann Rutka, HU

09:00 - 09:00 P0298NON-IBD CHANGES IN THE ORAL MUCOSA IN PATIENTSWITH INFLAMMATORY BOWEL DISEASES. A CROSSSECTIONAL STUDY IN POLISH PATIENTS Rafał Filip, PL






09:00 - 09:00 P0304THE APA I POLYMORPHISM IN THE VITAMIN D RECEPTORGENE IS ASSOCIATED WITH A STRICTURING BEHAVIOUR INCROHN´S DISEASE PATIENTS Cristina Bauset, ES09:00 - 09:00 P0305PECULIARITIES OF FATTY ACID PROFILES OFERYTHROCYTE MEMBRANES AND BLOOD SERUMDEPENDING ON ACTIVITY RATE OF CROHN’S DISEASE Margarita Vitalievna Kruchinina, RU

09:00 - 09:00 P0306COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITHLOWER DISABILITY THAN PARTIAL MUCOSAL HEALING INCROHN’S DISEASE: A PROSPECTIVE MULTICENTRICSTUDY. Clara Yzet, FR

09:00 - 09:00 P0307TELEDERMA: TELEMEDICINE SYSTEM FORDERMATOLOGICAL LESIONS IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Marta Ramos Alonso, ES










09:00 - 09:00 P0314CORRELATION OF EX VIVO MUCOSAL CYTOKINE PROFILESWITH CLINICAL AND ENDOSCOPIC SCORES IN ULCERATIVECOLITIS Vesna Eraković Haber, HR09:00 - 09:00 P0315IMPACT OF INFLAMMATORY BOWEL DISEASE IN PEDIATRICPATIENTS AND THEIR FAMILIES ACCORDING TO DISEASECONTROL Laura María Palomino Pérez, ES

09:00 - 09:00 P0316THE USE OF PANENTERIC CROHN’S CAPSULES TO ASSESSTREATMENT OUTCOME OF VEDOLIZUMAB IN IBDPATIENTS: A 1 YEAR PROOF OF CONCEPT STUDY Matthew Johnson

09:00 - 09:00 P0317THE OUTCOME OF COLONOSCOPIC SURVEILLANCE ANDSURGERY IN A COHORT OF INFLAMMATORY BOWELDISEASE PATIENTS WHO DEVELOPED COLO-RECTALCANCER OVER A 12 YEAR REVIEW PERIOD AT A DISTRICTGENERAL HOSPITAL John Wye, UK







09:00 - 09:00 P0325CORRELATION OF THE FIRST LATERAL FLOW-BASEDPOINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITHTHE REFERENCE ELISA TECHNIQUE M. Begoña Ruiz-Argüello, ES09:00 - 09:00 P0326THERAPEUTIC DRUG MONITORING: PERFORMANCE OFTHE FIRST LATERAL FLOW-BASED POINT OF CARE TESTFOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGERPRICK Amagoia Ametzazurra, ES

09:00 - 09:00 P0327NON-INVASIVE BIOMARKERS OF TYPE III COLLAGENCROSS-LINKING REFLECT FIBROLYSIS IN CROHN'SDISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR Martin Pehrsson, DK











09:00 - 09:00 P0335COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGHLEVELS BETWEEN POINT-OF-CARE TESTING ANDCURRENT STANDARD OF CARE (ENZYME LINKEDIMMUNOSORBENT ASSAY) IN PATIENTS WITHINFLAMMATORY BOWEL DISEASE Ilaria Marsilio, IT09:00 - 09:00 P0336PEDIATRIC INFLAMMATORY BOWEL DISEASE AFFECTS THEPATIENTS AND THEIR FAMILIES IN DIFFERENT WAYSDEPENDING ON THE AGE AT DIAGNOSIS Marta Velasco Rodríguez-Belvís, ES

09:00 - 09:00 P0337INCIDENCE AND RISK FACTORS FOR NEOPLASIA ININFLAMMATORY BOWEL DISEASE Joana Lemos Garcia, PT







09:00 - 09:00 P0344TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTSAND THE TYPE IV COLLAGEN FORMATION/DEGRADATIONRATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING(MONTREAL B2) CROHN'S DISEASE Arno R. Bourgonje, NL09:00 - 09:00 P0345TYPE IV COLLAGEN FORMATION/DEGRADATION RATIOPREDICTS RESPONSE TO INFLIXIMAB INDUCTIONTHERAPY IN PATIENTS WITH ULCERATIVE COLITIS Arno R. Bourgonje, NL

09:00 - 09:00 P0346INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITHRESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’SDISEASE Jose Luis Rueda García, ES

09:00 - 09:00 P0347COMPARATIVE ASSESSMENT C-REACTIVE PROTEINBETWEEN A POINT-OF-CARE TESTING AND CURRENTSTANDARD OF CARE (IMMUNONEPHELOMETRIC TESTING)

Greta Lorenzon, IT










09:00 - 09:00 P0354PSYCHOLOGICAL MORBIDITY PREDICTS MALADAPTIVEDECISION-MAKING IN PEOPLE WITH INFLAMMATORYBOWEL DISEASE Lydia Grinsted Tate09:00 - 09:00 P0355COLORECTAL CANCER SURVEILLANCE IN COMPLEX IBDPATIENTS WITH STRICTURES Alexander Kokrashvili, UK


09:00 - 09:00 P0357HUMAN NEUTROPHIL ELASTASE DERIVED FRAGMENT OFCALPROTECTIN (S100A9) IS A SERUM BIOMARKER(CPA9-HNE) FOR MONITORING OF ANTI-TNFΑ TREATMENTRESPONSE IN CROHN’S DISEASE Joachim Høg Mortensen, DK

09:00 - 09:00 P0358WATCH OUT FOR SIGNS OF ANXIETY AND DEPRESSION INIBD PATIENTS DURING AN ACUTE FLARE-UP Jochen Gerhard Klaus, DE






09:00 - 09:00 P0365COVID-19 PANDEMIC PSYCHOLOGICAL EFFECTS ONPATIENTS WITH INFLAMMATORY BOWEL DISEASE INTUNISIA Sahar Nasr, TN09:00 - 09:00 P0366DIAGNOSTIC WORK-UP OF CHILDREN AND ADOLESCENTSWITH INFLAMMATORY BOWEL DISEASE: EVOLUTION IN APOPULATION-BASED COHORT OVER A 26-YEAR PERIOD(1988-2014). Dominique Turck, FR


09:00 - 09:00 P0368DEEP REMISSION IN CROHN’S DISEASE ON BIOLOGICTHERAPY: TOWARDS A NEW DEFINITION Fabiana Castiglione, IT

09:00 - 09:00 P0369FEATURES OF THE COURSE OF COVID-19 ININFLAMMATORY BOWEL DISEASE PATIENTS WITHHERPESVIRUS LESIONS Gulustan Babayeva, AZ










09:00 - 09:00 P0377SLEEP DISORDERS AND CHRONIC INFLAMMATORY BOWELDISEASE: WHAT'S THE CONNECTION? Amani Hassine, TN09:00 - 09:00 P0378PREVALENCE AND RISK FACTORS FOR FATIGUE INCHRONIC INFLAMMATORY BOWEL DISEASE Amani Hassine, TN


09:00 - 09:00 P1122PSYCHOSOCIAL IMPACT OF THE COVID-19 PANDEMIC ONPATIENTS WITH INFLAMMATORY BOWEL DISEASE INSPAIN

09:00 - 09:00 P0380ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUSIN A COHORT OF PATIENTS WITH CROHN’S DISEASE Olga Maria Nardone, IT

09:00 - 09:00 P0381INTESTINAL ULTRASOUND RESPONSE AND TRANSMURALREMISSION AFTER 48 WEEKS OF TREATMENT WITHUSTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIALSUBSTUDY RESULTS BY LINE OF TREATMENT ANDLOCATION Torsten Kucharzik, DE





09:00 - 09:00 P0386EFFECT OF OZANIMOD TREATMENT ANDDISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNTIN PATIENTS WITH MODERATELY TO SEVERELY ACTIVEULCERATIVE COLITIS: RESULTS FROM A PHASE 3RANDOMIZED TRIAL Geert R. D'Haens, NL09:00 - 09:00 P0387EVALUATION OF THE EFFICACY OF TOFACITINIB ASMAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVECOLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINEENDOSCOPIC SUBSCORE Krisztina Barbara Gecse, NL

09:00 - 09:00 P0388EVALUATION OF A COMPUTATIONAL PLATFORM FORPREDICTING TEMPORAL PROGRESSION OF MUCOSALDAMAGE AND HEALING IN PATIENTS WITH CROHN’SDISEASE Ryuichi Iwakiri, JP

09:00 - 09:00 P0389QINGCHANG WENZHONG DECOCTION ACCELERATESINTESTINAL MUCOSAL HEALING THROUGH MODULATIONOF DYSREGULATED GUT MICROBIOTA IN DSS-INDUCEDCOLITIS MICE Tangyou Mao, CN

09:00 - 09:00 P0390PHARMACOKINETICS, SAFETY, AND TOLERABILITY OFETRASIMOD (APD334) IN SUBJECTS WITH MILD,MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY Caroline A. Lee, US






09:00 - 09:00 P0393ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIORDURATION OF REMISSION IN PATIENTS WITH ULCERATIVECOLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY(BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID:6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISEDRIVETING STUDY Joana Torres, PT09:00 - 09:00 P0394ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTSTREATED WITH TOFACITINIB IN THE ULCERATIVE COLITISCLINICAL PROGRAMME Christina Ha, US


09:00 - 09:00 P0396ALICAFORSEN ENEMA IN CHRONIC POUCHITIS: RESULTSOF A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO-CONTROLLED TRIAL Nermeen Varawalla

09:00 - 09:00 P0397CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATEDWITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICALPROGRAMME Alessandro Armuzzi, IT

09:00 - 09:00 P0398PREDICTORS OF CLINICAL RESPONSE ANDINFLAMMATORY BOWEL DISEASE QUESTIONNAIREIMPROVEMENT WITH GOLIMUMAB IN PATIENTS WITHMODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS INTHE PURSUIT-MAINTENANCE STUDY Cindy LJ Weinstein, US




09:00 - 09:00 P0402EARLY PRO-2 SYMPTOM REMISSION FOLLOWINGGUSELKUMAB INDUCTION TREATMENT: RESULTSTHROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY Walter Reinisch, AT09:00 - 09:00 P0403PATIENT-REPORTED OUTCOMES OF RESPONSE ANDREMISSION FOLLOWING GUSELKUMAB INDUCTIONTREATMENT AS MEASURED BY THE INFLAMMATORYBOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGHWEEK 12 OF THE PHASE 2 GALAXI 1 STUDY Julian Panés, ES



09:00 - 09:00 P0406ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITHMODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTSFROM THE PHASE 2 OASIS TRIAL AND OPEN-LABELEXTENSION Michael Chiorean, US

09:00 - 09:00 P0407IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVECOMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: AMULTICENTRE STUDY OF GETECCU Maria Jose Garcia, ES







09:00 - 09:00 P0411OPTIMIZING THE POSITION OF VEDOLIZUMAB INTREATMENT SEQUENCES FOR CROHN’S DISEASE:RESULTS FROM A MARKOV MODEL SIMULATION USINGREAL-WORLD EVIDENCE Alessandro Armuzzi, IT09:00 - 09:00 P0412OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USEIN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROMA EUROPEAN REAL-WORLD STUDY Alessandro Armuzzi, IT





09:00 - 09:00 P0416COMPARATIVE EFFICACY AND SAFETY OF ORAL FERRICMALTOL IN INFLAMMATORY BOWEL DISEASE PATIENTSWITH MILD-TO-MODERATE VS. MORE SEVERE IRONDEFICIENCY ANAEMIA Ian Jacob

09:00 - 09:00 P0417EFFECTS OF USTEKINUMAB INDUCTION ANDMAINTENANCE THERAPY ON DISEASE CLEARANCE IN THEUNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS Silvio Danese, IT




09:00 - 09:00 P0421AN AUDIT OF PROACTIVE THERAPEUTIC DRUGMONITORING OF PATIENTS WITH INFLAMMATORY BOWELDISEASE ON BIOLOGICS Kee Bin Ng, IE09:00 - 09:00 P0422EFFECTS OF COVID-19 ON TREATMENT AND PATIENTMANAGEMENT IN INFLAMMATORY BOWEL DISEASE:FINDINGS FROM A REAL-WORLD SURVEY IN EUROPE Fritha Hennessy




09:00 - 09:00 P0426REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUSTO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCETREATMENT FOR INFLAMMATORY BOWEL DISEASE Adriaan Volkers, NL

09:00 - 09:00 P0427RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSALHEALING AND BASELINE CHARACTERISTICS IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE ULCERATIVECOLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3SELECTION STUDY Jean-Frederic Colombel, US







09:00 - 09:00 P0431TASTY&AMP;HEALTHY IS A DIETARY APPROACH FORINDUCING AND MAINTAINING REMISSION IN CROHN'SDISEASE: A PROSPECTIVE CASE SERIES Luba Plotkin, IL09:00 - 09:00 P0432EFFECTIVENESS AND SAFETY OF ON-DEMAND FERRICCARBOXYMALTOSE INFUSION STRATEGY FOR IRONDEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASEPATIENTS Mauro Grova, IT




09:00 - 09:00 P0436A PILOT STUDY ON THE USE OF USTEKINUMAB INREFRACTORY PERIANAL CROHN’S DISEASE Federica Crispino, IT

09:00 - 09:00 P0437MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEDFATIGUE IN PATIENTS WITH MODERATELY TO SEVERELYACTIVE CROHN’S DISEASE Miguel Regueiro, US




09:00 - 09:00 P0442LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITHMODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS(UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS)STUDIES Silvio Danese, IT09:00 - 09:00 P0443IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGICMEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2STUDY OF PATIENTS WITH MODERATELY TO SEVERELYACTIVE CROHN’S DISEASE Rish Pai, US




09:00 - 09:00 P0447RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPYFOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONGPATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATAFROM A PROSPECTIVE COHORT Jacob Ollech, IL

09:00 - 09:00 P0448EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMABFOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OFTHE PHASE 4 EARNEST TRIAL Simon Travis






09:00 - 09:00 P0451THERAPEUTIC TARGETS IN PAEDIATRIC IBD: ARETROSPECTIVE ANALYSIS OF INTERMEDIATE GOALSBASED ON UPDATED STRIDE-II (SELECTING THERAPEUTICTARGETS IN INFLAMMATORY BOWEL DISEASE)RECOMMENDATIONS Hannes Hölz, DE09:00 - 09:00 P0452RESULTS FROM A LARGE SURVEY EXPLORING PATIENTPREFERENCES FOR TREATMENT ATTRIBUTES ININFLAMMATORY BOWEL DISEASE ACROSS 7 COUNTRIES INEUROPE Nawal Bent-Ennakhil, CH




09:00 - 09:00 P0456OBSERVATIONAL STUDY ON THE EFFECTIVENESS ANDSAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITISPOPULATION COMPRISED BY BIO-NAÏVE PATIENTS ANDPATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF(EVOLVE-IB STUDY) Francisco Casellas, ES

09:00 - 09:00 P0457CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITHULCERATIVE COLITIS TREATED WITH FILGOTINIB – A POSTHOC ANALYSIS OF SELECTION William J. Sandborn, US


09:00 - 09:00 P0459PHARMACOKINETICS, IMMUNOGENICITY, ANDEXPOSURE–RESPONSE RELATIONSHIPS OFUSTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’SDISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGETVS STANDARD OF CARE ANALYSIS OF THE STARDUSTSTUDY Geert R. D'Haens, NL09:00 - 09:00 P0460INFLAMMATORY COMPLICATIONS OF THE POUCH, ANDTHERAPEUTIC REQUIREMENTS AFTER COLECTOMY INPATIENTS WITH ULCERATIVE COLITIS. RESULTS FROMTHE RESERVO STUDY OF GETECCU Francisco Mesonero, ES





09:00 - 09:00 P0465INTRAABDOMINAL ABSCESSES IN CROHN'S DISEASE:TREATMENT AND OUTCOMES Salma Souissi, TN

09:00 - 09:00 P0466PHARMACOKINETIC AND NONCLINICAL SAFETYEVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, INNON-HUMAN PRIMATES Jay Tibbitts, US





09:00 - 09:00 P0468TREATMENT OPTIMIZATION WITH VEDOLIZUMAB INTREATMENT-REFRACTORY PATIENTS WITH ULCERATIVECOLITIS AND CROHN’S DISEASE – A REAL-WORLD TWO-CENTER COHORT STUDY Mohamed Attauabi, DK09:00 - 09:00 P0469MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE CROHN'SDISEASE Edward V. Loftus, US






09:00 - 09:00 P0475IS LONGER TIME BETWEEN IBD DIAGNOSIS AND FIRSTBIOLOGIC INITIATION LEADING TO HIGHER DISEASESEVERITY AND MORE HOSPITALIZATIONS IN ITALY ANDTHE UNITED KINGDOM? A COMPARISON TO SIMILARMETRICS IN THE UNITED STATES Eric John, US

09:00 - 09:00 P0476RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLYSYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN ANDSTOOL FREQUENCY IN PATIENTS WITH MODERATE TOSEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3INDUCTION STUDIES Jean-Frederic Colombel, US

09:00 - 09:00 P0477VEDOLIZUMAB AS THE FIRST LINE OF BIOLOGIC THERAPYFOR ULCERATIVE COLITIS AND CROHN’S DISEASE - ASYSTEMATIC REVIEW WITH META-ANALYSIS Mohamed Attauabi, DK09:00 - 09:00 P0478PROACTIVE THERAPEUTIC DRUG MONITORING OF ANTI-TNF AGENTS IS ASSOCIATED WITH HIGHER MUCOSALHEALING RATES IN CROHN'S DISEASE Marko Brinar, HR







09:00 - 09:00 P0485HISTOLOGICAL INFLAMMATION PREDICTS LOSS OFREMISSION AMONG CROHN’S PATIENTS WITHENDOSCOPIC REMISSION: A US COHORT ANALYSIS Harris Ahmad, US

09:00 - 09:00 P0486PATIENT PREFERENCES REGARDING TREATMENT WITHADVANCED THERAPIES IN ULCERATIVE COLITIS: ADISCRETE-CHOICE EXPERIMENT Stefan Schubert, DE




09:00 - 09:00 P0487LONG-TERM OUTCOMES FOLLOWING A SWITCH FROMORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5(IMRALDI) IN IBD Lauranne Derikx09:00 - 09:00 P0488PERFUSE: A FRENCH NON-INTERVENTIONAL COHORTSTUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONEDPATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5;BASELINE RESULTS Yoram Bouhnik, FR






09:00 - 09:00 P0494SYSTEMATIC REVIEW ON THE USE OF ENTERAL NUTRITIONFOR THE INDUCTION OF REMISSION IN PAEDIATRICCROHN’S DISEASE Gigi Veereman, BE

09:00 - 09:00 P0495BENEFICIAL EFFECTS OF NATURAL MINERAL WATERS ONINTESTINAL INFLAMMATION AND THE MUCOSA-ASSOCIATED MICROBIOTA Nicolas Barnich, FR

09:00 - 09:00 P0496A 12-WEEK TAILORED PHYSICAL TRAINING PROGRAMINCLUDING DIETARY ADVICE IN CHILDREN WITHINFLAMMATORY BOWEL DISEASE: A RANDOMIZEDCROSSOVER TRIAL Linda Elisabeth Scheffers, NL09:00 - 09:00 P0497UPADACITINIB TREATMENT IMPROVES HEALTH-RELATEDQUALITY OF LIFE AMONG PATIENTS WITH MODERATELYTO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTSFROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE ANDU-ACCOMPLISH Julian Panés, ES






09:00 - 09:00 P0503TOFACITINIB IN ULCERATIVE COLITIS: SHORT TERMOUTCOMES IN REAL WORLD EXPERIENCE IN THE SOUTHOF SPAIN Alvaro Hernández Martínez, ES

09:00 - 09:00 P0504SAFETY OF REDUCED CLINICAL MONITORING IN PATIENTSWITH STABLE INFLAMMATORY BOWEL DISEASE ONMAINTENANCE THIOPURINE THERAPY Fenna Minke Jansen, NL




09:00 - 09:00 P0505BOTH SINGLE AND MULTIPLE SWITCHING BETWEENINFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE INIBD: REAL WORLD OUTCOMES FROM THE EDINBURGH IBDUNIT Rachael Barrett09:00 - 09:00 P0506BIOLOGICS AND SMALL MOLECULES COMBOTHERAPIES:PROMISING EXPERIENCE IN REFRACTORY IBD PATIENTS Maude Martinho, CH







09:00 - 09:00 P0513REDO-SURGERY IN IBD PATIENTS: WHAT IS THE TIMEINTERVAL AND IS THIS EFFECTED BY SPECIFIC RISKFACTORS ? John Wye, UK

09:00 - 09:00 P0514DOES THE TYPE OF SURGERY OR DISEASE LOCATIONPREDICT THE NEED FOR SUBSEQUENT SURGERIES, IN IBDPATIENTS John Wye, UK

09:00 - 09:00 P0515THE CHANGING TRENDS SEEN WITH SURGERY INPATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER A25 YEAR REVIEW PERIOD John Wye, UK09:00 - 09:00 P0516MANAGEMENT AND OUTCOME OF POSTOPERATIVECROHN’S DISEASE IN THE ELDERLY AS COMPARED TOYOUNG ADULTS: DATA FROM ENEIDA REGISTRY Miriam Mañosa Ciria, ES







E-Poster Session

09:00 – 19:00 Poster ExhibitionE-Poster Session

E-Poster Session






09:00 - 09:00 P1060COLORECTAL CANCER SURVIVAL AT DR. ORLANDO SMITHHOSPITAL, TORTOLA, BRITISH VIRGIN ISLANDS David Nelson, VG09:00 - 09:00 P1061MORTALITY FOLLOWING APPENDICECTOMY IN PATIENTSWITH LIVER CIRRHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Adil Rashid

09:00 - 09:00 P1064FEATURES OF GUNSHOT COLON DAMAGE WITHEXPANSIVE BULLETS VS CONVENTIONAL BULLETS (DATAOF JOINT FORCES OPERATION AT THE EAST OF UKRAINE2014 - 2020 YY.) Kostiantyn Gumeniuk, UA

09:00 - 09:00 P1065RECTAL DEFECT HEALING: EXPERIMENTAL ASSESSMENTSTUDY OF DIFFERENT REINFORCEMENT PROCEDURES Freddy Mboti, BE






09:00 - 09:00 P1071INCIDENCE, RISK FACTORS AND OUTCOMES OF MESHINFECTION AFTER INCISIONAL HERNIA REPAIR SURGERYIN THE UNITED STATES: A NATIONWIDE DATABASESTUDY Andrea Carolina Quiroga Centeno, CO

09:00 - 09:00 P1072ENDOSCOPIC TREATMENT OF GASTRO-BRONCHIAL ANDGASTRO-COLIC FISTULAS POST SLEEVE GASTRECTOMY Alessandra D'Alessandro, IT09:00 - 09:00 P1073FEWER BRANCHES OF LEFT COLIC ARTERY AND THEIRIMPACTS ON LAPAROSCOPIC SURGERY IN PATIENTS WITHPERSISTENT DESCENDING MESOCOLON Hiroaki Nozawa, JP

09:00 - 09:00 P1074DEVELOPMENT OF GASTRIC ENDOSCOPIC FULL-THICKNESS RESECTION FOLLOWED BY BAND LIGATIONAND OVER-THE-SCOPE CLIP CLOSURE Hideki Kobara, JP

09:00 - 09:00 P1075PERORAL ENDOSCOPIC SEPTOTOMY USING ALAPAROSCOPIC VESSEL-TISSUE SEALER FOR TREATMENTOF ZENKER’S DIVERTICULUM: FEASIBILITY AND SAFETY OFENDOSCOPIC SCISSORS TECHNIQUE Filippo Mocciaro, IT

E-Poster Session


09:00 - 09:00 P0130SOLVING THE ENIGMA OF NON-IGE MEDIATEDGASTROINTESTINAL FOOD ALLERGY IN THE PEDIATRICAGE: RESULTS FROM THE NIGEFA STUDY Laura Carucci, IT

09:00 - 09:00 P0131RELEVANCE AND OUTCOME OF NON-SPECIFIC ENTERITISDURING LONG-TERM FOLLOW-UP Ana Catarina Gomes, PT








09:00 - 09:00 P0136GEOGRAPHIC EVOLUTION OF PEDIATRIC INTESTINALFAILURE (PIF) MANAGEMENT IN THE UNITED STATES (US) David F Mercer, US09:00 - 09:00 P0137SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROMEAND THERMAL FOOD PROCESSING PATTERN Vladimir Pilipenko, RU




09:00 - 09:00 P0141HLA RISK STRATIFICATION COULD BE USED TO TARGETSEROLOGICAL SCREENING OF CELIAC DISEASE AMONG AT-RISK RELATIVES Saana Paavola, FI

09:00 - 09:00 P0142CHANGES IN BODY COMPOSITION AMONG PATIENTS WITHCOELIAC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS Zsófia Vereczkei, HU





09:00 - 09:00 P0147CONCOMITANT AUTOIMMUNITY IN CELIAC DISEASE:ASSOCIATION TO THE DISEASE FEATURES AND LONG-TERM TREATMENT OUTCOMES Riku Tauschi, FI09:00 - 09:00 P0148WHAT IS THE ROLE OF MULTIPLE URINE GIPS INESTABLISHED COELIAC DISEASE? William Holland




09:00 - 09:00 P0153THE INCIDENCE OF CELIAC DISEASE AMONG PATIENTSWITH GASTROENTEROLOGICAL DISORDERS Svetlana Bykova, RU

09:00 - 09:00 P0154MICRORNAS ARE POTENTIAL EARLY MARKERS OF COELIACDISEASE AND MAY REGULATE THE COELIAC DISEASE-SPECIFIC TRANSCRIPTIONAL CHANGES IN THE SMALLINTESTINE Ineke Tan, NL







09:00 - 09:00 P0158FUNCTIONAL STATUS OF DUODENAL MUCOSA IN CELIACDISEASE PATIENTS Olga Akhmadullina, RU09:00 - 09:00 P0159NATURAL HISTORY OF CELIAC DISEASE: COMPARISONBETWEEN CHILDHOOD AND ADULT-ONSET DISEASE Hadrien Alric, FR





09:00 - 09:00 P0165SCREENING FOR ADULT COELIAC DISEASE IN THEGENERAL POPULATION Ina Lervåg Andersen, NO

09:00 - 09:00 P0166PREDICTIVE FACTORS FOR LONG-TERM COMPLICATIONSIN CELIAC DISEASE: A LARGE RETROSPECTIVE STUDYFROM THE CELAC GROUP Hadrien Alric, FR





09:00 - 09:00 P0172INCREASED PREVALENCE OF CELIAC DISEASE IN PATIENTSWITH CYSTIC FIBROSIS: A SYSTEMATIC REVIEW ANDMETA–ANALYSIS Marcell Imrei, HU09:00 - 09:00 P0174ADHERENCE TO CELIAC DIAGNOSTIC GUIDELINES:RESULTS FROM THE GERMAN CELIAC REGISTRY (GECER) Sibylle Koletzko, DE




09:00 - 09:00 P0178SHORT AND LONG-TERM OUTCOME OF COLDPOLYPECTOMY FOR SUPERFICIAL NON-AMPULLARYDUODENAL EPITHELIAL TUMORS Kenichiro Okimoto, JP

09:00 - 09:00 P0179TIMING OF ENTEROSCOPY IN OVERT-OBSCUREGASTROINTESTINAL BLEEDING - A SYSTEMATIC REVIEWAND META-ANALYSIS Ana Catarina Gomes, PT








E-Poster Session







09:00 - 09:00 P0636LIVER TRANSAMINASES, LEPTIN AND INTERLEUKIN-6LEVEL IN PATIENTS WITH NON-ALCOHOLICSTEATOHEPATITIS COMBINED WITH OBESITY ANDARTERIAL HYPERTENSION DURING TREATMENT WITHURSODEOXYCHOLIC ACID, STATINS AND SARTANS Olesia Bochar, UA

09:00 - 09:00 P0637UNDERSTANDING THE TRANSCRIPTOMIC CHANGES OFMAFLD IN HIGH FAT DIET MURINE MODELS AND ITSREVERSION BY ANTI-STEATOTIC TREATMENTS THROUGHMETA-ANALYSIS Nadezda Apostolova, ES




09:00 - 09:00 P0641HUMAN ALPHA-1-DEFENSIN IN PATIENTS WITHALCOHOLIC HEPATITIS AND LIVER CIRRHOSIS Viachaslau Pryshchepenka, BY09:00 - 09:00 P0642RELATIONSHIP BETWEEN INTESTINAL DYSBIOSIS ANDOBESITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVERDISEASE. Yana Nikiforova, UA




09:00 - 09:00 P0646HYPOADIPONECTINEMIA AS A MARKER OF INCREASEDCARDIOVASCULAR RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: CORRELATION WITHALBUMIN/CREATININE RATIO Mona Ahmed Amin, EG

09:00 - 09:00 P0647THE IMPACT OF PNPLA3 RS738409 RISK G ALLELES ONHEPATIC STEATOSIS, THE METABOLIC SYNDROME ANDPORTAL HYPERTENSION IN ADVANCED FATTY LIVERDISEASE Antonina Antonenko, AT







09:00 - 09:00 P0651METABOLIC ASSOCIATED FATTY LIVER DISEASE IN THECHRONIC HEPATITIS C PATIENTS Yasser Fouad, EG09:00 - 09:00 P0652DIETARY PATTERNS IN PATIENTS WITH SIMPLE STEATOSISAND NON-ALCOHOLIC STEATOHEPATITIS: PROSPECTIVECOMPARATIVE TRIAL Sergey Morozov, RU




09:00 - 09:00 P0656DISTINCTIVE CLINICAL FEATURES OF NON-ALCOHOLICAND MIXED FATTY LIVER DISEASE Nicolau Vallejo-Senra, ES

09:00 - 09:00 P0659NOVEL PATHOGENIC ALG8 VARIANTS AND EVIDENCE FORSOMATIC LOSS OF HETEROZYGOSITY IN 199 AUTOSOMALDOMINANT POLYCYSTIC LIVER DISEASE PATIENTS Melissa M. Boerrigter, NL




09:00 - 09:00 P0663FAST IS NOT SUPERIOR TO LSM FOR NONINVASIVEDIAGNOSIS OF FIBROSIS STAGE OR ‘ACTIVE FIBROTICNASH’ IN NONALCOHOLIC FATTY LIVER DISEASE Rudolf Stauber, AT09:00 - 09:00 P0664COLONIC DIVERTICULOSIS AND NON-ALCOHOLIC FATTYLIVER DISEASE: IS THERE A CONNECTION? Ivana Pantic, RS





09:00 - 09:00 P0669VITAMIN D DEFICIENCY IS ASSOCIATED WITH SIGNIFICANTSTEATOSIS, ADVANCED FIBROSIS AND NON-ALCOHOLICSTEATOHEPATITIS (NASH), IN NON-ALCOHOLIC FATTYLIVER DISEASE (NAFLD) Khellaf Amalou, DZ

09:00 - 09:00 P0670EFFECT OF CHOLECYSTECTOMY ON HEPATIC STEATOSISAND INSULIN RESISTANCE ASSESSED BY CONTROLLEDATTENUATION PARAMETER (CAP) AND MRI IN NON-ALCOHOLIC FATTY LIVER (NAFLD) ALGERIAN PATIENTS: APILOT STUDY Khellaf Amalou, DZ






09:00 - 09:00 P0674FEATURES OF THE SERUM LONG-CHAIN FREE FATTY ACIDSCONTENT IN CHILDREN WITH NON-ALCOHOLIC FATTYLIVER DISEASE Natalia Zavhorodnia, UA09:00 - 09:00 P0675INSULIN LEVELS ARE ASSOCIATED TO LIVER FUNCTIONTEST AND LIVER DISEASE IN COHORTS WITH UP TO 24YEARS OF FOLLOW-UP Andreas Schult, SE





09:00 - 09:00 P0680OUTCOMES OF PATIENTS WITH ALCOHOLIC LIVERDISEASE AFFECTED WITH THE METABOLIC SYNDROME Leore Cohen Mendel, IL

09:00 - 09:00 P0681ALCOHOL USE DISORDER AND ALCOHOL RELATED LIVERDISEASE: TIME FOR SCREENING? Camelia Gianina Foncea, RO



09:00 - 09:00 P0684DIP THE TAP - IMPROVING NEEDLE TO DIAGNOSIS TIME INSPONTANEOUS BACTERIAL PERIOTINITIS: A RENEWEDSCREENING ROLE FOR BEDSIDE LEUCOCYTE ESTERASETEST KITS - DURING COVID 19 PANDEMIC A MULTISITESTUDY Flora Kokwaro09:00 - 09:00 P0685CAN SERUM FERRITIN PREDICT 30 DAYS MORTALITY INPATIENTS WITH DECOMPENSATED CIRRHOSIS? Sahar Nasr, TN






09:00 - 09:00 P0693QUALITY OF LIFE IMPROVEMENT IS A TOP-RATED BUTRARELY ASSESSED OUTCOME IN EUROPEAN ANDAUSTRALIAN PATIENTS WITH HEPATICENCEPHALOPATHY: QUALITY OF LIFE TARGETING ANDMONITORING NEEDS TO BE PRIORITISED Juha Halonen

09:00 - 09:00 P0694PROCALCITONIN AS A PROGNOSTIC TOOL IN THEMANAGEMENT OF REFRACTORY ASCITES Margarida Gomes Gonçalves, PT





09:00 - 09:00 P0696WHAT IS THE CLINICAL IMPACT OF ASCITES CHOLESTEROLAND PROBNP LEVELS IN OUR ROUTINE PRACTICE FOR THEDIFFERENTIAL DIAGNOSIS OF ASCITES ETIOLOGY? Filiz Akyuz, TR09:00 - 09:00 P0697INTERNATIONAL FRENCH-SPEAKING MULTICENTREPRACTICE SURVEY ON HEPATIC HYDROTHORAX (HH) :RESULTS OF THE "HEP HEP" STUDY AMONG 529HEPATOGASTROENTEROLOGIST (HG) OR PNEUMOLOGIST(PN) RESPONDENTS Jean-François David Cadranel, FR






09:00 - 09:00 P0703PREDICTORS OF BLEEDING AFTER PROPHYLACTICENDOSCOPIC VARICEAL LIGATION Renato Medas, PT

09:00 - 09:00 P0704PREDICTIVE FACTORS OF BACTERIAL INFECTION INPATIENTS WITH LIVER CIRRHOSIS: EXPERIENCE OF THEHEPATO-GASTROENTEROLOGY DEPARTMENTCASABLANCA UNIVERSITY HOSPITAL Sara Nacer, MA


09:00 - 09:00 P0706THE SPECTRUM OF DECOMPENSATED CIRRHOSIS: WHICHSCORES PERFORM THE BEST IN PREDICTINGMORTALITY? Inês Costa-Santos, PT09:00 - 09:00 P0707A DEEP LEARNING-BASED SYSTEM FOR PREDICTING THERISK OF HEMORRHAGE OF GASTROESOPHAGEAL VARICESQUANTITATIVELY UNDER ENDOSCOPY Jing Wang, CN







09:00 - 09:00 P0714THE SUBPOPULATION COMPOSITION OF BLOOD T-KILLERS AND THE FREQUENCY OF SEVERE LIVER FIBROSISDIFFER IN PATIENTS WITH VIRAL HEPATITIS C WITHGENOTYPES 1 AND 3 IN THE INDUSTRIAL CENTER OFEASTERN SIBERIA Vladislav Tsukanov, RU

09:00 - 09:00 P0715THE SHIFT IN PREVALENCE, INCIDENCE, AND MORTALITYRATES OF VIRAL HEPATITIS TYPES A, B, C AND D INBRAZILIAN CITIZENS BETWEEN 1999 AND 2019 Lucas Monteiro, BR




09:00 - 09:00 P0716RETRIEVAL OF LOST PATIENTS IN THE SYSTEM FORHEPATITIS C MICROELIMINATION: A SINGLE-CENTERRETROSPECTIVE STUDY Hsu-Heng Yen, TW09:00 - 09:00 P0717CHRONIC HEPATITIS B UNDER TENOFOVIR OR ENTECAVIR:PERFORMANCE OF THE PAGE-B SCORE TO PREDICTHEPATOCELLULAR CARCINOMA Daniela Falcão, PT







09:00 - 09:00 P0725CHRONIC HEPATITIS B GENOTYPE E: A REALITY IN ADISTRICT HOSPITAL IN PORTUGAL Bárbara Morão, PT

09:00 - 09:00 P0726DIABETES MELLITUS DOES NOT INCREASE THE RISK OFRECURRENT HEPATOCELLULAR CARCINOMA AFTERDIRECT-ACTING ANTIVIRAL TREATMENT FOR HEPATITIS C:SYSTEMATIC REVIEW WITH META-ANALYSIS Szilárd Váncsa, HU

09:00 - 09:00 P0727CHRONIC HEPATITIS B GENOTYPE E: CLINICALCHARACTERISTICS AND RESPONSE TO ANTI-VIRALAGENTS Bárbara Morão, PT09:00 - 09:00 P0728SEROPREVALENCE OF HEPATITIS B AND C VIRUSES INCHILDREN ABOVE THE AGE OF 3 YEARS: AN EGYPTIANHOSPITAL-BASED CROSS-SECTIONAL SURVEY STUDY Muhammad Abdel-Gawad, EG







09:00 - 09:00 P0737PREVALENCE OF INSULIN RESISTANCE IN PATIENTSBEFORE AND AFTER LIVER TRANSPLANTATION, AND ITSPROGRESSION DURING THE FOLLOW-UP. A PROSPECTIVESTUDY Irena Mikova, CZ

09:00 - 09:00 P0738DRUG INDUCED LIVER INJURY: ROLE OF CIRCULATINGLIVER-SPECIFIC MICRORNAS AND KERATIN-18 Giacomo Germani, IT





09:00 - 09:00 P0740ULTRASOUND VISCOELASTIC LIVER MEASUREMENTS ANDFACTORS THAT INFLUENCE THEM Roxana Sirli, RO09:00 - 09:00 P0741THE ROLE OF VASCULARIZATION PARAMETERSQUANTIFICATION FOR THE ASSESSMENTS OFINCONCLUSIVE FOCAL LIVER LESIONS CHARACTERIZED BYCEUS Tudor Voicu Moga, RO






09:00 - 09:00 P0747COMPARISON BETWEEN ACOUSTIC RADIATION FORCEIMPULSE (ARFI) ELASTOGRAPHY AGAINST TRANSIENTELASTOGRAPHY (FIBROSCAN) IN NON-ALCOHOLIC FATTYLIVER DISEASE (NAFLD) Thazin Min

09:00 - 09:00 P0748TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) INPATIENTS WITH UNRESECTABLE HEPATOCELLULARCARCINOMA: EXPERIENCE OF A TUNISIAN CENTER Amani Hassine, TN


09:00 - 09:00 P0750MICRORNA-122 CONJUGATED POLYMER NANOPARTICLESAS A PROTECTIVE TOOL AGAINST DEVELOPMENT OFHEPATOCELLULAR CARCINOMA IN AN EXPERIMENTALMODEL Eman EL-Ahwany, EG09:00 - 09:00 P0751DISTINCT EFFECTS OF IGFBP2 ON VIABILITY OFHEPATOMA CELLS – A MATTER OF DOSE Frederik Kolligs, DE






09:00 - 09:00 P0758THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIESPATIENTS WITH ADVERSE CLINICAL OUTCOME FROMIMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA Ambreen Muhammed

09:00 - 09:00 P0759NEW TOOLS FOR PREDICTING SURVIVAL IN PATIENTSWITH HEPATOCELLULAR CARCINOMA TREATED WITHSORAFENIB Alexandra Pires, PT





09:00 - 09:00 P0761NURSE INTERVENTION OPTIMIZES THE CARE OF PATIENTSWITH HEPATOCELLULAR CARCINOMA UNDERSECOND/THIRD-LINE TREATMENTS Gemma Iserte Fort, ES09:00 - 09:00 P0762FAILURE OF ULTRASOUND-BASED SURVEILLANCE FORHEPATOCELLULAR CARCINOMA IN PATIENTS AT RISK ISFREQUENT AND ASSOCIATED WITH DETECTION AT LATERTUMOR STAGES, NON-CURATIVE TREATMENT OPTIONSAND REDUCED SURVIVAL. RESULTS FROM A GERMANMULTI-CENTER RETROSPECTIVE COHORT STUDY Christoph Schramm, DE






09:00 - 09:00 P0769DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABELUSE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS) Georg Semmler, AT

09:00 - 09:00 P0770NATURAL HISTORY OF PATIENTS WITH NON-CIRRHOTICPORTAL HYPERTENSION Joel Silva, PT



09:00 - 09:00 P0773HEPATOCELLULAR CARCINOMA (HCC) AWARENESS ANDSURVEILLANCE IN PATIENTS WITH CHRONIC LIVERDISEASES (CLD) FOLLOWED IN TERTIARY GREEK LIVERCENTERS Paraskevi Fytili, GR09:00 - 09:00 P0775PREVALENCE OF PERIODONTAL DISEASE IN PATIENTSWITH LIVER CIRRHOSIS AND ITS INFLUENCE ON THESHORT-TERM OUTCOME OF THE DISEASE Srinivas Reddy Thummala, IN




09:00 - 09:00 P0779DIABETES MELLITUS WAS ASSOCIATED WITH A HIGHERRATE OF ACUTE CHOLANGITIS AMONG PATIENTS WITHCOMMON BILE DUCT STONE Tawfik Khoury, IL

09:00 - 09:00 P0780THREE-MONTHS DURATION OF FULLY-COVERED METALSTENT FOR REFRACTORY DOMINANT EXTRA-HEPATICBILIARY STRICTURE AMONG PRIMARY SCLEROSINGCHOLANGITIS PATIENTS: EFFICACY AND SAFETY Tawfik Khoury, IL

09:00 - 09:00 P0781ROLE OF ENDOSCOPIC ULTRASOUND IN EVALUATION OFBILE DUCT DILATATION: EXPERIENCE OF A TERTIARYCENTER Marta Librero Jiménez, ES

09:00 - 09:00 P0782ERCP IN BILROTH-II CASES. EXPERIENCE, TIPS ANDTRICKS Aleksandr Filin, RU





E-Poster Session






09:00 - 09:00 P0096CORRELATION BETWEEN THE INTENSITY OFHELICOBACTER PYLORI COLONIZATION AND SEVERITY OFGASTRITIS: RESULTS OF A PROSPECTIVE STUDY Salma Souissi, TN

09:00 - 09:00 P0097THE ANATOMIC DISTRIBUTION AND FREQUENCY OFPREMALIGNANT LESIONS OF STOMACH RELATED TOHELICOBACTER PYLORI INFECTION IN MIDDLE-AGED ANDOLDER PATIENTS Cundullah Torun, TR




09:00 - 09:00 P0101FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPYIN EUROPE: RESULTS FROM 30,000 CASES OF THEEUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG) Olga P. Nyssen, ES09:00 - 09:00 P0102EMPIRICAL FIRST-LINE TREATMENT USE ANDEFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) Olga Perez Nyssen, ES



09:00 - 09:00 P0105ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTERPYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2020:ANALYSIS OF THE EUROPEAN REGISTRY ON H.PYLORI MANAGEMENT (HP-EUREG) Luis Bujanda, ES

09:00 - 09:00 P0106EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN426 PATIENTS FROM THE EUROPEAN REGISTRY ON H.PYLORI MANAGEMENT (HP-EUREG) Olga P. Nyssen, ES







09:00 - 09:00 P0111DIAGNOSIS, TREATMENT PATTERNS, AND EFFECTIVENESSOF HELICOBACTER PYLORI ERADICATION IN CHINA: STUDYDESIGN FOR A RETROSPECTIVE REAL-WORLD STUDY Fang Zhou, CN09:00 - 09:00 P0112FIRST LINE ERADICATION THERAPY FOR HELICOBACTERPYLORI GUIDED BY MOLECULAR ANALYSIS OF GENOTYPICRESISTANCES ON STOOLS: A PILOT STUDY Giuseppe Losurdo, IT




09:00 - 09:00 P0116FIRST-LINE HELICOBACTER PYLORI ERADICATION RATE INDAILY CLINICAL PRACTICE IN TWO SPANISH MEDICALCENTERS: 2010-2019 Inés Ariño Pérez, ES

09:00 - 09:00 P0117MANAGEMENT OF HELICOBACTER PYLORI INFECTIONDURING THE LAST DECADE: TEMPORAL PRESCRIPTIONTRENDS FOR THE FIRST-LINE OF NON-ALLERGICPATIENTS AND ITS ADEQUACY TO CLINICAL GUIDELINES Inés Ariño Pérez, ES




09:00 - 09:00 P0125LONG-TERM RISK OF UPPER GASTROINTESTINALBLEEDING AFTER HELICOBACTER PYLORI ERADICATION: APOPULATION-BASED COHORT STUDY Fang Jiang, CN09:00 - 09:00 P0126PRIMARY RESISTANCE OF HELICOBACTER PYLORI TOCLARITHROMYCIN IN TUNISIA Manel Moalla, TN




E-Poster Session


09:00 - 09:00 CC001A RARE AND SYMPTOMATIC CASE: LOCALIZED GASTRICAND DUODENAL AMYLOIDOSIS Mahnoor Khan, US

09:00 - 09:00 CC002A RARE CASE OF COLLAGENOUS GASTRITIS IN A 16 YEAROLD MALE PATIENT Corinna Lang-Schwarz, DE



09:00 - 09:00 CC005CMV DUODENITIS – A RARE CAUSE OF DUODENALULCERATION IN IMMUNE-COMPETENT HOST Muhammad Khan, QA




09:00 - 09:00 CC006ESOPHAGEAL-PULMONARY FISTULA AS THE INITIALPRESENTATION OF TUBERCULOSIS Mariel Dianne Velasco, PH09:00 - 09:00 CC007CYTOMEGALOVIRUS INFECTION PRESENTING AS GASTRICOUTLET OBSTRUCTION - AN UNUSUAL PRESENTATION Ashish Gandhi, IN







09:00 - 09:00 CC015PRIMARY DEDIFFERENTIATED LIPOSARCOMA OF THEESOPHAGUS Maryam Alahmad, AE

09:00 - 09:00 CC016PRIMARY GASTRIC ADENOSQUAMOUS CARCINOMA: ARARE VARIANT OF GASTRIC CANCER Joaquín García Márquez, ES



09:00 - 09:00 CC019GURVITS SYNDROME IN A YOUNG PATIENT WITH POORLYCONTROLLED DIABETES AND COCAINE USE María del Mar Díaz Alcázar, ES

09:00 - 09:00 CC020CHRONIC MESENTERIC ISCHEMIA MIMICKING GASTRICCANCER Jana Jarosova, CZ09:00 - 09:00 CC021MASSIVE ASCITES AS THE INITIAL PRESENTATION OFSYSTEMIC LUPUS ERYTHEMATOSUS Maryam Alahmad, AE






09:00 - 09:00 CC027GASTROINTESTINAL AMYLOIDOSIS: THE TONGUE GIVESTHE ANSWER Pedro Antunes, PT

09:00 - 09:00 CC030WHIPPLE DISEASE: A CASE REPORT Vaidota Maksimaityte, LT



09:00 - 09:00 CC033TRANSIENT SMALL BOWEL INTUSSUSCEPTIONUNMASKING ADULT CELIAC DISEASE Maryam Alahmad, AE




09:00 - 09:00 CC034CELIAC CRISIS – A RARE AND LIFE-THREATENINGPRESENTATION Isabel Garrido, PT09:00 - 09:00 CC035HOW MANY CALORIES ARE ENOUGH? Zrinka Šmuljić, HR







09:00 - 09:00 CC042ENDOSCOPIC BAND LIGATION FOR WEIGHT LOSS: SHORT-TERM RESULTS Mohamed Abeid, EG

09:00 - 09:00 CC043MIGRATED PEG BALLOON CAUSING ACUTE PANCREATITIS Muhammad Omar Saeed



09:00 - 09:00 CC046GANGRENOUS PYODERMA IN ULCERATIVE COLITIS - ANEXUBERANT AND PAINFUL COMPLICATION Margarida Gomes Gonçalves, PT

09:00 - 09:00 CC047SEVERE LOWER GASTROINTESTINAL BLEEDING IN APATIENT WITH CROHN'S DISEASE: A RARE CASE REPORT Isabel Garrido, PT09:00 - 09:00 CC048SPONTANEOUS PNEUMOMEDIASTINUM: A RARECOMPLICATION OF ACUTE SEVERE ULCERATIVE COLITIS Emanuel Dias, PT






09:00 - 09:00 CC054ASSOCIATION BETWEEN CROHN'S DISEASE ANDCOLORECTAL CANCER IN A YOUNG PATIENT: CASEREPORT Rafael Luporini, BR

09:00 - 09:00 CC055IMMUNE-MEDIATED COLITIS Mirza Faisal Anwar Baig



09:00 - 09:00 CC058PROCTITIS IN MEN HAVING SEX WITH MEN, ANYTHINGELSE YOU CAN THINK OF? María del Mar Díaz Alcázar, ES




09:00 - 09:00 CC059FRESH RECTAL BLEEDING WITH A RARE HIDDENHISTOPATHOLOGIC DIAGNOSIS Anastasios Koutsoumourakis, GR09:00 - 09:00 CC060RECTAL DIEULAFOY LESION - DIAGNOSTIC ANDTHERAPEUTIC CHALLENGE Ivo Klarin, HR






09:00 - 09:00 CC066DIFFUSE GASTROINTESTINAL MALT LYMPHOMA IN APATIENT WITH ULCERATIVE COLITIS IN REMISSION Costantino Sgamato, IT

09:00 - 09:00 CC067PRIMARY COLONIC LYMPHOMA : A CASE REPORT Hajar Koulali, MA



09:00 - 09:00 CC070NEUROMUSCULAR AND VASCULAR HAMARTOMA: ANUNUSUAL HAMARTOMATOUS LESION OF THEGASTROINTESTINAL TRACT Simona Gurzu, RO

09:00 - 09:00 CC071SOLITARY RECTAL ULCER SYNDROME WITH RECTALPROLAPSE :A CASE REPORT Mohammed Adil Kaddouri, MA09:00 - 09:00 CC072PAPILLOMA VS CONDYLOMA: AN IMPORTANT SUBTLEDISTINCTION Antonio Oliveira, PT







09:00 - 09:00 CC079ACUTE E HEPATITIS IN AN AUTOIMMUNITYENVIRONMENT Luísa Martins Figueiredo, PT

09:00 - 09:00 CC080A RARE CASE OF ACUTE LIVER INJURY SECONDARY TOCONCURRENT HEPATITIS A VIRUS INFECTION ANDDENGUE VIRUS INFECTION IN AN IMMUNOCOMPROMISEDPATIENT Nikko Theodore Raymundo, PH


09:00 - 09:00 CC082SUCCESSFUL TREATMENT OF HEPATITIS C IN A PATIENTWITH CONGENITAL SPHEROCYTOSIS BY RIBAVIRIN-FREEDIRECT-ACTING ANTIVIRALS REGIMEN: A CASE STUDY Ahmed Mansour, EG




09:00 - 09:00 CC084PEMBROLIZUMAB-INDUCED PANCREATIC EXOCRINEINSUFFICIENCY COMPLICATED BY SEVERE HEPATICSTEATOSIS Alex S Hong09:00 - 09:00 CC085CHARACTERISTICS OF IMMUNOGLOBULIN G4-RELATEDAUTOIMMUNE HEPATITIS: A CASE REPORT AND REVIEW OFLITERATURE Siyu Jiang, CN







09:00 - 09:00 CC093DIGESTIVE INVOLVEMENT IN RENDU OSLER WEBERDISEASE : A CASE REPORT Najoua Elmoutaoukil, MA

09:00 - 09:00 CC094ECTOPIC PAPILLA OF VATER IN THE GASTRIC ANTRUM Aikaterini Pappa, GR


09:00 - 09:00 CC096SECONDARY SCLEROSING CHOLANGITIS IN A CRITICALLY-ILL PATIENT PRECIPITATED BY SARS-COV2 INFECTION Bárbara Morão, PT

09:00 - 09:00 CC097GALLSTONE ILEUS: A RARE CAUSE OF BOWELOBSTRUCTION IN A LIVER TRANSPLANT PATIENT Tiago Ribeiro, PT09:00 - 09:00 CC098UNUSUAL APPEARANCE OF CHOLANGIOCARCINOMA:SOLID- CYSTIC LESION; A CASE REPORT Montri Gururatsakul, AU








09:00 - 09:00 CC106A RARE CAUSE OF OBSTRUCTIVE JAUNDICE Diana Ramos Silva, PT

09:00 - 09:00 CC107A CASE OF UNRESECTABLE LOCALLY ADVANCEDPANCREATIC CANCER IN WHICH RO RESECTION WASACHIEVED BY COMBINING CHEMOTHERAPY AND HIFUTHERAPY Atsushi Sofuni, JP





09:00 - 09:00 CC109AN EUS DIAGNOSIS OF A PANCREATIC NEUROENDOCRINETUMOUR: A RARE CASE OF OBSTRUCTIVE CHOLESTASISOVERLAPPING WITH CHOLEDOCHOLITHIASIS Rui de Sousa Magalhaes, PT09:00 - 09:00 CC110GASTRIC BAROTRAUMA INDUCED BY SELLICK MANEUVERPERFORMED TO ENABLE ENDOSCOPIC SUBMUCOSALDISSECTION Daniela Falcão, PT







09:00 - 09:00 CC117“METALLIC TULIP-BUNDLE” TECHNIQUE AS RESCUEHEMOSTATIC THERAPY AFTER ENDOSCOPIC MUCOSALRESECTION OF A GASTRIC LESION Ana Catarina Gomes, PT

09:00 - 09:00 CC118CLOSURE OF A JEJUNAL STUMP LEAK WITH AN OVER-THE-SCOPE-CLIP Ana Catarina Gomes, PT


09:00 - 09:00 CC120DUODENAL-TYPE FOLLICULAR LYMPHOMA Fernanda Lago, BR09:00 - 09:00 CC121UPPER GASTROINTESTINAL BLEEDING IN LIVERCIRRHOSIS: GASTROESOPHAGEAL VARICES ARE NOTALWAYS TO BLAME Emanuel Dias, PT








09:00 - 09:00 CC129INTESTINAL AMYLOIDOSIS PRESENTING AS A SOLITARYULCER OF THE CAECUM: A CASE REPORT Federica Crispino, IT

09:00 - 09:00 CC130RECTAL ULCERATIONS IN PATIENT WITH PERIANALHERPES SIMPLEX VIRUS TYPE 1 Lourdes Carreira Guillán, ES





09:00 - 09:00 CC132EXTENSIVE ACUTE OCCLUSIVE MESENTERIC ISCHEMIAWITH SEVERE ISCHEMIC COLITIS PRECIPITATED BYSEVERE CLOSTRIDIOIDES DIFFICILE INFECTION, A CASEREPORT Ana Ordonez Vazquez, MX09:00 - 09:00 CC133EXTENDED GASTROINTESTINAL MANTLE LYMPHOMA Ángela Martina Montero Moretón, ES







09:00 - 09:00 CC140ENDOSCOPY, RADIOLOGY AND PATHOLOGY: WHEN THEPIECES DON’T MATCH Ana Catarina Carvalho, PT

09:00 - 09:00 CC141UNUSUAL CASE OF HEAD OF PANCREAS MASS:METASTATIC PROSTATE CANCER Montri Gururatsakul, AU


09:00 - 09:00 CC143ENDOSCOPIC ULTRASOUND OF MENETRIER’S DISEASE,RARE CAUSE OF RESISTANT ANEMIA Mohammed Gouda, EG09:00 - 09:00 CC144PRIMARY EXTRA-NODAL PELVIC LYMPHOMA DIAGNOSEDBY ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLEBIOPSY (EUS-FNB) Omar AbdAllah, EG









E-Poster Session





09:00 - 09:00 P0784THE OBESTATIN/GPR39 SYSTEM REGULATES THESYNTHESIS AND SECRETION OF PANCREATIC ENZYMESFORM ACINAR CELLS Yolanda Pazos-Randulfe, ES09:00 - 09:00 P0785OPTIMIZATION OF DOSE LEVELS OF ORALLYADMINISTERED PANCREATIC ENZYME SUPPLEMENTS INTHE DYNAMIC IN-VITRO GASTROINTESTINAL MODEL TINY-TIM Mª Luisa Orera-Peña, ES

09:00 - 09:00 P0786CHARACTERIZATION OF HCO3






09:00 - 09:00 P0791FATTY PANCREAS REPRESENTS A RISK FACTOR FORACUTE PANCREATITIS: A PILOT STUDY Tawfik Khoury, IL




09:00 - 09:00 P0796HOW TO PREDICT MICROLITHIASIS IN IDIOPATHICPANCREATITIS – A MACHINE LEARNING DERIVED TOOL Michal Zorniak, DE09:00 - 09:00 P0797MACHINE LEARNING MODEL FOR EARLY PREDICTION OFNECROTISING PANCREATITIS: A COHORT ANALYSIS Szabolcs Kiss, HU

09:00 - 09:00 P0798THE CHARACTERISTICS AND THE POTENTIALPROGNOSTIC ROLE OF ACUTE ABDOMINAL ON-ADMISSIONPAIN IN ACUTE PANCREATITIS: A PROSPECTIVE COHORT-ANALYSIS OF 1432 CASES Mária Földi, HU












09:00 - 09:00 P0807THE ROLE OF CFTR MUTATIONS IN ACUTE BILIARYPANCREATITIS Ágnes Rita Martonosi, HU09:00 - 09:00 P0808METABOLIC ASSOCIATED FATTY LIVER DISEASE ISASSOCIATED WITH A MORE SEVERE ACUTE PANCREATITIS:A PROSPECTIVE COHORT ANALYSIS OF 2053 CASES Szilárd Váncsa, HU

09:00 - 09:00 P0809PREVALENCE OF GASTROINTESTINAL BLEEDING INPANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS Marie Anne Engh, HU









09:00 - 09:00 P0819COMMON CASR POLYMORPHISMS DO NOT INCREASECHRONIC PANCREATITIS RISK Amanda Takáts, HU09:00 - 09:00 P0821BICARBONATE DEFECTIVE CFTR VARIANTS IN CHRONICPANCREATITIS: A META-ANALYSIS Gergő Berke, HU

09:00 - 09:00 P0822OPEN LABEL, RANDOMIZED, CROSSOVER CLINICAL TRIALTO ASSESS THE EFFICACY OF INCREASING DOSES OFPANCREATIC ENZYMES, WITH OR WITHOUT INHIBITION OFGASTRIC ACID SECRETION, IN PATIENTS WITHPANCREATIC EXOCRINE INSUFFICIENCY SECONDARY TOCHRONIC PANCREATITIS Daniel De la Iglesia-Garcia, ES











09:00 - 09:00 P0830SYSTEMATIC REVIEW AND META-ANALYSIS OFOBSERVATIONAL STUDIES ON BD-IPMNS RISK OFPROGRESSION TO HIGH-RISK LESIONS Alberto Balduzzi, IT09:00 - 09:00 P0831INTERNATIONAL EXTERNAL VALIDATION OF ASTRATIFICATION TOOL TO IDENTIFY BRANCH-DUCTINTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS ATLOWEST RISK OF PROGRESSION Kasper A. Overbeek, NL

09:00 - 09:00 P0832NEW KID ON THE BLOCK: PANCREATIC CYST FLUIDGLUCOSE IS AN ACCURATE, BEDSIDE, LOW COSTDIAGNOSTIC TEST OF MUCINOUS CYSTS Dana Ben-Ami Shor, IL









09:00 - 09:00 P0841RNA-SEQUENCING OF PANCREATIC CANCER FROM EUS-ACQUIRED TISSUE IS USEFUL TO DEFINE MOLECULARSUBTYPES AND PROGNOSIS Livia Archibugi, IT09:00 - 09:00 P0842IMMUNOMODULATION INDUCED BY ENDOSCOPICULTRASOUND-GUIDED ABLATION WITH THEHYBRIDTHERM PROBE IN LOCALLY ADVANCED ANDBORDERLINE RESECTABLE PANCREATIC CANCER:RESULTS FROM A PHASE II RANDOMIZED CONTROLLEDTRIAL Sabrina Gloria Giulia Testoni, IT

09:00 - 09:00 P0843DISCRIMINATION BETWEEN PANCREATIC CANCER,PANCREATITIS AND HEALTHY CONTROLS USING URINARYPOLYAMINE PANEL Samuli Nissinen, FI











09:00 - 09:00 P0854CAUSES OF DEATH IN PATIENTS WITH METASTATICDIGESTIVE NEUROENDOCRINE TUMOURS Juliette Beringer, FR09:00 - 09:00 P0855SOMATOSTATIN ANALOGS IN PATIENTS WITH ZOLLINGERELLISON SYNDROME (ZES): AN OBSERVATIONAL STUDY Sara Massironi, IT

09:00 - 09:00 P0856QUANTITATIVE CONTRAST-ENHANCED ENDOSCOPICULTRASOUND IN PANCREATIC DUCTALADENOCARCINOMA AND PANCREATIC NEUROENDOCRINETUMORS: CAN WE PREDICT SURVIVAL USING PERFUSIONPARAMETERS? Alina Liliana Constantin, RO



E-Poster Session






09:00 - 09:00 P0188EFFICACY, SAFETY AND COST EFFECTIVENESS OFINTRAGASTRIC BALLOON THERAPY COMPARED TO AMULTIDISCIPLINARY WEIGHT LOSS PROGRAM IN A REAL-WORLD POPULATION – A PROPENSITY SCORE MATCHINGANALYSIS Jürgen Stein, DE09:00 - 09:00 P0189REDO ENDOSCOPIC SLEEVE GASTROPLASTY: REPEATINGDOES NOT MEAN FAILING Maria Valeria Matteo, IT

09:00 - 09:00 P0190OBESITY TREATMENT BY GASTRIC ENDOSCOPY SLEEVEPLICATION: EFFICACY AND SAFETY AT 24 MONTHSFOLLOW-UP Carmen H. Bautista Altamirano, ES

09:00 - 09:00 P0191ENDOSCOPIC SLEEVE GASTROPLASTY AS NEW HOPE FORMILD OBESITY Maria Valeria Matteo, IT

09:00 - 09:00 P0192HIGHER BODY MASS INDEX IS ASSOCIATED WITH BETTERCLINICAL OUTCOMES IN PATIENTS WITH CYSTICFIBROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF3100 PATIENTS Rita Nagy, HU









09:00 - 09:00 P0199PREVALENCE OF MICRONUTRIENT DEFICIENCY ANDRELATIONS WITH POLYENDOCRINE SYNDROME TYPE 3 INPATIENTS WITH CHRONIC AUTOIMMUNE ATROPHICGASTRITIS Safa Senel, TR09:00 - 09:00 P0200EARLY CHILDHOOD FOOD ALLERGY IN FAMILIES WITHATOPY IN BULGARIA Silviya Kuneva, BG


09:00 - 09:00 P0202LACTOSE MALABSORPTION BY THIRD-GENERATIONHYDROGEN BREATH TEST: NEW DATA COLLECTION ANDTIME IMPLEMENTATION Filippo Scevola, IT

09:00 - 09:00 P0203NATIVE AND SATURATED BOVINE LACTOFERRINMODULATE THE EXPRESSION OF TOLL-LIKE RECEPTORS(TLRS) IN MICE TREATED WITH ANTIBIOTICS Andrea Bellés, ES

09:00 - 09:00 P0204ASSESSMENT OF GUT MICROBIOTA IN IBS PATIENTSAFTER A 4-WEEK STARCH-AND SUCROSE-REDUCED DIETSHOWS INCREASED BETA DIVERSITY, UNALTERED ALPHADIVERSITY AND SPECIFIC CHANGES IN GENERA Clara Nilholm, SE





09:00 - 09:00 P0209ASSOCIATION OF IRRITABLE BOWEL SYNDROME ANDMICRONUTRIENTS: A SYSTEMATIC REVIEW Yao Neng Teo, SG09:00 - 09:00 P0210INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITHFRUCTOSE Raphael Fagundes Rosa, NL


09:00 - 09:00 P0213VITAMIN D RECEPTOR ACTIVATION EXERTS ANTI-SECRETORY ACTIONS IN COLONIC EPITHELIAL CELLS Caitriona E. Curley, IE

09:00 - 09:00 P0214DIETARY PATTERNS AND GASTROESOPHAGEAL REFLUXES:CORRELATION ANALYSIS Sergey Morozov, RU

09:00 - 09:00 P0216SAFE PATIENT SELECTION AND USE OF TRANSNASALENDOSCOPY(TNE) FOR PEG INSERTION IN MOTORNEURONE DISEASE(MND) Mohammed Shamsaldeen, UK


09:00 - 09:00 P0218SCHEDULED PERCUTANEOUS ENDOSCOPICGASTROSTOMY TUBE REPLACEMENT DID NOT REDUCEPEG RELATED COMPLICATIONS Tawfik Khoury, IL



E-Poster Session





09:00 - 09:00 P0859DOES ANTIBIOTIC PROPHYLAXIS REDUCE THE INFECTIONRATE IN CHILDREN AFTER PERCUTANEOUS ENDOSCOPICGASTROSTOMY INSERTION? Oana Belei, RO09:00 - 09:00 P0860I-SCAN ENDOSCOPIC PATTERNS OF HELICOBACTERPYLORI-INDUCED GASTRITIS Ahmed Altonbary, EG


09:00 - 09:00 P0862ME-BLI TO JUDGE THE DEPTH OF INVASION OF EARLYESOPHAGEAL CANCER WITH TYPE B2 BLOOD VESSELSAND ANALYSIS OF RELATED FACTORS Wei Ning, CN

09:00 - 09:00 P0863A PROMISING METHOD FOR ACCURATELY CALCULATINGTHE PERCENTAGE OF GASTRIC INTESTINAL METAPLASIAAREA Ning Wei, CN





09:00 - 09:00 P0868THE SWEDISH STANDARDIZED COURSE OF CARE FORUPPER GI CANCER – CANCER PREVALENCE ANDPREDICTIVE VALUES OF ENTRY CRITERIA Michiel Van Nieuwenhoven, SE

09:00 - 09:00 P0869DELIBERATE FOREIGN BODY SWALLOWING IN PATIENTSWITH UNDERLYING MENTAL HEALTH DISEASE: ARETROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY Warren Seow, AU09:00 - 09:00 P0870SAFETY AND EFFICACY OF DUAL EMISSION ENDOSCOPICLASER TREATMENT IN PATIENTS WITH UPPER OR LOWERGASTRO-INTESTINAL VASCULAR LESIONS CAUSINGCHRONIC ANAEMIA: RESULTS FROM THE FIRST MULTI-CENTRE COHORT STUDY Alessandro Rimondi, IT


09:00 - 09:00 P0872DIAGNOSTIC OUTCOMES AFTER CANCELLEDGASTROSCOPY: RESULTS OF TELEPHONE VETTING&GT;600 PATIENTS DURING THE COVID-19 PANDEMIC Ella Mozdiak

09:00 - 09:00 P0873THE ROLE OF COMPUTED TOMOGRAPHY IN FISH BONEIMPACTION IN ESOPHAGUS AND ACCURACY OF PATIENT'SCOMPLAINING LOCATION COMPARED WITH THEIMPACTION LOCATION: A RETROSPECTIVE, SINGLE-CENTER STUDY Gyu Man Oh, KR




09:00 - 09:00 P0877CLINICAL UTILITY OF DUODENAL BIOPSIES IN THEDIAGNOSIS OF IRON DEFICIENCY ANEMIA. ARETROSPECTIVE STUDY Theodoros Voulgaris, GR




09:00 - 09:00 P0878REAL-TIME USE OF ARTIFICIAL INTELLIGENCE FORDIAGNOSING EARLY GASTRIC CANCER BY ENDOSCOPY: AMULTICENTER, DIAGNOSTIC STUDY Xinqi He, CN09:00 - 09:00 P0879DOES IMAGE ENHANCED ENDOSCOPY IMPROVEDETECTION OF NEOPLASIA IN BARRETT’S OESOPHAGUSSURVEILLANCE: A NETWORK META ANALYSIS Chun Wai Sin



09:00 - 09:00 P0882GASTROINTESTINAL RESIDUE REMOVAL USING ABALLOON OVERTUBE UNDER ULTRATHIN ENDOSCOPICNAVIGATION: AN EXPERIMENTAL ANIMAL STUDY Kazuhiro Kozuka, JP

09:00 - 09:00 P0883WAFER PAPER AND RING-MOUNTED POLYGLYCOLIC ACIDSHEET METHOD FOR SHIELDING ULCER AFTER GASTRICENDOSCOPIC SUBMUCOSAL DISSECTION Nobuya Kobayashi, JP




09:00 - 09:00 P0887AZITHROMYCIN VERSUS ERYTHROMYCIN IN INTRAVENOUSINFUSION IN UPPER GASTROINTESTINAL BLEEDING:PRELIMINARY RESULTS OF A NON-INFERIOR,PROSPECTIVE, RANDOMIZED, DOUBLE-BLINDCONTROLLED CLINICAL TRIAL Maria Boquera Ferrer, ES

09:00 - 09:00 P0888IMPACT ON AEROSOL GENERATION OF A MOUTHPIECEDESIGNED TO REDUCE DROPLET SPREAD OF COVID-19DURING UPPER GASTROINTESTINAL ENDOSCOPY, ASINGLE CENTER RANDOMIZED CONTROLLED TRIAL Pieter Sinonquel, BE09:00 - 09:00 P0889ENDOSCOPIC GRADING OF GASTRIC INTESTINALMETAPLASIA IN PATIENTS WITH AUTOIMMUNE GASTRITIS:PSEUDOPYLORIC METAPLASIA MUDDIES THE WATERS Emanuele Dilaghi, IT



09:00 - 09:00 P0892PILLCAM ESO CAPSULE: AN ALTERNATIVE DIAGNOSTICTOOL DURING THE COVID-19 PANDEMIC. FIRST IRISHEXPERIENCE Mary Nwaezeigwe, IE

09:00 - 09:00 P0893DIRECT AND NON-DIRECT COSTS IN DIRECT-TO-TESTUPPER GASTROINTESTINAL ENDOSCOPY: NURSEENDOSCOPISTS VERSUS DOCTORS Ahaan Gupta



09:00 - 09:00 P0896EMERGENCY ENDOSCOPY IN CHILDREN DURING SARS-COV-2 PANDEMIC IN A TERTIARY CENTER – A CHANGINGPATTERN? Ana Sofia Vilardouro, PT




09:00 - 09:00 P0897DIFFERENTIAL DIAGNOSTICS AND LONG-TERMPROGNOSIS OF NON-ATROPHIC DUODENAL CHANGES INCHILDREN UNDERGOINGESOPHAGOGASTRODUODENOSCOPY WITH SYSTEMATICBIOPSY SAMPLING Sofia Kröger, FI09:00 - 09:00 P0898ARTIFICIAL INTELLIGENT CHRONIC ATROPHIC GASTRITISDIAGNOSTIC SYSTEM: AN EFFECTIVE GASTRICPRECANCEROUS RISK-SURVEILLANCE ASSISTED TOOL Yijie Zhu, CN




09:00 - 09:00 P0902PREMEDICATION WITH SIMETHICONE FOR IMPROVINGTHE QUALITY OF GASTRIC MUCOSAL VISUALISATIONDURING UPPER GASTROINTESTINAL ENDOSCOPY: ADOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL Léo Duez, BE

09:00 - 09:00 P0903TREATMENT OF DUODENAL ULCER BLEEDING - EFFICACYOF TRAUMATIC AND ATRAUMATIC OVER-THE-SCOPE-CLIPS (OTSC) – A MULTICENTER RETROSPECTIVEANALYSIS Marcus Hollenbach, DE



09:00 - 09:00 P0908DIAGNOSIS AND MANAGEMENT OF HYPERPLASTICGASTRIC POLYPS Salma Souissi, TN

09:00 - 09:00 P0909THE DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCEAND COMPUTER-AIDED DIAGNOSIS FOR THE DETECTIONAND CHARACTERISATION OF COLORECTAL POLYPS: ASYSTEMATIC REVIEW AND META-ANALYSIS Scarlet Nazarian09:00 - 09:00 P0910ENDOSCOPIC RETROGRADE APPENDICITIS THERAPY: ANEW THERAPEUTIC METHOD FOR ACUTE APPENDICITIS INCHILDREN WITH LEUKEMIA Jiyu Zhang, CN




09:00 - 09:00 P0914ACETO-ELECTRIC CHROMOENDOSCOPY FOR EVALUATINGTHE PIT PATTERN IN COLORECTAL POLYPS Shunsuke Yamamoto, JP

09:00 - 09:00 P0915THE ROLE OF CROSS-SECTIONAL IMAGING IN THEMANAGEMENT OF PATIENTS WITH COMPLEX COLORECTALPOLYPS Clare Westwood, UK



09:00 - 09:00 P0918INCREMENTAL YIELD OF ARTIFICIAL INTELLIGENCE INFOLLOW-UP SCREENING COLONOSCOPIES – AN INTERIMANALYSIS ON 432 PATIENTS Sebastian Manuel Milluzzo, IT




09:00 - 09:00 P0919A NOVEL ONE-DAY VIRTUAL-LIVE HYBRID TRAININGCOURSE IS FEASIBLE AND HAS A POSITIVE IMPACT ONCOLONOSCOPY KEY PERFORMANCE INDICATORS OFEXPERIENCED ENDOSCOPY TRAINEES Louise Krott, BE09:00 - 09:00 P0920SURVEILLANCE INTERVAL OF PATIENTS WITH HIGH-RISKADENOMAS REMOVED DURING SCREENINGCOLONOSCOPY Thomas Yuen Tung Lam, HK




09:00 - 09:00 P0925ESD KNIVES FEATURE COMPARISON - WHICH KNIFE TOUSE FOR ESD? Kota Momose, JP

09:00 - 09:00 P0926ENDOSCOPIC THERMAL DYNAMICS FOR EVALUATING THELESION WITH INFLAMMATION OR CANCER CORRELATESTO THE HISTOLOGICAL FINDINGS Hidetoshi Ohta, JP



09:00 - 09:00 P0929ENDOSCOPY AND RADIOLOGY IN THE EVALUATION OFRESPONSE TO CHEMORADIOTHERAPY IN LOW RECTALCANCER Pedro Currais, PT

09:00 - 09:00 P0930ENDOSCOPIC SUBMUCOSAL DISSECTION FOR LESIONSINVOLVING ILEOCECAL VALVE WITH/WITHOUT EXTENSIONINTO TERMINAL ILEUM: A MULTICENTER 10-YEAR STUDY Hidenori Tanaka, JP09:00 - 09:00 P0931EFFICACY OF SINGLE-BALLOON OVERTUBE FORENDOSCOPIC SUBMUCOSAL DISSECTION IN THEPROXIMAL COLON: A PROPENSITY SCORE MATCHEDANALYSIS Hidenori Tanaka, JP




09:00 - 09:00 P0935ARTIFICIAL INTELLIGENCE FOR POLYP DETECTIONDURING COLONOSCOPY – AN IN-DEPTH ANALYSIS OF ACOMMERCIALLY AVAILABLE SYSTEM Joel Troya, DE

09:00 - 09:00 P0936BOWEL PREPARATION QUALITY AND ITS IMPACT ONCOLONOSCOPY SCREENING INTERVAL AFTER A NEGATIVECOLONOSCOPY Lisa-Maria Rockenbauer, AT




09:00 - 09:00 P0940CHARACTERISTICS OF DEPRESSED TYPE COLORECTALNEOPLASMS IN MAGNIFYING ENDOSCOPY ANDENDOCYTOSCOPY Shinei Kudo, JP




09:00 - 09:00 P0941AN ARTIFICIAL INTELLIGENCE-BASED QUALITYIMPROVEMENT SYSTEM SIGNIFICANTLY IMPROVED THEEFFICACY OF COMPUTER-AIDED DETECTION SYSTEM INCOLONOSCOPY: A 2*2 FACTORIAL ANALYSIS Lihui Zhang, CN09:00 - 09:00 P0942NEW COMPUTER-AIDED POLYP DETECTION SYSTEM(ENDO-AID) INCREASED THE 5-10MM ADENOMADETECTION RATE IN JUNIOR ENDOSCOPISTS DURINGCOLONOSCOPIES – A PILOT STUDY Ho Shing Louis Lau, HK




09:00 - 09:00 P0946EFFICACY, TOLERABILITY AND SAFETY OF SPLIT-DOSEBOWEL CLEANSING REGIMEN OF MAGNESIUM CITRATEWITH SODIUM PICOSULFATE IN SPECIAL GROUPS OFPATIENTS Tamás Molnár, HU

09:00 - 09:00 P0947ARTIFICIAL INTELLIGENCE IN ENDOSCOPIC SCREENINGFOR COLORECTAL CANCER – EXPENSIVE ADD-ON OR COSTSAVING? Stephan Döring, DE



09:00 - 09:00 P0950REAL-TIME ARTIFICIAL INTELLIGENCE-AIDEDCOLONOSCOPY EXPERIENCE: THE IMPACT ON ROUTINECLINICAL PRACTICE IN A HIGH-VOLUME CENTER -PRELIMINARY DATA Costanza Alvisi, IT

09:00 - 09:00 P0951PATIENT ACCEPTABILITY OF OPTICAL DIAGNOSIS FORDIMINUTIVE POLYPS WITH A RESECT AND DISCARDSTRATEGY IN BOWEL CANCER SCREENINGCOLONOSCOPY Ahmir Ahmad09:00 - 09:00 P0952HIGH CONFIDENCE OPTICAL DIAGNOSIS OF SMALLPOLYPS AT COLONOSCOPY VERSUS HISTOPATHOLOGY:MOVING TOWARDS A NEW GOLD STANDARD? Ahmir Ahmad




09:00 - 09:00 P0956NO SURVEILLANCE INTERVAL CHANGE WITH OPTICALDIAGNOSIS OF SMALL POLYPS DURING BOWEL CANCERSCREENING COLONOSCOPY Ahmir Ahmad

09:00 - 09:00 P0957CLINICAL USEFULNESS OF THE “HOLD-AND-DRAG”CLOSURE USING SB CLIP FOR LARGE MUCOSAL DEFECTSAFTER COLORECTAL ENDOSCOPIC SUBMUCOSALDISSECTION Kenjiro Shigita, JP



09:00 - 09:00 P0960HIGH FREQUENCY OF COLORECTAL POLYPS IN PATIENTSOF SPORADIC ADENOMAS OR ADENOCARCINOMAS OF THEPAPILLA OF VATER: A PROPENSITY SCORE MATCHINGSTUDY Fan Zhou, CN




09:00 - 09:00 P0961INCOMPLETE RESECTION RATES OF 4-20MM NON-PEDUNCULATED COLORECTAL POLYPS WHEN USINGROUTINE SUBMUCOSAL INJECTION Leslie Motchum, CA09:00 - 09:00 P0962INFLUENCE OF SEDATION TYPE ON POLYP DETECTIONRATE IN DIAGNOSTIC AND SCREENING COLONOSCOPIES:A TERTIARY CARE CENTER EXPERIENCE Fady Daniel, LB




09:00 - 09:00 P0966TECHNICAL OUTCOMES AND RISK OF STRICTURE AFTERENDOSCOPIC SUBMUCOSAL DISSECTION FOR LARGECOLORECTAL LESIONS Roberta Maselli, IT

09:00 - 09:00 P0967HOT AVULSION VERSUS ARGON PLASMA COAGULATIONFOR THE MANAGEMENT OF THE NON-LIFTING POLYP: AMULTICENTRE, RANDOMISED CONTROLLED TRIAL Chloe Attree, AU



09:00 - 09:00 P0970DEVELOPMENT AND COMPARISON OF THE POLYPDETECTION SYSTEM ENDOMIND WITH A COMMERCIALLYAVAILABLE CADE SYSTEM Alexander Hann, DE

09:00 - 09:00 P097210-YEAR PREVALENCE OF OVERALL COLONOSCOPY ANDSCREENING COLONOSCOPY USE IN GERMANY: A CLAIMSDATA ANALYSIS Michel Hornschuch, DE09:00 - 09:00 P0973EFFICACY OF ARGON PLASMA COAGULATION INPREVENTION OF BLEEDING RECURRENCE FROMGASTROINTESTINAL ANGIODYSPLASIA Sahar Nasr, TN





09:00 - 09:00 P0978ENDOSCOPIC MANAGEMENT OF SIGMOID COLONVOLVULUS - A RETROSPECTIVE COHORT OF 76 CASES Maria Inês Canha, PT

09:00 - 09:00 P0979PROSPECTIVE OBSERVATIONAL STUDY OF 1L NER1006COMPARED TO 2L POLYETHYLENE GLYCOL IN INPATIENTSAND OUTPATIENTS Marcus Hollenbach, DE



09:00 - 09:00 P0983AUGMENTATION OF BOWEL PREPARATION FOR REPEATCOLONOSCOPY : WHAT IS THE BEST APPROACH? Thomas Archer, UK




09:00 - 09:00 P0985STRICTURE FORMATION FOLLOWING ENDOSCOPICRESECTION FOR LARGE NON-PEDUNCULATEDCOLORECTAL POLYPS Sunil Gupta, AU09:00 - 09:00 P0986IS THIS THE TIP OF THE ICEBERG? SIX MONTH OUTCOMESFOR PATIENTS DECLINING ENDOSCOPIC INVESTIGATION Thomas Archer, UK





09:00 - 09:00 P0991DOES COMBINING EUS-GUIDED TISSUE ACQUISITIONWITH ERCP IN PATIENTS WITH DISTAL BILIARYOBSTRUCTION INCREASE THE RISK OF PANCREATITIS? Myrte Gorris, NL

09:00 - 09:00 P0993SAFETY AND EFFICACY OF DIRECT PERORALCHOLANGIOPANCREATOSCOPY IN ELDERLY PATIENTS: ACASE-CONTROL STUDY Marcantonio Gesualdo, IT



09:00 - 09:00 P0996TIMING OF ADMISSION AND ENDOSCOPIC DRAINAGE INPATIENTS WITH ACUTE CHOLANGITIS: WEEKDAY VERSUSWEEKEND Bogdan Miutescu, RO

09:00 - 09:00 P0997THE USEFULNESS OF ERCP BILE ASPIRATED CULTURE INPATIENTS WITH ACUTE CHOLANGITIS Bogdan Miutescu, RO09:00 - 09:00 P0998USE OF FULLY COVERED SELF-EXPANDING METAL STENTSFOR MANAGEMENT OF BENIGN BILIARY STRICTURE: ASYSTEMATIC REVIEW AND META-ANALYSIS Arthur Schmidt, DE




09:00 - 09:00 P1002AUTOMATIC DETECTION OF BILIARY MASSES IN PATIENTSWITH INDETERMINATE BILIARY STENOSIS: THE FUTUREOF ARTIFICIAL INTELLIGENCE IN SINGLE-OPERATORCHOLANGIOSCOPY João Afonso, PT

09:00 - 09:00 P1004ENDOSCOPIC PAPILLECTOMY: RESULTS OF A TERTIARYREFERRAL CENTER EXPERIENCE Francesca Aprile, IT



09:00 - 09:00 P1009MORPHOLOGICAL CLASSIFICATION IN CHOLANGIOSCOPY:MORE OBJECTIVITY, MORE ACCURACY? Ana Luísa Santos, PT

09:00 - 09:00 P1010IS URGENT ERCP THE BEST CHOICE FOR ACUTE BILIARYPANCREATITIS? Sorin Alexandru Coman, RO




09:00 - 09:00 P1011ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY WASNOT MORE COST-EFFECTIVE THAN FINE NEEDLEASPIRATION WITH RAPID ON-SITE EVALUATION INGASTROINTESTINAL LESIONS DIAGNOSIS Tawfik Khoury, IL09:00 - 09:00 P1012ANXIETY AND CANCEROPHOBIA IN PATIENTS WITH SMALLGASTROINTESTINAL SUBEPITHELIAL LESIONS ANDTUMOURS: BASELINE RESULTS OF A PROSPECTIVE STUDY(QUALI-BANDING-SET) Francesc Bas-Cutrina, ES




09:00 - 09:00 P1016LUMEN-APPOSING METAL STENTS FOR EUS-GUIDEDDRAINAGE OF WALLED-OFF PANCREATIC NECROSIS:RESULTS OF A LARGE MULTICENTER COHORT Arnaldo Amato, IT

09:00 - 09:00 P1017ENDOSCOPIC ULTRASOUND GUIDED ELASTOGRAPHY FORTHE DIAGNOSIS OF MALIGNANCY IN RESECTABLEPANCREATIC TUMORS Julio Iglesias-Garcia, ES


09:00 - 09:00 P1019POSSIBILITIES OF ENDOSCOPIC ULTRASONOGRAPHY ANDOTHER MODERN ENDOSCOPIC TECHNIQUES ININFLAMMATORY BOWEL DISEASES Anastasia Titaeva, RU

09:00 - 09:00 P1020APPLICATION OF ARTIFICIAL INTELLIGENCE FOR REAL-TIME ANATOMICAL RECOGNITION DURING ENDOSCOPICULTRASOUND EVALUATION: A PILOT STUDY Roberto Oleas, EC

09:00 - 09:00 P1021WET SUCTION TECHNIQUE: THE CORNERSTONE OF EUS-GUIDED SAMPLING OF SOLID LESIONS? Inês Marques de Sá, PT09:00 - 09:00 P1022EUS AND PET-CT RESTAGING FOR ESOPHAGEAL ANDGASTRIC ADENOCARCINOMA.COMPARED PERFORMANCEAND SURVIVAL PREDICTION Eduardo Redondo-Cerezo, ES




09:00 - 09:00 P1026CREATION OF A PATIENT REPORTED EXPERIENCEMEASURE TOOL TO EVALUATE PATIENTS’ EXPERIENCEDURING ENDOSCOPIC ULTRASONOGRAPHY (EUS): PREUSSTUDY. Laura Apadula, IT

09:00 - 09:00 P1027DEEP LEARNING-BASED NAVIGATION SYSTEM FORPANCREATIC ENDOSCOPIC ULTRASONOGRAPHY Huiling Wu, CN


09:00 - 09:00 P1029DYNAMIC CONTRAST HARMONIC IMAGING BYENDOSCOPIC ULTRASOUND ANDIMMUNOHISTOCHEMICAL ANALYSIS IN GASTRIC CANCER-A FEASIBILITY STUDY Victor-Mihai Sacerdotianu, RO

09:00 - 09:00 P1030ENDOSCOPIC ULTRASOUND-GUIDED ETHANOL ANDRADIOFREQUENCY ABLATION OF FUNCTIONINGINSULINOMAS: A SYSTEMATIC LITERATURE REVIEW Ghassan El-Sayed




09:00 - 09:00 P1031ELECTROCAUTERY-ENHANCED DELIVERY SYSTEM OFLUMEN APPOSING METAL STENT FOR EUS-GUIDEDBILIARY AND GALLBLADDER DRAINAGE: A SINGLE-CENTRESTUDY Martha Arevalo-Mora, EC09:00 - 09:00 P1032ENDOSCOPIC ULTRASOUND SHARE-WAVE ELASTOGRAPHYOF THE RIGHT AND LEFT HEPATIC LOBE PREDICTS LIVERCIRRHOSIS: A DIAGNOSTIC TRIAL Miguel Puga-Tejada, EC




09:00 - 09:00 P1036CLINICAL PRACTICE OF SPIRAL ENTEROSCOPY (SPE) INTHE LEARNING PHASE OF A REAL-WORLD SETTING Martin Raithel, DE

09:00 - 09:00 P1037PERCEPTION AND EXPECTATIONS TOWARDS ARTIFICIALINTELLIGENCE IN CAPSULE ENDOSCOPY Romain Leenhardt, FR


09:00 - 09:00 P1039MAGNETIC-ASSISTED CAPSULE ENDOSCOPY IN CHILDREN:PRELIMINARY REPORT ON FEASIBILITY, SAFETY ANDIMPACT ON GASTRIC TRANSIT TIME. Letizia Zenzeri, IT

09:00 - 09:00 P1040USEFULNESS OF ENDOSCOPIC DELIVERY METHOD FORPATIENTS WITH CAPSULE ENDOSCOPY STAGNATION INTHE STOMACH Akihiko Sumioka, JP

09:00 - 09:00 P1041THE DIAGNOSTIC PERFORMANCE OF PAN-ENTERICCAPSULE ENDOSCOPY AND MAGNETIC RESONANCEENTEROCOLONOGRAPHY IN PATIENTS WITH SUSPECTEDCROHN’S DISEASE Jacob Broder Brodersen, DK09:00 - 09:00 P1042GUIDED CAPSULE FOR UPPER AND MIDGASTROINTESTINAL BLEEDING Jean-Francois Rey, FR





09:00 - 09:00 P1047ARTIFICIAL INTELLIGENCE AND CAPSULE ENDOSCOPY:AUTOMATIC DETECTION OF GASTRIC PROTRUDINGLESIONS USING A CONVOLUTIONAL NEURAL NETWORK João Afonso, PT

09:00 - 09:00 P1048PERFORMANCE OF A DEEP LEARNING SYSTEM FORAUTOMATIC DIAGNOSIS OF PROTRUDING LESIONS INCOLON CAPSULE ENDOSCOPY: A MULTICENTRIC STUDY Pedro Cardoso, PT

09:00 - 09:00 P1049AUTOMATIC DETECTION OF COLONIC ULCERS ANDEROSIONS IN COLON CAPSULE ENDOSCOPY IMAGESUSING A CONVOLUTIONAL NEURAL NETWORK João Afonso, PT

09:00 - 09:00 P1050AUTOMATIC DETECTION OF ULCERS AND EROSIONS IN PILLCAM™ CROHN’S CAPSULE USING A CONVOLUTIONALNEURAL NETWORK João Afonso, PT




09:00 - 09:00 P1051A PROSPECTIVE COMPARISON OF TWO HEADED ANDSINGLE HEADED CAPSULES FOR THE INVESTIGATION OFSUSPECTED SMALL BOWEL BLEEDING. ARE TWO HEADSBETTER THAN ONE? Eilís M. McCarthy, IE09:00 - 09:00 P1052ARTIFICIAL INTELLIGENCE AND CAPSULE ENDOSCOPY:AUTOMATIC DETECTION OF GASTRIC VASCULAR LESIONSUSING A CONVOLUTIONAL NEURAL NETWORK Miguel Jose Mascarenhas Saraiva, PT





09:00 - 09:00 P1057MODIFIED ENDOSCOPIC VACUUM THERAPY FOR THETREATMENT OF GASTROINTESTINAL FISTULAS ANDPERFORATIONS: EXPERIENCE FROM A BRAZILIANTERTIARY CARE CENTER Danielle Queiroz Bonilha, BR

09:00 - 09:00 P1058PROPHYLACTIC TRANSCATHETER ARTERIALEMBOLIZATION IS ASSOCIATED WITH LOWER ODDS OFREBLEEDING IN NON-VARICEAL UPPERGASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEWAND META-ANALYSIS Eszter Boros, HU

E-Poster Session


09:00 - 09:00 P1102COSTS SAVINGS ASSOCIATED WITH FERRIC MALTOL ANDTHE REDUCED USE OF INTRAVENOUS IRON BASED ONREAL WORLD DATA Stefanie Howaldt, DE09:00 - 09:00 P1103A 7 YEAR RETROSPECTIVE REVIEW OF IRON DEFICIENCYANAEMIA IN A CATCHMENT OF 330,000, DEMONSTRATINGTHE NEED FOR A DEDICATED ANAEMIA SERVICE Matthew Johnson








09:00 - 09:00 P1111RATE OF INAPPROPRIATE PROTON PUMP INHIBITORSPRESCRIPTION AT DISCHARGE FROM INTERNAL MEDICINEDEPARTMENTS ACCORDING TO A DEVELOPEDALGORITHM Orly Sneh-Arbib, IL




09:00 - 09:00 P1112ONLINE EDUCATION SIGNIFICANTLY IMPROVEDGASTROENTEROLOGISTS' KNOWLEDGE OF CROHNDISEASE MANAGEMENT Elaine Bell09:00 - 09:00 P1113ONLINE EDUCATION SIGNIFICANTLY IMPROVESGASTROENTEROLOGISTS' KNOWLEDGE OF URGENCY AS AKEY CONCERN FOR PATIENTS WITH ULCERATIVE COLITIS Elaine Bell








E-Poster Session



09:00 - 09:00 P0524IS ANTI-PD1-INDUCED COLITIS A DISTINCT HISTOLOGICALSUBTYPE? Stratigoula Sakellariou, GR09:00 - 09:00 P0525GUT BACTERIA FUNCTIONALITY PROFILES AND DIVERSITYINDEX DETECTED BY THE GA-MAP® DYSBIOSIS TEST LX Kristin Gravdal, NO

09:00 - 09:00 P0527STUDYING THE MUTUAL INTERACTION BETWEEN THEHUMAN GUT EPITHELIUM AND THE PREDOMINANTLYANAEROBIC GUT MICROBIOME IN HOXBAN-STOOL Raphael Fagundes Rosa, NL

































































































09:00 - 09:00 P0624THE IMPACT OVERWEIGHT ON DIVERTICULAR DISEASE: ACASE CONTROL MULTICENTER STUDY Tawfik Khoury, IL







E-Poster Session


09:00 - 09:00 P0001THE FIRST REPORT ON THE NUCLEOTIDE ECTO-ENZYMEMETABOLIC PATTERN IN THE RAT GASTRIC AND COLONICMUCOSA UNDER THE CONDITIONS OFCYCLOOXYGENASE-1/-2 BLOCKAGE WITH INDOMETHACIN Christina Nasadyuk, UA09:00 - 09:00 P0003ROLE OF MAFB TRANSCRIPTION FACTOR IN HUMANINTESTINAL METAPLASIA AND GASTRIC CANCERBIOPSIES Rachel Gingold-Belfer, IL








09:00 - 09:00 P0011CLOSTRIDIOIDES DIFFICILE INFECTION AFTER VARICEALBLEEDING, A RISK TO BE CONSIDERED Bogdan Ungureanu, RO

09:00 - 09:00 P0012SYSTEMATIC REVIEW WITH META-ANALYSIS: INFLUENCEOF INDIVIDUAL PROTON PUMP INHIBITORS ON CLINICALOUTCOMES IN PATIENTS RECEIVING CLOPIDOGRELFOLLOWING PERCUTANEOUS CORONARY INTERVENTION Beom Jin Kim, KR




09:00 - 09:00 P0013UPPER GASTROINTESTINAL BLEEDING IN VERY OLDPATIENTS. RISK FACTORS FOR IN-HOSPITAL AND DELAYEDMORTALITY Rita Jiménez-Rosales, ES09:00 - 09:00 P0014USE OF INTRAVENOUS IRON REDUCES MORTALITY,HOSPITAL RE-ATTENDANCE AND READMISSION AFTERACUTE PEPTIC ULCER BLEEDING Ting Ting Chan, HK




09:00 - 09:00 P0018THE UTILITY OF CT ANGIOGRAPHY IN IDENTIFICATION OFACUTE GASTROINTESTINAL BLEEDING SOURCE ANDPREDICTORS OF A POSITIVE EXAMINATION Tawfik Khoury, IL




09:00 - 09:00 P0022ACUTE UPPER GASTROINTESTINAL BLEEDING INPATIENTS USING ANTICOAGULANTS: DOES THE TIMING OFENDOSCOPY AFFECT OUTCOMES? Tiago Lima Capela, PT

09:00 - 09:00 P0023MODERN ANTICOAGULATION WITH FACTOR XAINHIBITORS IN ONCOLOGY: IS THE GASTROINTESTINALBLEEDING RATE (ALSO) DECISIVE? Martin Raithel, DE09:00 - 09:00 P0024OVERLAPPING OF IRRITABLE BOWEL SYNDROME ANDUNINVESTIGATED DYSPEPSIA IN THE ADMINISTRATIVECENTER OF EASTERN SIBERIA Vladislav Tsukanov, RU








09:00 - 09:00 P0032THE PARAVENTRICULAR HYPOTHALAMIC NUCLEUS ISINVOLVED IN EXENDIN-4-INDUCED EMESIS ANDINHIBITION OF FOOD AND WATER INTAKE IN SUNCUSMURINUS Sze Wa Chan, HK




09:00 - 09:00 P0033DEXTRAN SODIUM SULPHATE-INDUCEDGASTROINTESTINAL INJURY FURTHER AGGRAVATES THEIMPACT OF GALANTAMINE ON THE GASTRIC MYOELECTRICACTIVITY IN EXPERIMENTAL PIGS Jan Bures, CZ09:00 - 09:00 P0034ADHESION OF GASTRIC CANCER CELLS TO THE ENTERICNERVOUS SYSTEM IN A NEWLY DEVELOPED CO-CULTUREMODEL: COMPARISON BETWEEN THE INTESTINAL ANDDIFFUSE TYPE OF GASTRIC CANCER Nicolas Chapelle, FR








09:00 - 09:00 P0042A DIAGNOSTIC DELAY OF TEN YEARS IN THE DANEOECOHORT CALLS FOR FOCUS ON EDUCATION - APOPULATION-BASED STUDY OF INCIDENCE, DIAGNOSTICPROCESS AND COMPLICATIONS OF EOSINOPHILICOESOPHAGITIS IN THE NORTH DENMARK REGION Anne Lund Krarup, DK

09:00 - 09:00 P0043SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASEACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE INADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OFA NATIONWIDE PROSPECTIVE COHORT STUDY Philipp Schreiner, CH09:00 - 09:00 P0044EFFICACY OF STEPPED THERAPY WITH PROTON PUMPINHIBITORS IN ADULT PATIENTS WITH EOSINOPHILICESOPHAGITIS AFTER 12 MONTHS OF FOLLOW UP IN OURHEALTHCARE AREA Lucía Madero, ES







09:00 - 09:00 P0051ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTSWITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVEOF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY Philipp Schreiner, CH

09:00 - 09:00 P0052SYMPTOM AND QUALITY OF LIFE BURDEN AMONGPATIENTS WITH EOSINOPHILIC OESOPHAGITIS IN A REAL-WORLD SETTING Alain M. Schoepfer, CH




09:00 - 09:00 P0053COMPLIANCE FOR THE PROSE DAILY DIARY: MEASURINGCOMPLETION RATES OF A NEW INSTRUMENT TO MEASUREDYSPHAGIA EPISODES IN PATIENTS WITH EOSINOPHILICESOPHAGITIS Stella Karantzoulis, US09:00 - 09:00 P0054EOSINOPHILIC ESOPHAGITIS IS FREQUENTLY ASSOCIATEDWITH DISORDERS OF PERISTALSIS AT HIGH-RESOLUTIONMANOMETRY: A PROSPECTIVE SINGLE-CENTRE CASE-CONTROL STUDY Pierfrancesco Visaggi, IT







09:00 - 09:00 P0061FOCAL C2 CRYOBALLOONTM ABLATION WITH 8SEC DOSEHAS SIMILAR EFFICACY AS 10SEC FOR TREATMENT OFBARRETT’S ESOPHAGUS RELATED NEOPLASIA. Charlotte N. Frederiks, NL

09:00 - 09:00 P0062RISK OF BARRETT’S ESOPHAGUS AND ESOPHAGEALADENOCARCINOMA IN PATIENTS DIAGNOSED WITHBREAST CANCER – A NATIONWIDE STUDY Yonne Peters, NL

09:00 - 09:00 P0063INCREASED RISK OF BARRETT’S ESOPHAGUS ANDESOPHAGEAL ADENOCARCINOMA IN INDIVIDUALS WITH APOSITIVE FAMILY HISTORY Yonne Peters, NL09:00 - 09:00 P0064HYBRID ARGON PLASMA COAGULATION IN THE ABLATIONTREATMENT OF BARRETT´S ESOPHAGUS - LONG TERMRESULTS Radek Kroupa, CZ







09:00 - 09:00 P0073TUMOR THICKNESS IS ASSOCIATED WITH METASTASIS INSUBMUCOSAL INVASIVE ADENOCARCINOMA OF THEESOPHAGOGASTRIC JUNCTION Nobuhisa Minakata, JP

09:00 - 09:00 P0074A SYMPTOM AND RISK FACTOR QUESTIONNAIREACCURATELY PREDICTS UPPER GASTROINTESTINALCANCER Kai Man Alexander Ho




09:00 - 09:00 P0075ANASTOMOTIC LEAK IN ESOPHAGOGASTRIC ONCOLOGICSURGERY: MANAGEMENT WITH FULLY COVERED SELF-EXPANDABLE METALLIC STENTS Daniel Conceição, PT09:00 - 09:00 P0076PREVALENCE AND PREDICTORS OF MALNUTRITION INPATIENTS WITH ESOPHAGEAL CANCER- A SINGLE CENTERPROSPECTIVE STUDY Prachi Patil, IN







09:00 - 09:00 P0083HYPERGASTRINEMIA IS NOT ASSOCIATED WITHINCREASED MORTALITY IN GASTRIC ADENOCARCINOMA Eivind Ness-Jensen, NO

09:00 - 09:00 P0084LAUREN-TYPE GASTRIC CANCER VARIABLE BY AGE ANDSEX Hyeong Ho Jo, KR

09:00 - 09:00 P0085QUALITY OF LIFE IS ASSOCIATED WITH SURVIVAL INGASTRIC CANCER PATIENTS: RESULTS FROM THE CRITICSTRIAL Romy van Amelsfoort, NL09:00 - 09:00 P0086PERSONALITY TRAITS ARE STRONGLY ASSOCIATED WITHGASTROINTESTINAL CANCER PATIENTS’ PSYCHOSOCIALBURDEN: AN ONGOING STUDY Christos Sotiropoulos, GR






E-Poster Session


09:00 - 09:00 P1076AN ANALYSIS OF GI AND NON-GI MANIFESTATIONS OFCOVID-19 DURING THE FIRST WAVE OF THE COVID-19PANDEMIC IN DARLINGTON, UNITED KINGDOM Anjan Dhar

09:00 - 09:00 P1077COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIANCASE-CONTROL DOUBLE-CENTER STUDY Maria Guarino, IT





09:00 - 09:00 P1079SUCCESSFUL ENDOSCOPY RECOVERY STRATEGY AFTERTHE FIRST WAVE OF THE COVID-19 PANDEMIC IN ANORTHEAST LONDON HOSPITAL Paolo Giuffrida, UK09:00 - 09:00 P1080FREQUENCY AND OUTCOMES OF SARS-COV-2 INFECTIONIN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASINGLE TERTIARY CENTER EXPERIENCE Ilhami Yuksel, TR




09:00 - 09:00 P1084A NOVEL MICROBIOME FORMULA (SIM01) AS ANADJUVANT THERAPY FOR COVID-19: AN OPEN-LABELPILOT STUDY Lin Zhang, CN

09:00 - 09:00 P1085A PROSPECTIVE OBSERVATIONAL STUDY ON THEEVALUATION OF THE RISK OF TRANSMISSION DUE TODROPLETS AND AEROSOLS DURINGESOPHAGOGASTRODUODENOSCOPY AND THEUSEFULNESS OF EXTRAORAL SUCTION DEVICES Hironori Sunakawa, JP


09:00 - 09:00 P1087EVIDENCE-BASED SELECTION ON THE APPROPRIATE FITCUT-OFF POINT IN CRC SCREENING PROGRAMS IN THECOVID PANDEMIC Patricia Carrera-Lasfuentes, ES

09:00 - 09:00 P1088HEPATOKINES AND COVID-19 SEVERITY Michał Kukla, PL


09:00 - 09:00 P1090EVALUATION OF LIVER ALTERATIONS IN PATIENTS WITHPOST-ACUTE COVID-19 SYNDROME - A PILOT STUDY Felix Bende, RO09:00 - 09:00 P1091ELEVATED AMINOTRANSFERASES AT ADMISSION IS APREDICTOR OF ACUTE KIDNEY INJURY IN HOSPITALIZEDPATIENTS WITH COVID-19 Yulia Khruleva, RU



09:00 - 09:00 P1094IMPACT EVALUATION OF TELECONSULTATION ONGASTROENTEROLOGY DURING THE SARS-COV-2PANDEMIC Pedro Antunes, PT

09:00 - 09:00 P1095MAINTAINING ERCP CAPACITY AND HIGH QUALITY KEYPERFORMANCE QUALITY INDICATORS (KPIS) DURING THECHALLENGE OF COVID-19 RESTRICTIONS: WHAT HAVE WELEARNT? Ioannis Varmpompitis


09:00 - 09:00 P1097SATISFACTION WITH TELECONSULTATION ININFLAMMATORY BOWEL DISEASE PATIENTS DURING THECOVID-19 PANDEMIC Pedro Campelo, PT

09:00 - 09:00 P1098DOES THE PRESENCE OF GASTROINTESTINAL SYMPTOMSPREDICT MILDER DISEASE IN COVID-19 PATIENTS ? – APROSPECTIVE EVALUATION jayanta Samanta, IN





09:00 - 09:00 P1100THE IMPACT OF THE COVID-19 PANDEMIC ON THEMANAGEMENT OF CIRRHOTIC PATIENTS Amani Hassine, TN09:00 - 09:00 P1101OUTCOMES OF PATIENTS WITH DECOMPENSATEDCIRRHOSIS AND CORONAVIRUS DISEASE 19: MORTALITYAND SAFETY OF LIVER TRANSPLANTATION Ahad Eshraghian, IR

Recorded only

10:00 – 10:30 Hall 8From guidelines to clinical practice: Malnutrition is oftenmissed and obesity omnipresent? What are theimplications?

10:00 - 10:10 IP288What is the knowledge about malnutrition in Europe? Cristina Cuerda, ES

10:10 - 10:20 IP289Standards for diagnosing malnutrition Tommy Cederholm, SE

10:20 - 10:30 IP290The European guideline on obesity care in patients withGI and liver disease Stephan Bischoff, DE


10:30 – 11:30 TV StudioGastrointestinal painChairs: Jan Tack, BE

Asbjørn Mohr Drewes, DKAdam Donald Farmer, UKChloé Melchior, FR

10:30 - 10:40 IP291Atypical presentations of visceral pain Asbjørn Mohr Drewes, DK


10:50 - 11:00 IP292Chronic abdominal wall pain Chloé Melchior, FR


11:10 - 11:20 IP293Opioid-induced constipation and narcotic bowel Adam Donald Farmer, UK


Live Session

10:30 – 11:30 Hall 1Nutritional approaches in various GI disordersChairs: Sibylle Koletzko, DE

Richard K Russell, UK

10:30 - 10:50 IP294IBD: Nutrition as treatment modification Lihi Godny, IL

10:50 - 11:10 IP295How to deal with short bowel from a nutritional point ofview Francisca Joly, FR

11:10 - 11:30 IP296IBS: Diet as therapy Magnus Simrén, SE

Moderated Poster

10:30 – 11:30 Hall 2Lower GI malignanciesChairs: Georgina L. Hold, AU

Thomas Wirth, DE

10:30 - 10:40 MP103HIGH-GRADE TUMOR BUDDING INSTEAD OF &GT;1 MMFREE RESECTION MARGINS IMPORTANT FOR CANCERRECURRENCE AFTER LOCAL EXCISION OF T1 COLORECTALCANCER Kim M. Gijsbers, NL

10:40 - 10:50 MP104SURVEILLANCE WITH SALVAGE SURGERY AS ANALTERNATIVE TO COMPLETION SURGERY AFTER LOCALEXCISION OF A T1 CRC WITH HISTOLOGICAL RISKFACTORS Kim M. Gijsbers, NL

10:50 - 11:00 MP105SIMILAR SUCCESS AND SAFETY FOR PROXIMAL ANDDISTAL COLONIC STENTS: A RETROSPECTIVE SINGLE-CENTER STUDY Michail Galanopoulos

11:00 - 11:10 MP106A STRATEGY OF LOCAL FULL-THICKNESS SCAR RESECTIONFOLLOWING R1/RX EXCISED T1 COLORECTAL CANCERSHOWS SIMILAR METASTASIS-FREE AND OVERALLSURVIVAL AS COMPARED TO COMPLETION SURGERY Kim M. Gijsbers, NL

11:10 - 11:20 MP107RISK OF INTERVAL COLORECTAL CANCER AFTER NEGATIVEFIT BY QUANTITATIVE FIT-RESULT IN THE DUTCH CRCSCREENING PROGRAM Emilie C. H. Breekveldt, NL




11:20 - 11:30 MP108INTER-LABORATORY VARIATION IN THE ASSESSMENT OFLYMPHOVASCULAR INVASION IN T1 COLORECTAL CANCERIN THE NETHERLANDS Lisa van der Schee, NL


10:30 – 11:30 Hall 3Late-breaking Abstracts IV: FMT and GI cancerChairs: Antonio Gasbarrini, IT

Peter Hegyi, HU

10:30 - 10:42 LB18LONGITUDINAL EVALUATION OF GUT BACTERIOME ANDVIROME AFTER FECAL MICROBIOTA TRANSPLANTATIONFOR ERADICATING OF CARBAPENEM RESISTANTENTEROBACTERIACEAE Qin Liu, HK

10:42 - 10:54 LB19RECIPIENT’S GUT BACTERIA COMPOSITION PREDICTSEFFICACY OF FECAL MICROBIOTA TRANSPLANTATION ININDUCING WEIGHT LOSS IN OBESE SUBJECTS Zhilu Xu, HK

10:54 - 11:06 LB20SURVEILLANCE FOR PANCREATIC DUCTALADENOCARCINOMA IN CDKN2A MUTATION CARRIERS:YIELD AND OUTCOMES OF 20 YEARS PROSPECTIVEFOLLOW-UP D.C.F. Klatte, NL

11:06 - 11:18 LB22BLOCKING CTGF ALLEVIATES PERITONEAL METASTASISOF DIFFUSE-TYPE GASTRIC CANCER BY DISRUPTING THEINTERPLAY OF CANCER CELLS AND CANCER-ASSOCIATEDFIBROBLASTS Bonan Chen, HK


10:30 – 11:30 Hall 4Sedation in endoscopyChairs: Marjon De Pater-Godhelp, NL

Siiri Maasen, EE

10:30 - 10:50 IP297Sedation in endoscopy: Perfusor vs TCI pump vs bolus Björn Fehrke, CH

10:50 - 11:10 IP298Titration vs one dose procedural sedation withoutanesthesiologist. Need for a specific procedural nursesedation team (PROSA) Ricomaurits Haesaerts, BE

11:10 - 11:30 IP299Simulator based training programmes for sedation inendoscopy Stefan Nickl, DE

Moderated Poster

10:30 – 11:30 Hall 5Functional gastroduodenal disordersChairs: Tim Vanuytsel, BE

Jutta Keller, DE

10:30 - 10:40 MP109COMPARABLE EFFICACY OF CURCUMIN AND PROTONPUMP INHIBITOR FOR FUNCTIONAL DYSPEPSIA: ARANDOMIZED DOUBLE-BLINDED CONTROLLED TRIAL Krit Pongpirul, TH

10:40 - 10:50 MP110THE ASSOCIATION BETWEEN ANTIGENEMIA, HISTOLOGYWITH IMMUNOHISTOCHEMISTRY AND MUCOSAL PCR INDIAGNOSIS OF ULCERATIVE COLITIS WITH CONCOMITANTHUMAN CYTOMEGALOVIRUS INFECTION Tsukasa Yamakawa, JP

10:50 - 11:00 MP111TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTORANTAGONIST, SHOWED CONTINUED IMPROVEMENT INNAUSEA AND OTHER SYMPTOMS ASSOCIATED WITHGASTROPARESIS IN AN OPEN-LABEL EXTENSION OF APHASE II CLINICAL TRIAL Jesse L. Carlin, US

11:00 - 11:10 MP112CORRELATION BETWEEN GASTRIC EMPTYING PATTERNS,HUNGER AND SATIETY AS REGULATED BY GHRELIN ANDGLUCAGON-LIKE PEPTIDE-1 Moeen Ud-din, SE

11:10 - 11:20 MP113HIGH DISCOVERY RATE OF EOSINOPHILIC GASTRITISAND/OR DUODENITIS AMONG PATIENTS WITH CHRONICFUNCTIONAL GASTROINTESTINAL SYMPTOMS Nicholas J. Talley, AU

11:20 - 11:30 MP114GASTROPARESIS MIGHT BE A MANIFESTATION OF ANAUTONOMIC DYSFUNCTION SYNDROME IN PATIENTSWITH ALCOHOLIC CHRONIC LIVER DISEASE Antonio M Caballero-Mateos, ES

Live Session

10:30 – 11:30 Hall 6High throughput sequencing in practiceChairs: Azucena Salas, ES

Dror Shouval, IL




10:30 - 10:50 IP300Science translated to therapy: The case of very earlyonset IBD Holm Uhlig, UK10:50 - 11:10 IP301Proteomics signatures in IBD: Now is the time Edouard Louis, BE

11:10 - 11:30 IP302Epigenetics and in colorectal cancer modification Zohar Levi, IL

Moderated Poster

10:30 – 11:30 Hall 7Hepatology: Disease mechanismsChairs: Marta Bento Afonso, PT

Markus Peck-Radosavljevic, AT

10:30 - 10:40 MP115LIVER DISEASE-ASSOCIATED ACE ACTIVITY IMPACTS ONFIBRINOLYSIS AND INFLAMMATION - A POTENTIAL LINKTO COVID-19 Lukas Hartl, AT

10:40 - 10:50 MP116THE ERADICATION OF HEPATITIS C VIRUS WITH DIRECTANTIVIRAL AGENTS REPROGRAMS MITOCHONDRIALMETABOLISM IN PERIPHERAL BLOOD MONONUCLEARCELLS Moris Sangineto, IT

10:50 - 11:00 MP117REAL-WORLD ASSESSMENT OF THE EXCHANGEABLECOPPER (CUEXC) AND THE RATIO OF EXCHANGEABLECOPPER (REC) AS NON-INVASIVE TOOLS FOR WILSON´SDISEASE DIAGNOSIS AND FOLLOW-UP Zoe Mariño, ES

11:00 - 11:10 MP118ROLE OF PROGRAMMED DEATH-LIGAND 1 (PD-L1)POLYMORPHISMS AS RISK FACTORS FOR THEDEVELOPMENT OF CHRONIC HCV-RELATEDCOMPLICATIONS IN EGYPTIAN POPULATION Marwa Hassan, EG

11:10 - 11:20 MP119EARLIER IDENTIFICATION OF STEROID RESPONDERS INSEVERE ALCOHOLIC HEPATITIS Inês Marques de Sá, PT

11:20 - 11:30 MP120NOVEL PREDICTORS FOR LIVER TRANSPLANTATION ORDEATH IN DRUG-INDUCED ACUTE LIVER FAILURE Sabine Weber, DE

Moderated Poster

10:30 – 11:30 Hall 8Colorectal neoplasia: Characterisation and treatmentChairs: Roel Hompes, NL

10:30 - 10:40 MP121IS EARLY-ONSET COLORECTAL CANCER DIFFERENTACCORDING TO DISEASE LOCATION? ANALYSIS OF TUMORCHARACTERISTICS, RISK FACTORS AND CLINICALOUTCOMES OF 385 GENETICALLY TESTED PATIENTS Caterina Foppa, IT

10:40 - 10:50 MP122COMPARATIVE ANALYSIS OF TUMOR CHARACTERISTICSAND ONCOLOGIC OUTCOMES OF PATIENTS WITH EARLY-VERSUS LATE-ONSET RECTAL CANCER Caterina Foppa, IT

10:50 - 11:00 MP123THE IMPACT OF COVID-19 ON THE ONCOLOGICOUTCOMES OF 3236 PATIENTS UNDERGOINGCOLORECTAL CANCER SURGERY IN NORTHERN ITALY IN2019 AND 2020 (COVID-CRC): RESULTS OF AMULTICENTRIC COMPARATIVE COHORT STUDY. Gianluca Pellino, IT

11:00 - 11:10 MP124RISK FACTORS FOR METACHRONOUS COLORECTALCANCER OR ADVANCED POLYPS AFTER ENDOSCOPICRESECTION OF PREMALIGNANT LESIONS: A SYSTEMATICREVIEW AND METAANALYSIS Sandra Baile Maxía, ES

11:10 - 11:20 MP125LOW RISK OF LOCAL RECURRENCE AFTER A SUCCESSFULEN BLOC ENDOSCOPIC SUBMUCOSAL DISSECTION FORCOLORECTAL LESIONS WITH A POSITIVE HORIZONTALRESECTION MARGIN (R-ESD STUDY) Krijn J. C. Haasnoot, NL

11:20 - 11:30 MP126THE EFFICACY OF TUMOR CHARACTERIZATION FORCOLORECTAL LESIONS USING BLUE LIGHT IMAGING WITHA COMPACT SYSTEM-PROCESSOR COMBINED LEDENDOSCOPE COMPARED TO A LASER ENDOSCOPE Ken Inoue, JP



Her recipe for success: A discussion with UEG’s nextPresidentChairs: Helena Cortez-Pinto, PT

Jonathan McCrea, IE




Live Demo

11:00 – 12:00 Live Demo RoomLive Endoscopy IIChairs: Marianna Arvanitakis, BE

Michal Filip Kaminski, PLPhilip Wai Yan Chiu, HKLars Aabakken, NOUlrike Walburga Denzer, DECesare Hassan, ITHelmut Messmann, DEManuel Pérez-Miranda, ESJulius Spicak, CZJan Martinek, CZOndrej Urban, CZStanislav Rejchrt, CZZuzana Vackova, CZ

Vienna Live Session

12:00 – 13:00 TV StudioCase closed? Live expert lunch IIIChairs: Stephan Vavricka, CH

Iris Dotan, ILCharlotte R H Hedin, SEFernando Magro, PTDan Turner, IL

12:00 - 12:10 IP303Opportunistic infections in IBD Fernando Magro, PT


12:20 - 12:30 IP304What to do if everything fails? Dan Turner, IL


12:40 - 12:50 IP305Unexpected side effects Charlotte R H Hedin, SE


Live Session

12:00 – 13:00 Hall 1Appendix: The unknownChairs: Christianne Johanna Buskens, NL

Dan Lucian Dumitrascu, RO

12:00 - 12:20 IP306Why pathology is important Matteo Fassan, IT12:20 - 12:40 IP307The role of the appendix in IBD Johan Burisch, DK

12:40 - 13:00 IP308The difficult appendectomy: When and how shouldsurgery be performed? Nereo Vettoretto, IT

Live Session

12:00 – 13:00 Hall 2Therapy update: DyspepsiaChairs: Jutta Keller, DE

Daniel Pohl, CH

12:00 - 12:20 IP309New drugs Jan Tack, BE

12:20 - 12:40 IP310Invasive therapy for dyspepsia: Are electrical stimulationand G-POEM indicated? Guillaume Gourcerol, FR

12:40 - 13:00 IP311Behavioural and psychological therapies Daniel Keszthelyi, NL


12:00 – 13:00 Hall 3Diet, microbiota & moreChairs: Charlie Lees, UK

Arie Levine, IL

12:00 - 12:12 OP171A PHASE 1, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED PHARMACOKINETIC STUDY EVALUATINGORAL BX002-A BACTERIOPHAGE THERAPY FORINFLAMMATORY BOWEL DISEASE Urania Rappo, US

12:12 - 12:24 OP172PREVALENCE OF GASTROINTESTINAL SYMPTOMS IN SARS-COV-2 INFECTION: RESULTS OF THE PROSPECTIVECONTROLLED MULTINATIONAL GI-COVID19 STUDY Giovanni Marasco, IT

12:24 - 12:36 OP174WESTERN DIET AND DEFECTIVE AUTOPHAGY CAUSEDISRUPTED INTESTINAL HOMEOSTASIS, GUT DYSBIOSIS,INCREASED HOST SUSCEPTIBILITY TO AIEC INFECTIONAND INTESTINAL INFLAMMATION Hanh Thi My Hoang, FR




12:36 - 12:48 OP175EFFICACY AND TIMING OF A BLINDED REINTRODUCTIONPHASE FOR THE LOW-FODMAP DIET IN IBS Karen Van den Houte, BE


12:00 – 13:00 Hall 4Eosinophilic oesophagitis: The essentialChairs: Edoardo Vincenzo Savarino, IT

Javier Molina Infante, ES

12:00 - 12:12 OP176DIFFERENCES BETWEEN PAEDIATRIC AND ADULTEOSINOPHILIC ESOPHAGITIS AT DIAGNOSIS: RESULTSFROM THE EOE CONNECT REGISTRY Emilio Jose Laserna-Mendieta, ES

12:12 - 12:24 OP177THE IL-20 CYTOKINES DECREASE THE EXPRESSION OFEPITHELIAL BARRIER FILAGGRINS IN EOSINOPHILICESOPHAGITIS Tanay Kaymak, CH

12:24 - 12:36 OP178A 12-WEEK TREATMENT WITH BUDESONIDEORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FORINCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVESBOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPICFEATURES IN ADULT PATIENTS WITH ACTIVEEOSINOPHILIC ESOPHAGITIS Stephan Miehlke, DE

12:36 - 12:48 OP179BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THEESOPHAGEAL DISTENSIBILITY IN EOSINOPHILICESOPHAGITIS: RESULTS FROM SUBSET ANALYSES OF THERANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 AND EOS-2 TRIALS Alfredo J Lucendo, ES

12:48 - 13:00 OP180SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITHLIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINSTSIGLEC-8, IN PATIENTS WITH EOSINOPHILICGASTRITIS/DUODENITIS Evan S Dellon, US


12:00 – 13:00 Hall 5Prevention and management of bile stone diseaseChairs: Julia Mayerle, DE

Christian Lange, DE

12:00 - 12:12 OP181URSODEOXYCHOLIC ACID FOR THE PREVENTION OFSYMPTOMATIC GALLSTONE DISEASE AFTER BARIATRICSURGERY: A MULTICENTRE, DOUBLE-BLIND,RANDOMISED, PLACEBO-CONTROLLED SUPERIORITYTRIAL Sylke Haal, NL12:12 - 12:24 OP182RECURRENCE PATTERNS AFTER FIRST SYMPTOMATICGALLSTONE ADMISSION. WHO MUST BE PRIORITIZED ONTHE CHOLECYSTECTOMY WAITING LIST? RELAPSTONE, ANAEG YOUNG TALENT GROUP MULTICENTER STUDY Raul Velamazan Sandalinas, ES

12:24 - 12:36 OP183STUDY OF COMBINED ENDOSCOPIC LARGE BALLOONDILATION WITH PRIOR LIMITED PRECUT OF THE PAPILLAVERSUS SOLE SPHINCTEROTOMY FOR REMOVAL OFLARGE OR MULTIPLE COMMON BILE DUCT STONES Randa Mohamed Seddik, EG

12:36 - 12:48 OP184PREDICTORS OF RECURRENT BILE DUCT STONE AFTERCLEARANCE BY ENDOSCOPIC RETROGRADECHOLANGIOPANCREATOGRAPHY: A CASE-CONTROLSTUDY Tawfik Khoury, IL

12:48 - 13:00 OP185ENDOSCOPIC PAPILLARY BALLOON DILATATION WITHMINOR SPHINCTEROTOMY CAN BE A STANDARDTREATMENT FOR THE CONVENTIONAL BILE DUCT STONE Takeshi Hisa, JP


12:00 – 13:00 Hall 6Advanced imaging for GI neoplasiaChairs: Mario Dinis-Ribeiro, PT

Sergey V. Kashin, RU

12:00 - 12:12 OP186A DEEP LEARNING-BASED SYSTEM REDUCES THE MISSRATE OF GASTRIC NEOPLASMS IN UPPER ENDOSCOPY: ATANDEM CLINICAL TRIAL Renduo Shang, CN

12:12 - 12:24 OP187LINKED COLOR IMAGING IMPROVES IDENTIFICATION OFEARLY GASTRIC CANCER FOR BOTH EXPERT AND NON-EXPERT ENDOSCOPISTS Kiki Fockens, NL

12:24 - 12:36 OP188EVALUATION OF CANCEROUS MUCOSAL CONDITIONBASED ON EXTENT OF ENDOSCOPIC ATROPHY ANDINTESTINAL METAPLASIA WITHOUT MULTIPLE BIOPSIESIN GASTRIC CANCER Sayoko Kinowaki, JP




12:36 - 12:48 OP189A DEEP LEARNING-BASED AUTOMATIC IMAGE REPORTSYSTEM FOR ESOPHAGOGASTRODUODENOSCOPY ANDEVALUATED BY A NOVEL SCORING SCALE: A MULTI-CENTER VALIDATION Zehua Dong, CN12:48 - 13:00 OP190DEVELOPMENT OF MULTI-CLASS COMPUTER-AIDEDDIAGNOSIS SUPPORT SYSTEM FOR DIAGNOSIS OFNICE/JNET CLASSIFICATION IN COLORECTAL LESIONS Yuki Okamoto, JP

Live Session

12:00 – 13:00 Hall 7Therapy update: Novel and emerging treatments ofNAFLDChairs: Elisabetta Bugianesi, IT

Lawrence Serfaty, FR

12:00 - 12:20 IP312Glycomics in liver disease: A novel path to personalisedmedicine? Xavier Verhelst, BE

12:20 - 12:40 IP313Metabolic treatments Philip Newsome, UK

12:40 - 13:00 IP314Combination approaches Jörn Schattenberg, DE

Live Session

12:00 – 13:00 Hall 8New perspectives in coeliac diseaseChairs: Christophe Cellier, FR

Antonio Di Sabatino, IT

12:00 - 12:20 IP315Novel insights into pathomechanisms of coealiac disease Detlef Schuppan, DE

12:20 - 12:40 IP316Hunting for coealiac disease: The HUNT4 study Eivind Ness-Jensen, NO

12:40 - 13:00 IP317Gluten degrading enzymes: From discovery to clinicalapplication Carmen Gianfrani, IT



Cool solutions for hot GI information: How to stayupdated on gastroenterologyChairs: Joost P.H. Drenth, NL

Enrique de-Madaria, ESGabriele Capurso, ITKatarzyna Monika Pawlak, PLChloé Melchior, FR

Recorded only

13:00 – 13:30 Hall 8From guidelines to clinical practice: Coeliac disease

13:00 - 13:10 IP318How to diagnose adult CeD in 2021 Carolina Ciacci, IT

13:10 - 13:20 IP319Management of follow-up of pediatric CeD (ESPGHAN) Luisa Mearin, NL

13:20 - 13:30 IP320Risk factors of small bowel tumours in CeD Jonas Ludvigsson, SE

Live Demo

13:00 – 14:00 Live Demo RoomLive Endoscopy IIIChairs: Raf Bisschops, BE

Monika Ferlitsch, ATD. Nageshwar Reddy, INLars Aabakken, NOUlrike Walburga Denzer, DECesare Hassan, ITHelmut Messmann, DEManuel Pérez-Miranda, ESJulius Spicak, CZJan Martinek, CZOndrej Urban, CZStanislav Rejchrt, CZZuzana Vackova, CZ


13:30 – 14:30 TV StudioLeaks in colorectal surgeryChairs: Antonino Spinelli, IT

Marc Barthet, FRAlexander Meining, DEAlessandro Repici, IT




13:30 - 13:40 IP321Complication management/unusual histology case Alessandro Repici, IT13:40 - 13:50Panel discussion

13:50 - 14:00 IP322Fistula from the colon to the pleura after surgery Alexander Meining, DE


14:10 - 14:20 IP323Endoscopic management of complete colorectalanastomotic disunion Marc Barthet, FR



13:30 – 14:30 Hall 1IBD: Clinical trials IVChairs: Gerhard Rogler, CH

Britta Siegmund, DE

13:30 - 13:42 OP191EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVECOLITIS BY LINE OF THERAPY IN THE PHASE 2B/3SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTSWITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THEPHASE 2B/3 SELECTION TRIAL Iris Dotan, IL

13:42 - 13:54 OP192A RANDOMISED CONTROLLED CLINICAL TRIAL OFAUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) INPATIENTS WITH TREATMENT REFRACTORY CROHN’SDISEASE (LOW INTENSITY THERAPY EVALUATION):ASTICLITE James Lindsay, UK

13:54 - 14:06 OP193DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTSWITH CROHN’S DISEASE IN SUSTAINED, COMBINEDCLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: ADOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZEDCLINICAL TRIAL Mark Andrew Ainsworth, DK

14:06 - 14:18 OP194RISANKIZUMAB AS INDUCTION THERAPY IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE CROHN’SDISEASE WHO FAILED 1 VS &GT;1 PRIOR BIOLOGICTREATMENT: RESULTS FROM THE MOTIVATE STUDY Remo Panaccione, CA

14:18 - 14:30 OP195MECHANISMS OF NON-RESPONSE TO ADALIMUMAB ININFLAMMATORY BOWEL DISEASE: PERIPHERALPROTEOMIC AND TRANSCRIPTOMIC PROFILING FROM THESERENE-CD AND SERENE-UC STUDIES Julian Panés, ES

Moderated Poster

13:30 – 14:30 Hall 2News in IBSChairs: Michelle Bosman, NL

Jan Tack, BE

13:30 - 13:40 MP128MECHANISM OF ABDOMINAL DISTENSION IN PATIENTSWITH FUNCTIONAL GUT DISORDERS Elizabeth Barba Orozco, ES

13:40 - 13:50 MP129GLOBAL PREVALENCE OF MEAL-RELATED PAIN AND ITSRELEVANCE IN DISORDERS OF GUT-BRAIN INTERACTION Esther Colomier, SE

13:50 - 14:00 MP130INTEGRATED FAECAL MICROBIOME-METABOLOMESIGNATURES REFLECT STRESS AND SEROTONINMETABOLISM IN IRRITABLE BOWEL SYNDROME Zlatan Mujagic, NL

14:00 - 14:10 MP131DIETARY THERAPIES IN IRRITABLE BOWEL SYNDROME: AMULTICENTRE RANDOMISED CONTROL TRIAL Anupam Rej

14:10 - 14:20 MP132COLONIC VOLUME DETERMINED BY MAGNETICRESONANCE IMAGING IN PATIENTS WITH FUNCTIONALCONSTIPATION AND IRRITABLE BOWEL DISEASE Mette Winther Klinge, DK


13:30 – 14:30 Hall 4Service challenges and improvementsChairs: Tatjana Gjergek, SI


13:30 - 13:42 IP324ESGENA position statement: Simethicon in endoscopy Ulrike Beilenhoff, DE

13:42 - 13:54 IP325A comparison of two methods for the manual cleaning ofendoscopes Lucia Helena Lourenço Tomiato, BR

13:54 - 14:06 IP326COVID–19 pandemic and nursing experience Andreja Sajnic, HR




14:06 - 14:18 IP327Attitudes towards COVID-19 mitigation measuresimplemented at St. Mark’s Bowel Cancer ScreeningCentre: a cross-sectional analysis of survey data from anethnically diverse region in London Ghalia Kayal, UK14:18 - 14:30 IP328Opportunities to optimise the care and benefit of IBDpatients by IBD nurse Simone Breiteneicher, DE

Moderated Poster

13:30 – 14:30 Hall 5Clinical aspects of upper GI malignancyChairs: Mario Dinis-Ribeiro, PT

Andrea Tringali, IT

13:30 - 13:40 MP133NEW GASTRIC CANCER DETECTION RATE ONE YEAR AFTERINTENSIVE ENDOSCOPIC SURVEILLANCE FOR THESTOMACH IN HIGH-RISK PATIENTS: A LARGEPROSPECTIVE COHORT STUDY IN JAPAN Hiromitsu Kanzaki, JP

13:40 - 13:50 MP134MANAGEMENT OF TYPE-I GASTRIC NEUROENDOCRINENEOPLASMS: A SINGLE CENTER’S REAL WORLDEXPERIENCE Maria Cazzato, IT

13:50 - 14:00 MP135RISK FACTORS FOR GASTRIC CANCER IN PATIENTS WITHLYNCH SYNDROME Raquel Ortigão, PT

14:00 - 14:10 MP136DYSPLASTIC CYSTIC FUNDIC GLAND POLYPS: RATE ANDMORBIDITY IN NON-FAMILIAL ADENOMATOUS POLYPOSISSYNDROME Riad Alame

14:10 - 14:20 MP137GERMLINE COPY NUMBER VARIANTS: ANUNDERREPORTED GENETIC DIAGNOSIS INGASTROINTESTINAL TUMOUR RISK SYNDROMESUSPECTED INDIVIDUALS José García Peláez, PT

14:20 - 14:30 MP138FAILURE OF MAPS II CRITERIA TO SELECT FORSURVEILLANCE A LARGE PROPORTION OF PATIENTSPRESENTING WITH EARLY GASTRIC CANCER Maria Manuela Estevinho, PT

Live Session

13:30 – 14:30 Hall 6Fasting and diet restriction: The place ingastroenterologyChairs: Antonio Gasbarrini, IT

Francisca Joly, FR

13:30 - 13:50 IP329Appetite regulation and weight control: The role of guthormones Maude le Gall, FR

13:50 - 14:10 IP330A place for time restricted feeding in gastroenterology Dana Lukin, US

14:10 - 14:30 IP331From diet to orthorexia: Consequences of "trendy" diets Hellas Cena, IT

Moderated Poster

13:30 – 14:30 Hall 7Hepatology updateChairs: Javier Ampuero, ES

13:30 - 13:40 MP140NOVEL PROGNOSTIC SCORES TO PREDICT DISEASEOUTCOMES IN PRIMARY SCLEROSING CHOLANGITIS(PSC) Martti A. Färkkila, FI

13:40 - 13:50 MP141SIGNIFICANT LIVER FIBROSIS, AS ASSESSED BYFIBROSCAN, IS INDEPENDENTLY ASSOCIATED WITHCHRONIC VASCULAR COMPLICATIONS OF TYPE 2DIABETES: A MULTICENTER STUDY Ivana Mikolasevic, HR

13:50 - 14:00 MP142MZ GENOTYPE OF SERPINA1 GENE IS A RISK FACTOR FORLIVER CIRRHOSIS IN ALCOHOLIC LIVER DISEASE ANDNASH Zuzana Rabekova, CZ

14:00 - 14:10 MP143INDICATORS OF VISCERAL OBESITY IN PATIENTS WITHNON-ALCOHOLIC FATTY LIVER DISEASE WITH VARIOUSDEGREES OF LIVER STEATOSIS AND LIVER FIBROSIS Yana Nikiforova, UA

14:10 - 14:20 MP144 RISK FACTORS FOR LIVER DECOMPENSATION AND HCC INHCV-CIRRHOTIC PATIENTS AFTER DAAS: A MULTICENTERPROSPECTIVE STUDY Maria Guarino, IT




Moderated Poster

13:30 – 14:30 Hall 8Colon and small bowel endoscopyChairs: Cristiano Spada, IT

Cristina Carretero, ES

13:30 - 13:40 MP145OPTICAL DIAGNOSIS IN POLYPS BETWEEN 5-15 MM ANDITS IMPLICATIONS ON SURVEILLANCE. A PROSPECTIVE,MULTICENTER STUDY. (POPS STUDY) Eduardo Redondo-Cerezo, ES

13:40 - 13:50 MP146ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS OFESOPHAGEAL DISEASES: A SYSTEMATIC REVIEW WITHMETA-ANALYSIS Pierfrancesco Visaggi, IT

13:50 - 14:00 MP147MULTICENTRE INTERNATIONAL NON-INFERIORITY PHASEIII STUDY OF ORAL SULPHATE SOLUTION (OSS) VERSUSPOLYETHYLENE GLYCOL (PEG)+ ELECTROLYTECOLONOSCOPY PREPARATION IN PAEDIATRIC PATIENTS Piotr Socha, PL

14:00 - 14:10 MP148KILLING TWO BIRDS WITH ONE STONE: THE FIRSTMULTISYSTEM-COMPATIBLE, ARTIFICIAL INTELLIGENCESOLUTION FOR SMALL-BOWEL CAPSULE ENDOSCOPY Charles Houdeville, FR

14:10 - 14:20 MP149ENDOSCOPIC MUCOSAL RESECTION (EMR) ANDENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) IN THEMANAGEMENT OF LARGE (≥20 MM) NON-PEDUNCOLATECOLORECTAL LESIONS (LNPCLS): EXPERIENCE FROM ANITALIAN REFERRAL CENTER Giancarla Fiori, IT

14:20 - 14:30 MP150NEW CLASSIFICATION FOR ADVERSE EVENTS INGASTROINTESTINAL ENDOSCOPY: THE AGREECLASSIFICATION K.J. Nass, NL



Equity in medical care – raw realisationsChairs: Foteini Anastasiou, GR

Marina Berenguer, ESChristos D Lionis, GRAlanna Ebigbo, DE

Vienna Live Session

15:00 – 16:00 TV StudioGut talk: Lessons learned IIIChairs: Jacques Deviere, BE

15:00 - 15:20 IP332Food bolus impaction Marianna Arvanitakis, BE

15:20 - 15:40 IP333Recurrent object eater (psychiatric patient) Alexander Meining, DE

15:40 - 16:00 IP334Foreign body in a child Jorge Amil Dias, PT


15:00 – 16:00 Hall 1Safety and outcomes of interventions in IBDChairs: Laurent Beaugerie, FR

Sophie Restellini, CH

15:00 - 15:12 OP196WORLDWIDE POST-MARKETING SAFETY SURVEILLANCEEXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS Silvio Danese, IT

15:12 - 15:24 OP197HERPES ZOSTER INFECTION IN PATIENTS WITHULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTSFROM THE PHASE 2 AND PHASE 3 CLINICALPROGRAMMES Severine Vermeire, BE

15:24 - 15:36 OP198SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (≥60YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS INCD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS Subrata Ghosh, IE

15:36 - 15:48 OP199SAFETY OF USTEKINUMAB ACROSS APPROVED ADULTINDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’SDISEASE, ULCERATIVE COLITIS, PSORIASIS, ANDPSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS Silvio Danese, IT

15:48 - 16:00 OP200LONG-TERM ONCOLOGICAL OUTCOME OF SEGMENTALVERSUS EXTENDED COLECTOMY FOR COLORECTALCANCER IN CROHN’S DISEASE: RESULTS FROM ANINTERNATIONAL STUDY Gianluca Pellino, IT




Live Session

15:00 – 16:00 Hall 2Advances in diagnosis and therapeutic management incolorectal cancerChairs: Tamara Matysiak-Budnik, FR

Thomas Seufferlein, DE

15:00 - 15:20 IP335Impact of COVID-19 on CRC screening Luigi Ricciardiello, IT

15:20 - 15:40 IP336Role of liquid biopsis and other biomarkers in CRCmanagement Gorka Alkorta Aranburu, ES

15:40 - 16:00 IP337Molecular markers driving therapeutic decisions Michel Ducreux, FR

Live Session

15:00 – 16:00 Hall 3New options in eosinophilic esophagitisChairs: Arjan Bredenoord, NL

Alex Straumann, CH

15:00 - 15:20 IP338Diagnosis of EoE and how to measure response Ulrike von Arnim, DE

15:20 - 15:40 IP339Dietary treatment and nutrition in EoE Javier Molina Infante, ES

15:40 - 16:00 IP340New drugs in EoE Evan S Dellon, US


15:00 – 16:00 Hall 4Novelties on oesophageal cancer: From diagnosis totreatmentChairs: Matteo Fassan, IT

15:00 - 15:12 OP201INCREASING INCIDENCE OF OESOPHAGEAL CANCER INADULTS YOUNGER THAN 50 YEARS IN THE NETHERLANDS:A POPULATION-BASED COHORT STUDY Ali Al-Kaabi, NL

15:12 - 15:24 OP203TRACKING GENETIC AND TRANSCRIPTOMIC CHANGES INOESOPHAGEAL ADENOCARCINOMA DURINGNEOADJUVANT TREATMENT Melissa Schmidt

15:24 - 15:36 OP204RISK OF METASTATIC RECURRENCE AFTER ENDOSCOPICRESECTION FOR ESOPHAGEAL SQUAMOUS CELLCARCINOMA INVADING INTO THE MUSCULARIS MUCOSAOR SUBMUCOSA: A MULTICENTER RETROSPECTIVESTUDY Ippei Tanaka, JP15:36 - 15:48 OP205OUTCOME OF ENDOSCOPIC SUBMUCOSAL DISSECTIONFOR METACHRONOUS SUPERFICIAL ESOPHAGEALSQUAMOUS CELL CARCINOMA DEVELOPED CLOSE TO THESCAR AFTER ENDOSCOPIC RESECTION Motomitsu Fukuhara, JP

Live Session

15:00 – 16:00 Hall 5Progression from acute to chronic pancreatitisChairs: Vinciane Rebours, FR

Robert Sutton, UK

15:00 - 15:20 IP341Genetic preclinical models Miklós Sahin-Toth, US

15:20 - 15:40 IP342The role of endocrine-exocrine interaction Alexandra Miko, HU

15:40 - 16:00 IP343Changes of the gut microbiome: Cause or consequence Markus M. Lerch, DE

Live Session

15:00 – 16:00 Hall 6Search, implement and finally benefit: Why guidelinesare of paramount importanceChairs: Wafaa Khannoussi, MA

Giovanni Marchegiani, IT

15:00 - 15:20 IP344Can you benchmark the beneficial impact of a guideline? Jonas Rosendahl, DE

15:20 - 15:40 IP345Benefits from the patients' perspective: Pancreatic cancerguidelines Sako Zeverijn, NL

15:40 - 16:00 IP346Extracts from the 5 best guidelines I have ever read:Benefits for doctors, nurses & patients Glen A Doherty, IE





15:00 – 16:00 Hall 7Biomarkers in liver diseasesChairs: Michael Pavlides, UK

Xavier Verhelst, BE

15:00 - 15:12 OP206A NEO-EPITOPE SPECIFIC BIOMARKER OF FIBROSISRESOLUTION - DETECTION OF PROTEASE DEGRADED, ANDCROSS-LINKED TYPE III COLLAGEN DEGRADATIONMETABOLITES RELEASED WITH FIBROLYSIS Martin Pehrsson, DK

15:12 - 15:24 OP207ELASTOGRAPHIC PARAMETER OF LIVER STEATOSIS ANDFIBROSIS INDEPENDENTLY PREDICT THE DEVELOPMENTOF CHRONIC VASCULAR C COMPLICATIONS OF TYPE 2DIABETES - A PROSPECTIVE OBSERVATIONAL STUDY Bozena Delija, HR

15:24 - 15:36 OP208FACTOR VIII/PROTEIN C RATIO INDEPENDENTLY PREDICTSLIVER-RELATED EVENTS BUT DOES NOT REFLECT THEHYPERCOAGULABLE STATE IN PATIENTS WITH ADVANCEDCHRONIC LIVER DISEASE Lorenz Balcar, AT

15:36 - 15:48 OP209THE INFLUENCE OF GENETIC VARIANTS PNPLA3, TM6SF2,AND MBOAT7 ON THE RESPONSE TO A SILYBIN/VITAMIN D-BASED TREATMENT FOR METABOLIC (DYSFUNCTION)ASSOCIATED FATTY LIVER DISEASE PATIENTS Marcello Dallio, IT

15:48 - 16:00 OP210MACHINE LEARNING IN PRIMARY BILIARY CHOLANGITIS: ANOVEL APPROACH FOR RISK STRATIFICATION Alessio Gerussi, IT

Live Session

15:00 – 16:00 Hall 8Coeliac disease: Challenges in children and adultsChairs: Abdulbaqi Al-toma, NL

Riccardo Troncone, IT

15:00 - 15:30 IP347Seronegative patients, how many and why David Surendran Sanders, UK

15:30 - 16:00 IP349Unmet needs of gluten-free diet: Educational training,psychological aspects Nick Trott, UK

Live Demo

15:00 – 16:00 Live Demo RoomLive Endoscopy IVChairs: Evelien Dekker, NL

Ian Mark Gralnek, ILKlaus Mergener, USLars Aabakken, NOUlrike Walburga Denzer, DECesare Hassan, ITHelmut Messmann, DEManuel Pérez-Miranda, ESJulius Spicak, CZJan Martinek, CZ

Ondrej Urban, CZStanislav Rejchrt, CZZuzana Vackova, CZ



From ingredients to delicious dish: How basic science cancontribute to clinical trialsChairs: Pedro M. Rodrigues, ES

Jesús M. Bañales, ESJoost P.H. Drenth, NLGianluca Ianiro, ITBritta Siegmund, DE

Recorded only

16:00 – 16:30 Hall 1Hot topics from Latin America

16:00 - 16:10 IP350COVID-19 and gastrointestinal manifestations in LatinAmerica Jose Maria Remes Troche, MX

16:10 - 16:20 IP351Novel faecal biomarkers that precede clinical diagnosis ofulcerative colitis Elena Verdu, CA

16:20 - 16:30 IP352Inflammatory bowel diseases in Latin America Manuel Alvarez, CL


16:00 – 17:00 Industry HallIS-15 Getting a Better Sense of Sensitive Symptoms:What Matters Most to Patients With Ulcerative Colitis

Live Session

16:30 – 17:30 TV StudioWhat's really new in 2021? The broad viewChairs: Helmut Messmann, DE

16:30 - 16:50 IP353Ongoing evolution of new IBD therapies Laurent Peyrin-Biroulet, FR




16:50 - 17:10 IP354TNT in locally advanced rectal cancer: Ready forprimetime? Thierry Conroy, FR17:10 - 17:30 IP355Endoscopical developments in 2021 Ulrike Walburga Denzer, DE

Live Session

16:30 – 17:30 Hall 3H. pylori: What's new in 2021?Chairs: Marcis Leja, LV

Colm O'Morain, IE

16:30 - 16:50 IP356H. pylori as a model of dysbiosis Mirjana Rajilic-Stojanovic, RS

16:50 - 17:10 IP357H. pylori testing: Is breathless fine? Francis Megraud, FR

17:10 - 17:30 IP358Update on treatment Javier Gisbert, ES

Live Session

16:30 – 17:30 Hall 5Multidisciplinary approach for differential diagnosis andmanagement of IPMNChairs: Marco J. Bruno, NL

Gabriele Capurso, IT

16:30 - 16:50 IP359Diagnosis and surveillance of IPMN Maria Antonietta Bali, BE

16:50 - 17:10 IP360When is sampling of tissue indicated? Torsten Beyna, DE

17:10 - 17:30 IP361IPMN surveillance: Enough is enough Djuna L. Cahen, NL


16:30 – 17:30 Hall 6The secrets of visceral pain uncovered?Chairs: Inge Depoortere, BE

Adam Donald Farmer, UK

16:30 - 16:50 IP362Visceral pain signaling: Where does it go wrong? Nicolas Cenac, FR

16:50 - 17:10 IP363Immune activation in FBD: What is new? Guy E. Boeckxstaens, BE17:10 - 17:30 IP364Novel potential therapies for visceral pain Stephen Vanner, CA

Live Session

16:30 – 17:30 Hall 8Nutritional approaches: What's new in 2021?Chairs: Tim Vanuytsel, BE

Cristina Cuerda, ES

16:30 - 16:50 IP365IBD Lihi Godny, IL

16:50 - 16:55 IP366Short bowel: Role of dietetic optimisation Alison Culkin, UK

16:55 - 17:00 IP367Short bowel: Medical strategy Francisca Joly, FR

17:00 - 17:10Q&A

17:10 - 17:30 IP368Ultra processed food consumption and chronic diseaserisk: A significant association or belief? Mathilde Touvier, FR

Live Video Case Session

16:30 – 17:30 Live Demo RoomVideo case sessionChairs: Arnaud Lemmers, BE

Alanna Ebigbo, DE

16:30 - 16:36 VC01BILATERAL BILIARY DRAINAGE FOR MALIGNANT HILAROBSTRUCTION WITH EUS-GUIDEDHEPATICOGASTROSTOMY ANDHEPATICODUODENOSTOMY Khanh Do-Cong Pham, NO

16:36 - 16:45 VC02ENDOSCOPIC BRAUN JEJUNO-JEJUNOSTOMY TO TREAT ACASE OF SEVERE ALKALINE CHRONIC GASTRITIS AFTERSUBTOTAL GASTRECTOMY WITH BILLROTH IIRECONSTRUCTION USING DOUBLE-BALLOON TECHNIQUETO STABILIZE THE EFFERENT LOOP Alessio Renga, IT




16:45 - 16:55 VC04MUCOSAL DEFECT CLOSURE USING REOPENABLE-CLIPOVER THE LINE METHOD AND MODIFIED LOCKING-CLIPTECHNIQUE FOR MUCOSAL DEFECTS AFTERGASTROINTESTINAL ENDOSCOPIC SUBMUCOSALDISSECTION Tatsuma Nomura, JP16:55 - 17:03 VC05PADLOCK CLIP ASSISTED-ENDOSCOPIC FULL THICKNESSRESECTION FOR DUODENAL NEUROENDOCRINE TUMOUR:A SAFE ALTERNATIVE TO ENDOSCOPIC SUBMUCOSALDISSECTION Nikhil Sonthalia, IN

17:03 - 17:12 VC06ENDOSCOPIC CUTTING WAVE BIOPSY FOR SUBMUCOSALTUMORS SMALLER THAN 20 MM Akihiro Maruyama, JP

17:12 - 17:20 VC07THE ROLE OF CHOLANGIOSCOPY IN DIFFICULT ANDCOMPLICATED SURGERY Inês Marques de Sá, PT



Marinating on what’s to come: The future of researchChairs: Luigi Ricciardiello, IT

Silvio Danese, ITDirk Haller, DETamara Matysiak-Budnik, FR

Vienna Live Session

17:30 – 18:45 TV StudioBest of UEG WeekChairs: Axel Dignass, DE

Herbert Tilg, ATHelena Cortez-Pinto, PTJulia Mayerle, DEJeanin E. van Hooft, NLMagnus Simrén, SE

Powered by TCPDF (www.tcpdf.org)



http://www.tcpdf.org

Documents

Scientific Programme by Day Saturday, October 2, 2021